SHAREHOLDERS SHOULD CONSIDER MANY FACTORS | | | Our Board of Directors urges you to disregard Mr. Miller’s arguments and to consider the following: |
| | • | In the Merger, we are buying later-stage drug candidates that we believe offer significant commercial potential. | | | • | While your percentage ownership of the Company will be diluted in the Merger, after the Merger, you will have an interest in a larger, combined drug development company with a broader pipeline of potential drug candidates that fits with Pharmos’ core areas of strength. We believe a broader drug pipeline means reduced overall development risk for you, the Pharmos shareholder, and a greater ultimate chance of successfully developing and commercializing a new drug. | | | • | We are primarily using an issuance of stock, rather than paying all cash, to acquire Vela. We are doing this in order to preserve our cash for the clinical work that will be required to create value through product development. | | | • | We will only issue additional milestone shares if Vela’s lead product is moving successfully through the clinic. We structured the Merger this way precisely because we wanted Vela to share development risk with us. If we ultimately issue the milestone shares, we believe your Pharmos stock should be at a much higher price at that point, reflecting the higher value inherent in the successful progress of Vela’s lead product through development. | | | • | In the Merger, we are adding three representatives from well-known, industry leading life science investment funds to our Board of Directors. Mr. Miller may argue that the Pharmos board and management are entrenched and looking after their own interests. In fact, this Merger demonstrates that Pharmos is looking to continue to expand the management and board expertise of the Company by bringing in fresh thinking from the outside, as we did with the recent hire of Alan Rubino as President. | | | • | Pharmos’ shareholder base will be strengthened by the addition of three prestigious life science investment funds, who will become significant shareholders of Pharmos. Mr. Miller may try to cause you to be concerned that these three funds will control Pharmos to your detriment. We believe just the opposite is true. They will be common shareholders just like you and will have common interests with you. These funds are committed to the long-term success of Pharmos. | | | • | The Vela shareholders, who are sophisticated investors in the life sciences industry, are betting on the future of Pharmos by primarily taking stock, rather than cashing out. In fact, the Chairman of the Board of Vela, Robert Johnston, has demonstrated his confidence in Pharmos by recently purchasing 100,000 shares of our common stock in the market. | | | • | RBC Capital Markets Corporation and Tamir Fishman & Co. Ltd., have rendered their opinion to the Board of Directors that the consideration to be paid by Pharmos in the Merger is fair, from a financial point of view, to Pharmos. | | | • | | | | | • | While your percentage ownership of the Company will be diluted in the Merger, after the Merger, you will have an interest in a larger, combined drug development company with a broader pipeline of potential drug candidates that fits with Pharmos’ core areas of strength. We believe a broader drug pipeline means reduced overall development risk for you, the Pharmos shareholder, and a greater ultimate chance of successfully developing and commercializing a new drug.
| | | | | • | We are primarily using an issuance of stock, rather than paying all cash, to acquire Vela. We are doing this in order to preserve our cash for the clinical work that will be required to create value through product development.
| | | | | • | We will only issue additional milestone shares if Vela’s lead product is moving successfully through the clinic. We structured the Merger this way precisely because we wanted Vela to share development risk with us. If we ultimately issue the milestone shares, we believe your Pharmos stock should be at a much higher price at that point, reflecting the higher value inherent in the successful progress of Vela’s lead product through development.
| | | | | • | In the Merger, we are adding three representatives from well-known, industry leading life science investment funds to our Board of Directors. Mr. Miller may argue that the Pharmos board and management are entrenched and looking after their own interests. In fact, this Merger demonstrates that Pharmos is looking to continue to expand the management and board expertise of the Company by bringing in fresh thinking from the outside, as we did with the recent hire of Alan Rubino as President.
| | | | | • | Pharmos’ shareholder base will be strengthened by the addition of three prestigious life science investment funds, who will become significant shareholders of Pharmos. Mr. Miller may try to cause you to be concerned that these three funds will control Pharmos to your detriment. We believe just the opposite is true. They will be common shareholders just like you and will have common interests with you. These funds are committed to the long-term success of Pharmos.
| | | | | • | The Vela shareholders, who are sophisticated investors in the life sciences industry, are betting on the future of Pharmos by primarily taking stock, rather than cashing out. In fact, the Chairman of the Board of Vela, Robert Johnston, has demonstrated his confidence in Pharmos by recently purchasing 100,000 shares of our common stock in the market.
| | | | | • | RBC Capital Markets Corporation and Tamir Fishman & Co. Ltd., have rendered their opinion to the Board of Directors that the consideration to be paid by Pharmos in the Merger is fair, from a financial point of view, to Pharmos.
| | | | | • | Our Board of Directors believes that Vela’s drug candidates represent important and potentially valuable opportunities for the enhancement of shareholder value and that the consideration that the Company will pay in the Merger is fair and reasonable. |
| WE URGE YOU TO REVIEW THE ENCLOSED MATERIALS AND
TO RETURN YOUR SIGNED PROXY PROMPTLY IN FAVOR
OF THE ISSUANCE OF OUR SHARES OF COMMON STOCK IN THE MERGER The enclosed proxy statement provides detailed information about the Merger Agreement, the proposed Merger and the Meeting. You may obtain additional information about us from documents filed with the Securities and Exchange Commission. We urge you to read the entire proxy statement carefully, including the descriptions of the terms of the Merger Agreement and other important information related to the Merger. Your vote is very important. The Merger cannot be completed unless our shareholders approve of the issuance of the shares of Pharmos common stock in accordance with the Merger Agreement and applicable rules of the Nasdaq Capital Market. Regardless of whether you plan to attend the Meeting, it is important that your shares
are represented at the Meeting. To ensure that your shares will be represented, please complete, sign, date and mail the enclosed proxy at your first opportunity. |
This solicitation for your proxy is being made by the Company on behalf of our Board of Directors. If you complete, sign, date and submit the enclosed proxy card without indicating how you wish to vote, your proxy will be counted as a vote in favor of the issuance of shares of Pharmos common stock in accordance with the Merger Agreement. Returning the proxy will not deprive you of your right to attend the Meeting, revoke your proxy and vote your shares in person. On behalf of your Board of Directors and management team, we thank you for your continued support. | | | | Sincerely, | | | | | | Haim Aviv, Ph.D. | | Chairman of the Board and Chief Executive Officer | | | | Alan Rubino | | President and Chief Operating Officer |
| Sincerely, | | | | | | Haim Aviv, Ph.D.
Chairman of the Board and Chief Executive Officer | | | | Alan Rubino
President and Chief Operating Officer |
PHARMOS CORPORATION
99 Wood Avenue South, Suite 311
Iselin, NJ 08830
(732) 452-9556 | |
| | NOTICE OF SPECIAL MEETING OF SHAREHOLDERS | |
| |
NOTICE IS HEREBY GIVEN, that a Special Meeting of the Shareholders (the “Meeting”) of Pharmos Corporation (the “Company”) will be held on _________, 2006 at _________, local time, at [________________________] to (i) to approve the issuance of up to 19,500,000 shares of the Company’s common stock in connection with the proposed acquisition by the Company of Vela Pharmaceuticals Inc.; (ii) grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of the Company’s common stock in connection with the proposed acquisition of Vela Pharmaceuticals Inc.; and (ii) to(iii) transact such other business as may properly come before the Meeting or any adjournment or adjournments thereof.
The Meeting may be adjourned by vote of the holders of a majority of the shares of the Company’s common stock present in person or by proxy, even if a quorum is not present at the Meeting. At any adjourned Meeting, any business may be transacted which could have been transacted at the originally scheduled Meeting. Our Board of Directors has fixed the close of business on ___________, 2006 as the record date for the determination of shareholders entitled to notice of, and to vote at, the Meeting. If you do not expect to be present at the Meeting, but wish to have your stock voted for the business to be transacted thereat, our Board of Directors requests that you submit your proxy either (i) electronically, through the internet or by telephone (information for both provided on following page) or (ii) by filling in, signing and dating the enclosed proxy card and promptly returning it by mail in the postage paid envelope provided. If you are planning to attend the Meeting, you must have photo identification and proof of stock ownership as of the record date to be admitted. If your shares are not registered in your own name, you can obtain proof of stock ownership as of the record date from your bank or brokerage firm, typically in the form of your most recent statement. | |
| BY ORDER OF THE BOARD OF DIRECTORS | | | | Haim Aviv, Ph.D.
Chairman of the Board | | | __________, 2006 | |
| | | BY ORDER OF THE BOARD OF DIRECTORS | | | | Haim Aviv, Ph.D. | | Chairman of the Board |
__________, 2006 PLEASE SUBMIT YOUR PROXY (A) ELECTRONICALLY, THROUGH THE INTERNET OR BY TELEPHONE (INFORMATION FOR BOTH PROVIDED ON FOLLOWING PAGE) OR (B) BY FILLING IN, SIGNING AND DATING THE ENCLOSED WHITE PROXY CARD AND PROMPTLY RETURNING IT IN THE ENVELOPE PROVIDED. NO POSTAGE IS NECESSARY IF MAILED IN THE UNITED STATES. |
PLEASE VOTE YOUR PROXY! ELECTRONIC VOTINGSAVES YOUR COMPANY MONEY For the last few years, many of our shareholders have saved Pharmos money by voting their proxies via internet or telephone, rather than by return mail. We encourage all of our shareholders to take advantage of electronic voting. By internet –www.proxyvote.com; or
By touch-tone phone – please call the toll-free number on the enclosed proxy card. Have the enclosed white proxy card in hand when you access the website or call the toll-free number and follow the directions provided.
ELECTRONIC DELIVERY OF PROXY STATEMENTS AND ANNUAL REPORTSSAVES YOUR COMPANY MONEY Most shareholders can elect to view future proxy statements and annual reports over the internet instead of receiving paper copies in the mail. Doing so will save Pharmos printing and mailing expenses. If you are a shareholder of record, you can choose this option and save Pharmos the cost of production and mailing these documents by following the instructions provided when you vote over the internet. If you hold your Pharmos shares through a bank, broker or other holder of record, please refer to the information provided by that entity for instructions on how to elect to view future proxy statements and annual reports over the internet. If you choose to view future proxy statements and annual reports over the internet, you will receive an e-mail message next year containing the Internet address to access Pharmos’ proxy statement and annual report. |
TABLE OF CONTENTS |
SUMMARY TERM SHEET
This summary highlights the material terms of the proposed merger with Vela Pharmaceuticals Inc. and may not contain all of the information that may be important to you in evaluating the proposal to issue shares of our common stock in the merger. To understand the proposed merger fully and for a more complete description of the terms of the proposed merger, you should carefully read this proxy statement and the Agreement and Plan of Merger (the “Merger Agreement”) by and among Vela Pharmaceuticals Inc., the Company, and Vela Acquisition Corporation, a newly-formed, wholly-owned subsidiary that we formed for the purposes of the proposed acquisition (“Newco”). The Merger Agreement is attached to this proxy statement as Appendix A. • The Merger. The Company has entered into a Merger Agreement that provides for the merger of Vela Pharmaceuticals Inc. (“Vela”) with and into Newco (the “Merger”), with Newco surviving the Merger as our wholly-owned subsidiary and continuing to carry on the business of Vela. See “THE MERGER” beginning on page 3. | |
| Pharmos Corporation. Our Company is a specialty pharmaceutical company that is in the business of discovering and developing novel therapeutics to treat a range of indications including pain, inflammation, autoimmunity and select central nervous system disorders. We have a portfolio of drug candidates and compounds in various development states, including clinical, preclinical and discovery. Our lead drug candidate, cannibinor, is scheduled to begin Phase II clinical testing for neuropathic pain and post-surgical pain. We have also completed a Phase I clinical trial for the topical non-steroidal anti-inflammatory drug (“NSAID”), diclofenac, for the treatment of osteoarthritis using our NanoEmulsion drug delivery platform for topical delivery. See “THE PARTIES TO THE MERGER” beginning at page 3. Vela Acquisition Corporation. We formed Newco for the sole purpose of the Merger Agreement and completing the Merger. It has not conducted any operating business activities since its formation other than those incidental to its incorporation and as contemplated by the Merger Agreement. Vela Pharmaceuticals, Inc. Vela is a privately-held, drug development company specializing in the rediscovery and development of medicines related to the nervous system, including what is known as the “brain-gut” axis” — links between the nervous system and the digestive system. Vela seeks to minimize some of the costs of traditional drug discovery and development by working primarily with drug assets for which human safety data are already available. Vela’s lead drug candidates include dextofisopam and tianeptine for the treatment of irritable bowel syndrome (“IBS”) and VPI-013 for the treatment of neuropathic pain and female hypoactive sexual desire disorder. Vela has conducted three Phase I trials showing positive indications for dextofisopam’s tolerability in healthy volunteers and one Phase II trial showing positive indications for dextofisopam’s potential efficacy and tolerability in women and men with diarrhea-predominant or alternating-type IBS. See “THE PARTIES TO THE MERGER” beginning at page 3. • Reasons for the Merger. Our Board of Directors is unanimously recommending the Merger because it believes that Vela’s drug assets will broaden the Company’s overall drug pipeline, diversify clinical risk by the addition of multiple drug candidates, provide potentially valuable synergies in the area of central nervous system therapeutics, advance the Company several years forward in clinical development of drug candidates targeted to large, underserved markets, and offer significant commercial potential. We expect a number of benefits from the Merger, including obtaining several drug candidates related to the central nervous system, an area in which we currently have expertise and experience. We also expect to obtain a seasoned development and clinical team from Vela with particular expertise in irritable bowel syndrome drug development. We also expect to strengthen and enhance our board of directors with three new members from Vela, all of whom are well regarded, senior professionals associated with three leading life science venture capital firms. Additionally, our shareholder base will be expanded to include these three prestigious venture capital firms who will become significant shareholders, demonstrating their confidence in the future of the combined companies. |
The proposed acquisition of Vela is the culmination of a process of exploration, review and analysis begun in 2004. Since 2004, our Board of Directors has consistently pursued its announced strategy of expanding our pipeline of later stage drug candidates with the objective of enhancing shareholder value. Prior to entering into the Merger Agreement, our Board of Directors reviewed a number of possibilities including the acquisition of other drug candidates in various stages of clinical development and the acquisition of drug development companies with i
complementary drug assets. This process involved an analysis of approximately 120 drug candidates and drug development companies over a one-year period. Our Board of Directors also considered the option of focusing our operations on the continued investigation and development of our existing drug asset portfolio while continuing to explore available opportunities. See “BACKGROUND AND REASONS FOR THE MERGER” beginning at page 6. • Merger Consideration. At the closing of the Merger, we will issue 11,500,000 shares of our common stock to certain Vela shareholders, of which 1,725,000 shares will be held in escrow for up to 18 months for possible return to the Company in the event of indemnifiable breaches of Vela’s representations, warranties and covenants in the Merger Agreement. Also, at the closing of the Merger, we will pay $5,000,000 in cash to, or on behalf of, Vela, and will assume up to $100,000 of Vela’s qualified post-closing liabilities. In the event that two milestones in the development of dextofisopam are achieved over the next eight years, we will issue up to an additional 8,000,000 shares of our common stock in two installments to certain Vela shareholders. The two milestones are the successful completion of a Phase IIb clinical trial for dextofisopam within four years of the closing of the Merger, and the filing of a new drug application with the U.S. Food and Drug Administration for dextofisopam within eight years of the closing. See “THE MERGER” beginning at page 3, and “THE MERGER AGREEMENT AND THE MERGER” beginning at page 20. • Fairness Opinion of Financial Advisors. In deciding to approve the Merger Agreement and the Merger, one factor that our Board of Directors considered was the opinion of its financial advisors, RBC Capital Markets Corporation and Tamir Fishman & Co., Ltd., who concluded that as of March 14, 2006, and based upon and subject to the various considerations set forth in its opinion, the consideration to be paid by the Company in connection with the Merger was fair, from a financial point of view, to the Company. The complete opinion of RBC Capital Markets Corporation and Tamir Fishman & Co., Ltd., including applicable limitations and assumptions, is attached as Appendix B to this proxy statement. See “FAIRNESS OPINION” beginning at page 11. • Resulting Board of Directors and Management. Under the terms of the Merger Agreement, at the closing of the Merger we will expand the size of our Board of Directors from seven to nine members. One of our current directors, ____________, will resign, and three designees of each of the principal shareholders of Vela, JPMorgan Partners, Venrock Associates and New Enterprise Associates, will be appointed to the expanded Board of Directors. The initial designees of each of JPMorgan Partners, Venrock Associates and New Enterprise Associates are Dr. Srinivas Akkaraju, Dr. Anthony B. Evnin and Charles W. Newhall, III, respectively. We also anticipate hiring Dr. Steven Leventer, Senior Vice President, Research and Development of Vela, to lead clinical development of the Vela drug candidates, and several members of his staff at Vela. These potential new directors and employees will strengthen our board, management and scientific team following the Merger. See “THE MERGER” beginning at page 3, and “THE MERGER AGREEMENT AND THE MERGER” beginning at page 20. • Share Ownership at the Closing of the Merger. At the closing of the Merger, current Vela shareholders will own or control 11,500,000 shares of our common stock, representing approximately 38% of the total number of shares of our common stock outstanding as of the closing. See “THE MERGER” beginning at page 3, and “THE MERGER AGREEMENT AND THE MERGER” beginning at page 20. • Standstill Agreement. At the closing of the Merger, Vela’s principal shareholders will enter into standstill agreements that provide that for two years following the closing they will not acquire additional shares of our common stock, other than as agreed to by our Board of Directors or in a private placement or other transaction in an amount to maintain their percentage interest. Each standstill agreement also provides that it is the current intention of the shareholder not to initiate or support a proxy fight or hostile takeover of the Company. See “THE MERGER” beginning at page 3, and “THE MERGER AGREEMENT AND THE MERGER – Standstill Agreement” beginning at page 23. |
• Registration of Shares Issued in the Merger. We have agreed to file a registration statement with the Securities and Exchange Commission to register for resale all of the shares of our common stock to be issued in connection with the Merger. The shares of our common stock issued at the closing of the Merger and any additional shares that may be issued upon achievement of the milestones during the 18 months following the closing will be subject to certain transfer restrictions for a period of up to 18 months following the closing. Any additional shares to be issued upon achievement of the milestones more than 18 months after the closing will not be subject to such transfer restrictions. See “THE MERGER” beginning at page 3, and “THE MERGER AGREEMENT AND THE MERGER – Registration of Merger Shares and Lock-Up” beginning at page 23. ii
• Shareholder Vote. You are being asked to consider and vote upon a proposal to approve the issuance of up to 19,500,000 shares of our common stock in connection with the Merger. Such approval is required under applicable rules of the Nasdaq Capital Market. These rules require shareholder approval prior to the issuance of shares of common stock in connection with the acquisition of another company if the number of shares of common stock to be issued equals or exceeds 20% of the number of outstanding shares of common stock before the issuance. The affirmative vote of a majority of the votes cast by holders of shares of our common stock present in person or represented by proxy at the Meeting and entitled to vote on the matter is required for approval of thethis proposal. See “INTRODUCTION” beginning at page 1. Our directors and executive officers who beneficially own approximately ____% of the outstanding shares of our common stock have agreed to vote in favor of thethis proposal.
You are also being asked to consider and vote upon a proposal to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of our common stock in connection with the Merger. The affirmative vote of a majority of the votes cast by holders of shares of our common stock present in person or represented by proxy and entitled to vote on the matter is required for approval of this proposal, whether or not a quorum exists. See “PROPOSAL 2 – GRANT OF DISCRETIONARY AUTHORITY TO ADJOURN THE MEETING TO SOLICIT ADDITIONAL PROXIES” beginning at page 71. • Potential Opposition to the Merger.Merger. We understand that Lloyd I. Miller, III, a shareholder who beneficially owns approximately 8.8%9.4% of our outstanding shares of common stock, along with two other shareholders, Dr. Raymond E. McKee and Dr. Gerard Soula, oppose the Merger and may urge you to vote against the proposal to issue shares of our common stock in the Merger. We believe that you will find Mr. Miller’s position is a purely negative one and that his motives and objectives (beyond blocking the Merger) are focused on his own, personal investment strategy and not on the best interests of the Company and our shareholders as a whole. We don’t believe that these shareholders have any meaningful plan for enhancing or preserving shareholder value. Although they are under no obligation to present such a plan, we believe it is important for our shareholders to recognize that in contrast to the Company’s long term strategy to expand our pipeline of later stage drug candidates, Mr. Miller has articulated no plan for enhancing shareholder value if he is successful in defeating the proposal to issue shares of our common stock in the Merger. They may try to alarm you by focusing on dilution and so-called “cash drain” which they argue will occur as a result of the Merger. These arguments ignore the potential benefits to the Company and our shareholders from the Merger. We encourage you to consider the important potential benefits to the Company considered by our Board of Directors in concluding that the Merger is in the best interests of the Company and its shareholders.
Our management and Board of Directors are focused on building shareholder value. We encourage communication with our shareholders and carefully consider their suggestions. However, our management and Board of Directors develop and implement their strategy for the Company based on their judgment as to the best interests of the Company and our shareholders as a whole, not the personal investment strategy of one individual shareholder. We believe that the acquisition of Vela is consistent with our strategy, offers great potential and is in the best interests of the Company and our shareholders as a whole. See “SHAREHOLDER OPPOSITION TO THE MERGER” beginning at page 10.
• Recommendation of Our Board of Directors. Our Board of Directors has unanimously approved the Merger Agreement and the Merger and recommends that you vote FOR the proposal to approve the issuance of up to 19,500,000 shares of our common stock in connection with the Merger and FOR the proposal to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of our common stock in connection with the Merger. See “BACKGROUND AND REASONS FOR THE MERGER” beginning at page 6.6, and “PROPOSAL 2 – GRANT OF DISCRETIONARY AUTHORITY TO ADJOURN THE MEETING TO SOLICIT ADDITIONAL PROXIES” beginning at page 71.
|
QUESTIONS AND ANSWERS ABOUT THE MERGER The following section provides brief answers to some of the more likely questions you may have about the Merger. This section is not intended to contain all of the information that is important to you. You are urged to read the entire proxy statement carefully, including information in the Appendices. Why is the Company proposing to acquire Vela? iii
The Merger is being proposed as a means to enhance shareholder value by strategically adding to and diversifying our drug asset portfolio. If the Merger is completed, we anticipate that dextofisopam and the other drug assets of Vela will be among our leading drug candidates for further clinical testing and for potential regulatory approval and commercialization. We believe that the acquisition of Vela has the potential to advance the Company several years forward in clinical development of high-potential drug candidates. What are some other benefits of the Merger to the Company and its shareholders? | | • | We will be obtaining several drug candidates related to the central nervous system, an area in which we currently have expertise and experience; | | | | | • | We will be obtaining a seasoned development and clinical team from Vela with particular expertise in irritable bowel syndrome drug development; | | | | | • | We will have three new members join our Board of Directors from Vela, all of whom are well-regarded, senior professionals associated with three leading life science investors; and | | | | | • | | | | | • | We will be obtaining a seasoned development and clinical team from Vela with particular expertise in irritable bowel syndrome drug development;
| | | | | • | We will have three new members join our Board of Directors from Vela, all of whom are well-regarded, senior professionals associated with three leading life science investors; and
| | | | | • | Our shareholder base will be expanded to include these three prestigious investors, who will become significant shareholders, demonstrating their confidence in the future of the combined companies. |
| How will the Company pay for Vela? As the purchase price of the Merger, at the closing, we will issue 11,500,000 shares of our common stock to certain shareholders of Vela and will pay $5,000,000 in cash to, or on behalf of, Vela. Subsequently, Vela’s shareholders may also receive an additional 8,000,000 shares of our common stock if certain milestones in the development of dextofisopam are achieved over the next eight years. What will happen to my shares of common stock in the acquisition?
Your shares of our common stock will not change as a result of the Merger. However, after the Merger, your shares will represent a smaller percentage of the total outstanding shares of our common stock than before the Merger. This will occur because, as consideration for the acquisition of Vela, the Company will issue 11,500,000 shares of our common stock to certain shareholders of Vela.Vela on the effective date of the Merger. Based on the total number of shares outstanding on the record date for the Meeting, 11,500,000 shares represents ___% of the outstanding common stock (meaning that, if the 11,500,000 shares were issued to the Vela shareholders as of the record date, the percentage ownership of all of our other shareholders would be reduced from 100% to ___%). An additional 8,000,000 shares of our common stock may be issued in the future to former Vela shareholders upon the achievement of certain milestones relating to the development of one of Vela’s compounds (the 11,500,000 shares and the 8,000,000 shares are referred to collectively as the “Merger Shares”). If such additional shares are issued upon achievement of the milestones, the percentage of the total outstanding shares represented by the shares of common stock owned by you will be further reduced. Based on the total number of shares outstanding on the record date for the Meeting, the 19,500,000 Merger Shares represent ___% of the outstanding common stock (meaning that, if the Merger Shares were issued to the Vela shareholders as of the record date, the percentage ownership of all of our other shareholders would be reduced from 100% to ___%).
Will the Merger result in a change of control? After the Merger, and prior to the issuance of any shares of our common stock upon achievement of the milestones, affiliates of JPMorgan Partners, Venrock Associates, and New Enterprise Associates, who are currently the principal shareholders of Vela, are expected to own or control approximately 16.2%, 7.5% and 11.0%, respectively, of our outstanding shares of common stock. These shareholders will be some of our largest shareholders and may be able to influence future decisions of the Company. Upon the closing of the Merger, one of our current directors, __________________, will resign and the size of our Board of Directors will be expanded from seven to nine. The three resulting vacancies on our Board of Directors will be filled by three nominees designated by former shareholders of Vela. While the Vela designees |
will constitute a minority of the Board of Directors, they may be expected to influence future decisions of the Company. Where and when is the Meeting? The Meeting will be held at ____ a.m., local time, on _________, 2006 at ____________, located at ___________. Who is soliciting my proxy? iv
Our Board of Directors is soliciting proxies from each of our shareholders. We will pay the expenses of preparing and distributing this proxy statement and soliciting proxies, including the reasonable expenses incurred by brokers, dealers, banks and trustees or their nominees for forwarding solicitation materials to beneficial owners. We have also retained Georgeson Shareholder Communications Inc. to assist us in soliciting proxies, and estimate that their fees for such service will be as much as $120,000 in addition to reimbursement of their out-of-pocket expenses.
Who is entitled to vote on the proposalproposals at the Meeting?
Shareholders of record as of the close of business on _________, 2006, the record date for the Meeting, are entitled to notice of and to vote at the Meeting. Each share of our common stock is entitled to one vote. What am I being asked to vote on?
The first proposal you are being asked to approve is the issuance of up to 19,500,000 shares of our common stock in connection with the proposed acquisition by the Company of Vela.
The second proposal you are being asked approve is to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of the Company’s common stock in connection with the Merger. What shareholder approval is needed in connection with the issuance of the Merger Shares?Shares and the proposal to grant discretionary authority?
The affirmative vote of a majority of the votes cast by holders of shares of our common stock present or represented by proxy and entitled to vote at the Meeting is required to approve the issuance of the Merger Shares.
The affirmative vote of a majority of the votes cast by holders of shares of our common stock present in person or represented by proxy and entitled to vote on the matter, whether or not a quorum exists, is required for approval of the proposal to grant discretionary authority to the named proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares in connection with the Merger.
What will happen if the proposal to approve the issuance of the Merger Shares is approved by our shareholders?
If the proposal to approve the issuance of up to 19,500,000 shares of our common stock in connection with the proposed acquisition by the Company of Vela is approved by our shareholders, and the other conditions to the closing of the Merger are satisfied or waived, Vela will merge with and into our newly-formed, wholly-owned subsidiary, Vela Acquisition Corporation. Vela Acquisition Corporation will survive the Merger and will carry on the business of Vela following the closing.
What will happen if the proposal to approve the issuance of the Merger Shares is not approved by our shareholders?
If the proposal to approve the issuance of up to 19,500,000 shares of our common stock in connection with the proposed acquisition by the Company of Vela is not approved by our shareholders, the Merger will not be completed on the terms set forth in the Merger Agreement. When will the Merger occur? We currently expect to complete the Merger two business days after the issuance of the Merger Shares is approved by our shareholders and the other conditions to the Merger are satisfied or waived. Pharmos and Vela are working toward completing the Merger as quickly as possible. Has any shareholder already agreed to vote in favor of the proposal to issue the Merger Shares? The directors and executive officers of the Company beneficially own and have the right to vote _______________ shares of our common stock, or approximately ____% of the shares of our common stock entitled |
to be voted at the Meeting. We have entered into agreements with these individuals to vote in favor of approval of the issuance of the Merger Shares in connection with the Merger.
Are there any shareholders that have expressed their intent to oppose the Merger?
We understand that Lloyd I. Miller, III, a shareholder who beneficially owns approximately 8.8%9.4% of the Company’s outstanding shares of common stock, along with two other shareholders, Dr. Raymond E. McKee and
v
Dr. Gerard Soula, oppose the Merger and may urge you to vote against the proposal to issue shares of common stock in the Merger. We believe that you will find Mr. Miller’s position is a purely negative one and that his motives and objectives (beyond blocking the Merger) are focused on his own, personal investment strategy and not on the best interests of the Company and our shareholders as a whole. We don’t believe that these shareholders have any meaningful plan for enhancing or preserving shareholder value. Although they are under no obligation to present such a plan, we believe it is important for our shareholders to recognize that in contrast to the Company’s long term strategy to expand our pipeline of later stage drug candidates, Mr. Miller has articulated no plan for enhancing shareholder value if he is successful in defeating the proposal to issue shares of our common stock in the Merger. They may try to alarm you by focusing on dilution and so called “cash drain” which they argue will occur as a result of the Merger. These arguments ignore the potential benefits to the Company and our shareholders from the Merger. We encourage you to consider the important potential benefits to the Company considered by our Board of Directors in concluding that the Merger is in the best interests of the Company and our shareholders.
Our management and Board of Directors are focused on building shareholder value. We encourage communication with our shareholders and carefully consider their suggestions. However, our management and Board of Directors develop and implement their strategy for the Company based on their judgment as to the best interests of the Company and our shareholders as a whole, not the personal investment strategy of one individual shareholder. We believe that the acquisition of Vela is consistent with our strategy, offers great potential and is in the best interests of the Company and our shareholders as a whole. Will Vela’s shareholders be able to sell the Merger Shares that they receive in the Merger? Not immediately. It is intended that the Merger Shares will be issued in a private placement pursuant to Regulation D under the Securities Act of 1933, as amended. We have agreed to register the resale of the Merger Shares on behalf of Vela’s shareholders and expect to file the registration statement covering the Merger Shares within seven days after the Merger is completed. Once the registration statement is declared effective, the Merger Shares will be freely tradable. However, the Vela shareholders receiving the Merger Shares in the Merger have agreed to “lock-up” provisions pursuant to a Registration Rights Agreement which will be executed at the closing. Pursuant to the lock-up provisions, (i) none of the Merger Shares may be sold until six months after the closing, (ii) for each six-month period after that date, up to 33% of the Merger Shares originally issued to any shareholder may be sold, and (iii) after 18 months from the closing, all Merger Shares may be sold. Any of the Merger Shares issued upon achievement of the milestones during the lock-up period shall also be subject to such restrictions, and any of the Merger Shares issued upon achievement of the milestones after the lock-up period will not be subject to such restrictions. Why is my vote important? Under applicable Nasdaq rules, we must obtain the approval of our shareholders before we can issue the Merger Shares. We must first establish a quorum at the Meeting. A quorum will be established if one-third of the outstanding shares of our common stock are present in person or by proxy at the Meeting. Thus, your failure to submit a proxy or to attend the Meeting could have the effect of preventing a quorum and, thus, the approval of the issuance of the Merger Shares. If you do not submit a proxy or attend the Meeting and we nonetheless have sufficient shares to constitute a quorum, then your failure to vote will not have any effect on the outcome of any of these proposals.
Any proposal to adjourn the Meeting will be approved if a majority of the shares of our common stock present in person or by proxy at the Meeting votes in favor of the proposal.proposal, whether or not a quorum exists.
Our directors and executive officers beneficially own and have the right to vote ___________ shares of our common stock, or approximately _____% of the shares of common stock entitled to be voted at the Meeting. We |
have entered into agreements with these individuals to vote in favor of approval of the issuance of the Merger Shares in connection with the Merger.
A beneficial owner of approximately 8.8%9.4% of the Company’s outstanding shares of common stock, Lloyd I. Miller, III, filed a Schedule 13D in April 2006, as amended in June 2006, with the Securities and Exchange Commission indicating his current intention to vote against approval of the issuance of the Merger Shares in connection with the Merger. A group led by Mr. Miller then filed a preliminary proxy statement on May 25, 2006,
vi
as amended on June 22, 2006, indicating their intention to seek proxies from shareholders to oppose the Merger. To our knowledge, the group has not yet filed or mailed any definitive proxy materials.
What happens if I return my proxy but do not indicate how to vote my shares?
If you sign and return the enclosed proxy card, but do not provide instructions on how to vote your shares, your shares will be voted FOR approval of the issuance of the Merger Shares, FOR the proposal to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of our common stock in connection with the Merger, and upon any other matters that may properly come before the Meeting, in accordance with the judgment of the named proxies. The persons named as proxies will have the discretionary authority to vote in favor of a proposal to adjourn the Meeting if necessary to solicit additional proxies to vote in favor of the proposal to issue the Merger Shares. If you return an unsigned proxy card, your proxy will be invalid, and your shares will not be deemed present or voted at the Meeting.
Can I change my vote after I have mailed my signed proxy card? | |
| Yes. You may change your vote at any time before your proxy is voted at the Meeting, as follows: | | | | | • | You may send a written notice stating that you would like to revoke your proxy and provide new instructions on how to vote; | | | | | • | You may complete and submit a later-dated proxy card; | | | | | • | If you voted electronically, you may return to the website and recast your votes; or | | | | | • | You may attend the Meeting and vote in person. |
| | | | Yes. You may change your vote at any time before your proxy is voted at the Meeting, as follows: | | | | | • | You may send a written notice stating that you would like to revoke your proxy and provide new instructions on how to vote; | | | | | • | You may complete and submit a later-dated proxy card; | | | | | • | If you voted electronically, you may return to the website and recast your votes; or | | | | | • | You may attend the Meeting and vote in person. |
If you choose the first, second or third method above, you must submit your notice of revocation or your new proxy card to us or cast your votes on the website prior to the Meeting. If my shares are held in “street name” by my broker, will my broker vote my shares for me?
Your broker will not be permitted to exercise voting discretion with respect to the proposalproposals to be voted on at the Meeting. Thus, if you do not give your broker or nominee specific instructions on a specific proposal, your shares will not be voted on thesuch proposal, and will not be counted in determining the number of shares voting in favor of the specific proposal. You should follow the directions provided by your broker regarding how to instruct your broker to vote your shares.
What do I need to do now? Important information is presented in greater detail elsewhere in this proxy statement and the documents attached as appendices to this proxy statement. We encourage you to read this proxy statement in its entirety, together with our Annual Report to Shareholders for the fiscal year ended December 31, 2005 and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006 which are being mailed together with this proxy statement. Following review of this proxy statement, please complete, sign, and date the enclosed proxy card and return it in the enclosed envelope as soon as possible so that your shares can be voted at the Meeting. Who can help answer my questions? |
If you have questions about the Merger, the Meeting, or your proxy, or if you need additional copies of this document or a proxy card, you should contact: | | | | Pharmos Corporation | | 99 Wood Avenue South, Suite 311 | | Iselin, NJ 08830 | | Attention: President | | 732-542-9656 | | | | or | | | | Georgeson Shareholder Communications, Inc. | | 800-509-0957 |
| Pharmos Corporation
99 Wood Avenue South, Suite 311
Iselin, NJ 08830
Attention: President
732-542-9656 | | | | or | | | | Georgeson Shareholder Communications, Inc.
800-509-0957 |
FORWARD-LOOKING STATEMENTS Some of the statements contained in this proxy statement are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to statements regarding: the timing of completion of the acquisition of Vela; the possible achievement of clinical milestones; the possible issuance of shares of Pharmos common stock upon achievement of milestones; the anticipated benefits of the acquisition; the expected effect of such acquisition on the business of Pharmos; the development, commercialization and market expectations of Pharmos’ drug candidates; the establishment of corporate collaborations; and the operational and financial projections of Pharmos.
These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Risks and uncertainties that may affect Pharmos’ ability to consummate the acquisition or that could cause its actual results to differ materially include, among others: the shareholders of Pharmos may not approve the issuance of shares of common stock to be issued in the Merger; the parties may be unable to complete the acquisition or completing the acquisition may be more costly than expected because, among other reasons, conditions to the closing of the acquisition may not be satisfied or the effect of opposing solicitations from any dissident shareholder; problems may arise with the ability to successfully integrate the businesses of Pharmos and Vela, which may result in the combined company not operating as effectively and efficiently as expected; Pharmos may not be able to achieve the expected benefits from the acquisition or it may take longer than expected to achieve those benefits; the acquisition may involve unexpected costs or unexpected liabilities; the combined company may be adversely affected by future legislative, regulatory or tax changes, as well as other economic, business and/or competitive factors; risks related to new product development; risks related to action of regulatory authorities and the results of further clinical trials, including the possibility that such further clinical trials may not have positive results for one or more drug candidates; and other factors identified in Pharmos’ filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent Pharmos’ estimates and assumptions only as of the date hereof. Except as otherwise required by law, Pharmos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this proxy statement to reflect any change in Pharmos’ expectations or any change in events, conditions or circumstances on which any of Pharmo’Pharmos’ forward-looking statements are based.
|
PHARMOS CORPORATION
99 Wood Avenue South, Suite 311
Iselin, NJ 08830
(732) 452-9556 PROXY STATEMENT FOR SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD ON ___________ __, 2006 INTRODUCTION
The Meeting is being called to (i) approve the issuance of up to 19,500,000 shares of the Company’s common stock in connection with the proposed acquisition by the Company of Vela Pharmaceuticals Inc. (“Vela”) and (ii) grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of our common stock in connection with the Merger. The Meeting will be open for the transaction of such other business as may properly come before it, although, as of the date of this proxy statement, management does not know of any other business that will come before the Meeting. If any other matters do come before the Meeting, the persons named in the enclosed form of proxy are expected to vote said proxy in accordance with their judgment on such matters.
This proxy statement and the accompanying proxy card are first being mailed on or about [__________], 2006 to shareholders of record as of _____________, 2006. A copy of the Company’s Annual Report to Shareholders for the fiscal year ended December 31, 2005, which includes audited financial statements, and the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006, are also included.
The solicitation of proxies in the accompanying form is made by, and on behalf of, our Board of Directors, and the Company will bear the entire cost of such solicitation. We may use the services of our officers and directors to solicit proxies, personally or by telephone, mail, electronically or other means of communication, without additional compensation. Certain information regarding our officers and directors who may solicit proxies is set forth in this proxy statement under the heading “Stock Ownership of Certain Beneficial Owners and Management”. We have also retained Georgeson Shareholder Communications Inc. (“Georgeson”) to assist us in soliciting proxies, and estimate that their fees for such service will be as much as $120,000, in addition to reimbursement of their out-of-pocket expenses. Our agreement with Georgeson contains customary indemnification provisions and provides for exclusive solicitation services under certain circumstances for a one-year period. Although no precise estimate can be made at this time, we anticipate the aggregate amount we will spend in connection with the solicitation of proxies will be approximately $250,000. This amount includes fees payable to Georgeson, but excludes salaries and expenses of our officersandofficers and directors and the normal expenses of an uncontested solicitation. The aggregate amount to be spent will vary depending on, among other things, any development that may occur in our solicitation of proxies. The Company or Georgeson will make arrangements with brokerage houses and other custodians, nominees and fiduciaries for the forwarding of proxy material to the beneficial owners of shares held of record by such persons, and such persons will be reimbursed for reasonable expenses incurred by them. A shareholder executing the accompanying proxy has the power to revoke it at any time prior to the exercise thereof by filing with the Secretary of the Company: (i) a duly executed proxy bearing a later date; (ii) a written instrument revoking the proxy; (iii) voting electronically or by telephone until 11:59 PM Eastern Time on the day prior to the date of the Meeting; or (iv) by attending the Meeting and voting in person. In the event that a shareholder casts more than one proxy vote, electronically or otherwise, the latest vote received will be the vote that will be recorded.
The presence, in person or by proxy, of the holders of one-third of the outstanding shares of Common Stockour common stock entitled to vote at the Meeting is necessary to constitute a quorum. Abstentions are counted as present for purposes of determining the presence or absence of a quorum for the transaction of business. |
The affirmative vote of a majority of the votes cast by holders of shares of our common stock present in person or represented by proxy at the Meeting and entitled to vote on such matter is required for approval of the proposal to approve the issuance of up to 19,500,000 shares of the Company’sour common stock in connection with the proposed acquisition by the Company of Vela. The affirmative vote of a majority of the votes cast by holders of
shares of our common stock present in person or represented by proxy and entitled to vote on the matter, whether or not a quorum exists, is required for approval of the proposal to grant discretionary authority to the named proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares in connection with the Merger. Abstentions are included in the number of shares present and voting on each matter.
All materials filed by the Company with the Securities and Exchange Commission (the “SEC”) can be obtained at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or through the SEC’s website at www.sec.gov. You may obtain information on the operation of the Public Reference Room by calling 1-800-SEC-0330. VOTING SECURITIES The Board of Directors has fixed the close of business on [____________], 2006 as the record date for the determination of shareholders entitled to notice of, and to vote at, the Meeting. As of the record date, the outstanding capital stock of the Company consisted of [__________] shares of common stock. Each holder of common stock is entitled to one vote for each share of common stock held by him or her at the close of business on the record date.
The shares of common stock for which the accompanying proxy is solicited will be voted in accordance with the direction given, or if no direction is given, for the proposal to approve the issuance of up to 19,500,000 shares of the Company’sour common stock in connection with the proposed acquisition by the Company of Vela, for proposal to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the proposal to issue up to 19,500,000 shares of our common stock in connection with the Merger, and in accordance with the judgment of the named proxies on any other matters that are properly brought before the Meeting, provided that the proxy is executed and returned by the shareholder prior to the Meeting. The named proxies will have the discretionary authority to vote in favor of a proposal to adjourn the Meeting if necessary to solicit additional proxies to vote in favor of the proposal to issue the 19,500,000 shares of the Company’s common stock.
PROPOSAL 1 - APPROVAL OF THE ISSUANCE OF UP TO 19,500,000 SHARES OF THE COMPANY’S
COMMON STOCK IN CONNECTION WITH THE PROPOSED ACQUISITION BY THE COMPANY OF
VELA PHARMACEUTICALS INC On March 15, 2006, we announced our intent to acquire Vela through the merger of Vela into Vela Acquisition Corporation, our newly-formed, wholly-owned subsidiary (the “Merger”). Vela shareholders will receive 11,500,000 shares of Pharmos common stock at the closing of the Merger in exchange for all outstanding Vela securities after conversion of any outstanding Vela bridge notes. In addition, at the closing, we will pay $5,000,000 in cash to, or on behalf of, Vela, which will be used to pay certain of Vela’s outstanding liabilities, including Vela’s transaction costs, obligations under Vela’s Acquisition Bonus Plan established to compensate members of its management in the event of a successful sale of Vela, accrued interest and a portion of the principal amount of Vela’s outstanding bridge notes and all principal and accrued interest on Vela’s outstanding senior notes. Vela’s shareholders will also receive up to an additional 8,000,000 shares of Pharmos common stock upon the achievement of performance-based milestones related to Vela’s Phase II product candidate, dextofisopam, which is in development to treat irritable bowel syndrome. The number of shares to be issued in connection with the Merger based upon the achievement of the milestones will be adjusted in the future to account for any stock splits, stock dividends or other similar recapitalizations. One of the remaining steps to complete the Merger is securing the approval by our shareholders of the issuance of the shares of our common stock in connection with the Merger. Such approval is required under applicable rules of the Nasdaq Capital Market. These rules require shareholder approval prior to the issuance of shares of common stock in connection with the acquisition of another company if the number of shares of common stock to be issued equals or exceeds 20% of the number of outstanding shares of common stock before the issuance. No further approval is required from any regulatory body. |
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” APPROVAL OF THE ISSUANCE OF THE SHARES OF PHARMOS COMMON STOCK IN CONNECTION WITH THE PROPOSED ACQUISITION OF VELA. THE PARTIES TO THE MERGER Pharmos is a specialty pharmaceutical company that is in the business of discovering and developing novel therapeutics to treat a range of indications including pain, inflammation, autoimmunity and select central
nervous system (CNS) disorders. Pharmos has a portfolio of drug candidates and compounds in various development stages, including clinical, preclinical and discovery. The lead candidate from the pipeline of its CB2-selective cannabinoid platform technology, cannabinor, is scheduled to begin Phase II clinical testing for neuropathic pain and post-surgical pain. A Phase IIa clinical trial in patients undergoing third-molar extractions is scheduled for the second quarter of 2006, and a Phase IIa clinical trial to treat a model of neuropathic pain is planned to begin during the third quarter of 2006. In addition, CB2 agonists in the Company’s pipeline are in preclinical development for several indications addressing unmet clinical needs. Also, Pharmos has completed a Phase I clinical trial and is moving into a Phase II clinical trial of the topical NSAID, diclofenac, for the treatment of osteoarthritis using its NanoEmulsion drug delivery platform for topical delivery, as Pharmos continues to advance this novel, proprietary technology. Pharmos’ executive offices are located at 99 Wood Avenue South, Suite 311, Iselin, New Jersey 08830. Our telephone number is 732-452-9556.
Vela Acquisition Corporation is our newly formed,newly-formed, wholly-owned subsidiary. We formed it for the sole purpose of the Merger. It has not conducted any operating business activities since its formation other than those incidental to its incorporation and as contemplated in connection with the Merger. Its address and telephone number is the same as ours.
Vela is a privately-held Delaware corporation specializing in the rediscovery and development of medicines related to the nervous system, including the brain-gut axis (links between the nervous system and the digestive system). Vela seeks to minimize some of the risks of traditional drug discovery and development by working primarily with drug assets for which human safety data are already available and by employing a clinical development team with extensive clinical trial experience. Since its inception, Vela has raised approximately $58 million in equity and debt financing from leading venture capital investors, including affiliates of JPMorgan Partners, New Enterprise Associates and Venrock Associates.Associates. More than half of Vela’s research and development spending since inception has been for the development of dextofisopam for the treatment of irritable bowel syndrome (“IBS”). Vela has established a composition-of-matter patent position on dextofisopam to at least 2019, has conducted three Phase I clinical trials showing positive indications for tolerability in healthy volunteers, and has conducted one Phase II trial showing positive indications for potential efficacy and tolerability in women and men with diarrhea-predominant or alternating-type IBS. Vela has planned a Phase IIb dose-ranging trial for dextofisopam in IBS patients.patients. Vela’s other clinical-stage assets include VPI-013 (previously known as OPC-14523) for the treatment of neuropathic pain and female hypoactive sexual desire disorder and tianeptine for the treatment of IBS and related functional gastrointestinal disorders. Vela currently has seven employees and leases approximately 10,500 square feet of office space at 820 Bear Tavern Road in Ewing, New Jersey 08628. Its telephone number is (609) 771-8660. THE MERGER The Merger will be accomplished pursuant to the Agreement and Plan of Merger dated March 14, 2006 between Pharmos, its newly-formed, wholly-owned subsidiary, Vela Acquisition Corporation, and Vela (the “Merger Agreement”). A copy of the Merger Agreement is attached asAppendix A. The key provisions of the Merger are as follows: | | • | Pharmos will acquire Vela by means of a “forward merger”, whereby Vela will merge into Vela Acquisition Corporation, a newly-created acquisition subsidiary of Pharmos that will be the surviving corporation in the Merger. | | | | | • | All of Vela’s outstanding capital stock will be cancelled. | | | | | • | At the closing of the Merger, Pharmos will issue 11,500,000 shares of its common stock to those of Vela’s shareholders entitled under Vela’s certificate of incorporation to receive shares. 1,725,000 of these shares will be placed in escrow. | | | | | • | Pharmos will also pay $5,000,000 in cash to, or on behalf of, Vela at closing which will be used to pay certain of Vela’s outstanding liabilities, including Vela’s transaction costs, obligations under Vela’s Acquisition Bonus Plan established to compensate members of its management in the event of a successful sale of Vela (the “Acquisition Bonus Plan”), accrued interest and a portion of the outstanding principal on Vela’s outstanding bridge notes, and all principal and accrued interest on Vela’s outstanding senior notes.
| • | All of Vela’s outstanding capital stock will be cancelled. | | | | | • | At the closing of the Merger, Pharmos will issue 11,500,000 shares of its common stock to those of Vela’s shareholders entitled under Vela’s certificate of incorporation to receive shares. 1,725,000 of these shares will be placed in escrow. | | | | | • | Pharmos will also pay $5,000,000 in cash to, or on behalf of, Vela at closing which will be used to pay certain of Vela’s outstanding liabilities, including Vela’s transaction costs, obligations under Vela’s Acquisition Bonus Plan established to compensate members of its management in the event of a successful sale of Vela (the “Acquisition Bonus Plan”), accrued interest and a portion of the outstanding principal on Vela’s outstanding bridge notes, and all principal and accrued interest on Vela’s outstanding senior notes. | | | | | • | At closing, all of Vela’s outstanding bridge notes will either be paid off or will be converted into equity of Vela, and all of Vela’s outstanding senior notes will be paid off. | | | | | • | Pharmos will assume up to $100,000 of Vela’s qualified post-closing liabilities. | | | |
| • | Vela’s shareholders and participants in its Acquisition Bonus Plan may also receive: (i) an additional 4,000,000 shares of Pharmos’ common stock upon successful completion of a Phase IIb clinical trial related to the development of dextofisopam within four years of closing; and (ii) an additional 4,000,000 shares of Pharmos’ common stock upon the filing of a New Drug Application with the U.S. Food and Drug Administration for dextofisopam within eight years of closing. | | | | | • | After completion of the Merger, Pharmos will have complete flexibility to determine the appropriate preclinical and clinical development of Vela compounds. In the Merger Agreement, Pharmos acknowledges that it currently intends to continue Vela’s programs for no less than two years following the closing, subject to ongoing and periodic review and analysis by management and the Board of Directors, and also subject to future budgetary needs of the combined business as well as the availability of outside financing. | | | | | • | Upon closing, all Vela operations will be transferred to Pharmos. Vela currently has seven employees. Pharmos anticipates hiring Dr. Steven Leventer, Vela’s Senior Vice President, Research and Development, to lead clinical development of the Vela technologies, reporting to Pharmos’ President & COO. Pharmos also anticipates hiring several members of Dr. Leventer’s clinical development team. No additional hiring of Vela employees is anticipated. | | | | | • | Pharmos has entered into a voting agreement with the holders of a majority of Vela’s outstanding capital stock (determined on an as-converted to common stock basis) to ensure their approval of the transactions contemplated by the Merger Agreement, subject to the satisfaction of certain closing conditions set forth in the Merger Agreement. | | | | | • | Upon closing, [____________], a member of the Pharmos Board of Directors, will resign from the Board of Directors. At the closing, Pharmos will also increase the size of its classified Board of Directors from seven to nine, thereby creating three vacancies (one for each class of the Board of Directors). The vacancies will be filled with three new directors, as designated by Vela’s three largest shareholders. Initially, the three new directors will be Srinivas Akkaraju, designee of JPMorgan Partners, Anthony Evnin, designee of Venrock Associates, and Charles W. Newhall, III, designee of New Enterprise Associates. | | | | | •
| | | | • | At closing, all of Vela’s outstanding bridge notes will either be paid off or will be converted into equity of Vela, and all of Vela’s outstanding senior notes will be paid off. | | | | | • | Pharmos will assume up to $100,000 of Vela’s qualified post-closing liabilities. | | | | | • | Vela’s shareholders and participants in its Acquisition Bonus Plan may also receive: (i) an additional 4,000,000 shares of Pharmos’ common stock upon successful completion of a Phase IIb clinical trial related to the development of dextofisopam within four years of closing; and (ii) an additional 4,000,000 shares of Pharmos’ common stock upon the filing of a New Drug Application with the U.S. Food and Drug Administration for dextofisopam within eight years of closing. | | | | | • | After completion of the Merger, Pharmos will have complete flexibility to determine the appropriate preclinical and clinical development of Vela compounds. In the Merger Agreement, Pharmos acknowledges that it currently intends to continue Vela’s programs for no less than two years following the closing, subject to ongoing and periodic review and analysis by management and the Board of Directors, and also subject to future budgetary needs of the combined business as well as the availability of outside financing. | | | | | • | Upon closing, all Vela operations will be transferred to Pharmos. Vela currently has seven employees. Pharmos anticipates hiring Dr. Steven Leventer, Vela’s Senior Vice President, Research and Development, to lead clinical development of the Vela technologies, reporting to Pharmos’ President & COO. Pharmos also anticipates hiring several members of Dr. Leventer’s clinical development team. No additional hiring of Vela employees is anticipated. | | | | | • | Pharmos has entered into a voting agreement with the holders of a majority of Vela’s outstanding capital stock (determined on an as-converted to common stock basis) to ensure their approval of the transactions contemplated by the Merger Agreement, subject to the satisfaction of certain closing conditions set forth in the Merger Agreement. | | | | | • | Upon closing, [____________], a member of the Pharmos Board of Directors, will resign from the Board of Directors. At the closing, Pharmos will also increase the size of its classified Board of Directors from seven to nine, thereby creating three vacancies (one for each class of the Board of Directors). The vacancies will be filled with three new directors, as designated by Vela’s three largest shareholders. Initially, the three new directors will be Srinivas Akkaraju, designee of JPMorgan Partners, Anthony Evnin, designee of Venrock Associates, and Charles W. Newhall, III, designee of New Enterprise Associates. | | | | | • | Pursuant to a Registration Rights Agreement to be executed at the closing, Pharmos will file a Registration Statement on Form S-3 within seven days after closing to register for resale the shares issued to the former Vela shareholders. Following registration, the Vela shareholders receiving the shares of common stock will be subject to a “lock-up” providing that, without the consent of Pharmos, (i) no shares may be sold until six months after the closing, (ii) for each six-month period after that date, up to 33% of the shares originally issued to any shareholder may be sold, and (iii) after 18 months from the closing, all shares may be sold. Any milestone shares that may be issued during the lock-up period shall also be subject to such restrictions, and any milestone shares issued after the lock-up period will not be subject to such restrictions. | | | | | • | At closing, Vela’s principal shareholders will enter into standstill agreements providing that for two years they will not acquire any Pharmos capital stock, other than as agreed to by the Pharmos Board of Directors or in a private placement or other transaction in an amount to maintain their percentage interest. Each standstill agreement also provides that it is the current intention of the shareholder not to initiate or support a proxy fight or hostile takeover of Pharmos. | | | | | • | The Vela shareholders that receive the Pharmos shares of common stock upon the closing of the Merger will indemnify Pharmos for material breaches of representations, warranties and covenants for a period of 18 months. The sole source of the indemnity (absent fraud) will be an escrow holdback of 1,725,000 of the 11,500,000 shares of common stock issued at closing, to be reduced to 1,150,000 shares six months after the closing, 575,000 shares 12 months after the |
| | closing and to zero 18 months after the closing. The shares of common stock will be held in escrow pursuant to an escrow agreement. The indemnity will have a deductible of $250,000. | | | | | • | Pharmos will indemnify the Vela shareholders for material breaches of representations, warranties and covenants for a period of 18 months. The indemnity will not exceed a total of the market value at closing of 15% of 11,500,000 shares of common stock, to be reduced by one-third six months after the closing, by another one-third 12 months after the closing and to zero 18 months after closing. The indemnity will have a deductible of $250,000 and can be paid in cash or shares of common stock at Pharmos’ discretion, except for certain situations involving the indemnification of Vela’s directors and officers where satisfaction must be in cash. | | | | | • | Either party may terminate the Merger Agreement upon notice to the other (i) if the other party is in material breach of its obligations under the Merger Agreement and such breach shall not have been cured within a period of ten (10) days after written notice, or (ii) if the conditions necessary to close shall not have been satisfied or waived by the other party on or prior to August 31, 2006, or (iii) if there has been a material adverse change in the representations and warranties made by either party, or (iv) upon any material adverse change in the business or operations of the other party. If either party terminates the Merger Agreement other than in compliance with the foregoing provisions, it shall become liable to the other party for a payment of $1,500,000. In addition, a party shall be liable for such payment if it is in material breach of the Merger Agreement and the other party terminates the Merger Agreement as a result.
| date, up to 33% of the shares originally issued to any shareholder may be sold, and (iii) after 18 months from the closing, all shares may be sold. Any milestone shares that may be issued during the lock-up period shall also be subject to such restrictions, and any milestone shares issued after the lock-up period will not be subject to such restrictions. | | |
| • | At closing, Vela’s principal shareholders will enter into standstill agreements providing that for two years they will not acquire any Pharmos capital stock, other than as agreed to by the Pharmos Board of Directors or in a private placement or other transaction in an amount to maintain their percentage interest. Each standstill agreement also provides that it is the current intention of the shareholder not to initiate or support a proxy fight or hostile takeover of Pharmos. | | | | | • | The Vela shareholders that receive the Pharmos shares of common stock upon the closing of the Merger will indemnify Pharmos for material breaches of representations, warranties and covenants for a period of 18 months. The sole source of the indemnity (absent fraud) will be an escrow holdback of 1,725,000 of the 11,500,000 shares of common stock issued at closing, to be reduced to 1,150,000 shares six months after the closing, 575,000 shares 12 months after the closing and to zero 18 months after the closing. The shares of common stock will be held in escrow pursuant to an escrow agreement. The indemnity will have a deductible of $250,000. | | | | | • | Pharmos will indemnify the Vela shareholders for material breaches of representations, warranties and covenants for a period of 18 months. The indemnity will not exceed a total of the market value at closing of 15% of 11,500,000 shares of common stock, to be reduced by one-third six months after the closing, by another one-third 12 months after the closing and to zero 18 months after closing. The indemnity will have a deductible of $250,000 and can be paid in cash or shares of common stock at Pharmos’ discretion, except for certain situations involving the indemnification of Vela’s directors and officers where satisfaction must be in cash. | | | | | • | Either party may terminate the Merger Agreement upon notice to the other (i) if the other party is in material breach of its obligations under the Merger Agreement and such breach shall not have been cured within a period of ten (10) days after written notice, or (ii) if the conditions necessary to close shall not have been satisfied or waived by the other party on or prior to August 31, 2006, or (iii) if there has been a material adverse change in the representations and warranties made by either party, or (iv) upon any material adverse change in the business or operations of the other party. If either party terminates the Merger Agreement other than in compliance with the foregoing provisions, it shall become liable to the other party for a payment of $1,500,000. In addition, a party shall be liable for such payment if it is in material breach of the Merger Agreement and the other party terminates the Merger Agreement as a result. |
BACKGROUND AND REASONS FOR THE MERGER Overview Our Board of Directors is unanimously recommending the Merger because it believes that Vela’s drug assets will broaden the Company’s overall drug pipeline, diversify clinical risk by the addition of multiple drug candidates, provide potentially valuable synergies in the area of central nervous system therapeutics, advance the Company several years forward in clinical development of drug candidates targeted to large, underserved markets, and offer significant commercial potential. The Merger also brings to Pharmos three new, highly qualified and prominent directors for our Board of Directors, expands our shareholder base to include three leading life science venture capital firms and obtains for Pharmos a seasoned development and clinical team with particular expertise in irritable bowel syndrome drug development. The proposed acquisition of Vela is the culmination of our efforts to strengthen and expand our pipeline of potential drug candidates through the acquisition of complementary later-stage drug candidate assets. Pursuant to our strategy, since 2004, our Board of Directors has engaged in a sustained and disciplined search for drug candidate assets which will complement our existing portfolio of drug candidate assets. Prior to entering into the Merger Agreement, our Board of Directors reviewed a number of possibilities, including the acquisition of other drug candidate assets in various stages of clinical development, the acquisition of drug development companies with complementary drug assets and strategic partnerships and technology licenses with companies with complementary technology and drug candidate assets. This process involved an analysis of approximately 120 drug candidates and drug development companies over a one-year period. Our Board of Directors also considered the option of focusing our operations on the continued investigation and development of our existing drug asset portfolio while continuing to explore available opportunities. Before deciding to move forward with the Vela acquisition, our Board of Directors and management obtained and reviewed extensive scientific due diligence on Vela’s drug development programs and assets and analyzed the projected costs and the business and clinical risks associated with undertaking clinical development of the drug candidate assets to be acquired. Our Board of Directors analyzed these costs and risks in light of their judgment regarding the potential benefits to the Company of the drug candidates being pursued by Vela. The Board of Directors also considered the opinion of our financial advisors, RBC Capital Markets Corporation and Tamir Fishman & Co. Ltd., that the consideration to be paid by the Company in the Merger is fair, from a financial point of view, to the Company.
How Did the Merger Come About?
In July 2004, RBC Capital Markets Corporation (“RBC”), an investment banking firm, and Tamir Fishman & Co. LTD. (“TF”), RBC’s strategic partner in Israel, which engages in certain investment banking services, made an initial presentation to Pharmos’ management regarding the mergers and acquisitions environment in the pharmaceutical industry and the strategic strengths and weakness of various potential acquisition candidates. Vela was included in the list of candidates.
In August 2004, Pharmos signed an engagement letter with RBC and TF for those firms to assist Pharmos’ Board of Directors in its pursuit of strategic opportunities. Following execution of the engagement letter, RBC and TF presented certain opportunities to Pharmos. Over the subsequent months, Pharmos reviewed in depth many target companies and products and entered into discussions and diligence with several potential acquisition and merger candidates. In several instances, the portfolios of the acquisition candidates represented only early stage technologies or, upon due diligence, key products of the acuisitionacquisition candidates did not meet Pharmos’ criteria relating to risk or relative product development position. When Pharmos elected not to pursue these opportunities, the parties terminated the August 2004 engagement letter in July 2005.
|
In October 2005 Cowen & Co., LLC (“Cowen”), the investment banking firm representing Vela, contacted Pharmos to inquire whether Pharmos would be interested in considering a partnership or other strategic relationship with Vela. Pharmos expressed preliminary interest, and on October 26, 2005, Cowen sent RBC a non-confidential executive summary of Vela. On October 28, 2005, Pharmos and Vela executed a confidentiality agreement that permitted them to exchange information in confidence as part of conducting due diligence. On November 4, 2005, Gad Riesenfeld, the former president of Pharmos, met with members of Vela’s senior management. At the meeting, the parties engaged in a preliminary discussion concerning the potential benefits of an acquisition of Vela by Pharmos. The parties also discussed financial, operational and managerial issues. On November 9, 2005, senior management of Pharmos met with RBC to discuss the Vela opportunity. Following the meeting, Pharmos and RBC/TF began preparing a draft outline of terms for a potential transaction with Vela. On November 28, 2005, Pharmos submitted a non-binding term sheet to Vela outlining the proposed terms of an acquisition of Vela by Pharmos. On December 2, 2005, Pharmos’ senior management met with Vela’s board of directors and senior management to propose the range of terms for a potential merger between the two companies. On December 5, 2005, Pharmos entered into a new engagement letter with RBC and TF for those firms to provide financial advisory services to Pharmos in connection with a proposed merger with Vela. While discussions and negotiations of a potential merger continued, Pharmos conducted scientific due diligence on Vela during December 2005 and January 2006. On December 20, 2005, Cowen, on behalf of Vela, sent a counterproposal to Pharmos’ term sheet. �� On January 15, 2006, Pharmos’ management forwarded to the Pharmos Board of Directors materials setting forth the rationale behind the proposed merger with Vela. Also on that date, Pharmos’ management delivered a memorandum to the Pharmos Board of Directors setting forth the results of the scientific and regulatory due diligence concerning Vela and a comprehensive report on the market for irritable bowel syndrome therapeutics. Management recommended that the Vela acquisition opportunity be evaluated further by the Board of Directors’ Clinical Development and Scientific Committee, as well as by the Board of Directors at upcoming meetings. On January 18, 2006, the Clinical Development and Scientific Committee of the Pharmos Board of Directors met to discuss the results of the scientific and regulatory due diligence concerning Vela. On January 18, 2006, Vela’s Board of Directors approved the continuation of negotiations with Pharmos on the basis of the provisions outlined in a term sheet, subject to certain adjustments. On January 19, 2006, Pharmos and Vela executed the term sheet, which was conditioned on approval by Pharmos’ Board of Directors at its upcoming meeting. On January 24 and 25, 2006, Pharmos’ Board of Directors convened a regularly-scheduled meeting, at which the proposed Vela acquisition was one of several agenda items. At the meeting, the Board of Directors gave extensive consideration to the Vela opportunity. The Board of Directors reviewed the principal terms of the Vela transaction and authorized Pharmos’ management to continue due diligence and negotiations with Vela. On January 30, 2006, Pharmos’ counsel delivered a preliminary draft of the Merger Agreement to Vela’s counsel. During February and March 2006, the parties negotiated the terms of the definitive Merger Agreement and continued to conduct due diligence.
On March 14, 2006, Pharmos’ Board of Directors convened a special meeting to consider the final terms of the merger with Vela. At the meeting, the Board of Directors unanimously approved the Merger and the Merger Agreement and authorized Haim Aviv and Alan Rubino to execute the Merger Agreement. Reasons For The Merger – Pharmos The Pharmos Board of Directors views the Merger as a potentially transformative event for Pharmos. We believe completing the Merger would fulfill several strategic objectives previously set by the Board of Directors for Pharmos: |
7
| • | Advance Pharmos several years forward in clinical development by acquiring a high-potential drug candidate, dextofisopam, prepared to enter Phase IIb clinical trials for the treatment of irritable bowel syndrome (“IBS”). | | | |
| | Pharmos believes the IBS market opportunity to be large and poorly served by current therapy. Overall, it is estimated that IBS accounts for approximately 12% of all visits to primary care physicians in the U.S. and is the second most common disease treated by gastroenterologists. In addition, it is estimated that IBS-associated health care costs are in the range of $20-$25 billion annually. Vela’s lead candidate for the treatment of IBS, dextofisopam, has demonstrated positive Phase IIa indications for the potential treatment of diarrhea-predominant and alternating-type IBS. Pharmos believes, given its strong balance sheet and managerial expertise, that it can quickly move dextofisopam into a larger, confirmatory Phase IIb clinical trial upon consummation of the Merger. Pharmos believes that a positive Phase IIb trial result has the potential to create significant value for Pharmos’ shareholders.
| | |
| • | Broaden Pharmos’ overall drug candidate pipeline and diversify clinical trial risk by acquiring multiple drug candidates, including tianeptine and VPI-013. | | | |
| In addition to dextofisopam, Vela has another potential drug candidate for the treatment of IBS, tianeptine. Vela’s third drug candidate is VPI-013 for the treatment of neuropathic pain and female hypoactive sexual desire disorder. While we anticipate that dextofisopam will become our lead drug candidate, we are also optimistic about the potential prospects for tianeptine and VPI-013 which will further expand and diversify our pipeline of drug candidates. Completing the Merger will provide Pharmos with an expanded drug portfolio that includes later-stage, early-stage, and preclinical drug candidates that complements Pharmos’ long-term experience with the central nervous system.
| | |
| • | Strengthen Pharmos’ Board of Directors and expand Pharmos shareholder base with three well-known, industry-leading life science venture capital firms and their representatives. | | | |
| If the Merger is completed, designees of JP Morgan Partners, Venrock Associates, and New Enterprise Associates, Inc., currently the principal shareholders of Vela, will be appointed to our Board of Directors. JP Morgan Partners, Venrock Associates and New Enterprise Associates, are well-known, industry leading life science venture capital firms. After the Merger, and prior to the issuance of any shares of our common stock upon achievement of the milestones, affiliates of JP Morgan Partners, Venrock Associates and New Enterprise Associates are expected to own or control approximately 16.2%, 7.5% and 11.0%, respectively, of our outstanding shares of common stock. These venture capital firms have significant experience in building life sciences and drug discovery companies. Their acceptance of a substantial portion of the purchase price for Vela in shares of our common stock, rather than in cash, demonstrates their commitment to and confidence in the future of Pharmos.
| | |
| • | Expand Pharmos’ management expertise by adding Vela’s clinical development team. | | | |
| Upon closing of the Merger, Pharmos anticipates employing Dr. Steven Leventer, Vela’s Senior Vice President, Research and Development, to lead clinical development of the Vela technologies and several members of his staff reporting to Alan Rubino, Pharmo’s President and COO. We expect these potential new employee to strengthen our management and scientific team following the Merger. |
| | • | Advance Pharmos several years forward in clinical development by acquiring a high-potential drug candidate, dextofisopam, prepared to enter Phase IIb clinical trials for the treatment of irritable bowel syndrome (“IBS”). | | | | | | Pharmos believes the IBS market opportunity to be large and poorly served by current therapy. Overall, it is estimated that IBS accounts for approximately 12% of all visits to primary care physicians in the U.S. and is the second most common disease treated by gastroenterologists. In addition, it is estimated that IBS-associated health care costs are in the range of $20-$25 billion annually. Vela’s lead candidate for the treatment of IBS, dextofisopam, has demonstrated positive Phase IIa indications for the potential treatment of diarrhea-predominant and alternating-type IBS. Pharmos believes, given its strong balance sheet and managerial expertise, that it can quickly move dextofisopam into a larger, confirmatory Phase IIb clinical trial upon consummation of the Merger. Pharmos believes that a positive Phase IIb trial result has the potential to create significant value for Pharmos’ shareholders. | | | | | • | Broaden Pharmos’ overall drug candidate pipeline and diversify clinical trial risk by acquiring multiple drug candidates, including tianeptine and VPI-013. | | | | | | In addition to dextofisopam, Vela has another potential drug candidate for the treatment of IBS, tianeptine. Vela’s third drug candidate is VPI-013 for the treatment of neuropathic pain and female hypoactive sexual desire disorder. While we anticipate that dextofisopam will become our lead drug candidate, we are also optimistic about the potential prospects for tianeptine and VPI-013 which will further expand and diversify our pipeline of drug candidates. Completing the Merger will provide Pharmos with an expanded drug portfolio that includes later-stage, early-stage, and preclinical drug candidates that complements Pharmos’ long-term experience with the central nervous system. | | | | | • | Strengthen Pharmos’ Board of Directors and expand Pharmos shareholder base with three well-known, industry-leading life science venture capital firms and their representatives. | | | | | | If the Merger is completed, designees of JPMorgan Partners, Venrock Associates, and New Enterprise Associates, Inc., currently the principal shareholders of Vela, will be appointed to our Board of Directors. JPMorgan Partners, Venrock Associates and New Enterprise Associates, are well-known, industry leading life science venture capital firms. After the Merger, and prior to the issuance of any shares of our common stock upon achievement of the milestones, affiliates of JPMorgan Partners, Venrock Associates and New Enterprise Associates are expected to own or control approximately 16.2%, 7.5% and 11.0%, respectively, of our outstanding shares of common stock. These venture capital firms have significant experience in building life sciences and drug discovery companies. Their acceptance of a substantial portion of the purchase price for Vela in shares of our common stock, rather than in cash, demonstrates their commitment to and confidence in the future of Pharmos. | | | | | • | Expand Pharmos’ management expertise by adding Vela’s clinical development team. | | | | | | | | • | Upon closing of the Merger, Pharmos anticipates employing Dr. Steven Leventer, Vela’s Senior Vice President, Research and Development, to lead clinical development of the Vela technologies and several members of his staff reporting to Alan Rubino, Pharmos’ President and COO. We expect these potential new employees to strengthen our management and scientific team following the Merger. | | | |
In reaching their decision to acquire Vela, our Board of Directors consulted with Pharmos’ management as well as its financial, accounting and legal advisors, and considered a number of factors including the following: | |
| • | The effectiveness of the Merger in implementing and accelerating Pharmos’ growth strategy; | | | | | • | A presentation by management of (i) its due diligence review of Vela, including the business, operations, asset quality, financial condition, and corporate culture of Vela on an historical, prospective, and pro forma basis, (ii) product compatibility, the compatibility of corporate goals and the respective contributions the parties would bring to Pharmos, (iii) the enhanced opportunities for |
8
| growth that the Merger makes possible as a result of a wider and more diversified clinical pipeline and the potential for greater market breadth and (iv) the expanded opportunities for revenue enhancement and synergies that are expected to result from the Merger and the acquisition of a later-stage drug candidate; | | |
| • | The terms of the Merger Agreement and other documents to be executed in connection with the Merger; | | | | | • | The opinion of RBC and TF, discussed elsewhere in this proxy statement, that as of March 14, 2006, the Merger was fair, from a financial point of view, to Pharmos; and | | | | | • | The opportunity to strengthen and deepen Pharmos’ Board of Directors and management team. |
| | • | The effectiveness of the Merger in implementing and accelerating Pharmos’ growth strategy; |
| | | | • | A presentation by management of (i) its due diligence review of Vela, including the business, operations, asset quality, financial condition, and corporate culture of Vela on an historical, prospective, and pro forma basis, (ii) product compatibility, the compatibility of corporate goals and the respective contributions the parties would bring to Pharmos, (iii) the enhanced opportunities for growth that the Merger makes possible as a result of a wider and more diversified clinical pipeline and the potential for greater market breadth and (iv) the expanded opportunities for revenue enhancement and synergies that are expected to result from the Merger and the acquisition of a later-stage drug candidate; | | | | | • | The terms of the Merger Agreement and other documents to be executed in connection with the Merger; | | | | | • | The opinion of RBC and TF, discussed elsewhere in this proxy statement, that as of March 14, 2006, the Merger was fair, from a financial point of view, to Pharmos; and | | | | | • | The opportunity to strengthen and deepen Pharmos’ Board of Directors and management team. |
The Pharmos board of directors did not assign any specific or relative weight to the foregoing factors in the course of its consideration. |
Reasons For The Merger – Vela The Board of Directors of Vela and its principal shareholders believe that the Merger of Vela into Pharmos will bring together complementary asset portfolios and team skills and will provide several benefits to the combined entity and its shareholders, including the following: | | | | | • | Broaden portfolio of product candidates by combining Vela’s later-stage assets, including dextofisopam, with Pharmos’ cannabinoid platform and assets; | | | | | • | Vela’s experience in clinical drug development and clinical trial design and implementation will complement Pharmos’ drug discovery and early-stage development capabilities; | | | | | • | Vela’s shareholders will have the opportunity to own stock in a company with greater financial and management resources than Vela would otherwise have on its own; and | | | | | • | Pharmos’ status as a publicly-traded company may provide Vela’s shareholders with greater potential liquidity on their investment. |
| | | | • | Broaden portfolio of product candidates by combining Vela’s later-stage assets, including dextofisopam, with Pharmos’ cannabinoid platform and assets; | | | | | • | Vela’s experience in clinical drug development and clinical trial design and implementation will complement Pharmos’ drug discovery and early-stage development capabilities; | | | | | • | Vela’s shareholders will have the opportunity to own stock in a company with greater financial and management resources than Vela would otherwise have on its own; and | | | | | • | Pharmos’ status as a publicly-traded company may provide Vela’s shareholders with greater potential liquidity on their investment. |
| SHAREHOLDER OPPOSITION TO THE MERGER
We understand that Lloyd I. Miller, III, a shareholder who beneficially owns approximately 8.8%9.4% of the Company’s outstanding shares of common stock, along with two other shareholders, Dr. Raymond E. McKee and Dr. Gerard Soula, oppose the Merger and may urge you to vote against the proposal to issue shares of our common stock in the Merger. We don’t believe that these shareholders have any meaningful plan for enhancing or preserving shareholder value. Although they are under no obligation to present such a plan, we believe it is important for our shareholders to recognize that in contrast to the Company’s long term strategy to expand our pipeline of later stage drug candidates, Mr. Miller has articulated no plan for enhancing shareholder value if he is successful in defeating the proposal to issue shares of our common stock in the Merger. They may try to alarm you by focusing on dilution and so-called “cash drain” which they argue will occur as a result of the Merger. These arguments ignore the potential benefits to the Company and our shareholders from the Merger. We believe that you will find Mr. Miller’s position is a purely negative one and that his motives and objectives (beyond blocking the Merger) are focused on his own, personal investment strategy and not on the best interests of the Company and our shareholders as a whole. We encourage you to consider the important potential benefits to the Company considered by our Board of Directors in concluding that the Merger is in the best interests of the Company and its shareholders.
On June 20, 2006, we filed a lawsuit against one of the members of Mr. Miller’s group, Dr. Raymond E. McKee, a former officer of the Company, in the United States District Court for the District of Connecticut. The lawsuit alleges that Dr. McKee wrongfully disclosed confidential information about the Company to Mr. Miller, in breach of his fiduciary duty while an officer of the Company and asserts other related claims concerning Dr. McKee’s conduct while an officer of the Company and thereafter. The complaint seeks damages and injunctive relief.
Our management and Board of Directors are focused on building shareholder value. We encourage communication with our shareholders and carefully consider their suggestions. However, our management and Board of Directors develop and implement their strategy for the Company based on their judgment as to the best interests of the Company and our shareholders as a whole, not the personal investment strategy of one individual shareholder. We believe that the acquisition of Vela is consistent with our strategy, offers great potential and is in the best interests of the Company and our shareholders as a whole. |
FAIRNESS OPINION Pursuant to an engagement letter dated December 5, 2005, RBC and TF were retained by Pharmos to furnish an opinion as to the fairness, from a financial point of view, of the total consideration to be paid pursuant to the terms of the Merger Agreement. RBC and TF are jointly referred to in this proxy statement as RBC/TF. On March 14, 2006, RBC/TF rendered their opinion to Pharmos’ Board of Directors, that, as of such date and based on the procedures followed, factors considered and assumptions made by RBC/TF and certain other limitations, the total consideration to be paid was fair, from a financial point of view, to Pharmos. A copy of RBC/TF’s written opinion is attached as Appendix B to this proxy statement and is incorporated into this proxy statement by reference. Pharmos shareholders are urged to read the opinion of RBC/TF carefully and in its entirety. RBC/TF’s opinion was provided for the information and assistance of Pharmos’ Board of Directors in connection with the consideration to be paid by Pharmos in connection with the Merger. RBC/TF’s opinion does not constitute a recommendation to any shareholder as to how such shareholder should vote with respect to the issuance of shares of Pharmos common stock in the Merger. RBC/TF’s opinion related solely to the total consideration to be paid. RBC/TF did not review, nor did its opinion in any way address, other Merger terms or arrangements, including, without limitation, the financial or other terms of any employment or non-competition agreement with any Vela employees or any break-up or termination fee. Further, RBC/TF’s opinion did not address, nor should it be construed to address, the relative merits of the underlying decision by Pharmos to engage in the Merger compared to any alternative business strategies or transaction in which Pharmos might engage. RBC/TF was not engaged as an agent or fiduciary of Pharmos’ shareholders or any other third party. In rendering its opinion, RBC/TF assumed and relied upon the accuracy and completeness of the financial, legal, tax, operating and other information provided by Pharmos and Vela (including, without limitation, the financial statements and related notes thereto of Pharmos and Vela, as well as other publicly available information with respect to Pharmos and Vela). RBC/TF did not assume responsibility for independently verifying and did not independently verify this information. With respect to the data and discussions relating to the business prospects and financial outlook of Pharmos and Vela, upon advice of Pharmos, RBC/TF assumed that such data was reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of Pharmos and Vela as to the future financial performance of Pharmos and Vela, respectively, and that Pharmos and Vela will perform substantially in accordance with such financial data and estimates. RBC/TF expressed no opinion as to such financial data and estimates or the assumptions on which they were based. RBC/TF did not assume responsibility for, and did not perform, any independent evaluation or appraisal of any of the respective assets or liabilities of Pharmos or Vela, nor was RBC/TF furnished with any evaluations or appraisals. RBC/TF expressed no opinion regarding the liquidation value of any entity. RBC/TF did not assume any obligation to conduct, and did not conduct, any physical inspection of the property or facilities of Pharmos or Vela. Additionally, RBC/TF was not asked to and did not consider the possible effects of any litigation or other contingent matters. RBC/TF’s opinion speaks only as of the date of such opinion, and is based on market conditions as they existed as of March 10, 2006 (the trading day upon which the analysis is based) and the information supplied to RBC/TF as of the date of its opinion, and is without regard to market, economic, financial, legal or other circumstances or events of any kind or nature which may exist or occur after such date. RBC/TF has not undertaken to reaffirm or revise its opinion or otherwise comment upon events occurring after the date of the opinion and RBC/TF does not have any obligation to update, revise or reaffirm its opinion. RBC/TF expressed no opinion as to the price at which shares of Pharmos common stock have traded or at which such shares may trade following the announcement or consummation of the merger. For purposes of its opinion, RBC/TF assumed that the Merger will qualify as a reorganization for U.S. federal income tax purposes. RBC/TF assumed that the executed merger agreement was in all material respects identical to the last draft reviewed by RBC/TF. RBC/TF also assumed that the merger will be consummated pursuant to the terms of the merger agreement, without amendments thereto and without waiver by any party of any material conditions or obligations thereunder. | |
In arriving at its opinion, RBC and/or TF: |
| |
| • | reviewed and analyzed the financial terms of a draft of the merger agreement dated as of March 10, 2006; | | | | | • | reviewed and analyzed certain available financial and other data with respect to Pharmos and Vela and certain other historical operating data relating to Pharmos and Vela made available to RBC/TF from published sources and from the internal records of Pharmos and Vela; | | | | | • | received and reviewed financial forecasts prepared by Evidec, a third party valuation consultant hired by Vela, that projected the potential future performance of dextofisopam, and Vela’s own forecast (the “Vela Forecast”), as well as adjustments made to the Vela Forecast by Pharmos management; | | | | | • | conducted discussions with members of the senior management of Vela with respect to the business prospects and financial outlook of Vela independently and as combined; | | | | | • | conducted discussions with Cowen with respect to the business prospects and financial outlook of Vela independently and as combined; | | | | | • | conducted discussions with members of the senior management of Pharmos with respect to the business prospects and financial outlook of Pharmos independently and as combined; | | | | | • | reviewed the historical reported prices and trading activity for Pharmos common stock; and | | | | | • | reviewed publicly available materials and analysts’ reports with respect to the business and financial outlook of Pharmos. |
| | • | reviewed and analyzed the financial terms of a draft of the merger agreement dated as of March 10, 2006; |
| | | | • | reviewed and analyzed certain available financial and other data with respect to Pharmos and Vela and certain other historical operating data relating to Pharmos and Vela made available to RBC/TF from published sources and from the internal records of Pharmos and Vela; | | | | | • | received and reviewed financial forecasts prepared by Evidec, a third party valuation consultant hired by Vela, that projected the potential future performance of dextofisopam, and Vela’s own forecast (the “Vela Forecast”), as well as adjustments made to the Vela Forecast by Pharmos management; | | | | | • | conducted discussions with members of the senior management of Vela with respect to the business prospects and financial outlook of Vela independently and as combined; | | | | | • | conducted discussions with Cowen with respect to the business prospects and financial outlook of Vela independently and as combined; | | | | | • | conducted discussions with members of the senior management of Pharmos with respect to the business prospects and financial outlook of Pharmos independently and as combined; | | | | | • | reviewed the historical reported prices and trading activity for Pharmos common stock; and | | | | | • | reviewed publicly available materials and analysts’ reports with respect to the business and financial outlook of Pharmos. |
The preparation of a fairness opinion is a complex process that involves the application of subjective business judgment in determining the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, is not necessarily susceptible to partial consideration of the analyses or summary description. RBC/TF believes that its analyses must be considered as a whole and that selecting portions of the analyses and of the factors considered, without considering all factors and analyses, could create an incomplete or misleading view of the processes underlying its opinion. In view of the wide variety of factors considered in connection with its evaluation of the fairness of the total consideration to be paid from a financial point of view, RBC/TF did not find it practicable to assign relative weights to the factors considered in reaching its opinion. No single company or transaction used in the above analyses as a comparison is identical to Pharmos or Vela or the proposed merger. The analyses were prepared solely for purposes of RBC/TF providing an opinion as to the fairness of the total consideration to be paid, from a financial point of view, to Pharmos and do not purport to be appraisals or necessarily reflect the prices at which businesses or securities actually may be sold, which are inherently subject to uncertainty. In connection with its analyses, RBC/TF made, and was provided by Pharmos’ management with, numerous assumptions with respect to industry performance, general business and economic conditions and other matters, many of which are beyond Pharmos’ or Vela’s control. Analyses based upon forecasts of future results are not necessarily indicative of actual future results, which may be significantly more or less favorable than suggested by these analyses. Because these analyses are inherently subject to uncertainty, and are based upon numerous factors or events beyond the control of Pharmos, Vela, or their advisors, none of Pharmos, Vela, RBC/TF, or any other person assumes responsibility if future results or actual values are materially different from these forecasts or assumptions. In delivering its opinion to the Pharmos Board of Directors, RBC/TF prepared and delivered to Pharmos’ Board of Directors written materials containing various analyses and other information material to the opinion. The following is a summary of these materials, including information presented in tabular format. To understand fully the summary of the financial analyses used by RBC/TF, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analysis. Transaction Overview |
Given the closing stock price of Pharmos common stock of $2.19 on March 10, 2006, the implied value of the initial consideration offered by Pharmos was determined to be $25.2 million in Pharmos common stock and $5.0 million in cash consideration for a total implied initial consideration of $30.2 million at that date. Taking into account shares of common stock, options and other dilutive securities on a fully diluted basis using the treasury stock method of accounting, new securities issued by Pharmos as part of the initial consideration would represent 37.7% of Pharmos’ outstanding stock on a pro forma combined basis. In addition, the merger consideration included two additional payments of 4 million shares of Pharmos common stock upon the satisfaction of two independent milestones. Given the closing stock price of Pharmos common stock of $2.19 on March 10, 2006, each milestone
payment had implied value of $8.8 million at that date for a total consideration of $47.7 million at that date, including the initial consideration and first and second milestone payments. Pharmos Stock Price History RBC/TF reviewed the historical prices of the common stock of Pharmos from March 10, 2005 to March 10, 2006. RBC/TF reviewed the volume of shares of Pharmos common stock traded as well as the volume weighted average prices of Pharmos shares of common stock during the 1-month, 3-month, 6-month and 12-month periods through and including March 10, 2006. In addition, RBC/TF reviewed Pharmos’ common stock price performance since December 20, 2004, when Pharmos announced that its Phase III trial for Dexanabinol did not demonstrate efficacy. Fairness Considerations and Analysis In arriving at its opinion, in addition to reviewing the matters previously mentioned, RBC and/or TF performed the following analyses: | |
| • | compared market valuations of selected comparable publicly-traded companies to Vela with the valuation implied by the merger consideration; | | | | | • | compared venture financing valuations of selected comparable private companies to Vela with the valuation implied by the merger consideration; | | | | | • | compared the implied valuation of Vela following its most recent venture financing round with the valuation implied by the merger consideration; | | | | | • | compared the initial consideration paid and the total valuation implied, to the extent publicly available, of selected comparable precedent transactions with the valuation implied by the merger consideration; and | | | | | • | prepared discounted cash flow analyses using the Vela Forecast, as adjusted by Pharmos management. |
| | | | • | compared market valuations of selected comparable publicly-traded companies to Vela with the valuation implied by the merger consideration; | | | | | • | compared venture financing valuations of selected comparable private companies to Vela with the valuation implied by the merger consideration; | | | | | • | compared the implied valuation of Vela following its most recent venture financing round with the valuation implied by the merger consideration; | | | | | • | compared the initial consideration paid and the total valuation implied, to the extent publicly available, of selected comparable precedent transactions with the valuation implied by the merger consideration; and | | | | | • | prepared discounted cash flow analyses using the Vela Forecast, as adjusted by Pharmos management. |
In addition, RBC and/or TF conducted such other analyses and examinations and considered such other financial, economic and market criteria as RBC/TF deemed necessary in arriving at its opinion. Because the structure of the merger calls for the payment of consideration upon the successful completion of milestone events, RBC/TF performed valuation analyses at three points in time to evaluate the fairness of this Merger to Pharmos. First, RBC/TF compared the current value of Vela to the value of the initial consideration to be paid by Pharmos as of the date of RBC/TF’s analysis. Second, RBC/TF compared the expected value of Vela as of the projected completion of the first milestone (discounted back to present value from the end of 2008) to the cumulative current value of the initial consideration and the first milestone consideration. Finally, RBC/TF compared the expected future value of Vela as of the projected completion of the second milestone (discounted back to present value from the midpoint of 2012) to the cumulative current value of the initial consideration, the first milestone consideration and the second milestone consideration. For purposes of this analysis, RBC/TF determined (i) a current enterprise value range for current Vela, (ii) an enterprise value range for Vela after successful completion of the first milestone, and (iii) an enterprise value range for Vela after successful completion of the second milestone. The methodologies for calculating these value ranges are explained in detail in the sections below. |
VALUATION OF VELA AT CURRENT STAGE OF DEVELOPMENT RBC/TF utilized several approaches to determine an enterprise value range for Vela at its current stage of development. These valuation approaches are classified as either income approaches, such as the discounted cash flow, or DCF method, or aggregate market value approaches, such as comparable public companies’ market trading, comparable venture capital funding transactions, and comparable mergers and acquisition transactions. Under the income approach, the selected enterprise value range is derived from a range of present values of projected future cash flows. Under the aggregate market approaches, the enterprise value associated with each comparable company or transaction is calculated and is the basis for deriving an enterprise value range for Vela, based on qualitative and quantitative criteria. To calculate the average enterprise value range for Vela at present, RBC/TF blended the average of each of these approaches equally, as shown in the table below.
Vela Valuation Summary – Current Company
($ in millions) | |
| | | Valuation Range | |
|---|
| |
| |
|---|
| | | Low | | | | High | |
|---|
| | |
| | | |
| |
|---|
Enterprise Value Summary | | | | | | | | Comparable Public Companies | | $ | 64.4 | | - | | $ | 120.7 | | Comparable Venture Capital Funding Transactions | | $ | 30.0 | | - | | $ | 76.0 | | Comparable Mergers and Acquisitions Transactions | | $ | 18.0 | | - | | $ | 86.3 | | Discounted Cash Flow | | $ | 34.1 | | - | | $ | 73.1 | | | |
|
| | | |
|
| | Average Enterprise Value | | $ | 36.6 | | - | | $ | 89.0 | |
| | | | | | | | | | | | | | Valuation Range | | | |
| | | | Low | | | | High | | | |
| | | |
| | Enterprise Value Summary | | | | | | | | | | | Comparable Public Companies | | $ | 64.4 | | | — | | $ | 120.7 | | Comparable Venture Capital Funding Transactions | | $ | 30.0 | | | — | | $ | 76.0 | | Comparable Mergers and Acquisitions Transactions | | $ | 18.0 | | | — | | $ | 86.3 | | Discounted Cash Flow | | $ | 34.1 | | | — | | $ | 73.1 | | | | | | | | | | | | | | |
|
| | | | |
|
| | Average Enterprise Value | | $ | 36.6 | | | — | | $ | 89.0 | |
Each method considered in this analysis is described in further detail below. Comparable Public Companies Method RBC/TF reviewed the enterprise value of comparable companies that were publicly traded as of the date of its analysis. RBC/TF’s selection of comparable public companies was based on a comparison of Vela’s current stage of development, market opportunities, and other relevant business factors with that of the comparable public companies. Market capitalization figures are based upon fully diluted shares outstanding using the treasury stock method of accounting. Comparable Public Companies Method – Current Company Analysis
($ in millions) | |
Company Name | | Public Market
Capitalization | | Net Debt
(Net Cash) | | Enterprise Value | |
| |
| |
| |
| | CytRx | | $ | 106.6 | | $ | (24.6 | ) | $ | 82.0 | | EntreMed | | | 162.9 | | | (54.6 | ) | | 108.2 | | Kosan Biosciences | | | 171.8 | | | (51.1 | ) | | 120.7 | | Point Therapeutics | | | 109.0 | | | (44.7 | ) | | 64.4 | | XTL Biopharmaceuticals | | | 128.4 | | | (16.6 | ) | | 111.8 | |
| | | | | | | | | | | | Company Name | | Public Market
Capitalization | | Net Debt
(Net Cash) | | Enterprise Value | |
| |
| |
| |
| | CytRx | | $ | 106.6 | | $ | (24.6 | ) | $ | 82.0 | | EntreMed | | | 162.9 | | | (54.6 | ) | | 108.2 | | Kosan Biosciences | | | 171.8 | | | (51.1 | ) | | 120.7 | | Point Therapeutics | | | 109.0 | | | (44.7 | ) | | 64.4 | | XTL Biopharmaceuticals | | | 128.4 | | | (16.6 | ) | | 111.8 | |
Comparable Venture Capital Funding Transactions Method The venture capital funding method involved developing indications of value through the review of transactions in which venture capital firms invested new capital in privately-held biotechnology companies. These transactions were deemed to be comparable to Vela if, among other things, their value was derived primarily from technologies in or near early stage proof-of-concept clinical trials. RBC/TF determined the enterprise value range of pre-money valuations based upon the qualitative similarities among the comparable companies and Vela at its current stage of development. |
Comparable Venture Capital Funding Transactions – Current Company Analysis
($ in millions) | |
Company Name | | Financing
Round Type | | Closing Date | | Pre-Money
Valuation | | Money
Raised | | Post-Money
Valuation | |
| |
| |
| |
| |
| |
| | Surface Logix | | Series D | | 10/28/2005 | | $ | 76.0 | | $ | 32.0 | | $ | 108.0 | | Dynogen | | Series B | | 4/5/2004 | | | 30.0 | | | 50.0 | | | 80.0 | | Favrille | | Series C | | 3/26/2004 | | | 46.5 | | | 44.0 | | | 90.5 | | Plexxikon | | Series B-1 | | 2/26/2004 | | | 56.0 | | | 15.0 | | | 71.0 | |
| | | | | | | | | | | | | | | | | | Company Name | | Financing
Round Type | | Closing Date | | Pre-Money
Valuation | | Money
Raised | | Post-Money
Valuation | |
| |
| |
| |
| |
| |
| | Surface Logix | | Series D | | | | 10/28/2005 | | $ | 76.0 | | $ | 32.0 | | $ | 108.0 | | Dynogen | | Series B | | | | 4/5/2004 | | | 30.0 | | | 50.0 | | | 80.0 | | Favrille | | Series C | | | | 3/26/2004 | | | 46.5 | | | 44.0 | | | 90.5 | | Plexxikon | | Series B-1 | | | | 2/26/2004 | | | 56.0 | | | 15.0 | | | 71.0 | |
Vela Financing Analysis In January 2002, Vela solicited an investment of new preferred equity capital from current and new investors in a Series D preferred stock financing. From October 2004 through October 2005, Vela obtained additional capital in the form of bridge notes from existing investors that were convertible into Series D preferred stock. RBC/TF
considered the implied post-money enterprise value of Vela at which new capital was raised to be relevant to its analysis. The post-money enterprise value of Vela following the consummation of the most recent bridge financing was approximately $69.0 million. Comparable Mergers and Acquisitions Transactions Method RBC/TF reviewed publicly available financial information relating to selected transactions since March 2003 involving biotechnology companies which RBC/TF deemed to be similar to Vela. RBC/TF’s selection of a range indicated by this approach was based on a comparison of Vela’s current stage of development, market opportunities, and other relevant business factors with that of the comparable transactions. Those comparable transactions are identified in the following chart. Comparable Mergers and Acquisitions Transactions – Current Company Analysis
($ in millions) | |
| | | | | | | | | | | | Announcement Date | | Target Name | | Acquiror Name | | Initial Consideration | | Consideration including
Milestones | |
| |
| |
| |
| |
| | 1/27/2006 | | Montigen | | SuperGen | | $ | 18.0 | | $ | 40.0 | | 1/9/2006 | | Micromet | | CancerVax | | | 86.3 | | | 86.3 | | 9/14/2005 | | Cellective | | MedImmune | | | 44.0 | | | 149.0 | | 9/1/2004 | | Zycos | | MGI | | | 50.0 | | | 50.0 | |
| | | | | | | | | | | | | | | Announcement Date | | Target Name | | Acquiror Name | | Initial Consideration | | Consideration
including
Milestones | |
| |
| |
| |
| |
| | 1/27/2006 | | Montigen | | | SuperGen | | | $ | 18.0 | | $ | 40.0 | | 1/9/2006 | | Micromet | | | CancerVax | | | | 86.3 | | | 86.3 | | 9/14/2005 | | Cellective | | | MedImmune | | | | 44.0 | | | 149.0 | | 9/1/2004 | | Zycos | | | MGI | | | | 50.0 | | | 50.0 | |
DCF Method The enterprise value range based upon the discounted cash flow method was determined by calculating the present value of the estimated future unlevered free cash flows that Vela’s dextofisopam could generate until patent expiry in 2023. In connection with its engagement, Evidec prepared revenue estimates for dextofisopam assuming successful marketability of the drug under various commercial scenarios, and these revenue estimates were further adjusted by Pharmos management. Furthermore, Pharmos management assumed that the likely commercial path for dextofisopam was the licensing to a pharmaceutical company partner after successful completion of Phase IIb. The Vela Forecast included research and development cost data and estimated general and administrative expenses. The present value of interim cash flows was determined using a discount rate range of 20.3% to 24.3%. RBC/TF estimated the discount rate based upon the cost of capital of comparable public companies to Vela at its current stage of development: CytRx, EntreMed, Kosan Biosciences, Point Therapeutics, and XTL Biopharmaceuticals. These companies were chosen because, for the purposes of the cost of capital analysis, RBC/TF considered them to have operational, market and economic similarity with Vela’s current business. The selected public companies may significantly differ from Vela based on, among other things, the stage of development of their product candidates, the disease indications on which they are focused, and the market opportunities for their product candidates. A premium was included in Vela’s discount rate in correlation with its relatively small current size. |
The value ranges of the cash flows were then multiplied by a factor weighing the probability of successful commercial viability from its current stage of development. RBC/TF estimated the likelihood of achieving the commercial scenarios at its current stage of development to be a range of 40% to 50%, based upon the Vela Forecast, industry reports and discussions with Pharmos management. This analysis estimated the value for the dextofisopam compound on a stand-alone basis and RBC/TF added no value to Vela’s other scientific programs under this approach. VALUATION OF VELA FOLLOWING COMPLETION OF FIRST MILESTONE RBC/TF utilized several methods to determine an enterprise value range for Vela at the first milestone stage of development, projected to occur at the end of 2008. The methods utilized in this analysis are the same as those used in the valuation for Vela at its current stage of development: DCF method and analysis of comparable public companies, venture capital funding transactions and mergers and acquisition transactions. For each method, the future enterprise value ranges for Vela at the first milestone stage of development were then discounted back to present value using a time discount calculation based upon the current company’s weighted-average cost of capital.
Valuation Summary – at First Milestone
($ in millions) | |
| | | | | | | | | | Present Valuation Range | | | |
| | | | Low | | High | | | |
| |
| | Enterprise Value Summary | | | | | | | | Comparable Public Companies | | $ | 76.5 | | $ | 163.5 | | Comparable Venture Capital Funding Transactions | | $ | 26.8 | | $ | 88.3 | | Comparable Mergers and Acquisitions Transactions | | $ | 16.8 | | $ | 76.5 | | Discounted Cash Flow | | $ | 94.8 | | $ | 163.5 | | | | | | | | | | | |
|
| |
|
| | Average Enterprise Value | | $ | 53.7 | | $ | 123.0 | |
| Each method considered in this analysis is described in further detail below. Comparable Public Companies Method RBC/TF reviewed the enterprise value of comparable companies to Vela at its projected first milestone stage of development that were publicly traded as of the date of its analysis. RBC/TF’s selection of comparable public companies was based on a comparison of Vela’s stage of development at the first milestone, market opportunities, and other relevant business factors with that of the comparable public companies. Market capitalization figures are based upon fully diluted shares outstanding using the treasury stock method of accounting. Comparable Public Companies Method – First Milestone Analysis
($ in millions) | |
Company Name | | Market Capitalization | | Net Debt
(Net Cash) | | Enterprise Value | |
| |
| |
| |
| | CuraGen | | $ | 285.8 | | $ | (49.6 | ) | $ | 236.2 | | Dynavax Technologies | | | 189.3 | | | (55.0 | ) | | 134.3 | | Genitope | | | 328.3 | | | (151.5 | ) | | 176.8 | | NeoPharm | | | 272.8 | | | (68.8 | ) | | 204.0 | | Panacos Pharmaceuticals | | | 374.1 | | | (86.9 | ) | | 287.2 | |
| | | | | | | | | | | | Company Name | | Market Capitalization | | Net Debt
(Net Cash) | | Enterprise Value | |
| |
| |
| |
| | CuraGen | | $ | 285.8 | | $ | (49.6 | ) | $ | 236.2 | | Dynavax Technologies | | | 189.3 | | | (55.0 | ) | | 134.3 | | Genitope | | | 328.3 | | | (151.5 | ) | | 176.8 | | NeoPharm | | | 272.8 | | | (68.8 | ) | | 204.0 | | Panacos Pharmaceuticals | | | 374.1 | | | (86.9 | ) | | 287.2 | |
The resulting future enterprise value range at the end of 2008 was then discounted back to present value using a time discount calculation with the current company’s discount rate for a present enterprise value range of $76.5 million to $163.5 million. |
Comparable Venture Capital Funding Transactions Method The comparable venture capital funding transactions method involved the derivation of indications of value through the review of transactions in which venture capital firms invested new capital in privately-held biotechnology companies. RBC/TF deemed these transactions to be comparable to Vela at the first milestone stage of development if, among other things, their value was derived primarily from technologies that had shown encouraging trends supporting clinical efficacy in a larger, controlled Phase IIb or similar clinical trial. RBC/TF determined the enterprise value range of pre-money valuations based upon the qualitative similarities among the comparable companies and Vela following successful completion of the first milestone.
Comparable Venture Capital Funding Transactions – First Milestone Analysis
($ in millions) | |
| | | | | | | | | | | | | | | | | | Company Name | | Financing
Round Type | | Closing Date | | Pre-Money
Valuation | | Money
Raised | | Post-Money
Valuation | | |
| |
| |
| |
| |
| |
| | | Novacea | | | Series C | | | 12/20/2005 | | $ | 135.0 | | $ | 25.0 | | $ | 160.0 | | | Acologix | | | Series C | | | 12/16/2005 | | | 119.7 | | | 29.8 | | | 149.5 | | | Somaxon | | | Series D | | | 12/15/2005 | | | 155.1 | | | 55.0 | | | 210.1 | | | Prestwick | | | Series B | | | 12/6/2004 | | | 47.1 | | | 37.0 | | | 84.1 | | | Intarcia | | | Series E | | | 11/30/2004 | | | 70.2 | | | 50.0 | | | 120.2 | | |
| The resulting pre-money valuation range was then discounted back to present value from the projected first milestone date at the end of 2008 using a time discount calculation with the current company’s discount rate for a present enterprise value range of $26.8 million to $88.3 million. Comparable Mergers and Acquisitions Transactions Method RBC/TF reviewed publicly available financial information relating to selected transactions since January 2003 involving biotechnology companies deemed by RBC/TF to be similar to Vela at its projected stage of development following successful completion of the first milestone. RBC/TF’s selection of a range indicated by this method was based on a comparison of Vela’s stage of development, market opportunities, and other relevant business factors with that of the comparable transactions. Those transactions are identified on the following chart. Comparable Mergers and Acquisitions Transactions – First Milestone Analysis
($ in millions) | |
| | | | | | | | | | | | | | Announcement Date | | Target Name | | Acquiror Name | | Initial
Consideration | | Consideration
including
Milestones | |
| |
| |
| |
| |
| | 9/6/2005 | | | Epicept | | | Maxim | | $ | 97.7 | | $ | 97.9 | | 11/18/2005 | | | Cita | | | Vernalis plc | | | 29.5 | | | 64.5 | | 7/19/2005 | | | Arakis | | | Sosei | | | 134.4 | | | 134.4 | | 12/15/2004 | | | Igneon | | | Aphton | | | 82.0 | | | 82.0 | | 9/1/2004 | | | Aesgen | | | MGI | | | 33.1 | | | 91.1 | | 11/18/2003 | | | Genesoft | | | Genome Therapeutics | | | 103.8 | | | 103.8 | |
| The resulting initial consideration range was then discounted back to present value from the projected first milestone date at the end of 2008 using a time discount calculation with the current company’s discount rate for a present enterprise value range of $16.8 million to $76.5 million. |
DCF Method RBC/TF applied the same methodology in the DCF method as described above under Valuation of Vela at Current Stage of Development, with adjusted present value and probability assumptions. The unlevered free cash flows associated with dextofisopam were discounted back to the end of 2008 when the drug is expected to have successfully completed the first milestone. The value of interim cash flows was determined using a discount rate range of 16.1% to 20.1%. RBC/TF estimated the discount rate based upon the cost of capital of comparable public companies to projected Vela upon successful completion of the first milestone: CuraGen, Dynavax Technologies, Genitope, NeoPharm, and Panacos Pharmaceuticals. These companies were chosen because, for the purposes of the cost of capital analysis, RBC/TF considered them to have similarity with Vela’s projected business following successful completion of the first milestone. The selected public companies may significantly differ from Vela based on, among other things, the stage of development of their product candidates, the disease indications on which they are focused, and the market opportunities for their product candidates. A premium was included in Vela’s discount rate in correlation to its projected size at the first milestone stage of development. The value ranges of the cash flows were then multiplied by a factor weighing the probability of successful commercial viability from the first milestone stage of development. RBC/TF estimated the likelihood of achieving
the commercial scenarios following successful completion of the first milestone to be a range of 60% to 70%, based upon the Vela Forecast, industry reports and discussions with Pharmos management. The resulting future enterprise value range at the end of 2008 was then discounted back to present value using a time discount calculation with the current company’s discount rate for a present enterprise value range of $94.8 million to $163.5 million. VALUATION OF VELA FOLLOWING COMPLETION OF SECOND MILESTONE RBC/TF utilized the DCF method and comparable public companies analysis to determine an enterprise value range for Vela in the event the second milestone is successfully achieved at the projected date of the midpoint of 2012. The sample size of the other two methods, venture capital financing transactions and mergers and acquisitions transactions, was not adequate to perform these analyses for companies comparable to Vela projected at the second milestone stage of development. For each method utilized, the future enterprise value ranges for Vela at the second milestone stage of development were then discounted back to present value using a time discount calculation based upon the current company’s weighted-average cost of capital. Valuation Summary – at Second Milestone
($ in millions) | |
| | | | | | | | | | Present Valuation Range | | | |
| | | | Low | | High | | | |
| |
| | Enterprise Value Summary | | | | | | | | Comparable Public Companies | | $ | 109.5 | | $ | 145.3 | | Discounted Cash Flow | | $ | 171.1 | | $ | 236.6 | | | |
|
| |
|
| | Average Enterprise Value | | $ | 140.3 | | $ | 190.9 | |
Each method considered in this analysis is described in further detail below. Comparable Public Companies Method RBC/TF reviewed the enterprise value of comparable companies to Vela at its projected second milestone stage of development that were publicly traded as of the date of its analysis. RBC/TF’s selection of comparable public companies was based on a comparison of Vela’s stage of development at the second milestone, market opportunities, and other relevant business factors with that of the comparable public companies. Market capitalization figures are based upon fully diluted shares outstanding using the treasury stock method of accounting. Comparable Public Companies Method – Second Milestone Analysis
($ in millions) | |
| | | | | | | | | | | Company Name | | Market Capitalization | | Net Debt
(Net Cash) | | Enterprise Value | |
| |
| |
| |
| | Avanir Pharmaceuticals | | $ | 505.4 | | $ | (50.4 | ) | $ | 455.0 | | GPC Biotech AG | | | 557.3 | | | (168.5 | ) | | 388.8 | | NPS Pharmaceuticals | | | 404.6 | | | 111.1 | | | 515.7 | | Pozen | | | 555.1 | | | (45.8 | ) | | 509.3 | |
| The resulting future enterprise value range at the midpoint of 2012 was then discounted back to present value using a time discount calculation with the current company’s discount rate for a present enterprise value range of $109.5 million to $145.3 million. | | DCF Method | | RBC/TF applied the same methodology in the DCF method as described above underValuation of Vela at Current Stage of Development, with adjusted present value and probability assumptions. The unlevered free cash flows associated with dextofisopam were discounted back to the midpoint of 2012 when the company is expected to have successfully completed and filed an NDA with the Food and Drug Administration. The value of interim cash flows was determined using a discount rate range of 14.1% to 18.1%. RBC/TF estimated the discount rate based
upon the cost of capital of comparable public companies to projected Vela upon successful completion of the second milestone: Avanir Pharmaceuticals, GPC Biotech AG, NPS Pharmaceuticals, and Pozen. These companies were chosen because, for the purposes of the cost of capital analysis, RBC/TF considered them to have similarity with Vela’s projected business following successful completion of the second milestone. The selected public companies may significantly differ from Vela based on, among other things, the stage of development of their product candidates, the disease indications on which they are focused, and the market opportunities for their product candidates. A premium was included in Vela’s discount rate in correlation to its projected size at the second milestone stage of development. | | The value ranges of the cash flows were then multiplied by a factor weighing the probability of successful commercial viability from the second milestone stage of development. RBC/TF estimated the likelihood of achieving the commercial scenarios following successful completion of the second milestone to be a range of 75% to 85%, based upon the Vela Forecast, industry reports and discussions with Pharmos management. | | The resulting future enterprise value range at the midpoint of 2012 was then discounted back to present value using a time discount calculation with the current company’s discount rate for a present enterprise value range of $171.1 million to $236.6 million. | | Other Considerations | | Pharmos selected RBC/TF to render its opinion based on RBC/TF’s experience in mergers and acquisitions and in securities valuation generally. RBC, a member company of RBC Capital Markets, is a globally recognized investment banking firm and is regularly engaged in the valuation of businesses and securities in connection with mergers and acquisitions, corporate restructurings, underwritings, secondary distributions of listed and unlisted |
securities, private placements and valuations for corporate and other purposes. RBC provides research coverage on Pharmos’ common stock. TF, RBC’s strategic partner in Israel, is a recognized full-service financial group which regularly performs various investment banking services, including mergers and acquisitions, underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for businesses, their securities and other purposes. RBC/TF and its affiliates actively trade securities of Pharmos for their own accounts or the accounts of their customers and, accordingly, may from time to time hold a long or short position in those securities. Pursuant to the engagement letter, Pharmos has paid RBC/TF a customary, nonrefundable fee upon the rendering of its opinion. Payment of this fee to RBC/TF was not contingent upon the closing of the Merger. RBC/TF will also be entitled to an additional fee in the event the Merger is consummated. Whether or not the transaction closes, Pharmos has agreed to reimburse RBC/TF for its out-of-pocket expenses and to indemnify RBC/TF against certain liabilities relating to or arising out of services performed by RBC/TF in connection with the Merger. The terms of the engagement letter were negotiated at arm’s-length between Pharmos and RBC/TF, and Pharmos’ Board of Directors was aware of this fee arrangement at the time of its approval of the Merger Agreement. THE MERGER AGREEMENT AND THE MERGER The following description of the Merger Agreement and the Merger does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, attached as Appendix A. Shareholders are urged to read the Merger Agreement in its entirety. General Under the Merger Agreement, two business days after Pharmos’ shareholders approve the Merger, Vela will merge with and into Vela Acquisition Corporation, a wholly-owned subsidiary of Pharmos. Vela Acquisition Corporation will be the surviving corporation in the Merger and it will hold the business and assets of Vela. Certain of the shareholders of Vela will become shareholders of Pharmos. Not all of the shareholders of Vela will receive shares of Pharmos common stock in the Merger because the shares of common stock being issued by Pharmos in the Merger will be allocated in accordance with Vela’s certificate of incorporation only to the holders of Vela’s senior securities of Vela’s capital stock. Closing Date and Effective Date of The Merger The Closing Date is defined as a date no later than the second business day after approval of the Merger by Pharmos’ shareholders, assuming satisfaction or waiver of the conditions to the Merger (unless the parties agree to
another Closing Date). On the Closing Date, Pharmos and Vela shall sign the Certificate of Merger in the form attached as Exhibit A to the Merger Agreement and shall cause the Certificate of Merger to be filed with the Secretary of State of the State of Delaware, in order to cause the Merger contemplated by the Merger Agreement to become effective under the laws of the State of Delaware. The Effective Date of the Merger shall be the date and at the time of the filing of the Certificate of Merger with the Secretary of State of the State of Delaware (the “Effective Date”). Issuance of Merger Shares; Cash Payment; Cancellation of Vela Capital Stock At the Effective Date of the Merger, the outstanding shares of Vela’s capital stock shall be cancelled. Pharmos will issue 11,500,000 shares of its common stock which will be allocated in accordance with instructions from representatives of Vela’s shareholders on the basis of the provisions in Vela’s Restated Certificate of Incorporation as in effect on the Effective Date. Pharmos will also pay $5,000,000 in cash to or on behalf of Vela at the Effective Date. This cash, together with any remaining cash on hand, will be used by Vela to pay certain of Vela’s liabilities, including Vela’s costs and expenses incurred in connection with the Merger, obligations under its Acquisition Bonus Plan established by Vela to compensate its management in the event of a successful sale of Vela (the “Acquisition Bonus Plan”), all interest accrued through the Effective Date on Vela’s outstanding bridge notes and a portion of the principal of those notes, and all principal and accrued interest on Vela’s outstanding senior notes. The holders of Vela’s bridge notes have agreed to convert the remaining principal of the notes into Vela’s Series D Redeemable Convertible Preferred Stock which will be cancelled in connection with the Merger. |
Milestone Shares As part of the Merger, Pharmos may also issue (i) an additional 4,000,000 shares of its common stock upon successful completion of a Phase IIb clinical trial related to the development of dextofisopam within four years of the Effective Date and (ii) an additional 4,000,000 shares of its common stock upon the filing of a New Drug Application with the U.S Food and Drug Administration for dextofisopam within eight years of the Effective Date. If either of the milestones is attained, the shares to be issued to Vela’s shareholders will be valued on the then current market price of Pharmos’ common stock and shall be allocated in accordance with instructions from representatives of Vela’s shareholders on the basis of the provisions in Vela’s Restated Certificate of Incorporation as in effect on the Effective Date and Vela’s Acquisition Bonus Plan. The 4,000,000 shares of common stock issuable upon timely satisfaction of the second milestone may be issued even if the first milestone has not been attained in a timely manner. Expenses of the Merger Under the Merger Agreement, Pharmos and Vela will each pay their respective costs and expenses incurred in connection with the negotiation and consummation of the Merger as described in the Merger Agreement. However, Pharmos and Vela have agreed that a portion of the $5,000,000 to be paid by Pharmos on the Effective Date shall be used to pay a portion of Vela’s costs and expenses associated with completing the Merger. Share Ownership at Effective Date As a result of the Merger, current Vela shareholders will own or control 11,500,000 shares of Pharmos common stock representing approximately 38% of the outstanding shares of Pharmos common stock. Depending upon the market price of Pharmos’ common stock and the extent of repayment and/or conversion of Vela’s outstanding indebtedness as of the closing, and prior to the issuance of any shares of Pharmos common stock upon achievement of the milestones, affiliates of JPMorgan Partners, Venrock Associates and New Enterprise Associates, the principal stockholders of Vela, are expected to own approximately 16.2%, 7.5% and 11.0%, respectively, of our outstanding shares of common stock. JPMorgan Partners, New Enterprise Associates, Venrock Associates and their respective affiliates are among the premier venture capital firms in the life sciences industry, with a wealth of scientific, clinical, commercial and financial experience and substantial pools of investment capital as summarized below. The life sciences investment team at JPMorgan Partners has a long track record of successful venture investments in the biopharmaceutical area. The principals of JPMorgan Partners are value-added, lead investors in therapeutically focused biopharmaceutical companies at all stages of development. They are highly respected throughout the life sciences community for their deep scientific, commercial, clinical and financial contributions to each of their portfolio companies. The venture capital practice within JPMorgan Partners currently manages a
portfolio of approximately $1 billion (invested and reserved) in healthcare and technology companies. Recent noteworthy transactions in the life sciences include a lead investment role in Barrier Therapeutics, Corus Pharmaceuticals, Eyetech Pharmaceuticals, Kemia, Myogen, Phenomix, Piramed, Seattle Genetics and Vela Pharmaceuticals. The venture capital team of JPMorgan Partners has created a new firm, Panorama Capital, which will be dedicated to venture capital investments in healthcare and information technology. New Enterprise Associates is a venture capital firm investing in new, growth-oriented businesses with a focus on the information technology and healthcare sectors. NEA’s healthcare practice specializes in the biopharmaceutical, medical device, healthcare services and healthcare information technology sectors and to date has invested in nearly 200 healthcare companies. Since its founding in 1978, NEA has invested in more than 660 companies, of which over 150 have gone public and over 205 have been acquired. The firm currently has in excess of $6 billion under management and maintains offices in Reston, Virginia, Menlo Park, California, and Baltimore, Maryland. Venrock is a venture capital firm that invests in technology-based companies in the information technology and healthcare sectors. The Venrock Partnership was among the original investors in biopharmaceuticals, starting |
in 1980, and has a long record of successful investments in the area. The firm is generally recognized in the investment community as a value-added, long-term investor. Venrock continues to be an active and lead investor in biopharmaceuticals, with an emphasis on companies developing novel and important therapeutic products. Recent biopharmaceutical companies in which Venrock played a lead role include Coley Pharmaceutical Group, Icagen, Infinity Pharmaceuticals, Renovis, Sirna Therapeutics, and Xenoport. Older investments included Centocor, Genetics Institute, IDEC Pharmaceuticals, Millennium Pharmaceuticals, Sepracor, and Sugen. Venrock has in excess of $1.4 billion under management and has offices in New York, New York, Menlo Park, California, and Cambridge, Massachusetts. Fractional Shares No fractional shares will be issued by Pharmos in connection with the cancellation of the Vela shares. Instead, Pharmos will pay cash for any fractional share that a holder of Vela shares has the right to receive under the Merger Agreement. Resulting Board of Directors In connection with the Merger and under the terms of the Merger Agreement, at the closing, Pharmos shall expand the size of its classified Board of Directors by two, for a new total of nine members, and one current member, [____________], shall resign. In addition, one of the Class III directors will be reclassified as a Class [__] director, replacing the resigned director. The two newly-created positions on the Board of Directors, together with the vacated position, will represent the following vacancies: (i) one vacancy with a term commencing as of the Effective Date and expiring at Pharmos’ annual shareholders meeting in 2006; (ii) one vacancy with a term commencing as of the Effective Date and expiring at Pharmos’ annual shareholders meeting in 2007; and (iii) one vacancy with a term commencing as of the Effective Date and expiring at Pharmos’ annual shareholders meeting in 2008. Such vacancies will be filled by our Board of Directors immediately after the Closing with three designees of Vela, with each of the affiliates of (i) JPMorgan Partners, (ii) Venrock Associates and (iii) New Enterprise Associates initially appointing one such designee, in each case subject to approval of Pharmos’ Board of Directors. Pharmos and Vela have agreed that Srinivas Akkaraju, Anthony B. Evnin and Charles W. Newhall, III, are acceptable designees and that the Vela designee who fills the vacancy with a term expiring at Pharmos’ annual shareholders meeting in 2006 will be nominated for re-election at such meeting. If the Merger does not close for any reason, Messrs. Akkaraju, Evnin and Newhall will not take office. Srinivas Akkaraju, M.D., Ph.D., 38, is a co-founder and Managing Director of Panorama Capital. Prior to co-founding Panorama, Dr. Akkaraju was a partner with JPMorgan Partners, LLC on the Life Sciences team of the Healthcare Group. Dr. Akkaraju joined JPMorgan Partners, LLC in April 2001. Prior to JPMorgan Partners, LLC, from October 1998 to April 2001, Dr. Akkaraju was in the Business and Corporate Development group at Genentech, Inc. where he served in various capacities, most recently as Senior Manager and project team leader for one of Genentech’s clinical development products. Dr. Akkaraju is currently a member of the Board of Directors of Barrier Therapeutics, Inc., Seattle Genetics, Inc., and several private biotechnology companies. Dr. Akkaraju received his undergraduate degrees in Biochemistry and Computer Science from Rice University and his M.D. and Ph.D. in Immunology from Stanford University.
Anthony B. Evnin, 65, is a Managing General Partner of Venrock Associates, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Coley Pharmaceutical Group, Inc., Icagen, Inc., Memory Pharmaceuticals Corp., Renovis, Inc., and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. He was formerly a director of IDEC Pharmaceuticals Corporation, Dianon Systems, Inc., BioSurface Technologies, Inc., Sepracor, Inc., IDEXX Laboratories, Inc., Athena Neurosciences, Inc., Genetics Institute, Inc., SUGEN, Inc., Axys Pharmaceuticals, Inc., Centocor, Inc., Ribozyme Pharmaceuticals, Inc., Triangle Pharmaceuticals, Inc., Caliper Life Sciences, Inc., and Sonic Innovations, Inc. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology. Charles W. Newhall, III, 61, co-founded New Enterprise Associates (“NEA”) in 1978 and has been a General Partner of the firm since its inception. While with NEA, his investment activities have focused on healthcare services, healthcare information services and biopharmaceutical companies. Prior to co-founding NEA, |
Mr. Newhall was a Vice President with T. Rowe Price Associates and Vice President of its New Horizons Fund. His board memberships include Vitae Pharmaceuticals, Inc., ElderHealth, Inc., Hospital Partners of America, Inc., Sensors for Medicine & Science, Inc., TargetRx, Inc., and Trine Pharmaceuticals, Inc.. Mr. Newhall is also a founder of the Mid-Atlantic Venture Association. He received his M.B.A. from the Harvard University Graduate School of Business and his B.A. in English Literature with honors from the University of Pennsylvania. For as long as the affiliates of each of (i) JPMorgan Partners, (ii) Venrock Associates and (iii) New Enterprise Associates hold at least 50% of the Pharmos shares issued on the Effective Date to them and their affiliates (including any escrow shares allocable to it not previously forfeited to Pharmos in accordance with the terms of the Escrow Agreement), then (A) its designee shall remain on the Pharmos Board of Directors for the duration of his initial term, (B) each designated director shall be replaced during the initial term or any renewal term only by another individual designated by such shareholder, subject to the approval of Pharmos’ Board of Directors, and (C) in connection with the pending expiration of the term of any such director, the Governance and Nominating Committee of Pharmos’ Board of Directors shall consider, in connection with the deliberations in accordance with its certificate of incorporation, the re-nomination of such director to the Board of Directors. Standstill Agreement
At closing, Vela’s principal shareholders will enter into standstill agreements that provide that for two years they will not acquire any additional shares of Pharmos capital stock, other than as agreed to by the Pharmos Board or in a private placement or other transaction in an amount to maintain their percentage interest. Each standstill agreement also provides that it is the current intention of the shareholder not to initiate or support a proxy fight or hostile takeover of Pharmos. Executive Officers of Pharmos Except as discussed above with respect to the additional members of the Board of Directors of Pharmos, it is anticipated that each of the current executive officers of Pharmos will continue to serve in those roles following the Effective Date. Registration of Merger Shares and Lock-Up In accordance with a Registration Rights Agreement that will be signed at closing, Pharmos has agreed to file a registration statement with the Securities and Exchange Commission within seven days of the Effective Date to register for resale all shares to be issued in connection with the Merger Agreement, including the 8,000,000 milestone shares. Under the Registration Rights Agreement, sales of the 11,500,000 shares issued on the Effective Date and any milestone shares issued during the 18 months following the Effective Date shall be restricted as follows: none of such shares may be sold for a period of six months following the closing; one-third of such shares may be sold commencing six months after closing; two-thirds of such shares may be sold commencing one year after closing; and all of the shares may be sold commencing 18 months after the closing.
Effect of Merger on Pharmos “Poison Pill” In October 2002, Pharmos adopted a shareholder rights plan that imposes a significant penalty upon any person or group that acquires 15% or more of our outstanding common stock in certain types of transactions without the approval of our Board of Directors. Completion of the Merger would constitute a triggering event under this plan, since oneaffiliates of Vela’s shareholdersJPMorgan Partners will acquire more than 15% of our outstanding common stock. In view of the fact that Pharmos’ Board of Directors favors completion of the Merger, the Board of Directors will amend the shareholder rights plan prior to the Effective Date to exempt acquisition of common stock pursuant to the Merger from the terms of the plan. Conduct of Business By Vela and Pharmos Pending The Merger Unless otherwise agreed to by Pharmos, the Merger Agreement provides that prior to the Effective Date, Vela shall: | | | | • | use its best efforts to preserve all of its accounting and business records, corporate records, trade secrets and proprietary information and other intellectual property for the benefit of the surviving corporation; | | | | | • | not declare or pay any dividends (whether in cash, shares of stock or otherwise) on, or make any other distribution in respect of, any shares of capital stock, or issue, purchase, redeem or acquire for value any shares of its capital stock, or issue any options, warrants or other rights to acquire shares of its capital stock or securities exchangeable for or convertible into shares of its capital stock, except for the issuance of shares of capital stock of Vela upon the exercise of options or warrants outstanding on the date of the Merger Agreement or upon the conversion of its bridge notes; | | | | | • | except for payments and allocations under its Acquisition Bonus Plan, shall not: increase the compensation payable to or to become payable to any director, officer or employee; grant any severance or termination pay to, or enter into any employment, consulting or severance agreement with, any director, officer or employee or their respective affiliates; or establish, adopt, enter into or amend any employee benefit plan or arrangement except as may be required by applicable law; | | | | | • | not enter into any contract or commitment or engage in any transaction not in the usual and ordinary course of business and consistent with its normal business practices, including without limitation, any contract or commitment relating to its intellectual property or any contract or commitment relating to the acquisition of assets, technologies or products or the in-licensing thereof; | | | | | • | not (i) sell, lease as lessor, license as licensor, or otherwise dispose of any capital asset with a market value in excess of $10,000, (ii) sell, lease as lessor, license as licensor, or otherwise dispose of any asset other than in the ordinary course of business; provided, that Vela shall not license any of its intellectual property, (iii) borrow money, (iv) incur or pay any material liability other than in the ordinary course of business, or (v) guarantee or otherwise incur any material liability with respect to the obligation of any other person; | | | | | • | use its best efforts to preserve for Pharmos the present relationships with suppliers, scientists, researchers, licensors, parties to contracts and others having business relations with Vela; | | | | | • | not amend its certificate of incorporation or by-laws; | | | | | • | not merge or consolidate with any other corporation, or acquire any stock of, or, except in the ordinary course of business, acquire any assets or property of any other business entity whatsoever; | | | | | • | not do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any material contract, commitment or obligation of Vela; | | | | | • | duly comply in all material respects with all laws, regulations and orders applicable with respect to its business; | | | | | • | promptly advise Pharmos in writing of any development or change in circumstance (including any litigation to which it may become a party or of which it may gain knowledge) that does or could reasonably be expected to (i) call into question the validity of the Merger Agreement or any action taken or to be taken pursuant thereto, (ii) adversely affect the ability of the parties to consummate the |
| | transactions contemplated thereby, or (iii) have any material adverse effect on the business, financial condition, or assets of Vela; | | | | | • | either call a special meeting of its shareholders to consider and vote upon the approval of the Merger Agreement and the Merger and the other transactions contemplated thereby or shall obtain the requisite minimum required shareholder approval by written consent in accordance with its certificate of incorporation and by-laws and applicable Delaware law. The Board of Directors of Vela shall recommend to its shareholders the approval of the Merger Agreement and the Merger and the other transactions contemplated thereby and shall use its best efforts to solicit and obtain the requisite vote of approval; and | | | | | • | secure, before the Effective Date, the consent to the consummation of the transactions contemplated by the Merger Agreement, by each party to any material contract, commitment or obligation of Vela, in each case under which such consent is required. | | | | Unless otherwise agreed to by Vela, the Merger Agreement provides that prior to the Effective Date, Pharmos shall: | | | • | duly comply in all material respects with all laws, regulations and orders applicable to its business; | | | | | • | not, except in the ordinary course of business, (i) sell, lease as lessor, license as licensor, or otherwise dispose of any capital asset with a market value in excess of $10,000, (ii) sell, lease as lessor, license as licensor, or otherwise dispose of any asset; provided that Pharmos may enter into a product in-licensing agreement without the prior written consent of Vela, if (a) the in-licensed product is not competitive with, or will not reduce the value of, dextofisopam, and (b) the aggregate then-irrevocable payment obligations of Pharmos under such in-licensing agreement do not exceed $4,000,000 (that is, excluding, without limitation, any potential or contingent up-front, royalty, license maintenance or milestone based payments that would not be due and payable by Pharmos if it elected at some future date to terminate such in-licensing agreement), (iii) borrow money, (iv) incur or pay any material liability, or (v) guarantee or otherwise incur any material liability with respect to the obligation of any other person; | | | | | • | use its best efforts to preserve its present relationships with suppliers, scientists, researchers, licensors, parties to contracts and others having business relations it; | | | | | • | not merge or consolidate with any other corporation, or acquire any stock of, or, except in the ordinary course of business, acquire any assets or property of any other business entity whatsoever; | | | | | • | do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any its material contracts, commitments or obligations; | | | | | • | advise Vela in writing of any development or change in circumstance (including any litigation to which it may become a party or of which it may gain knowledge) that does or could reasonably be expected to (i) call into question the validity of the Merger Agreement or any action taken or to be taken pursuant thereto, (ii) adversely affect the ability of the parties to consummate the transactions contemplated thereby, or (iii) have any material adverse effect on its business or financial condition; | | | | | | | | • | use all commercially reasonable efforts to secure the consent to the consummation of the transactions contemplated by the Merger Agreement by each party to any material contract, commitment or obligation of Pharmos under which such consent is required; and | | | | | • | use its best efforts to carry on its business in the usual and ordinary course and to preserve its organization and relationships and not to (i) declare or pay any dividends to its shareholders, or repurchase any shares of its stock, (iii) amend its certificate of incorporation or by-laws, (ii) pledge or agree to pledge, any shares of its capital stock or (iii) increase the size of its Board of Directors beyond nine members.
| • | use its best efforts to preserve all of its accounting and business records, corporate records, trade secrets and proprietary information and other intellectual property for the benefit of the surviving corporation; | | | | | • | not declare or pay any dividends (whether in cash, shares of stock or otherwise) on, or make any other distribution in respect of, any shares of capital stock, or issue, purchase, redeem or acquire for value any shares of its capital stock, or issue any options, warrants or other rights to acquire shares of its capital stock or securities exchangeable for or convertible into shares of its capital stock, except for the issuance of shares of capital stock of Vela upon the exercise of options or warrants outstanding on the date of the Merger Agreement or upon the conversion of its bridge notes; | | | | | • | except for payments and allocations under its Acquisition Bonus Plan, shall not: increase the compensation payable to or to become payable to any director, officer or employee; grant any severance or termination pay to, or enter into any employment, consulting or severance agreement with, any director, officer or employee or their respective affiliates; or establish, adopt, enter into or amend any employee benefit plan or arrangement except as may be required by applicable law; | | | | | • | not enter into any contract or commitment or engage in any transaction not in the usual and ordinary course of business and consistent with its normal business practices, including without limitation, any contract or commitment relating to its intellectual property or any contract or commitment relating to the acquisition of assets, technologies or products or the in-licensing thereof; | | | | | • | not (i) sell, lease as lessor, license as licensor, or otherwise dispose of any capital asset with a market value in excess of $10,000, (ii) sell, lease as lessor, license as licensor, or otherwise dispose of any asset other than in the ordinary course of business; provided, that Vela shall not license any of its intellectual property, (iii) borrow money, (iv) incur or pay any material liability other than in the ordinary course of business, or (v) guarantee or otherwise incur any material liability with respect to the obligation of any other person; | | | | | • | use its best efforts to preserve for Pharmos the present relationships with suppliers, scientists, researchers, licensors, parties to contracts and others having business relations with Vela; | | | | | • | not amend its certificate of incorporation or by-laws; | | | |
| • | not merge or consolidate with any other corporation, or acquire any stock of, or, except in the ordinary course of business, acquire any assets or property of any other business entity whatsoever; | | | | | • | not do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any material contract, commitment or obligation of Vela; | | | | | • | duly comply in all material respects with all laws, regulations and orders applicable with respect to its business; | | | | | • | promptly advise Pharmos in writing of any development or change in circumstance (including any litigation to which it may become a party or of which it may gain knowledge) that does or could reasonably be expected to (i) call into question the validity of the Merger Agreement or any action taken or to be taken pursuant thereto, (ii) adversely affect the ability of the parties to consummate the transactions contemplated thereby, or (iii) have any material adverse effect on the business, financial condition, or assets of Vela; | | | | | • | either call a special meeting of its shareholders to consider and vote upon the approval of the Merger Agreement and the Merger and the other transactions contemplated thereby or shall obtain the requisite minimum required shareholder approval by written consent in accordance with its certificate of incorporation and by-laws and applicable Delaware law. The Board of Directors of Vela shall recommend to its shareholders the approval of the Merger Agreement and the Merger and the other |
| transactions contemplated thereby and shall use its best efforts to solicit and obtain the requisite vote of approval; and | | |
secure, before the Effective Date, the consent to the consummation of the transactions contemplated by the Merger Agreement, by each party to any material contract, commitment or obligation of Vela, in each case under which such consent is required.
| Unless otherwise agreed to by Vela, the Merger Agreement provides that prior to the Effective Date, Pharmos shall:
| |
| • | duly comply in all material respects with all laws, regulations and orders applicable to its business; | | | | | • | not, except in the ordinary course of business, (i) sell, lease as lessor, license as licensor, or otherwise dispose of any capital asset with a market value in excess of $10,000, (ii) sell, lease as lessor, license as licensor, or otherwise dispose of any asset; provided that Pharmos may enter into a product in-licensing agreement without the prior written consent of Vela, if (a) the in-licensed product is not competitive with, or will not reduce the value of, dextofisopam, and (b) the aggregate then-irrevocable payment obligations of Pharmos under such in-licensing agreement do not exceed $4,000,000 (that is, excluding, without limitation, any potential or contingent up-front, royalty, license maintenance or milestone based payments that would not be due and payable by Pharmos if it elected at some future date to terminate such in-licensing agreement), (iii) borrow money, (iv) incur or pay any material liability, or (v) guarantee or otherwise incur any material liability with respect to the obligation of any other person; | | | | | • | use its best efforts to preserve its present relationships with suppliers, scientists, researchers, licensors, parties to contracts and others having business relations it; | | | | | • | not merge or consolidate with any other corporation, or acquire any stock of, or, except in the ordinary course of business, acquire any assets or property of any other business entity whatsoever; | | | | | • | do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any its material contracts, commitments or obligations; | | | | | • | advise Vela in writing of any development or change in circumstance (including any litigation to which it may become a party or of which it may gain knowledge) that does or could reasonably be expected to (i) call into question the validity of the Merger Agreement or any action taken or to be taken pursuant thereto, (ii) adversely affect the ability of the parties to consummate the transactions contemplated thereby, or (iii) have any material adverse effect on its business or financial condition; |
| use all commercially reasonable efforts to secure the consent to the consummation of the transactions contemplated by the Merger Agreement by each party to any material contract, commitment or obligation of Pharmos under which such consent is required; and
| |
use its best efforts to carry on its business in the usual and ordinary course and to preserve its organization and relationships and not to (i) declare or pay any dividends to its shareholders, or repurchase any shares of its stock, (iii) amend its certificate of incorporation or by-laws, (ii) pledge or agree to pledge, any shares of its capital stock or (iii) increase the size of its Board of Directors beyond nine members.
| Indemnity and Escrow The Vela shareholders that receive Pharmos shares upon the closing of the Merger will indemnify Pharmos for damages resulting from material breaches of Vela’s representations, warranties and covenants under the Merger Agreement for a period of 18 months after the Effective Date. The sole source of the indemnity (absent fraud) will be 1,725,000 of the 11,500,000 shares issued at closing, which shall be held in escrow pursuant to an escrow |
agreement. If no claims for indemnification are pending, the 1,725,000 shares shall be reduced to 1,150,000 shares six months after the closing and shall be further reduced to 575,000 shares 12 months after the closing if no claims are pending. All remaining shares shall be released from escrow 18 months after the closing if no claims are pending. The indemnity will have a deductible of $250,000 and will only apply to claims in excess of that amount. Pharmos will indemnify the former Vela shareholders and former Vela directors and officers for damages resulting from material breaches of its representations, warranties and covenants under the Merger Agreement for a period of 18 months after the Effective Date. The indemnity will be capped at the total market value at closing of 15% of 11,500,000 shares of Pharmos common stock. This cap amount shall be reduced by one-third six months after the closing and by another one-third 12 months after the closing. If no claims are pending, all indemnification obligations shall cease 18 months after the Effective Date. The indemnity will have a deductible of $250,000 and will only apply to claims in excess of that amount. Pharmos has the discretion to satisfy indemnification claims by tendering cash or stock in the case of the former Vela shareholders, but must use cash to satisfy claims raised by Vela’s former officers and directors. Employment-Related Matters Pharmos anticipates hiring Dr. Steven Leventer, Vela’s Senior Vice President, Research and Development, to lead clinical development of the Vela technologies and several members of his staff, reporting to Alan Rubino, Pharmos’ President & COO. No additional hires of Vela employees are anticipated. Conditions to The Merger The Merger is subject to certain conditions set forth in the Merger Agreement. In the event that those conditions remain unsatisfied and the Merger has not been completed on or before August 31, 2006, the Merger Agreement may be terminated by either party as more fully described below. Pharmos is obligated to effect the Merger only if the following additional conditions are satisfied by Vela or waived by Pharmos: | | | | | • | The representations and warranties of Vela set forth in the Merger Agreement shall be true and correct in all material respects as of the Closing Date, except for changes permitted or required by the Merger Agreement; | | | | | • | Vela shall have performed and complied in all material respects with all covenants and agreements contained in the Merger Agreement required to be performed or complied with by it on or before the Closing Date; | | | | | • | The shareholders of Vela shall have authorized and approved the Merger Agreement and the Merger contemplated thereby as required by applicable law and Vela’s restated certificate of incorporation and by-laws, and the holders of at least 95% of the issued and outstanding shares of Vela’s capital stock (voting together as a single class on an as-converted basis) shall have voted in favor of or consented to the Merger or shall have otherwise waived or failed to perfect any appraisal rights to which they may otherwise be entitled under the Delaware General Corporation Law; | | | | | • | Vela shall have duly executed and delivered to Pharmos the Certificate of Merger; | | | | | • | No restraining order or injunction or other order issued by any court of competent jurisdiction, or other legal restraint or prohibition shall prevent the consummation of the Merger or other transactions contemplated by the Merger Agreement, and no petition or request for any such injunction or other order shall be pending; | | | | | • | Counsel to Vela shall have delivered to Pharmos a legal opinion in form and substance satisfactory to Pharmos and its counsel; | | | | | • | There shall not have been any material adverse change in the business or assets of Vela, excluding the incurrence of cash losses from operations in accordance with the conduct of Vela’s business in the ordinary course; | | | | | • | Each outstanding stock option, warrant, and other right to acquire the capital stock of Vela shall have been exercised, waived, released and/or terminated, and Vela’s stock option plan shall have been terminated as of the Closing Date and shall be of no further force or effect; |
| • | The representations and warranties of Vela set forth in the Merger Agreement shall be true and correct in all material respects as of the Closing Date, except for changes permitted or required by the Merger Agreement; | | | | | • | Vela shall have performed and complied in all material respects with all covenants and agreements contained in the Merger Agreement required to be performed or complied with by it on or before the Closing Date; | | | | | • | The shareholders of Vela shall have authorized and approved the Merger Agreement and the Merger contemplated thereby as required by applicable law and Vela’s restated certificate of incorporation and by-laws, and the holders of at least 95% of the issued and outstanding shares of Vela’s capital stock (voting together as a single class on an as-converted basis) shall have voted in favor of or consented to the Merger or shall have otherwise waived or failed to perfect any appraisal rights to which they may otherwise be entitled under the Delaware General Corporation Law; | | | | | • | Vela shall have duly executed and delivered to Pharmos the Certificate of Merger; | | |
| • | No restraining order or injunction or other order issued by any court of competent jurisdiction, or other legal restraint or prohibition shall prevent the consummation of the Merger or other transactions contemplated by the Merger Agreement, and no petition or request for any such injunction or other order shall be pending; | | | | | • | Counsel to Vela shall have delivered to Pharmos a legal opinion in form and substance satisfactory to Pharmos and its counsel; | | • | After payment by Pharmos of the $5,000,000 at closing to or on behalf of Vela and the use of the proceeds thereof, the remaining liabilities of Vela as of the Closing Date, as determined in accordance with generally accepted accounting principles, shall not exceed $100,000, provided that such liabilities do not include any expenses associated with the transactions contemplated by this Agreement and that such liabilities were incurred in the ordinary course of business; |
26
| | | | | • | All of the employment and consulting agreements to which Vela is a party or to or by which Vela is bound shall have been terminated upon terms and conditions acceptable to Pharmos, and participants in Vela’s Acquisition Bonus Plan will have executed and delivered a general release in form and substance reasonably acceptable to Pharmos; and | | | | | • | Vela shall have executed and/or delivered all documents and instruments required to be executed and/or delivered by it on the Closing Date under the Merger Agreement. | | | | Vela is obligated to effect the Merger only if the following additional conditions are satisfied by Pharmos or waived by Vela: | | | | | • | The representations and warranties of Pharmos in the Merger Agreement shall be true and correct in all material respects as of the Closing Date, except for changes permitted or required by the Merger Agreement; | | | | | • | Pharmos shall have performed and complied in all material respects with all of the covenants and agreements required to be performed or complied with by it by the Closing Date; | | | | | • | The shareholders of Pharmos shall have authorized and approved the issuance of the Pharmos shares pursuant to the Merger Agreement; | | | | | • | Vela Acquisition Corporation shall have executed and delivered to Vela the Certificate of Merger; | | | | | • | No restraining order or injunction or other order issued by any court of competent jurisdiction, or other legal restraint or prohibition shall prevent the Merger or other transactions contemplated by the Merger Agreement, and no petition or request for any such injunction or other order shall be pending; | | | | | • | Counsel to Pharmos shall have delivered to Vela a legal opinion in form and substance satisfactory to Vela and its counsel; | | | | | • | There shall not have been any material adverse change in the business or assets of Pharmos, which shall not include the incurrence of cash losses from operations in accordance with the conduct of Pharmos’ business in the ordinary course or the unsuccessful outcome in Pharmos’ motions to dismiss pending class action and derivative litigations described in its SEC reports; | | | | | • | Pharmos shall have expanded the size of its Board of Directors by two; and | | | | | • | Pharmos shall have executed and/or delivered all documents and instruments required to be executed and/or delivered by it on the Closing Date under the Merger Agreement.
|
| • | There shall not have been any material adverse change in the business or assets of Vela, excluding the incurrence of cash losses from operations in accordance with the conduct of Vela’s business in the ordinary course; | | | | | • | Each outstanding stock option, warrant, and other right to acquire the capital stock of Vela shall have been exercised, waived, released and/or terminated, and Vela’s stock option plan shall have been terminated as of the Closing Date and shall be of no further force or effect; | | | | | • | After payment by Pharmos of the $5,000,000 at closing to or on behalf of Vela and the use of the proceeds thereof, the remaining liabilities of Vela as of the Closing Date, as determined in accordance with generally accepted accounting principles, shall not exceed $100,000, provided that such liabilities do not include any expenses associated with the transactions contemplated by this Agreement and that such liabilities were incurred in the ordinary course of business; | | | | | • | All of the employment and consulting agreements to which Vela is a party or to or by which Vela is bound shall have been terminated upon terms and conditions acceptable to Pharmos, and participants in Vela’s Acquisition Bonus Plan will have executed and delivered a general release in form and substance reasonably acceptable to Pharmos; and | | | | | • | Vela shall have executed and/or delivered all documents and instruments required to be executed and/or delivered by it on the Closing Date under the Merger Agreement. |
| Vela is obligated to effect the Merger only if the following additional conditions are satisfied by Pharmos or waived by Vela:
| |
| • | The representations and warranties of Pharmos in the Merger Agreement shall be true and correct in all material respects as of the Closing Date, except for changes permitted or required by the Merger Agreement; | | | | | • | Pharmos shall have performed and complied in all material respects with all of the covenants and agreements required to be performed or complied with by it by the Closing Date; | | | | | • | The shareholders of Pharmos shall have authorized and approved the issuance of the Pharmos shares pursuant to the Merger Agreement; | | | | | • | Vela Acquisition Corporation shall have executed and delivered to Vela the Certificate of Merger; | | | | | • | No restraining order or injunction or other order issued by any court of competent jurisdiction, or other legal restraint or prohibition shall prevent the Merger or other transactions contemplated by the Merger Agreement, and no petition or request for any such injunction or other order shall be pending; | | | | | • | Counsel to Pharmos shall have delivered to Vela a legal opinion in form and substance satisfactory to Vela and its counsel; | | | | | • | There shall not have been any material adverse change in the business or assets of Pharmos, which shall not include the incurrence of cash losses from operations in accordance with the conduct of Pharmos’ business in the ordinary course or the unsuccessful outcome in Pharmos’ motions to dismiss pending class action and derivative litigations described in its SEC reports; | | | |
| • | Pharmos shall have expanded the size of its Board of Directors by two; and | | | | | • | Pharmos shall have executed and/or delivered all documents and instruments required to be executed and/or delivered by it on the Closing Date under the Merger Agreement. |
| Amendment of The Merger Agreement |
The Merger Agreement may be amended prior to closing only by a written instrument executed by Pharmos, Vela Acquisition Corporation and Vela and approved by their respective Boards of Directors (i) in any manner and at any time prior to the first to occur of (A) submission for approval of the Merger Agreement to the shareholders of Vela and (B) submission for approval of the Merger Agreement to the shareholders of Pharmos, and (ii) after the earliest such submission for approval, to extend the Closing Date and termination date or to make other amendments which, in the opinion of the respective counsel for Pharmos and Vela, do not substantially alter the terms of the Merger Agreement. The Merger Agreement may be amended after the Closing Date only by written instrument executed by Pharmos and the representatives of Vela’s former shareholders designated in the Merger Agreement. Termination; Effect of Termination Either party may terminate the Merger Agreement upon notice to the other (i) if the other party is in material breach of its obligations under the Merger Agreement and such breach shall not have been cured within a period of ten (10) days after written notice or (ii) if the conditions necessary to close shall not have been satisfied, or waived by the other party, on or prior to August 31, 2006 or (iii) if there has been a material adverse change in the
representations and warranties made by either party or (iv) upon any material adverse change in the business or operations of the other party. The parties may also terminate the Merger Agreement by mutual agreement. If either party terminates the Merger Agreement other than in compliance with the foregoing provisions, it shall become liable to the other party for a payment of $1,500,000. In addition, a party shall be liable for such payment if it is in material breach of the Merger Agreement and the other party terminates the Merger Agreement as a result of such material breach. Provided that Pharmos is not otherwise in breach of the Merger Agreement, failure to obtain approval by Pharmos’ shareholders of the issuance of shares in connection with the Merger will not give rise to the obligation to make the $1,500,000 payment. Accounting Treatment of the Merger The Merger will be accounted for under the purchase method of accounting in accordance with U.S. generally accepted accounting principles. Under the purchase method of accounting, the purchase price of Vela, including the direct costs of the transaction, will be allocated to the assets acquired based upon their estimated fair values, with the excess purchase consideration allocated to goodwill. The results of Vela’s operations will be included in our results from the effective time of the Merger. No Dissenters’ Rights Under applicable Nevada law, Pharmos shareholders do not have the right to dissent from the approval of the issuance of the Merger Shares and obtain payment for the appraised value of their shares.
SELECTED PHARMOS FINANCIAL DATA
| | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | | | |
| | | | | 2005 | | 2004 | | 2003 | | 2002 | | 2001 | | | | |
| |
| |
| |
| |
| | | Revenues | | | — | | | — | | | — | | | — | | $ | 4,298,441 | 1 | | Cost of Goods Sold (exclusive of depreciation & amortization) | | | — | | | — | | | — | | | — | | | 1,268,589 | 1 | | Operating expenses | | ($ | 15,708,888 | )2,3 | ($ | 19,880,151 | )2,4 | | ($16,034,146 | ) | ($ | 16,858,414 | ) | | (13,789,291 | ) | | Other (expense), income, net | | | 12,288,382 | 5,6,7 | | (2,532,390 | )6,7 | | (2,679,517 | )6,7,8 | | (426,409 | ) | | 15,579,261 | 9,10 | | Income (Loss) Before Income Taxes | | | (3,420,506 | ) | | (22,412,541 | ) | | (18,713,663 | )5 | | (17,284,823 | ) | | 4,819,822 | 6 | | Net (Loss) Income | | | (2,929,872 | )11 | | (21,967,767 | )11 | | (18,485,865 | )11 | | (17,069,600 | )11 | | 5,045,855 | | | Net (loss) income applicable to common shareholders | | ($ | 2,929,872 | ) | ($ | 21,967,767 | ) | ($ | 18,485,865 | ) | ($ | 17,069,600 | ) | $ | 5,045,855 | | | | |
|
| |
|
| |
|
| |
|
| |
|
| | | | | | | | | | | | | | | | | | | | | Net (loss) income per share applicable to common shareholders – basic | | ($ | 0.15 | ) | ($ | 1.22 | ) | ($ | 1.37 | ) | ($ | 1.51 | ) | $ | 0.46 | | | | |
|
| |
|
| |
|
| |
|
| |
|
| | | | | | | | | | | | | | | | | | | | | Net (loss) income per share applicable to common shareholders – diluted | | ($ | 0.15 | ) | ($ | 1.22 | ) | ($ | 1.37 | ) | ($ | 1.51 | ) | $ | 0.46 | | | | |
|
| |
|
| |
|
| |
|
| |
|
| | | Total assets | | $ | 48,990,772 | | $ | 57,664,842 | | $ | 69,622,482 | | $ | 25,250,146 | | $ | 44,757,946 | | | | |
|
| |
|
| |
|
| |
|
| |
|
| | | Long term obligations | | $ | 1,125,551 | | $ | 1,236,451 | | $ | 5,772,344 | | $ | 878,031 | | $ | 6,640,851 | | | | |
|
| |
|
| |
|
| |
|
| |
|
| | | Cash dividends declared | | | — | | | — | | | — | | | — | | | — | | | Average shares outstanding - basic | | | 18,974,175 | | | 18,033,358 | | | 13,479,435 | | | 11,304,008 | | | 10,935,786 | | | Average shares outstanding – diluted | | | 18,974,175 | | | 18,033,358 | | | 13,479,435 | | | 11,304,008 | | | 11,059,613 | | |
| | 1. | The Company sold its ophthalmic product line in October 2001. | | | 2. | Includes retention award expense of approximately $459,564 and $1,378,695 in 2005 and 2004, respectively. | | | 3. | Includes severance costs of $609,701 related to the departure of two executives | | | 4. | Includes non cash charge for options of $578,238 | | | 5. | Includes a $10.7 million milestone payment received in 2005 related to the sale of the ophthalmic product line in October 2001. | | | 6. | Other expenses include a non cash gain (loss) related to the value of warrants of $259,075, $525,074 and ($1,759,184) in 2005, 2004 and 2003, respectively. | | | 7. | Interest expense on declining balances on the $21 million September 2003 Convertible Debentures plus the accretion of debt discount and the amortization of debt issuance costs associated with September 2003 Convertible Debentures. | | | 8. | Includes a non cash beneficial conversion reversal of $786,000. | | | 9. | Includes a $16.3 million gain on sale of the ophthalmic product line in October 2001. | | | 10. | Includes a non cash beneficial conversion charge of $1.8 million. | | | 11. | Includes sales of NJ Net Operating Loss in 2005, 2004, 2003 and 2002 of $490,634, $444,744, $227,798 and $215,223, respectively. |
BUSINESS CONDUCTED BY VELA Overview Vela is a privately-held Delaware corporation specializing in the rediscovery and development of medicines related to the nervous system, including the brain-gut axis (links between the nervous system and the digestive system). Vela seeks to minimize some of the risks of traditional drug discovery and development by working primarily with drug assets for which human safety data are already available and by employing a clinical development team with extensive clinical trial experience. Since its inception, Vela has raised approximately $58 million in equity and debt financing from leading venture capital investors, including affiliates of JPMorgan Partners, New Enterprise Associates and Venrock Associates.Associates. More than half of Vela’s research and development spending since inception has been for the development of dextofisopam for the treatment of irritable bowel syndrome (“IBS”). Vela has established a composition-of-matter patent position on dextofisopam to at least 2019, has conducted three Phase I clinical trials showing positive indications for tolerability in healthy volunteers, and has conducted one Phase II trial showing positive indications for potential efficacy and tolerability in women and men with diarrhea-predominant or alternating-type IBS. Vela has planned a Phase IIb dose-ranging trial for dextofisopam in IBS patients.patients. Vela’s other
|
clinical-stage assets include VPI-013 (previously known as OPC-14523) for the treatment of neuropathic pain and female hypoactive sexual desire disorder, and tianeptine for the treatment of IBS and related functional gastrointestinal disorders. Vela currently has seven employees and leases approximately 10,500 square feet of office space at 820 Bear Tavern Road in Ewing, New Jersey 08628. Its telephone number is (609) 771-8660. Principal Assets Vela’s assets include dextofisopam and tianeptine for the treatment of irritable bowel syndrome and VPI-013 (previously known as OPC-14523) for the treatment of neuropathic pain and female hypoactive sexual desire disorder. Dextofisopam to Treat IBS Irritable bowel syndrome, or IBS, is a chronic, recurring condition with symptoms that affect up to 15% of American adults, more often women than men. IBS is characterized by multiple symptoms that include bowel dysmotility—diarrhea, constipation, or alternating diarrhea and constipation—and abdominal discomfort. Studies have shown that diarrhea-predominant IBS appears to be the most common subtype. For patients with diarrhea-predominant and alternating-type IBS, there are no recently approved treatments for any but the most severely affected women, and none for men. Vela’s lead asset is dextofisopam, a novel agent in development for the treatment of IBS. Many drugs and drug candidates are produced in mixtures that include “mirror-image” versions of the molecular form of the drug, which include “right-handed” (or “R”) and “left-handed” (or “S”) forms. The mixture of equal amounts of “R” and “S” forms of the same drug are called racemic mixtures. Research has shown that in certain cases the “R” and “S” forms can exert different therapeutic effects and/or side effects. Dextofisopam is the R-enantiomer, or “R” form, of racemic tofisopam, a molecule marketed and used outside the United States for over three decades for multiple indications, including IBS. Vela is developing the R-enantiomer, rather than the racemic mixture, of tofisopam. Several drugs in development for the treatment of IBS and other conditions target a molecular family known as serotonin. Interacting with serotonin is known to cause several undesirable side effects. Dextofisopam exerts its therapeutic effect through a novel mechanism that does not interact with serotonin, thus minimizing the risk of causing these side effects. Vela holds an issued composition-of-matter patent on dextofisopam in the United States which expires in 2019 and holds certain related foreign patents and patent applications; Vela has filed additional, related patent applications for the treatment of IBS in the United States, and foreign counterparts. Vela owns the dextofisopam patent portfolio free of any licensing milestones or royalties payable to third parties. Vela conducted over 100 preclinical tests with dextofisopam and conducted several Phase I trials to establish tolerability in humans. Vela completed a twelve-week Phase II study in both women and men with diarrhea-predominant and alternating-type (alternating between diarrhea and constipation) IBS. In January 2005, Vela announced positive
results from its Phase II clinical trial. On the primary endpoint of “adequate overall relief,” dextofisopam provided statistically significant benefit in patients with either diarrhea-predominant or alternating-type IBS. The “p-value” of this clinical trial was 0.033, meaning the likelihood that the positive results of the trial were due to chance alone was 3.3%. In patients with diarrhea-predominant IBS, reduced stool frequency and improved stool consistency were noted as early as the second day of treatment. Dextofisopam appeared well tolerated and did not cause significant constipation. Further analyses of Vela’s Phase II study results indicated that while dextofisopam provided benefit in both men and women, improvement was demonstrated across more endpoints in women. Dextofisopam provided similar benefit in men and in women on the primary endpoint of adequate overall relief and on the secondary endpoint of stool consistency. For two other secondary endpoints, stool frequency and abdominal pain/discomfort, dextofisopam appeared to provide more benefit in women than in men. Vela met with the FDA in April 2005 to discuss a Phase IIb protocol, and Vela and Pharmos are planning a dose-ranging trial with dextofisopam in women with diarrhea-predominant and alternating-type IBS. This study is anticipated to enroll approximately 480 patients across up to 80 sites in the United States and is expected to begin later this year or early next year. |
Tianeptine to Treat IBS or Functional Dyspepsia Tianeptine is a racemic molecule marketed and used outside the United States since 1988 for the treatment of depression. Vela’s patent protection for tianeptine consists of a United States method-of-use patent covering tianeptine and its two enantiomers for the treatment of IBS and non-ulcer dyspepsia. This patent expires in 2023. Additional foreign patents related to this United States patent are pending. Vela does not owe any licensing milestones or royalties to any other company in connection with this asset. In Vela’s preclinical studies, tianeptine showed significant activity in animal models of altered bowel motility, visceral hypersensitivity, and pain. Specifically, tianeptine normalized stimulated colonic motility and reduced visceral hypersensitivity following provocative colorectal distension, while having little effect on basal colonic motility. These data suggest the possibility that tianeptine might provide symptomatic relief to IBS patients without producing constipation or diarrhea. Tianeptine also demonstrated activity in animal models of visceral pain and neuropathic pain. Vela has not conducted any clinical trials with tianeptine, although, as noted earlier, tianeptine is marketed and used in certain countries outside the United States. VPI-013 to Treat Neuropathic Pain and/or HSDD Neuropathic pain is caused by a primary lesion or dysfunction in the nervous system. The injury can be to the central nervous system (brain and spinal cord) or the peripheral nervous system (nerves outside the brain and spinal cord). Neuropathic pain is a component of many disorders, including infections, diabetes, and lumbar disc disease. The current therapeutic market for neuropathic pain is underserved, largely by the off-label use of antidepressants and anticonvulsants. The anticonvulsant gabapentin (Neurontin®), while not broadly approved for the treatment of neuropathic pain, is widely used off-label for this indication. Treatment with gabapentin is limited by significant side-effect issues, including high rates of dizziness, sleepiness and sedation. Sexual dysfunction of some type has been reported in up to 31% of adult men and 43% of adult women. Hypoactive sexual desire disorder, or HSDD, is the most common form of sexual dysfunction in women. Approved therapies for sexual dysfunction currently target only a small subset of patients (e.g., men with erectile dysfunction). Most of the recent approaches to the treatment of HSDD have focused on hormonal therapies, but safety concerns about the chronic use of hormonal therapies in women have limited the success of this approach. In March 2004, Vela in-licensed North American and European rights (and rights in select additional countries) to VPI-013 from Otsuka Pharmaceutical Co., Ltd. The VPI-013 patent estate consists of a United States composition-of-matter patent (which expires in 2014), a United States method-of-use patent, and foreign counterparts. The patents are owned by Otsuka and are licensed exclusively to Vela in the geographic areas noted above. Vela and Otsuka recently jointly filed additional patent applications covering the treatment of sexual dysfunction and neuropathic pain. Vela licensed VPI-013 with the intent of conducting a Phase II trial or trials and then sub-licensing the asset to a third party. Any milestones and royalties paid by a sublicensee would be shared by Vela and Otsuka. Preclinical testing by Otsuka suggested the potential for utility of VPI-013 in multiple disorders related to the central nervous system. Otsuka tested the tolerability of VPI-013 in multiple Phase I studies. Otsuka also tested VPI-013VPI-
013 in two large Phase II trials for the treatment of major depression. Results indicated that while VPI-013 showed some antidepressant activity, this effect did not reach statistical significance. In Otsuka’s Phase 2 trials, VPI-013 was well tolerated and produced little or no sexual dysfunction. Vela conducted a Phase II trial comparing VPI-013 to placebo in depressed patients. In this trial, VPI-013 showed some antidepressant activity but did not achieve statistical significance on the primary depression endpoint. VPI-013 was well tolerated at the trial dosage. Based on internally generated information and clinical data from the Otsuka trials, Vela assessed sexual function in this trial using the Changes in Sexual Function Questionnaire (CSFQ). At the start of the trial, most of the depressed patients were experiencing sexual dysfunction according to the CSFQ. During the trial, compared with placebo, treatment with VPI-013 significantly improved overall sexual function (CSFQ total score; p = 0.050), sexual desire/frequency (p = 0.015) and sexual desire/interest (p = 0.011). The apparent improvement in sexual function in men and women during the study did not correlate well with |
| | amelioration of depression, making it unlikely that the improvement in sexual function was driven by change in depressive symptomatology. These data suggest that VPI-013 may have improved libido in patients in the trial. Vela is exploring further development of VPI-013 as a treatment for HSDD. | | Vela has also conducted preclinical studies in rodents, with results suggesting the possibility that VPI-013 may have potential as a treatment for neuropathic pain. In a preclinical model of neuropathic pain, certain doses of VPI-013 performed as well as or better than the tested dose of gabapentin. Gabapentin, while not broadly approved for the treatment of neuropathic pain, is widely used off-label for this indication. Vela is considering further development of VPI-013 as a treatment for neuropathic pain. | | VELA MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS | | The following discussion should be read in conjunction with Vela’s financial statements and related notes and the other financial information included elsewhere in this proxy statement. This discussion does not take into account the impact of the contemplated merger with Pharmos. | | Background Vela specializes in the rediscovery and development of medicines related to the nervous system, including the brain-gut axis (links between the nervous system and the digestive system). Vela’s efforts over the past two years have focused primarily on three clinical-stage assets. These assets are dextofisopam for IBS, VPI-013 for neuropathic pain or HSDD (although originally tested for major depression), and tianeptine for IBS or functional dyspepsia. These medical disorders are all prevalent, and current treatment options for these are limited. | | As of March 31, 2006, Vela had cumulative losses of approximately $63,820,000, negative working capital, and negative cash flows from operations. With several drugs in clinical development, Vela expects operating losses to continue for at least the next several years. These conditions raise substantial doubt about Vela’s ability to continue as a going concern in the absence of additional equity funding or funding from a strategic partner. Vela has been engaged in strategic discussions related to partnering or sublicensing of its assets; a goal of such discussions would be to bring in cash from a partner and to have such a partner assume certain clinical development costs in return for a portion of potential future profits. Vela has also from time to time considered potential asset sales to, and potential mergers with, third parties. Results of Operations Comparison of Years Ended December 31, 2005 and December 31, 2004 Revenues Vela does not generate and has not generated any revenues from product sales or licensing. Vela has from time to time been in discussions with potential partners for the possible licensing of certain of its assets, but does not expect to generate revenues from product sales in the foreseeable future. Expenses Research and development expenses for 2005 were $5.1 million, compared to $10.3 million for 2004. The decrease in research and development expenses is primarily attributable to the completion of the dextofisopam
Phase II trial in 2004. The majority of the 2005 research and development expenses were in connection with the VPI-013 Phase II trial. General and administrative expenses for 2005 were $2.6 million, compared to $2.1 million for 2004. The factors primarily contributing to this increase were increased legal fees and other expenses in connection with the consideration of strategic alternatives and increased expenses related to the expansion and maintenance of intellectual property. |
Business development expenses for 2005 were $1.1 million, compared to $1.3 million for 2004. This decrease was primarily the result of a decrease in activities related to the search for, evaluation of, and potential in-licensing of additional drug assets. Interest expense for 2005 was $596,949, compared to $36,629 for 2004. The increase in interest expense resulted from Vela’s issuance of an aggregate of $10 million of convertible notes in 2005. The outstanding principal and accrued interest on such convertible notes were $14 million and $633,580 as of December 31, 2005, and $4 million and $36,629 as of December 31, 2004, respectively. Income Tax Benefit As a result of its operating losses, Vela had no federal or state income tax liability for 2005 or 2004. During 2005 and 2004, Vela sold unused state net operating loss carry-forwards through a program sponsored by the State of New Jersey and the New Jersey Economic Development Authority. Cash proceeds of $333,660, net of fees of $9,321, were received by Vela in 2005. Cash proceeds of $395,642, net of fees of $11,051, were received by Vela in 2004. As of December 31, 2005, Vela had a net operating loss carry-forward for federal income tax purposes of approximately $57 million. The ability of Pharmos to utilize Vela’s net operating losses to offset any income after the closing of the merger will be subject to limitation under section 382 of the Internal Revenue Code. Vela also had a research and development tax credit for federal income tax purposes of approximately $2 million at December 31, 2005. Comparison of Three Months Ended March 31, 2006 and March 31, 2005 Revenues Vela does not generate and has not generated any revenues from product sales or licensing. Vela does not expect to generate revenues from product sales in the next several years; however, Vela has from time to time been in discussions with potential partners regarding the possible licensing of certain of its assets.
Expenses Research and development expenses for the three months ended March 31, 2006 were $363,362, compared to $1,884,904 for the three months ended March 31, 2005. The decrease in research and development expenses is primarily attributable to the completion of the VPI-013 Phase II depression trial in 2005. The majority of the research and development expenses for the three months ended March 31, 2005 were in connection with the VPI-013 Phase II depression trial. General and administrative expenses for the three months ended March 31, 2006 were $856,803, compared to $631,106 for the three months ended March 31, 2005. The factors primarily contributing to this increase were increased legal fees and other expenses in connection with the consideration of strategic alternatives and increased expenses related to the expansion and maintenance of intellectual property. Business development expenses for the three months ended March 31, 2006 were $221,751, compared to $410,498 for the three months ended March 31, 2005. This decrease was primarily the result of a decrease in activities related to the search for and evaluation of additional drug assets. Interest income and interest expense for the three months ended March 31, 2006 were $12,826 and $217,565 compared to interest income and interest expense of $7,550 and $83,746 for the three months ended March 31, 2005. The increase in interest expense resulted from Vela’s issuance of an aggregate of $10 million of convertible notes in 2005. The outstanding principal and accrued interest on such convertible notes were $14 million and $851,145 as of March 31, 2006. Income Tax Benefit |
At March 31, 2006, Vela had a net operating loss carry-forward for federal income tax purposes of approximately $59 million. The ability of Pharmos to utilize Vela’s net operating losses to offset any income after the closing of the merger will be subject to limitation under section 382 of the Internal Revenue Code. Vela also had a research and development tax credit for federal income tax purposes of approximately $2 million at March 31, 2006. Liquidity and Capital Resources Vela’s principal sources of funding through March 31, 2006 have been through the issuance and sale of convertible preferred stock and convertible bridge notes and proceeds from the sale of net operating losses. In October 2004, Vela entered into a Note and Warrant Purchase Agreement with certain of its existing investors pursuant to which Vela issued $8 million in senior convertible bridge notes in four equal installments of $2 million between October 2004 and March 2005. Interest on these notes is compounded monthly at a rate of 6% per annum. With each installment of such bridge notes, Vela issued to the lenders warrants to purchase an aggregate of 300,297 shares of its common stock. In May 2006, the maturity date of these notes was extended to the earlier of the date of sale of Vela or September 29, 2006. In June 2005, Vela entered into a second Note and Warrant Purchase Agreement with certain of its existing investors pursuant to which Vela issued $6 million in senior convertible bridge notes in three equal installments of $2,000,000 between June 2005 and October 2005. Interest is compounded monthly at a rate of 6% per annum. With each installment of such bridge notes, the Company issued to the lenders warrants to purchase an aggregate of 400,002 shares of its common stock. In May 2006, the maturity date of these notes was extended to the earlier of the date of sale of Vela or September 29, 2006. At March 31, 2006, Vela had cash and cash equivalents of $903,912, compared to $1,786,935 as of December 31, 2005 (and an additional $345,600 of restricted cash that was set aside for the payment of one-half of the minimum stay bonuses under Vela’s Acquisition Bonus Plan, which were paid in March 2006). Net cash used in operating activities was $883,023 for the three months ended March 31, 2006, compared to $3,661,494 for the three months ended March 31, 2005. This decrease was attributable to the decreased research and development activities and expenses for the three months ended March 31, 2006. No net cash was used in investing activities for the three months ended March 31, 2006 compared to $3,592 for the three months ended March 31, 2005. No net cash was provided by financing activities for the three months ended March 31, 2006 compared to $4 million (from the issuance of the convertible bridge notes described above) for the three months ended March 31, 2005.
Vela’s cash at March 31, 2006 was not expected to be sufficient to fund operations through the expected closing date of the merger with Pharmos. On June 6, 2006, Vela entered into a Senior Note Purchase Agreement with certain of its existing investors providing for a credit facility pursuant to which Vela may draw down up to $1 million in aggregate principal amount of 20% promissory notes, which are senior to Vela’s convertible bridge notes. The maturity date of these senior notes is the earlier of the date of sale of Vela or September 29, 2006. If Vela were to require additional capital to fund operations, Vela would need either to raise additional equity from investors or to sublicense or sell a stake in one or more of its drug assets to a development partner. Vela has had and continues to have indications of interest in its drug assets from potential development partners. |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Financial Statements Contents |
| | | | | | Report of Independent Registered Public Accounting Firm | | 34 | Balance Sheets at December 31, 2005 and 2004 | | 35 | Statements of Operations for the years ended December 31, 2005 and 2004 and for the period from February 4, 1998 (inception) through December 31, 2005 | | 36 | Statements of Stockholders’ Deficiency for the period from February 4, 1998 (inception) through December 31, 2005 | | 37 | Statements of Cash Flows for the years ended December 31, 2005 and 2004 and for the period from February 4, 1998 (inception) through December 31, 2005 | | 39 | Notes to Financial Statements | | 40 | | | | Condensed Balance Sheets at March 31, 2006 and December 31, 2005 | | 52 | Condensed Statements of Operations for the three months ended March 31, 2006 and 2005 and for the period from February 4, 1998 (inception) through March 31, 2006 | | 53 | Condensed Statements of Cash Flows for the three months ended March 31, 2006 and 2005 and for the period from February 4, 1998 (inception) through March 31, 2006 | | 54 | Notes to Unaudited Condensed Financial Statements | | 55 |
Report of Independent Registered Public Accounting Firm | | 36 | | Balance Sheets at December 31, 2005 and 2004 | | 37 | | Statements of Operations for the years ended December 31, 2005 and 2004 and for the period from
February 4, 1998 (inception) through December 31, 2005 | | 38 | | Statements of Stockholders’ Deficiency for the period from February 4, 1998 (inception) through
December 31, 2005 | | 39 | | Statements of Cash Flows for the years ended December 31, 2005 and 2004 and for the period from
February 4, 1998 (inception) through December 31, 2005 | | 41 | | Notes to Financial Statements | | 42 | | | | | | Condensed Balance Sheets at March 31, 2006 and December 31, 2005 | | 57 | | Condensed Statements of Operations for the three months ended March 31, 2006 and 2005 and for the
period from February 4, 1998 (inception) through March 31, 2006 | | 58 | | Condensed Statements of Cash Flows for the three months ended March 31, 2006 and 2005 and for the
period from February 4, 1998 (inception) through March 31, 2006 | | 59 | | Notes to Unaudited Condensed Financial Statements | | 60 | |
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Vela Pharmaceuticals Inc. We have audited the accompanying balance sheets of Vela Pharmaceuticals Inc. (a development stage enterprise) as of December 31, 2005 and 2004, and the related statements of operations, stockholders’ deficiency and cash flows for the years then ended and the period from February 4, 1998 (inception) to December 31, 2005. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Vela Pharmaceuticals Inc. at December 31, 2005 and 2004 and the results of its operations and its cash flows for the years then ended and the period from February 4, 1998 (inception) to December 31, 2005 in conformity with accounting principles generally accepted in the United States. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has incurred operating losses and has a significant accumulated deficit, negative working capital and negative cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. /s/ Ernst & Young LLP March 15, 2006 |
35Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Balance Sheets
|
| | | | | | | | | | December 31, | | | |
| | | | 2005 | | 2004 | | | |
| |
| | Assets | | | | | | | | Current assets: | | | | | | | | Cash and cash equivalents | | $ | 1,786,935 | | $ | 1,861,858 | | Restricted cash | | | 345,600 | | | — | | Interest receivable | | | 1,117 | | | 743 | | Prepaid expenses and other current assets | | | 54,740 | | | 185,117 | | | |
|
| |
|
| | Total current assets | | | 2,188,392 | | | 2,047,718 | | Property and equipment, net | | | 138,246 | | | 232,257 | | Other assets | | | 11,997 | | | 12,073 | | | |
|
| |
|
| | | | $ | 2,338,635 | | $ | 2,292,048 | | | |
|
| |
|
| | Liabilities, redeemable preferred stock and stockholders’ deficiency | | | | | | | | Current liabilities: | | | | | | | | Accounts payable | | $ | 106,091 | | $ | 1,269,683 | | Accrued bonuses | | | 281,008 | | | 415,575 | | Other accrued expenses | | | 225,187 | | | 369,517 | | Bridge notes payable | | | 14,000,000 | | | 4,000,000 | | Accrued interest payable | | | 633,580 | | | 36,629 | | | |
|
| |
|
| | Total current liabilities | | | 15,245,866 | | | 6,091,404 | | Series C Redeemable Convertible Preferred Stock; par value $0.001 per share, authorized, issued and outstanding 2,859,650 shares at December 31, 2005 and 2004. Liquidation value: $40,750,013 at December 31, 2005 and 2004 | | | 21,147,128 | | | 21,136,994 | | Series D Redeemable Convertible Preferred Stock; par value $0.001 per share, authorized 11,959,215 and 10,048,175 shares at December 31, 2005 and 2004, respectively; issued and outstanding 7,500,075 shares at December 31, 2005 and 2004. Liquidation value: $62,500,375 at December 31, 2005 and 2004 | | | 24,906,084 | | | 24,874,779 | | Stockholders’ deficiency: | | | | | | | | Series A Convertible Preferred Stock; par value 0.001 per share, authorized, issued and outstanding 1,436,651 shares at December 31, 2005 and 2004. Liquidation value: $3,591,628 at December 31, 2005 and 2004 | | | 1,437 | | | 1,437 | | Series B Convertible Preferred Stock; par value 0.001 per share, authorized and issued 554,859 shares at December 31, 2005 and 2004, outstanding 454,859 and 554,859 shares at December 31, 2005 and 2004, respectively. Liquidation value: $3,411,443 and $4,161,443 at December 31, 2005 and 2004, respectively | | | 555 | | | 555 | | Common stock; par value 0.001 per share, authorized 25,000,000 and 22,000,000 shares at December 31, 2005 and 2004, respectively; issued 1,297,504 shares at December 31, 2005 and 2004 and outstanding 1,210,004 and 1,297,504 shares at December 31, 2005 and 2004, respectively | | | 1,299 | | | 1,298 | | Additional paid-in capital | | | 3,209,968 | | | 3,248,787 | | Deficit accumulated during development stage | | | (62,173,702 | ) | | (53,063,206 | ) | Treasury Stock: | | | | | | | | Series B Convertible Preferred Stock; at cost, 100,000 shares at December 31, 2005 | | | — | | | — | | Common stock; at cost, 88,500 shares at December 31, 2005 | | | — | | | — | | | |
|
| |
|
| | Total stockholders’ deficiency | | | (58,960,443 | ) | | (49,811,129 | ) | | |
|
| |
|
| | | | $ | 2,338,635 | | $ | 2,292,048 | | | |
|
| |
|
| |
See accompanying notes.
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Balance SheetsStatements of Operations
| |
| | December 31, | |
|---|
| | 2005 | | 2004 | |
|---|
| |
| |
|---|
Assets | | | | | | | | Current assets: | | | | | | | | Cash and cash equivalents | | $ | 1,786,935 | | $ | 1,861,858 | | Restricted cash | | | 345,600 | | | — | | Interest receivable | | | 1,117 | | | 743 | | Prepaid expenses and other current assets | | | 54,740 | | | 185,117 | | | |
| | Total current assets | | | 2,188,392 | | | 2,047,718 | | | | | | | | | | Property and equipment, net | | | 138,246 | | | 232,257 | | Other assets | | | 11,997 | | | 12,073 | | | |
| | | | $ | 2,338,635 | | $ | 2,292,048 | | | |
| | | | | | | | | | Liabilities, redeemable preferred stock and stockholders’ deficiency | | | | | | | | Current liabilities: | | | | | | | | Accounts payable | | $ | 106,091 | | $ | 1,269,683 | | Accrued bonuses | | | 281,008 | | | 415,575 | | Other accrued expenses | | | 225,187 | | | 369,517 | | Bridge notes payable | | | 14,000,000 | | | 4,000,000 | | Accrued interest payable | | | 633,580 | | | 36,629 | | | |
| | Total current liabilities | | | 15,245,866 | | | 6,091,404 | | | | | | | | | | Series C Redeemable Convertible Preferred Stock; par value $0.001 per share, authorized, issued and outstanding 2,859,650 shares at December 31, 2005 and 2004. Liquidation value: $40,750,013 at December 31, 2005 and 2004 | | | 21,147,128 | | | 21,136,994 | | Series D Redeemable Convertible Preferred Stock; par value $0.001 per share, authorized 11,959,215 and 10,048,175 shares at December 31, 2005 and 2004, respectively; issued and outstanding 7,500,075 shares at December 31, 2005 and 2004. Liquidation value: $62,500,375 at December 31, 2005 and 2004 | | | 24,906,084 | | | 24,874,779 | | | | | | | | | | Stockholders’ deficiency: | | | | | | | | Series A Convertible Preferred Stock; par value 0.001 per share, authorized, issued and outstanding 1,436,651 shares at December 31, 2005 and 2004. Liquidation value: $3,591,628 at December 31, 2005 and 2004 | | | 1,437 | | | 1,437 | | Series B Convertible Preferred Stock; par value 0.001 per share, authorized and issued 554,859 shares at December 31, 2005 and 2004, outstanding 454,859 and 554,859 shares at December 31, 2005 and 2004, respectively. Liquidation value: $3,411,443 and $4,161,443 at December 31, 2005 and 2004, respectively | | | 555 | | | 555 | | Common stock; par value 0.001 per share, authorized 25,000,000 and 22,000,000 shares at December 31, 2005 and 2004, respectively; issued 1,297,504 shares at December 31, 2005 and 2004 and outstanding 1,210,004 and 1,297,504 shares at December 31, 2005 and 2004, respectively | | | 1,299 | | | 1,298 | | Additional paid-in capital | | | 3,209,968 | | | 3,248,787 | | Deficit accumulated during development stage | | | (62,173,702 | ) | | (53,063,206 | ) | Treasury Stock: | | | | | | | | Series B Convertible Preferred Stock; at cost, 100,000 shares at December 31, 2005 | | | — | | | — | | Common stock; at cost, 88,500 shares at December 31, 2005 | | | — | | | — | | | |
| | Total stockholders’ deficiency | | | (58,960,443 | ) | | (49,811,129 | ) | | |
| | | | $ | 2,338,635 | | $ | 2,292,048 | | | |
| |
| | | | | | | | | | | | | | | | Period from
February 4, 1998
(Inception) to
December
31, 2005 | | | | Year ended December 31, | | | | |
| | | | | 2005 | | 2004 | | | | |
| |
| |
| | | | | | | | | | Consulting revenues | | $ | — | | $ | — | | $ | 234,018 | | | | | | | | | | | | | Operating expenses: | | | | | | | | | | | Research and development | | | 5,115,830 | | | 10,328,872 | | | 41,912,055 | | General and administrative | | | 2,632,490 | | | 2,099,187 | | | 11,254,838 | | Business development | | | 1,134,280 | | | 1,308,058 | | | 6,063,336 | | | | | | | | | | | | | | |
|
| |
|
| |
|
| | Total expenses | | | 8,882,600 | | | 13,736,117 | | | 59,230,229 | | | |
|
| |
|
| |
|
| | | | | | | | | | | | | Operating loss | | | (8,882,600 | ) | | (13,736,117 | ) | | (58,996,211 | ) | | | | | | | | | | | | Interest income | | | 35,393 | | | 56,754 | | | 1,367,421 | | Interest expense | | | (596,949 | ) | | (36,629 | ) | | (643,315 | ) | | |
|
| |
|
| |
|
| | | | | | | | | | | | | Loss before tax | | | (9,444,156 | ) | | (13,715,992 | ) | | (58,272,105 | ) | | | | | | | | | | | | Income tax benefit | | | 333,660 | | | 395,642 | | | 975,926 | | | |
|
| |
|
| |
|
| | | | | | | | | | | | | Net loss | | | (9,110,496 | ) | | (13,320,350 | ) | | (57,296,179 | ) | | | | | | | | | | | | Preferred stock accretion | | | (41,439 | ) | | (41,439 | ) | | (177,880 | ) | | | | | | | | | | | | | |
|
| |
|
| |
|
| | Net loss attributable to common stockholders | | $ | (9,151,935 | ) | $ | (13,361,789 | ) | $ | (57,474,059 | ) | | |
|
| |
|
| |
|
| |
See accompanying notes.notes. |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Statements of Operations
| |
| | Year ended December 31, | | Period from
February 4, 1998
(Inception) to
December
31, 2005 | |
|---|
2005 | | 2004 |
|---|
| |
| |
|---|
| | | | | | | | | | | Consulting revenues | | $ | — | | $ | — | | $ | 234,018 | | | | | | | | | | | | | Operating expenses: | | | | | | | | | | | Research and development | | | 5,115,830 | | | 10,328,872 | | | 41,912,055 | | General and administrative | | | 2,632,490 | | | 2,099,187 | | | 11,254,838 | | Business development | | | 1,134,280 | | | 1,308,058 | | | 6,063,336 | | | |
| | Total expenses | | | 8,882,600 | | | 13,736,117 | | | 59,230,229 | | | |
| | | | | | | | | | | | | Operating loss | | | (8,882,600 | ) | | (13,736,117 | ) | | (58,996,211 | ) | | | | | | | | | | | | Interest income | | | 35,393 | | | 56,754 | | | 1,367,421 | | Interest expense | | | (596,949 | ) | | (36,629 | ) | | (643,315 | ) | | |
| | Loss before tax | | | (9,444,156 | ) | | (13,715,992 | ) | | (58,272,105 | ) | | | | | | | | | | | | Income tax benefit | | | 333,660 | | | 395,642 | | | 975,926 | | | |
| | Net loss | | | (9,110,496 | ) | | (13,320,350 | ) | | (57,296,179 | ) | | | | | | | | | | | | Preferred stock accretion | | | (41,439 | ) | | (41,439 | ) | | (177,880 | ) | | |
| | Net loss attributable to common stockholders | | $ | (9,151,935 | ) | $ | (13,361,789 | ) | $ | (57,474,059 | ) | | |
| |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Statements of Stockholders’ Deficiency
| |
| | Stockholders’ Deficiency | |
|---|
| |
| |
|---|
| | Series A
Convertible
Preferred Stock | | Series B
Convertible
Preferred Stock | | Common Stock | | Additional
Paid-in
Capital | | Accumulated
Other
Comprehensive
Income | | Deficit
Accumulated
During
Development
Stage | | Treasury
Stock | | Total
Shareholders’
Deficiency | |
|---|
| |
| |
| |
| | | | | | |
|---|
| | Shares | | Amount | | Shares | | Amount | | Shares | | Amount | | | | | | |
|---|
| |
| |
| |
| | Balance at February 4, 1998 (Inception) | | | — | | $ | — | | | — | | $ | — | | | — | | $ | — | | $ | — | | $ | — | | $ | — | | $ | — | | $ | — | | Issuance of common shares in exchange for services, March 1998 | | | — | | | — | | | — | | | — | | | 530,000 | | | 530 | | | 4,770 | | | — | | | — | | | — | | | 5,300 | | Issuance of common shares in exchange for patent rights, March 1998 | | | — | | | — | | | — | | | — | | | 250,000 | | | 250 | | | 2,250 | | | — | | | — | | | — | | | 2,500 | | Issuance of common shares in exchange for services, April 1998 | | | — | | | — | | | — | | | — | | | 12,000 | | | 12 | | | 108 | | | — | | | — | | | — | | | 120 | | Net loss for the period | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | | | | (198,680 | ) | | — | | | (198,680 | ) | | |
| |
| |
| | Balance at December 31, 1998 | | | — | | | — | | | — | | | — | | | 792,000 | | | 792 | | | 7,128 | | | — | | | (198,680 | ) | | — | | | (190,760 | ) | Issuance of common shares in exchange for services, January 1999 | | | — | | | — | | | — | | | — | | | 5,000 | | | 5 | | | 45 | | | — | | | — | | | — | | | 50 | | Issuance of common shares in exchange for cash, February 1999 | | | — | | | — | | | — | | | — | | | 202,500 | | | 202 | | | 20,048 | | | — | | | — | | | — | | | 20,250 | | Issuance of common shares in exchange for services, June 1999 | | | — | | | — | | | — | | | — | | | 75,000 | | | 75 | | | 675 | | | — | | | — | | | — | | | 750 | | Issuance of common shares in exchange for cash and services, September 1999 | | | — | | | — | | | — | | | — | | | 5,588 | | | 6 | | | 1,112 | | | — | | | — | | | — | | | 1,118 | | Issuance of Series A preferred in exchange for cash, July - December 1999 | | | 1,146,916 | | | 1,147 | | | — | | | — | | | — | | | — | | | 1,121,447 | | | — | | | — | | | — | | | 1,122,594 | | Issuance of Series B preferred in exchange for cash, December 1999 | | | — | | | — | | | 173,000 | | | 173 | | | — | | | — | | | 506,516 | | | — | | | — | | | — | | | 506,689 | | Conversion of note payable with interest to Series A Preferred, September 1999 | | | 289,735 | | | 290 | | | — | | | — | | | — | | | — | | | 289,445 | | | — | | | — | | | — | | | 289,735 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 8,179 | | | — | | | — | | | — | | | 8,179 | | Net loss for the year (restated) | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | | | | (549,955 | ) | | — | | | (549,955 | ) | | |
| |
| |
| | Balance at December 31, 1999(restated) | | | 1,436,651 | | | 1,437 | | | 173,000 | | | 173 | | | 1,080,088 | | | 1,080 | | | 1,954,595 | | | — | | | (748,635 | ) | | — | | | 1,208,650 | | Issuance of common shares in exchange for services, March 2000 | | | — | | | — | | | — | | | — | | | 10,500 | | | 11 | | | 4,714 | | | — | | | — | | | — | | | 4,725 | | Issuance of common shares in exchange for services, April 2000 | | | — | | | — | | | — | | | — | | | 6,500 | | | 6 | | | 2,919 | | | — | | | — | | | — | | | 2,925 | | Issuance of common shares in exchange for patent rights, April 2000 | | | — | | | — | | | — | | | — | | | 5,000 | | | 5 | | | 2,245 | | | — | | | — | | | — | | | 2,250 | | Issuance of common shares in exchange for services, June 2000 | | | — | | | — | | | — | | | — | | | 8,000 | | | 8 | | | 4,792 | | | — | | | — | | | — | | | 4,800 | | Issuance of common shares in exchange for services, September 2000 | | | — | | | — | | | — | | | — | | | 10,500 | | | 11 | | | 12,589 | | | — | | | — | | | — | | | 12,600 | | Issuance of Series B preferred in exchange for cash, March - June 2000 | | | — | | | — | | | 381,859 | | | 382 | | | — | | | — | | | 1,129,133 | | | — | | | — | | | — | | | 1,129,515 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 79,545 | | | — | | | — | | | — | | | 79,545 | | Issuance of common shares for exercise of stock options, December 2000 | | | — | | | — | | | — | | | — | | | 26,667 | | | 26 | | | 3,974 | | | — | | | — | | | — | | | 4,000 | | Net loss for the year | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (2,591,658 | ) | | — | | | (2,591,658 | ) | | |
| |
| |
| | Balance at December 31, 2000(restated) | | | — | | | — | | | 554,859 | | | 555 | | | 1,147,255 | | | 1,147 | | | 3,194,506 | | | — | | | (3,340,293 | ) | | — | | | (142,648 | ) | Issuance of common shares in exchange for services, January 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 5 | | | 6,295 | | | — | | | — | | | — | | | 6,300 | | Issuance of common shares in exchange for services, April 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 6,296 | | | — | | | — | | | — | | | 6,300 | | Issuance of common shares in exchange for services, July 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 5 | | | 6,295 | | | — | | | — | | | — | | | 6,300 | | Issuance of common shares in exchange for services, October 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 6,296 | | | — | | | — | | | — | | | 6,300 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | | | | 63,600 | | | — | | | — | | | — | | | 63,600 | | Issuance of common shares for exercise of stock options at $0.45/share, December 2001 | | | — | | | — | | | — | | | — | | | 30,333 | | | 31 | | | 13,619 | | | — | | | — | | | — | | | 13,650 | | Issuance of common shares for exercise of stock options at $1.40/share, December 2001 | | | — | | | — | | | — | | | — | | | 1,200 | | | 1 | | | 1,679 | | | — | | | — | | | — | | | 1,680 | | Net loss for the year | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (8,836,840 | ) | | — | | | (8,836,840 | ) | | |
| |
| |
| | Balance at December 31, 2001 | | | 1,436,651 | | | 1,437 | | | 554,859 | | | 555 | | | 1,196,788 | | | 1,197 | | | 3,298,586 | | | — | | | (12,177,133 | ) | | — | | | (8,875,358 | ) | Issuance of common shares in exchange for services, January 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 3,596 | | | — | | | — | | | — | | | 3,600 | | Issuance of common shares in exchange for services, April 2002 | | | — | | | — | | | — | | | — | | | 7,000 | | | 7 | | | 5,593 | | | — | | | — | | | — | | | 5,600 | | Issuance of common shares in exchange for services, July 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 3,596 | | | — | | | — | | | — | | | 3,600 | | Issuance of common shares in exchange for services, October 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 5 | | | 3,595 | | | — | | | — | | | — | | | 3,600 | | Issuance of common shares in exchange for services, December 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 3,596 | | | — | | | — | | | — | | | 3,600 | | Deemed dividend | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (4,877,523 | ) | | — | | | (4,877,523 | ) | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 7,840 | | | — | | | — | | | — | | | 7,840 | | Accretion of mandatorily redeemable preferred stock | | | — | | | — | | | — | | | — | | | — | | | — | | | (53,563 | ) | | — | | | — | | | — | | | (53,563 | ) | Issuance of shares for exercise of stock options at $1.20/per share, March 2002 | | | — | | | — | | | — | | | — | | | 33,750 | | | 34 | | | 40,466 | | | — | | | — | | | — | | | 40,500 | | Issuance of shares for exercise of stock options at $1.40/per share, March 2002 | | | — | | | — | | | — | | | — | | | 200 | | | — | | | 280 | | | — | | | — | | | — | | | 280 | | Issuance of shares for exercise of stock options at $0.45/per share, June 2002 | | | — | | | — | | | — | | | — | | | 8,000 | | | 8 | | | 3,592 | | | — | | | — | | | — | | | 3,600 | | Issuance of shares for exercise of stock options at $1.40/per share, June 2002 | | | — | | | — | | | — | | | — | | | 600 | | | 1 | | | 839 | | | — | | | — | | | — | | | 840 | | Issuance of shares for exercise of stock options at $0.20/per share, December 2002 | | | — | | | — | | | — | | | — | | | 11,666 | | | 12 | | | 2,321 | | | — | | | — | | | — | | | 2,333 | | Comprehensive (loss) income: | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Unrealized gain on marketable securities | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | 3,286 | | | | | | | | | 3,286 | | Net loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (12,487,160 | ) | | — | | | (12,487,160 | ) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| | Total comprehensive loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (12,483,874 | ) | | |
| |
| |
| | Balance at December 31, 2002 | | | 1,436,651 | | | 1,437 | | | 554,859 | | | 555 | | | 1,276,004 | | | 1,276 | | | 3,320,337 | | | 3,286 | | | (29,541,816 | ) | | — | | | (26,214,925 | ) |
| Statements of Stockholders’ Deficiency (continued) | |
| Stockholders’ Deficiency | |
|---|
|
| |
|---|
| | Series A
Convertible
Preferred Stock | | Series B
Convertible
Preferred Stock | | Common Stock | | Additional Paid-in
Capital | | Accumulated
Other Comprehensive
Income | | Deficit
Accumulated
During
Development
Stage | | Treasury
Stock | | Total
Shareholders’
Deficiency | |
|---|
| |
| |
| | | | | | |
|---|
| | Shares | | | Amount | | Shares | | | Amount | | Shares | | Amount | | | | | | |
|---|
| |
| |
| |
| | | | | | | | | | | Balance at December 31, 2002 (carried forward) | | 1,436,651 | | $ | 1,437 | | 554,859 | | $ | 555 | | 1,276,004 | | $ | 1,276 | | $ | 3,320,337 | | $ | 3,286 | | $ | (29,541,816 | ) | $ | — | | $ | (26,214,925 | ) | Issuance of common shares in exchange for services, April 2003 | | — | | | — | | — | | | — | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Issuance of common shares in exchange for services, May 2003 | | — | | | — | | — | | | — | | 2,500 | | | 3 | | | 1,997 | | | — | | | — | | | — | | | 2,000 | | Issuance of common shares in exchange for services, July 2003 | | — | | | — | | — | | | — | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Issuance of common shares in exchange for services, October 2003 | | — | | | — | | — | | | — | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Amortization of deferred stock compensation | | — | | | — | | — | | | — | | — | | | — | | | 3,332 | | | — | | | — | | | — | | | 3,332 | | Accretion of mandatorily redeemable preferred stock | | — | | | — | | — | | | — | | — | | | — | | | (41,439 | ) | | — | | | — | | | — | | | (41,439 | ) | Issuance of shares for exercise of stock options at $0.20/per share, October 2003 | | — | | | — | | — | | | — | | 16,000 | | | 16 | | | 3,184 | | | — | | | — | | | — | | | 3,200 | | Comprehensive (loss) income: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Unrealized loss on marketable securities | | — | | | — | | — | | | — | | — | | | — | | | — | | | (3,286 | ) | | — | | | — | | | (3,286 | ) | Net loss | | — | | | — | | — | | | — | | — | | | — | | | — | | | — | | | (10,201,040 | ) | | — | | | (10,201,040 | ) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Total comprehensive loss | | — | | | — | | — | | | — | | — | | | — | | | — | | | — | | | — | | | — | | | (10,204,326 | ) | | |
| |
| |
| | Balance at December 31, 2003 | | 1,436,651 | | | 1,437 | | 554,859 | | | 555 | | 1,297,504 | | | 1,298 | | | 3,289,808 | | | — | | | (39,742,856 | ) | | — | | | (36,449,758 | ) | Amortization of deferred stock compensation | | — | | | — | | — | | | — | | — | | | — | | | 418 | | | — | | | — | | | — | | | 418 | | Accretion of mandatorily redeemable preferred stock | | — | | | — | | — | | | — | | — | | | — | | | (41,439 | ) | | — | | | — | | | — | | | (41,439 | ) | Net loss | | — | | | — | | — | | | — | | — | | | — | | | — | | | — | | | (13,320,350 | ) | | — | | | (13,320,350 | ) | | |
| |
| |
| | Balance at December 31, 2004 | | 1,436,651 | | | 1,437 | | 554,859 | | | 555 | | 1,297,504 | | | 1,298 | | | 3,248,787 | | | — | | | (53,063,206 | ) | | — | | | (49,811,129 | ) | Amortization of deferred stock compensation | | — | | | — | | — | | | — | | — | | | — | | | 1,821 | | | — | | | — | | | — | | | 1,821 | | Accretion of mandatorily redeemable preferred stock | | — | | | — | | — | | | — | | — | | | — | | | (41,439 | ) | | — | | | — | | | — | | | (41,439 | ) | Surrender of common shares, December 2005 | | — | | | — | | — | | | — | | (88,500 | ) | | — | | | — | | | — | | | — | | | — | | | — | | Surrender of Series B Convertible Preferred Stock, December 2005 | | — | | | — | | (100,000 | ) | | — | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Issuance of shares for exercise of stock options at $0.80/per share, August 2005 | | — | | | — | | — | | | — | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Net loss | | — | | | — | | — | | | — | | — | | | — | | | — | | | — | | | (9,110,496 | ) | | | | | (9,110,496 | ) | | |
| |
| |
| | Balance at December 31, 2005 | | 1,436,651 | | $ | 1,437 | | 454,859 | | $ | 555 | | 1,210,004 | | $ | 1,299 | | $ | 3,209,968 | | $ | — | | $ | (62,173,702 | ) | $ | — | | $ | (58,960,443 | ) | | |
| |
| |
| |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Statements of Cash FlowsStockholders’ Deficiency | |
| | |
Year ended December 31, | | Period from
February
4, 1998
(Inception) to
December 31,
2005 | |
|---|
2005 | | 2004 |
|---|
| |
| | Operating activities | | | | | | | | | | | Net loss | | $ | (9,110,496 | ) | $ | (13,320,350 | ) | $ | (57,296,179 | ) | Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | Depreciation and amortization | | | 91,036 | | | 97,761 | | | 327,162 | | Loss on disposal of property and equipment | | | 7,716 | | | 7,050 | | | 14,766 | | Deferred stock compensation to consultants | | | 1,821 | | | 418 | | | 164,736 | | Common stock issued to consultants for services and patent rights | | | — | | | — | | | 85,618 | | Preferred stock issued for interest expense | | | — | | | — | | | 9,737 | | Changes in operating assets and liabilities: | | | | | | | | | | | Other current assets | | | 130,003 | | | (86,174 | ) | | (55,857 | ) | Other assets | | | 76 | | | 1,184 | | | (11,997 | ) | Accounts payable | | | (1,163,592 | ) | | 144,810 | | | 106,091 | | Accrued bonuses | | | (134,567 | ) | | 142,575 | | | 281,008 | | Other accrued expenses | | | (144,330 | ) | | (114,193 | ) | | 225,187 | | Accrued interest payable | | | 596,951 | | | 36,629 | | | 633,580 | | | |
| | Net cash used in operating activities | | | (9,725,382 | ) | | (13,090,290 | ) | | (55,516,148 | ) | | | | | | | | | | | | Investing activities | | | | | | | | | | | Additions to property and equipment | | | (9,086 | ) | | (195,947 | ) | | (484,519 | ) | Proceeds from the sale of property and equipment | | | 4,345 | | | | | | 4,345 | | Sale of marketable securities | | | — | | | 1,600,000 | | | — | | Restricted cash | | | (345,600 | ) | | — | | | (345,600 | ) | | |
| | Net cash (used in) provided by investing activities | | | (350,341 | ) | | 1,404,053 | | | (825,774 | ) | | | | | | | | | | | | Financing activities | | | | | | | | | | | Proceeds from issuance of bridge notes | | | 10,000,000 | | | 4,000,000 | | | 14,280,000 | | Proceeds from issuance of common stock | | | 800 | | | — | | | 92,251 | | Proceeds from issuance of Series A preferred stock | | | — | | | — | | | 1,122,592 | | Proceeds from issuance of Series B preferred stock | | | — | | | — | | | 1,636,205 | | Proceeds from issuance of Series C preferred stock | | | — | | | — | | | 16,216,402 | | Proceeds from issuance of Series D preferred stock | | | — | | | — | | | 24,781,407 | | | |
| | Net cash provided by financing activities | | | 10,000,800 | | | 4,000,000 | | | 58,128,857 | | | |
| | Net (decrease) increase in cash and cash equivalents | | | (74,923 | ) | | (7,686,237 | ) | | 1,786,935 | | Cash and cash equivalents at beginning of period | | | 1,861,858 | | | 9,548,095 | | | — | | | |
| | Cash and cash equivalents at end of period | | $ | 1,786,935 | | $ | 1,861,858 | | $ | 1,786,935 | | | |
| | | | | | | | | | | | | Schedule of noncash transactions | | | | | | | | | | | Deemed dividends on Series C preferred stock | | $ | — | | $ | — | | $ | 4,877,523 | | Conversion of note payable to Series A preferred stock | | | — | | | — | | | 280,000 | | Issuance of common stock for patent rights | | | — | | | — | | | 8,750 | | Issuance of common stock for services | | | — | | | — | | | 76,870 | | Issuance of common stock warrants | | | — | | | 96,095 | | | 98,595 | | | | | | | | | | | | | Supplemental disclosure of cash flow information | | | | | | | | | | | Proceeds from sale of unused NJ State NOL tax benefit | | | 333,660 | | | 395,642 | | | 975,926 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Stockholders’ Deficiency | | | |
| | | | Series A
Convertible
Preferred Stock | | Series B
Convertible
Preferred Stock | | Common Stock | | Additional
Paid-in
Capital | | Accumulated
Other
Comprehensive
Income | | Deficit
Accumulated
During
Development
Stage | | Treasury
Stock | | Total
Shareholders’
Deficiency | | | |
| |
| |
| | | | | | | | | Shares | | Amount | | Shares | | Amount | | Shares | | Amount | | | | | | | | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| | Balance at February 4, 1998 (Inception) | | | — | | $ | — | | | — | | $ | — | | | — | | $ | — | | $ | — | | $ | — | | $ | — | | $ | — | | $ | — | | Issuance of common shares in exchange for services, March 1998 | | | — | | | — | | | — | | | — | | | 530,000 | | | 530 | | | 4,770 | | | — | | | — | | | — | | | 5,300 | | Issuance of common shares in exchange for patent rights, March 1998 | | | — | | | — | | | — | | | — | | | 250,000 | | | 250 | | | 2,250 | | | — | | | — | | | — | | | 2,500 | | Issuance of common shares in exchange for services, April 1998 | | | — | | | — | | | — | | | — | | | 12,000 | | | 12 | | | 108 | | | — | | | — | | | — | | | 120 | | Net loss for the period | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | | | | (198,680 | ) | | — | | | (198,680 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 1998 | | | — | | | — | | | — | | | — | | | 792,000 | | | 792 | | | 7,128 | | | — | | | (198,680 | ) | | — | | | (190,760 | ) | Issuance of common shares in exchange for services, January 1999 | | | — | | | — | | | — | | | — | | | 5,000 | | | 5 | | | 45 | | | — | | | — | | | — | | | 50 | | Issuance of common shares in exchange for cash, February 1999 | | | — | | | — | | | — | | | — | | | 202,500 | | | 202 | | | 20,048 | | | — | | | — | | | — | | | 20,250 | | Issuance of common shares in exchange for services, June 1999 | | | — | | | — | | | — | | | — | | | 75,000 | | | 75 | | | 675 | | | — | | | — | | | — | | | 750 | | Issuance of common shares in exchange for cash and services, September 1999 | | | — | | | — | | | — | | | — | | | 5,588 | | | 6 | | | 1,112 | | | — | | | — | | | — | | | 1,118 | | Issuance of Series A preferred in exchange for cash, July - December 1999 | | | 1,146,916 | | | 1,147 | | | — | | | — | | | — | | | — | | | 1,121,447 | | | — | | | — | | | — | | | 1,122,594 | | Issuance of Series B preferred in exchange for cash, December 1999 | | | — | | | — | | | 173,000 | | | 173 | | | — | | | — | | | 506,516 | | | — | | | — | | | — | | | 506,689 | | Conversion of note payable with interest to Series A Preferred, September 1999 | | | 289,735 | | | 290 | | | — | | | — | | | — | | | — | | | 289,445 | | | — | | | — | | | — | | | 289,735 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 8,179 | | | — | | | — | | | — | | | 8,179 | | Net loss for the year (restated) | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | | | | (549,955 | ) | | — | | | (549,955 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 1999 (restated) | | | 1,436,651 | | | 1,437 | | | 173,000 | | | 173 | | | 1,080,088 | | | 1,080 | | | 1,954,595 | | | — | | | (748,635 | ) | | — | | | 1,208,650 | | Issuance of common shares in exchange for services, March 2000 | | | — | | | — | | | — | | | — | | | 10,500 | | | 11 | | | 4,714 | | | — | | | — | | | — | | | 4,725 | | Issuance of common shares in exchange for services, April 2000 | | | — | | | — | | | — | | | — | | | 6,500 | | | 6 | | | 2,919 | | | — | | | — | | | — | | | 2,925 | | Issuance of common shares in exchange for patent rights, April 2000 | | | — | | | — | | | — | | | — | | | 5,000 | | | 5 | | | 2,245 | | | — | | | — | | | — | | | 2,250 | | Issuance of common shares in exchange for services, June 2000 | | | — | | | — | | | — | | | — | | | 8,000 | | | 8 | | | 4,792 | | | — | | | — | | | — | | | 4,800 | | Issuance of common shares in exchange for services, September 2000 | | | — | | | — | | | — | | | — | | | 10,500 | | | 11 | | | 12,589 | | | — | | | — | | | — | | | 12,600 | | Issuance of Series B preferred in exchange for cash, March - June 2000 | | | — | | | — | | | 381,859 | | | 382 | | | — | | | — | | | 1,129,133 | | | — | | | — | | | — | | | 1,129,515 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 79,545 | | | — | | | — | | | — | | | 79,545 | | Issuance of common shares for exercise of stock options, December 2000 | | | — | | | — | | | — | | | — | | | 26,667 | | | 26 | | | 3,974 | | | — | | | — | | | — | | | 4,000 | | Net loss for the year | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (2,591,658 | ) | | — | | | (2,591,658 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 2000 (restated) | | | — | | | — | | | 554,859 | | | 555 | | | 1,147,255 | | | 1,147 | | | 3,194,506 | | | — | | | (3,340,293 | ) | | — | | | (142,648 | ) | Issuance of common shares in exchange for services, January 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 5 | | | 6,295 | | | — | | | — | | | — | | | 6,300 | | Issuance of common shares in exchange for services, April 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 6,296 | | | — | | | — | | | — | | | 6,300 | | Issuance of common shares in exchange for services, July 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 5 | | | 6,295 | | | — | | | — | | | — | | | 6,300 | | Issuance of common shares in exchange for services, October 2001 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 6,296 | | | — | | | — | | | — | | | 6,300 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | | | | 63,600 | | | — | | | — | | | — | | | 63,600 | | Issuance of common shares for exercise of stock options at $0.45/share, December 2001 | | | — | | | — | | | — | | | — | | | 30,333 | | | 31 | | | 13,619 | | | — | | | — | | | — | | | 13,650 | | Issuance of common shares for exercise of stock options at $1.40/share, December 2001 | | | — | | | — | | | — | | | — | | | 1,200 | | | 1 | | | 1,679 | | | — | | | — | | | — | | | 1,680 | | Net loss for the year | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (8,836,840 | ) | | — | | | (8,836,840 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 2001 | | | 1,436,651 | | | 1,437 | | | 554,859 | | | 555 | | | 1,196,788 | | | 1,197 | | | 3,298,586 | | | — | | | (12,177,133 | ) | | — | | | (8,875,358 | ) | Issuance of common shares in exchange for services, January 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 3,596 | | | — | | | — | | | — | | | 3,600 | | Issuance of common shares in exchange for services, April 2002 | | | — | | | — | | | — | | | — | | | 7,000 | | | 7 | | | 5,593 | | | — | | | — | | | — | | | 5,600 | | Issuance of common shares in exchange for services, July 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 3,596 | | | — | | | — | | | — | | | 3,600 | | Issuance of common shares in exchange for services, October 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 5 | | | 3,595 | | | — | | | — | | | — | | | 3,600 | | Issuance of common shares in exchange for services, December 2002 | | | — | | | — | | | — | | | — | | | 4,500 | | | 4 | | | 3,596 | | | — | | | — | | | — | | | 3,600 | | Deemed dividend | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (4,877,523 | ) | | — | | | (4,877,523 | ) | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 7,840 | | | — | | | — | | | — | | | 7,840 | | Accretion of mandatorily redeemable preferred stock | | | — | | | — | | | — | | | — | | | — | | | — | | | (53,563 | ) | | — | | | — | | | — | | | (53,563 | ) | Issuance of shares for exercise of stock options at $1.20/per share, March 2002 | | | — | | | — | | | — | | | — | | | 33,750 | | | 34 | | | 40,466 | | | — | | | — | | | — | | | 40,500 | | Issuance of shares for exercise of stock options at $1.40/per share, March 2002 | | | — | | | — | | | — | | | — | | | 200 | | | — | | | 280 | | | — | | | — | | | — | | | 280 | | Issuance of shares for exercise of stock options at $0.45/per share, June 2002 | | | — | | | — | | | — | | | — | | | 8,000 | | | 8 | | | 3,592 | | | — | | | — | | | — | | | 3,600 | | Issuance of shares for exercise of stock options at $1.40/per share, June 2002 | | | — | | | — | | | — | | | — | | | 600 | | | 1 | | | 839 | | | — | | | — | | | — | | | 840 | | Issuance of shares for exercise of stock options at $0.20/per share, December 2002 | | | — | | | — | | | — | | | — | | | 11,666 | | | 12 | | | 2,321 | | | — | | | — | | | — | | | 2,333 | | Comprehensive (loss) income: | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Unrealized gain on marketable securities | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | 3,286 | | | | | | | | | 3,286 | | Net loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (12,487,160 | ) | | — | | | (12,487,160 | ) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| | Total comprehensive loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (12,483,874 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 2002 | | | 1,436,651 | | | 1,437 | | | 554,859 | | | 555 | | | 1,276,004 | | | 1,276 | | | 3,320,337 | | | 3,286 | | | (29,541,816 | ) | | — | | | (26,214,925 | ) |
Statements of Stockholders’ Deficiency (continued) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Stockholders’ Deficiency | | | |
| | | | Series A
Convertible
Preferred Stock | | Series B
Convertible
Preferred Stock | | Common Stock | | Additional Paid-in
Capital | | Accumulated
Other Comprehensive
Income | | Deficit
Accumulated
During
Development
Stage | | Treasury
Stock | | Total
Shareholders’
Deficiency | | | |
| |
| |
| | | | | | | | | Shares | | Amount | | Shares | | Amount | | Shares | | Amount | | | | | | | | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| | Balance at December 31, 2002 (carried forward) | | | 1,436,651 | | $ | 1,437 | | | 554,859 | | $ | 555 | | | 1,276,004 | | $ | 1,276 | | $ | 3,320,337 | | $ | 3,286 | | $ | (29,541,816 | ) | $ | — | | $ | (26,214,925 | ) | Issuance of common shares in exchange for services, April 2003 | | | — | | | — | | | — | | | — | | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Issuance of common shares in exchange for services, May 2003 | | | — | | | — | | | — | | | — | | | 2,500 | | | 3 | | | 1,997 | | | — | | | — | | | — | | | 2,000 | | Issuance of common shares in exchange for services, July 2003 | | | — | | | — | | | — | | | — | | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Issuance of common shares in exchange for services, October 2003 | | | — | | | — | | | — | | | — | | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 3,332 | | | — | | | — | | | — | | | 3,332 | | Accretion of mandatorily redeemable preferred stock | | | — | | | — | | | — | | | — | | | — | | | — | | | (41,439 | ) | | — | | | — | | | — | | | (41,439 | ) | Issuance of shares for exercise of stock options at $0.20/per share, October 2003 | | | — | | | — | | | — | | | — | | | 16,000 | | | 16 | | | 3,184 | | | — | | | — | | | — | | | 3,200 | | Comprehensive (loss) income: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Unrealized loss on marketable securities | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (3,286 | ) | | — | | | — | | | (3,286 | ) | Net loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (10,201,040 | ) | | — | | | (10,201,040 | ) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| | Total comprehensive loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (10,204,326 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 2003 | | | 1,436,651 | | | 1,437 | | | 554,859 | | | 555 | | | 1,297,504 | | | 1,298 | | | 3,289,808 | | | — | | | (39,742,856 | ) | | — | | | (36,449,758 | ) | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 418 | | | — | | | — | | | — | | | 418 | | Accretion of mandatorily redeemable preferred stock | | | — | | | — | | | — | | | — | | | — | | | — | | | (41,439 | ) | | — | | | — | | | — | | | (41,439 | ) | Net loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (13,320,350 | ) | | — | | | (13,320,350 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 2004 | | | 1,436,651 | | | 1,437 | | | 554,859 | | | 555 | | | 1,297,504 | | | 1,298 | | | 3,248,787 | | | — | | | (53,063,206 | ) | | — | | | (49,811,129 | ) | Amortization of deferred stock compensation | | | — | | | — | | | — | | | — | | | — | | | — | | | 1,821 | | | — | | | — | | | — | | | 1,821 | | Accretion of mandatorily redeemable preferred stock | | | — | | | — | | | — | | | — | | | — | | | — | | | (41,439 | ) | | — | | | — | | | — | | | (41,439 | ) | Surrender of common shares, December 2005 | | | — | | | — | | | — | | | — | | | (88,500 | ) | | — | | | — | | | — | | | — | | | — | | | — | | Surrender of Series B Convertible Preferred Stock, December 2005 | | | — | | | — | | | (100,000 | ) | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Issuance of shares for exercise of stock options at $0.80/per share, August 2005 | | | — | | | — | | | — | | | — | | | 1,000 | | | 1 | | | 799 | | | — | | | — | | | — | | | 800 | | Net loss | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (9,110,496 | ) | | | | | (9,110,496 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | Balance at December 31, 2005 | | | 1,436,651 | | $ | 1,437 | | | 454,859 | | $ | 555 | | | 1,210,004 | | $ | 1,299 | | $ | 3,209,968 | | $ | — | | $ | (62,173,702 | ) | $ | — | | $ | (58,960,443 | ) | | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
See accompanying notes. |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Statements of Cash Flows | | | | | | | | | | | | | | | | | | | Period from
February
4, 1998
(Inception) to
December 31,
2005 | | | | | | | | | | | | | Year ended December 31, | | | | |
| | | | | 2005 | | 2004 | | | | |
| |
| |
| | Operating activities | | | | | | | | | | | Net loss | | $ | (9,110,496 | ) | $ | (13,320,350 | ) | $ | (57,296,179 | ) | Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | Depreciation and amortization | | | 91,036 | | | 97,761 | | | 327,162 | | Loss on disposal of property and equipment | | | 7,716 | | | 7,050 | | | 14,766 | | Deferred stock compensation to consultants | | | 1,821 | | | 418 | | | 164,736 | | Common stock issued to consultants for services and patent rights | | | — | | | — | | | 85,618 | | Preferred stock issued for interest expense | | | — | | | — | | | 9,737 | | Changes in operating assets and liabilities: | | | | | | | | | | | Other current assets | | | 130,003 | | | (86,174 | ) | | (55,857 | ) | Other assets | | | 76 | | | 1,184 | | | (11,997 | ) | Accounts payable | | | (1,163,592 | ) | | 144,810 | | | 106,091 | | Accrued bonuses | | | (134,567 | ) | | 142,575 | | | 281,008 | | Other accrued expenses | | | (144,330 | ) | | (114,193 | ) | | 225,187 | | Accrued interest payable | | | 596,951 | | | 36,629 | | | 633,580 | | | |
|
| |
|
| |
|
| | Net cash used in operating activities | | | (9,725,382 | ) | | (13,090,290 | ) | | (55,516,148 | ) | | | | | | | | | | | | Investing activities | | | | | | | | | | | Additions to property and equipment | | | (9,086 | ) | | (195,947 | ) | | (484,519 | ) | Proceeds from the sale of property and equipment | | | 4,345 | | | 4,345 | | | | | Sale of marketable securities | | | — | | | 1,600,000 | | | — | | Restricted cash | | | (345,600 | ) | | — | | | (345,600 | ) | | |
|
| |
|
| |
|
| | Net cash (used in) provided by investing activities | | | (350,341 | ) | | 1,404,053 | | | (825,774 | ) | | | | | | | | | | | | Financing activities | | | | | | | | | | | Proceeds from issuance of bridge notes | | | 10,000,000 | | | 4,000,000 | | | 14,280,000 | | Proceeds from issuance of common stock | | | 800 | | | — | | | 92,251 | | Proceeds from issuance of Series A preferred stock | | | — | | | — | | | 1,122,592 | | Proceeds from issuance of Series B preferred stock | | | — | | | — | | | 1,636,205 | | Proceeds from issuance of Series C preferred stock | | | — | | | — | | | 16,216,402 | | Proceeds from issuance of Series D preferred stock | | | — | | | — | | | 24,781,407 | | | |
|
| |
|
| |
|
| | Net cash provided by financing activities | | | 10,000,800 | | | 4,000,000 | | | 58,128,857 | | | |
|
| |
|
| |
|
| | Net (decrease) increase in cash and cash equivalents | | | (74,923 | ) | | (7,686,237 | ) | | 1,786,935 | | Cash and cash equivalents at beginning of period | | | 1,861,858 | | | 9,548,095 | | | — | | | |
|
| |
|
| |
|
| | Cash and cash equivalents at end of period | | $ | 1,786,935 | | $ | 1,861,858 | | $ | 1,786,935 | | | |
|
| |
|
| |
|
| | | | | | | | | | | | | Schedule of noncash transactions | | | | | | | | | | | Deemed dividends on Series C preferred stock | | $ | — | | $ | — | | $ | 4,877,523 | | Conversion of note payable to Series A preferred stock | | | — | | | — | | | 280,000 | | Issuance of common stock for patent rights | | | — | | | — | | | 8,750 | | Issuance of common stock for services | | | — | | | — | | | 76,870 | | Issuance of common stock warrants | | | — | | | 96,095 | | | 98,595 | | | | | | | | | | | | | Supplemental disclosure of cash flow information | | | | | | | | | | | Proceeds from sale of unused NJ State NOL tax benefit | | | 333,660 | | | 395,642 | | | 975,926 | |
See accompanying notes.
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Notes to Financial Statements
December 31, 2005 | | 1. | 1. Organization and Description of Business
|
Vela Pharmaceuticals Inc. (the “Company”) was incorporated in Delaware on February 4, 1998. The Company is focused on the identification, development and testing of selected and important therapeutic agents for the treatment of patients with psychiatric, neurologic and other disorders. Upon completion of development, it intends to market such products. Since inception, the Company has principally been active in performing research and product development. Accordingly, the Company has been classified as a development stage enterprise. The Company’s operations constitute one business segment. Since August 2005, the Company has been working with an investment banker to find a merger partner or to sell some or all of its assets (see Note 15). If a merger or sale does not occur, the Company’s ability to continue as a going concern is dependent upon the continued sale of its securities for funds to meet its cash requirements. If a sale appears likely, the Company can elect to request additional support from their current investors to continue operations until a sale or license of technology can be consummated or raise additional equity funds and/or obtain additional funding to finance the development of their assets. However, there are no assurances that these plans will be achieved; as such, the Company may shut down without a merger or sale of its assets. At December 31, 2005, the Company has cumulative losses of approximately $62,174,000, negative working capital and negative cash flows from operations. Operating losses are expected to continue for the foreseeable future. To date the Company has funded its activities through equity investments, convertible notes and the sale of net operating losses. | | 2. | 2. Summary of Significant Accounting Policies
|
Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company invests its cash in deposits with major financial institutions. Fair Value of Financial Instruments Certain financial instruments reflected in the balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximate fair value due to their short-term nature. Restricted Cash The restricted cash as of December 31, 2005 is cash set aside and reserved for the payment of one-half of the minimum stay bonuses under the Company’s Acquisition Bonus Plan (see Note 12). This amount was paid to key employees at the Company on March 1, 2006. Property and Equipment Property, equipment and leasehold improvements are stated at cost. Depreciation is provided using the straight-line method over the lesser of the estimated useful lives of the related assets, which range from three to seven years, or the term of the related lease. Liquidation Value Liquidation value of the Company’s Preferred Stock is reflected at the stated liquidation preference amounts per share, multiplied by the number of shares of Preferred Stock outstanding for each series of Preferred Stock issued |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Notes to Financial Statements (continued) | | 2. | 2. Summary of Significant Accounting Policies (continued)
|
(see Note 7). Depending on future liquidation events (including a sale of the Company), realized liquidation value may be less than or greater than these amounts, but no greater than 2.5 times the liquidation preference. Liquidation values as reflected on the balance sheets at December 31, 2005 and 2004 are greater than the net assets of the Company at such dates. Research and Development All research and development costs are charged to operations as incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research for the Company. Income Taxes The Company utilizes the asset and liability method to account for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation. Stock-Based Compensation As allowed by Statement of Financial Accounting Standards (“SFAS”) No. 123 “Accounting for Stock-Based Compensation”, the Company has elected to continue to apply the intrinsic value-based method of accounting prescribed in Accounting Principles Board Opinion No. 25 “Accounting for Stock Issued to Employees” and, accordingly, does not recognize compensation expense for stock option grants made at an exercise price equal to or in excess of the fair market value of the stock at the date of grant. Had compensation cost for the Company’s outstanding employee stock options been determined based on the fair value at the grant dates for those options consistent with SFAS No. 123, the Company’s net loss would have been changed to the following pro forma amounts: | |
| | | | | | | | | | Year ended December 31, | | | |
| | | | 2005 | | 2004 | | | |
| |
| | Net loss attributable to common stockholders, as reported | | $ | (9,110,496 | ) | $ | (13,320,350 | ) | | |
|
| |
|
| | Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards | | | 194,048 | | | 151,953 | | | |
|
| |
|
| | SFAS 123 pro forma net loss | | $ | (9,304,544 | ) | $ | (13,472,303 | ) | | |
|
| |
|
| |
Vela Pharmaceuticals Inc.
(A Development StageState Enterprise) Notes to Financial Statements (continued) | | 2. | 2. Summary of Significant Accounting Policies (continued)
|
SFAS 123 pro forma information regarding net loss is required by SFAS 123, and has been determined as if the Company had accounted for its stock-based compensation under the fair value method prescribed in SFAS 123. The fair value of the options was estimated at the date of grant using the minimum value pricing model with the following assumptions: | |
| | | | | | | | | | Year ended December 31, | | | |
| | | | 2005 | | 2004 | | | |
| |
| | Risk-free interest rate | | | 4.4 | % | | 4.6 | % | Dividend yield | | | 0 | % | | 0 | % | Expected life | | | 5 years | | | 5 years | |
| The effects of applying SFAS 123 in this pro forma disclosure may not be representative of future amounts since the estimated fair value of stock options is amortized to expense over the vesting period and additional options may be granted in future years. | | The Company accounts for options issued to nonemployees under SFAS 123 and EITF No. 96-18 “Accounting for Equity Investments that are Issued to Other than Employees for Acquiring or in Conjunction with Selling Goods or Services” (“EITF 96-18”). Therefore, the fair value of options issued to nonemployees is recorded as an expense and periodically remeasured over the vesting terms. | | Impairment of Long Lived Assets | | In accordance with SFAS No. 144, long-lived assets, such as property, plant, and equipment, software costs and purchased intangibles subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted net cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheet. | | Effects of New Accounting Standards | | On December 16, 2004, the Financial Accounting Standards Board (“FASB”) issued FASB Statement No. 123 (revised 2004),Share-Based Payment,which is a revision of FASB Statement No. 123,Accounting for Stock-Based Compensation. Statement 123(R) supersedes APB Opinion No. 25,Accounting for Stock Issued to Employees, and amends FASB Statement No. 95,Statement of Cash Flows. Generally, the approach in Statement 123(R) is similar to the approach described in Statement 123. However, Statement 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company has adopted Statement 123(R) effective January 1, 2006. | | As permitted by Statement 123, the Company currently accounts for share-based payments to employees using APB 25’s intrinsic value method and as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of Statement 123(R)’s fair value method will have an impact on the Company’s results of |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
operations, although it will have no impact on the Company’s overall financial position. The impact of adoption of Statement 123(R) cannot be predicted at this time because it will depend on levels of share-based payments granted |
Vela Pharmaceuticals Inc.
(A Development StageState Enterprise) Notes to Financial Statements (continued) | | 2. | 2. Summary of Significant Accounting Policies (continued)
|
in the future. However, had the Company adopted Statement 123(R) in prior periods, the impact of that standard would have approximated the impact of Statement 123 as described above in the disclosure of pro forma net loss. Preferred Stock Dividends The Company records deemed dividends when modification to its preferred stock is required in accordance with EITF 98-5 and EITF 00-27. A modification occurred in 2002 resulting in deemed dividends for the Series C of $4,877,523. Comprehensive Income Statement of Financial Accounting Standards No. 130, “Reporting Comprehensive Income,” requires components of other comprehensive income, including unrealized appreciation on marketable securities, to be included as part of total comprehensive income. The components of comprehensive income are included in the statement of redeemable preferred stock and stockholders’ deficiency. | | 3. | 3. Property and Equipment
|
Property and equipment consist of the following: | |
| | | | | | | | | | December 31, | | | |
| | | | 2005 | | 2004 | | | |
| |
| | Furniture, fixtures and equipment | | $ | 297,036 | | $ | 358,405 | | Leasehold improvements | | | 65,354 | | | 79,284 | | | |
|
| |
|
| | | | | 362,390 | | | 437,689 | | Less accumulated depreciation | | | (224,144 | ) | | (205,432 | ) | | |
|
| |
|
| | Property and equipment, net | | $ | 138,246 | | $ | 232,257 | | | |
|
| |
|
| |
In December 2003, the Company executed a lease for office space in West Trenton, New Jersey. The term of this lease is from April 1, 2004 to March 31, 2007. The existing lease, which was executed in December 2000, was to cover the term from March 1, 2001 to February 28, 2006, was terminated as of March 31, 2004 without penalty to the Company. The future minimum lease commitments are as follows: | |
| | | | | 2006 | | $ | 155,752 | | 2007 | | | 39,595 | | | |
|
| | Total | | $ | 195,347 | | | |
|
| |
| Rent expense for the years ended December 31, 2005 and 2004 and for the period from February 4, 1998 (inception) to December 31, 2005 was $231,548, $204,182 and $840,688, respectively. | | 5. | 5. Bridge Notes Payable
|
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
The Company has two Bridge notes outstanding as of December 31, 2005. Pursuant to the Note and Warrant Purchase Agreement dated as of October 6, 2004 the Company is authorized to issue up to $8,000,000 in senior convertible promissory notes in four equal installments of $2,000,000 to certain current investors (the “Lenders”). Interest is compounded monthly at a rate of 6% per annum. With each installment of the Bridge Loan, the Company
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) will issue the Lenders 300,297 warrants to purchase common stock (see Note 6). The four installments were issued in October 2004, December 2004, January 2005 and March 2005. All installments were outstanding at December 31, 2005. In October 2005, the maturity date of the October 6, 2004 Bridge Loan was extended until June 1, 2006. Pursuant to the Note and Warrant Purchase Agreement dated as of June 1, 2005 the Company is authorized to issue up to $6,000,000 in senior convertible promissory notes in three equal installments of $2,000,000 to certain current investors. Interest is compounded monthly at a rate of 6% per annum. With each installment of the Bridge Loan, the Company will issue the Lenders 400,002 warrants to purchase common stock (see Note 6). The three installments were issued in June 2005, August 2005 and October 2005. All installments were outstanding as of December 31, 2005. The maturity date of the Bridge Loan dated June 1, 2005 is June 1, 2006. If the Company consummates a subsequent round of financing at an aggregate price of $30,000,000 (including outstanding bridge loan) prior to the maturity date, the outstanding principal and accrued interest will automatically convert into the subsequent round securities at the same price and at the same terms per share as such capital stock or equity securities being issued. If the Company does not consummate a subsequent round of financing, the outstanding principal and accrued interest of the notes are payable to the lenders on the maturity date. The maturity date is defined as the earlier of: stated maturity date of the note, the sale or transfer of a majority of the capital stock of the Company, a sale of the corporation or the acceleration of the notes in the event of a default. In the event that a qualified public offering (see Note 7) occurs prior to a subsequent round of financing at an aggregate price of $30,000,000 (including outstanding bridge loan) or the Lenders holding at least 80% of the outstanding principal amount of the notes consent in writing, the outstanding principal and accrued interest due shall convert into shares of Series D preferred stock. The amount of shares issued will be calculated by dividing the outstanding principal and interest by the current conversion price of the Series D preferred stock. The outstanding principal and interest payable balances as of December 31, 2005 and 2004 are $14,000,000 and $633,580 and $4,000,000 and $36,629, respectively. | | 6. | 6. Stockholders’ Deficiency
|
Common Stock The Company is authorized to issue 25,000,000 shares of common stock. Common stockholders are entitled to one vote for each share held and to receive dividends if and when declared by the Board of Directors. During 2005 and 2004, the Company issued 1,000 and 0 shares, respectively, of common stock. As of December 31, 2005 and 2004, the Company has reserved 23,701,496 and 20,056,344 shares, respectively, of common stock for future issuance for the conversion of preferred stock and the exercise of stock options and warrants. In connection with the issuance of the Series D Preferred Stock in 2002, the conversion price of the Series C Preferred Stock was decreased from $5.70 to $4.3872; and the number of shares of common stock to be issued upon conversion of the Series C Preferred Stock was increased from 2,859,650 to 3,715,359. The Company reserved |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
6. Stockholders’ Deficiency (continued)
an additional 855,709 shares of its common stock for issuance to the holders of Series C Preferred Stock as well as reserved 250,000 shares of its common stock for issuance to the holders of warrants upon exercise or conversion. In connection with the Bridge Loan dated October 6, 2004, the Company is authorized to issue up to 1,201,300 warrants and as such has reserved 1,201,300 shares of common stock upon the exercise of the warrants. In connection with the Bridge Loan dated June 1, 2005, the Company is authorized to issue up to 1,200,006 warrants and as such has reserved an additional 1,200,006 shares of common stock upon the exercise of the warrants. Warrants In January 2002, the Company issued 250,000 warrants to purchase common stock to the holders of the Series C Preferred Stock. The warrants are exercisable for a period of five years at an exercise price of $0.80 per share. As
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) | | 6. | Stockholders’ Deficiency (continued) |
required by EITF-00-19, the warrants granted to the holders of the Series C were recorded in the financial statements as equity and are included in additional paid-in capital. The warrants are reviewed on each balance sheet date to determine if the classification as equity is still appropriate. As of December 31, 2005 and 2004 the warrants were valued at $2,500 and all warrants remain outstanding. In October 2004, December 2004, January 2005 and March 2005 the Company issued 300,297 warrants, in each month, to purchase common stock to the Lenders of the Bridge Loan dated October 6, 2004. The warrants issued with each installment of the Bridge Loan are exercisable until October 6, 2014 at an exercise price of $0.85 per share. As required by EITF-00-19, the warrants were recorded in the financial statements as equity and are included in additional paid-in capital. The warrants are reviewed on each balance sheet date to determine if the classification as equity is still appropriate. As of December 31, 2005 and 2004 the warrants were valued at $144,159 and $54,053, respectively, and all warrants remain outstanding. In June, August and October 2005 the Company issued 400,002 warrants, in each month, to purchase common stock to the Lenders of the Bridge Loan dated June 1, 2005. The warrants issued with each installment of the bridge loan are exercisable until June 1, 2015 – June 3, 2015 at an exercise price of $0.40 per share. As required by EITF-00-19, the warrants were recorded in the financial statements as equity and are included in additional paid-in capital. The warrants are reviewed on each balance sheet date to determine if the classification as equity is still appropriate. As of December 31, 2005 the warrants were valued at $0 and all warrants remain outstanding. Treasury Stock In December 2005, an investor surrendered 100,000 shares of Series B Convertible Preferred Stock and 88,500 shares of common stock. Management does not plan to reissue the shares held as Treasury Stock. | | 7. | 7. Redeemable Preferred Stock
|
The Company has authorized 16,810,375 and issued 12,351,235 shares of preferred stock and has also issued 250,000 warrants to purchase common stock to the holders of Series C Preferred Stock. The warrants were issued to Series C Preferred Stock holders during 2002, at an exercise price of $0.80 per share for five years. The Company has issued Series C and Series D Redeemable Convertible Preferred Stock and Series A and Series B Preferred Stock (collectively, the “Preferred Stock”). Such stock is subject to the following rights and privileges: | | | | Voting | | | | Preferred stockholders are entitled to the number of votes equal to the number of shares of common stock into which each share of Preferred Stock is then convertible. Except for certain corporate matters described in the Company’s Amended and Restated Certificate of Incorporation or as otherwise required by law, the holders of Preferred Stock shall vote together with all other classes and series of stock of the Corporation as a class. | | | | Dividends | | | | The Company’s Preferred Stock does not bear a fixed or cumulative dividend. Preferred stockholders shall be entitled to receive dividends at the same rate as dividends are paid with respect to the common stock. Such preferred dividends will be determined by the number of shares of common stock into which each share of Preferred Stock is convertible. | | | | Conversion | | | | The holders of the outstanding shares of Preferred Stock shall be entitled, at any time, to cause their shares to be converted into common stock on a share-for-share basis. However, if there is a stock dividend, stock split |
| Voting | | | | Preferred stockholders are entitled to the number of votes equal to the number of shares of common stock into which each share of Preferred Stock is then convertible. Except for certain corporate matters described in the |
Vela Pharmaceuticals Inc.
(A Development StageState Enterprise) Notes to Financial Statements (continued) | | 7. | 7. Redeemable Preferred Stock (continued)
| | | | or reverse stock split that takes place before conversion of Preferred Stock, then a new conversion factor would be calculated. This calculation is intended for the Preferred Stockholders to maintain the same equity interest upon conversion into common stock as before the common stock dividend or split. | | | | The initial conversion price for each series of Convertible Preferred Stock shall be adjusted from time to time in accordance with the agreement. In accordance with the anti-dilution feature in the Series C Preferred Stock, there was a deemed dividend in the year ended December 31, 2002 of $4,877,523. | | | | The Preferred Stock will convert automatically upon the closing of a Qualified Public Offering of the Company’s common stock in which the aggregate price paid for such shares by the public shall be at least $25,000,000 and the price per share paid by the public shall be at least $13.3332 per share. | | | | The holders of any share or shares of Preferred Stock shall have the right, at its option at any time, to convert any shares of Preferred Stock into shares of Common Stock. | | | | Mandatory Redemption | | | | Commencing on January 29, 2007 and on each of the next two anniversaries thereafter, the Company shall redeem, to the extent that it shall have funds legally available therefore, any outstanding shares of Series D Preferred Stock and Series C Preferred Stock according to the percentages listed below: | |
| | | | | Date of
Redemption | | Percentages of Shares of Series C Preferred Stock
Then Outstanding to be Redeemed | |
| |
| | January 29, 2007 | | 33-1/3% of all the shares of Series D Preferred Stock and Series C Preferred Stock outstanding on January 29, 2007 | | January 29, 2008 | | 50% of all the shares of Series D Preferred Stock and Series C Preferred Stock outstanding on January 29, 2008 | | January 29, 2009 | | 100% of all the shares of Series D Preferred Stock and Series C Preferred Stock outstanding on January 29, 2009 |
| Company’s Amended and Restated Certificate of Incorporation or as otherwise required by law, the holders of Preferred Stock shall vote together with all other classes and series of stock of the Corporation as a class. | | | | Dividends | | | | The Company’s Preferred Stock does not bear a fixed or cumulative dividend. Preferred stockholders shall be entitled to receive dividends at the same rate as dividends are paid with respect to the common stock. Such preferred dividends will be determined by the number of shares of common stock into which each share of Preferred Stock is convertible. | | | | Conversion | | | | The holders of the outstanding shares of Preferred Stock shall be entitled, at any time, to cause their shares to be converted into common stock on a share-for-share basis. However, if there is a stock dividend, stock split or reverse stock split that takes place before conversion of Preferred Stock, then a new conversion factor would be calculated. This calculation is intended for the Preferred Stockholders to maintain the same equity interest upon conversion into common stock as before the common stock dividend or split. | | | | The initial conversion price for each series of Convertible Preferred Stock shall be adjusted from time to time in accordance with the agreement. In accordance with the anti-dilution feature in the Series C Preferred Stock, there was a deemed dividend in the year ended December 31, 2002 of $4,877,523. | | | | The Preferred Stock will convert automatically upon the closing of a Qualified Public Offering of the Company’s common stock in which the aggregate price paid for such shares by the public shall be at least $25,000,000 and the price per share paid by the public shall be at least $13.3332 per share. | | | | The holders of any share or shares of Preferred Stock shall have the right, at its option at any time, to convert any shares of Preferred Stock into shares of Common Stock. | | | | Mandatory Redemption | | | | Commencing on January 29, 2007 and on each of the next two anniversaries thereafter, the Company shall redeem, to the extent that it shall have funds legally available therefore, any outstanding shares of Series D Preferred Stock and Series C Preferred Stock according to the percentages listed below: | | |
| | Date of
Redemption | | Percentages of Shares of Series C Preferred Stock
Then Outstanding to be Redeemed | | | |
| | | | | | | | | | January 29, 2007 | | 33-1/3% of all the shares of Series D Preferred Stock and Series C
Preferred Stock outstanding on January 29, 2007 | | | | January 29, 2008 | | 50% of all the shares of Series D Preferred Stock and Series C
Preferred Stock outstanding on January 29, 2008 | | | | January 29, 2009 | | 100% of all the shares of Series D Preferred Stock and Series C
Preferred Stock outstanding on January 29, 2009 | |
| | | The shares of Series D Preferred Stock and Series C Preferred Stock shall be redeemed for cash at the redemption price of $3.3333 and $5.70 per share, respectively, plus an amount equal to all dividends declared but unpaid. |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
| |
| The carrying amount of the Series C and Series D redeemable convertible preferred stock has been increased by periodic accretions so as to equal the redemption amounts at the respective dates. The future minimum |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
| |
7. | Redeemable Preferred Stock (continued) | | |
| accretions of the Series C and Series D redeemable convertible preferred stock based on the shares outstanding as of December 31, 2005 is as follows: | | |
| | | | | | | Accretion of
Redeemable
Convertible
Preferred Stock | | | |
| | 2006 | | $ | 41,439 | | 2007 | | | 41,439 | | 2008 | | | 41,439 | | | |
|
| | Total accretion | | $ | 124,317 | | | |
|
| |
| | | Liquidation
| | | | In the event of any liquidation, dissolution, or winding up (either voluntary or involuntary) of the Company, (the consolidation or merger of the Company with or into another entity, or the sale, lease, abandonment, transfer or other disposition by the Company of all or substantially all of its assets, shall be deemed to be a liquidation, dissolution or winding up of the Company) the holders of the Preferred Stock are entitled to receive, prior to and in preference to the holders of common stock or any other capital stock of the Company ranking on liquidation junior to the Preferred Stock, an amount equal to $1.00, $3.00, $5.70 and $3.3333, respectively, for each outstanding share of Series A, B, C and D Preferred Stock, plus any and all accrued and unpaid dividends as of the date of liquidation (collectively, the “Series A, B, C and D Liquidation Preference”). | | | | In the event that the assets of the Company to be distributed are less than the Series A, B, C and D Liquidation Preference, then the assets of the Company shall be paid to the Series A, B, C and D preferred stockholders in the following priority: (i) to the Series D preferred stockholders; (ii) to the Series C preferred stockholders; (iii) to the Series A preferred stockholders; and (iv) to the Series B preferred stockholders. |
| | | Liquidation | | | | In the event of any liquidation, dissolution, or winding up (either voluntary or involuntary) of the Company, (the consolidation or merger of the Company with or into another entity, or the sale, lease, abandonment, |
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) | | 7. | Redeemable Preferred Stock (continued) | | | | transfer or other disposition by the Company of all or substantially all of its assets, shall be deemed to be a liquidation, dissolution or winding up of the Company) the holders of the Preferred Stock are entitled to receive, prior to and in preference to the holders of common stock or any other capital stock of the Company ranking on liquidation junior to the Preferred Stock, an amount equal to $1.00, $3.00, $5.70 and $3.3333, respectively, for each outstanding share of Series A, B, C and D Preferred Stock, plus any and all accrued and unpaid dividends as of the date of liquidation (collectively, the “Series A, B, C and D Liquidation Preference”). | | | | In the event that the assets of the Company to be distributed are less than the Series A, B, C and D Liquidation Preference, then the assets of the Company shall be paid to the Series A, B, C and D preferred stockholders in the following priority: (i) to the Series D preferred stockholders; (ii) to the Series C preferred stockholders; (iii) to the Series A preferred stockholders; and (iv) to the Series B preferred stockholders. |
After payment in full of the Series A, B, C, and D Liquidation Preference, the remaining net assets of the Company shall be distributed ratably to the holders of common stock and holders of Preferred Stock as if the holders of Preferred Stock had converted their shares into common stock immediately prior to the liquidation; provided that the amount payable in liquidation (including the applicable Liquidation Preference) to each series of Preferred Stock shall not exceed the greater of (i) the amount each share of such series would receive if it had been converted to common stock immediately prior to the liquidation, dissolution or winding up, and (ii) $2.50 per share for the Series A, $7.50 per share for the Series B, $14.25 per share for the Series C and $8.333 per share for the Series D; and provided further that in the event the Company obtains at least $30,000,000 in an equity financing where the price per share is at least $10.00, then after the holders of Preferred Stock shall be paid in full the greater of (x) the applicable Liquidation Preference and (y) the amount each share of such Preferred Stock would receive if it had converted to common stock immediately before such liquidation, dissolution or winding up, the remaining net assets of the Company shall be distributed ratably among the holders of common stock. Due to operating losses, the Company has no current federal or state income tax liability for the years ended December 31, 2005 and 2004. The components of the income tax benefit for the years ended December 31, 2005 and 2004 are: |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
8. Income Taxes (continued)
| |
| | December 31 | | |
|---|
| | 2005 | | 2004 | | |
|---|
| |
| | | | | Federal income taxes: | | | | | | | | | | Current expense | $ | — | | $ | — | | | | | Deferred expense | | — | | | — | | | | | State income taxes: | | | | | | | | | | Current benefit | | (333,660 | ) | | (395,642 | ) | | | | Deferred expense | | — | | | — | | | | |
| | | | | Income tax benefit | $ | (333,660 | ) | $ | (395,642 | ) | | | |
| | |
| | | | | | | | | | | December 31, | | | |
| | | | 2005 | | 2004 | | | |
| |
| | Federal income taxes: | | | | | | | | Current expense | | $ | — | | $ | — | | Deferred expense | | | — | | | — | | State income taxes: | | | | | | | | Current benefit | | | (333,660 | ) | | (395,642 | ) | Deferred expense | | | — | | | — | | | |
|
| |
|
| | Income tax benefit | | $ | (333,660 | ) | $ | (395,642 | ) | | |
|
| |
|
| |
During 2005 and 2004, the Company sold unused state net operating loss carryforwards through a program sponsored by the State of New Jersey and the New Jersey Economic Development Authority. Cash proceeds of $333,660, net of fees of $9,321, were received by the Company in 2005. Cash proceeds of $395,642, net of fees of $11,051, were received by the Company in 2004. At December 31, 2005, the Company has a net operating loss carryforward for federal income tax purposes of approximately $57,019,000 which expires as follows: $27,000 in 2018, $470,000 in 2019, $2,369,000 in 2020, $7,796,000 in 2021, $13,718,000 in 2022, $10,250,000 in 2023, $13,340,000 in 2024 and $9,049,000 in 2025. The
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) | | 8. | Income Taxes (continued) |
Company also has a research and development tax credit for federal income tax purposes of approximately $2,018,000, which expires between 2019 and 2025. The Company has not performed a detailed analysis to determine whether an ownership change under Section 382 of the Internal Revenue Code has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change in ownership. Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets for federal and state income taxes are as follows: | |
| | December 31 | |
|---|
| | 2005 | | 2004 | |
|---|
| |
| | | | Deferred tax assets – non-current: | | | | | | | | | Future tax benefits of NOL
carryforwards | $ | 22,559,117 | | $ | 18,706,191 | | | | Future tax benefit of research and
development tax credit
carryforwards | | 2,018,134 | | | 1,758,011 | | | | Future tax benefit – other items | | (6,020 | ) | | 22,400 | | | |
| | | | Gross deferred tax assets | | 24,571,231 | | | 20,486,602 | | | | Valuation allowance | | (24,571,231 | ) | | (20,486,602 | ) | | |
| | | | Net deferred tax assets | $ | — | | $ | — | | | |
| |
| | | | | | | | | | | December 31, | | | |
|
|
| | | | 2005 | | 2004 | | | |
| |
| | Deferred tax assets – non-current: | | | | | | | | Future tax benefits of NOL carryforwards | | $ | 22,559,117 | | $ | 18,706,191 | | Future tax benefit of research and development tax credit carryforwards | | | 2,018,134 | | | 1,758,011 | | Future tax benefit – other items | | | (6,020 | ) | | 22,400 | | | |
|
| |
|
| | Gross deferred tax assets | | | 24,571,231 | | | 20,486,602 | | Valuation allowance | | | (24,571,231 | ) | | (20,486,602 | ) | | |
|
| |
|
| | Net deferred tax assets | | $ | — | | $ | — | | | |
|
| |
|
| |
Reconciliation of the U.S. statutory income tax rate to our effective tax rate for continuing operations is as follows: |
| | | | | | | | Percentages | | 2005 | | 2004 | | | |
| |
| | U.S. statutory rate | | | (34.0 | )% | | (34.0 | )% | State taxes | | | (6.0 | ) | | (6.0 | ) | Research and development credit | | | (4.9 | ) | | (6.0 | ) | Other | | | (1.9 | ) | | 3.0 | | Change in valuation allowance | | | 43.3 | | | 40.1 | | | |
|
| |
|
| | Effective tax benefit rate | | | (3.5 | )% | | (2.9 | )% | | |
|
| |
|
| |
51
|
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
| | 8. Income Taxes (continued) | |
| | Percentages | 2005 | | 2004 | | | | |
| | | | | | | | | | | | | U.S. statutory rate | | (34.0 | )% | | (34.0 | )% | | | State taxes | | (6.0 | ) | | (6.0 | ) | | | Research and development credit | | (4.9 | ) | | (6.0 | ) | | | Other | | (1.9 | ) | | 3.0 | | | | Change in valuation allowance | | 43.3 | | | 40.1 | | | |
| | | | Effective tax benefit rate | | (3.5 | )% | | (2.9 | )% | | |
| |
| | In 2005 and 2004, the Company recorded valuation allowances to offset the benefits of net operating losses, research and development tax credits, and other tax benefit items generated during those years. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased $4,084,629 and $5,493,360 during 2005 and 2004, respectively. | | 9. Stock Options
| The Company has two stock option plans (the “Plans”). In accordance with the Plans, the Company reserved up to 2,700,000 shares of common stock to be issued. The term of each stock option grant is generally 10 years from the date of grant. Vesting is determined by the Company’s Board of Directors and generally occurs over a period of not greater than five years. | | During the years ended December 31, 2005 and 2004, and the period from February 4, 1998 to December 31, 2005, in connection with the grant of stock options to employees, the Company recorded no deferred employee stock compensation as all employee options were issued with an exercise price equal to the deemed fair value.
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) | | 9. | Stock Options (continued) | | |
In December 2004, the Company’s Board of Directors approved a change to all previously issued and outstanding options to provide an additional two years of vesting in the event of a change of control. Additionally, in February 2005 the Company’s Board of Director’s approved a “double-trigger” for all of the senior management teams options. The “double trigger” allows for full vesting of the options granted to the senior management team in specific circumstances when a change of control has occurred. As required by FASB Interpretation 44—Accounting for Certain Transactions involving Stock Compensation—an interpretation of APB Opinion No. 25, the Company performed an analysis to determine if an additional charge to compensation expense would be required for the change in intrinsic value from the date of grant to the date of the modification to the outstanding stock option awards. Based upon the analysis performed no additional expense was necessary. | | During the years ended December 31, 2005 and 2004 and the period from February 4, 1998 to December 31, 2005, in connection with the grant of certain stock options to non-employees, the Company recorded stock compensation expense of $1,821, $418 and $164,735, respectively. Deferred stock compensation expense to non-employees is determined by utilizing the Black-Scholes pricing model as required by SFAS 123 with the following weighted-average assumptions for 2005 and 2004, respectively: risk-free interest rate of 4.4% and 4.6%, dividend yield of 0% in each period; annualized historical volatility of 80.0% in each period. | | The minimal value pricing model is similar to the Black-Scholes option valuation model which was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable, except that it excludes the factor for volatility. In addition, option valuation models require the input of highly subjective assumptions. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. 9. Stock Options (continued)
A summary of the Company’s stock option activity and related information for the years ended December 31, 2005 and 2004 follows: | |
| | | 2005 | | 2004 | |
|---|
| |
| |
| | | | | Options | | Weighted-
Average
Exercise
Price | | Options | | Weighted-
Average
Exercise
Price | |
|---|
| |
| |
| | | | | | | | | | | | | | | | | | | Outstanding, beginning of year | | 2,529,196 | | $ | 0.76 | | | 1,806,946 | | $ | 0.74 | | | | Granted | | 41,200 | | | 0.21 | | | 806,900 | | | 0.84 | | | | Exercised | | (1,000 | ) | | 0.80 | | | — | | | 0.00 | | | | Expired/cancelled | | (440,341 | ) | | 0.81 | | | (84,650 | ) | | 0.92 | | | |
| | | |
| | | | | | Outstanding, end of year | | 2,129,055 | | $ | 0.74 | | | 2,529,196 | | $ | 0.76 | | | |
| | | |
| | | | | | | | | | | | Exercisable, at end of year | | 1,461,349 | | $ | 0.70 | | | 1,089,846 | | $ | 0.67 | | | |
| | | |
| | | | | | | | | | | | | | | | | | | | | Weighted-average fair value of
options granted during the year | $ | 0.14 | | | | | $ | 0.56 | | | | | | |
| | |
| | | | | | | | | | | | | | | | | | | | | Weighted-average remaining
contractual life | | 6.5 yrs | | | | | | 7.9 yrs | | | | | | |
| | |
| | | |
| | | | | | | | | | | | | | | | 2005 | | 2004 | | | |
| |
| | | | Options | | Weighted-
Average
Exercise
Price | | Options | | Weighted-
Average
Exercise
Price | | | |
| |
| |
| |
| | | Outstanding, beginning of year | | | 2,529,196 | | $ | 0.76 | | | 1,806,946 | | $ | 0.74 | | Granted | | | 41,200 | | | 0.21 | | | 806,900 | | | 0.84 | | Exercised | | | (1,000 | ) | | 0.80 | | | — | | | 0.00 | | Expired/cancelled | | | (440,341 | ) | | 0.81 | | | (84,650 | ) | | 0.92 | | | |
|
| | | | |
|
| | | | | Outstanding, end of year | | | 2,129,055 | | $ | 0.74 | | | 2,529,196 | | $ | 0.76 | | | |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Exercisable, at end of year | | | 1,461,349 | | $ | 0.70 | | | 1,089,846 | | $ | 0.67 | | | |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Weighted-average fair value of options granted during the year | | $ | 0.14 | | | | | $ | 0.56 | | | | | | |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Weighted-average remaining contractual life | | | 6.5 yrs | | | | | | 7.9 yrs | | | | | | |
|
| | | | |
|
| | | | |
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) | | 9. | Stock Options (continued) |
Stock options outstanding at December 31, 2005 are summarized as follows: | |
| | | | | | | | | | | | Range of
Exercise
Prices | | Outstanding
Options at
December
31, 2005 | | Weighted-
Average
Remaining
Contractual Life | | Weighted-
Average
Exercise
Price | |
| |
| |
| |
| | $ | 0.01 – 0.21 | | | 129,533 | | | 3.5 yrs | | $ | 0.11 | | | 0.45 – 0.85 | | | 1,894,986 | | | 6.8 yrs | | | 0.75 | | | 0.90 – 1.40 | | | 104,536 | | | 4.6 yrs | | | 1.38 | |
| | 10. | 10. Employee Savings Plan
|
Effective January 1, 2000, the Company implemented a 401(k) savings plan covering substantially all employees of the Company. The Company began contributing to the 401(k) savings plan in 2003. Total Company contribution in 2005 and 2004 and for the period from February 4, 1998 (inception) to December 31, 2005 was $20,000, $10,000 and $38,880, respectively. Total plan administration expenses recorded by the Company for the years ended December 31, 2005 and 2004 and for the period from February 4, 1998 (inception) to December 31, 2005 were $0, $900 and $5,525, respectively. | | 11. | 11. Reduction in Headcount
|
In August 2005, as a result of the failed clinical trial of one of the Company’s therapeutic agents and the failure to raise additional funds, the Company initiated a reduction in headcount. The reduction was designed to reduce |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
unnecessary overhead. As part of the reduction in headcount each employee was given one month notice that their position was being eliminated. After their position was eliminated each employee was given one month severance and, if they signed a Release from Liability, they were given an extra two weeks of pay. If an employee had an employment agreement which had a longer severance period the employee was paid the amount of severance |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Notes to Financial Statements (continued)
11. Reduction in Headcount (continued)
outlined in the employment agreement. In 2005, all costs associated with the reduction in headcount were accrued and as of December 31, 2005, the Company has a remaining liability of $6,768. Total severance costs in 2005 approximated $292,200. | | 12. | 12. Acquisition Bonus Plan
|
In August 2005, the Board approved the Acquisition Bonus Plan. The plan is designed to provide an incentive bonus to key employees and advisors upon the sale of the Company or the license of its major assets. The plan provides for a Minimum Stay Bonus to be paid to the key employees in the event the Company does not enter into a transaction for the sale or license of its assets. The Minimum Stay Bonus is to be paid on two increments within 15 days of March 1, 2006 and June 30, 2006 and provides that one half of the Minimum Stay Bonus be put into an escrow account which was used for the March 1, 2006 payment. At December 31, 2005, the Company has recorded an accrual for the Minimum Stay Bonus, net of advances (see Note 13), of $281,008. | | 13. | 13. Related Party Transactions
|
Two of the Board members provide consulting services to the Company in exchange for a monthly fee, common stock, or stock options. Compensation paid for these consulting fees was approximately $0, $0 and $310,569 for the years ended December 31, 2005 and 2004 and for the period from February 4, 1998 (inception) to December 31, 2005, respectively.
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Financial Statements (continued) | | 13. | Related Party Transactions (continued) |
In December 2005, the Company paid an advance of the Minimum Stay Bonus to the key employees of $86,400. The advance was equal to 20% of one half of the Minimum Stay Bonus which was paid on March 1, 2006. The advance was payable back to the Company if the employee failed to remain an employee as of March 1, 2006. As of December 31, 2005, the Company has recorded the advances to offset the accrual. | | 14. | 14. Co-employment Agreement with ADP TotalSource
|
On August 1, 2005 the Company entered into a Co-employment Agreement with ADP TotalSource (“ADP”), whereby the Company’s employees became the employees of ADP and ADP provided benefits to the employees, the costs of which were charged back to the Company. All payroll and benefits, except the Company’s 401K plan, are provided through ADP. The agreement can be cancelled by either party within 30 days with written notice or immediately with cause. Sale of the Company On March 14, 2006, the Company entered into a definitive merger agreement with Pharmos Corporation (“Pharmos”) to sell all of the Company’s rights and assets for cash and shares of common stock. The sale transaction includes an initial payment of $5 million in cash and the issuance of 11.5 million shares of Pharmos common stock for a combined value of approximately $29.7 million. The transaction also includes the issuance of up to 8 million additional Pharmos common stock shares contingent on achieving specific clinical milestones. No adjustments have been made to these financial statements as a result of this transaction. |
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Condensed Balance Sheets | |
| | March 31,
2006 | | December 31,
2005 | | | |
| | | | (unaudited) | | | | | | Assets | | | | | | | | Current assets: | | | | | | | | Cash and cash equivalents | $ | 903,912 | | $ | 1,786,935 | | | Restricted cash | | — | | | 345,600 | | | Prepaid expenses and other current assets | | 35,009 | | | 55,857 | | |
| | | Total current assets | | 938,921 | | | 2,188,392 | | | | | | | | | | | | | | Property and equipment, net | | 120,310 | | | 138,246 | | | Other assets | | 11,997 | | | 11,997 | | |
| | | | $ | 1,071,228 | | $ | 2,338,635 | | |
| | | Liabilities, redeemable preferred stock and shareholders’ deficiency | | | | | | | | Current liabilities: | | | | | | | | Accounts payable | $ | 486,862 | | $ | 106,091 | | | Accrued expenses | | 287,107 | | | 506,195 | | | Bridge loans payable | | 14,000,000 | | | 14,000,000 | | | Accrued interest payable | | 851,145 | | | 633,580 | | |
| | | Total current liabilities | | 15,625,114 | | | 15,245,866 | | | | | | | | | | | | | | Series C Redeemable Convertible Preferred Stock; par value $0.001 | | | | | | | | per share, authorized, issued and outstanding 2,859,650 shares at | | | | | | | | March 31, 2006 and December 31, 2005. | | | | | | | | Liquidation value: $40,750,013 at March 31, 2006 and December 31, 2005 | | 21,149,627 | | | 21,147,128 | | | Series D Redeemable Convertible Preferred Stock; par value $0.001 | | | | | | | | per share, authorized 11,959,215 shares at March 31, 2006 and | | | | | | | | December 31, 2005; issued and outstanding | | | | | | | | 7,500,075 shares at March 31, 2006 and December 31, 2005. Liquidation value: | | | | | | | | $62,500,375 at March 31, 2006 and December 31, 2005 | | 24,913,803 | | | 24,906,084 | | | | | | | | | | | | | | Shareholders’ deficiency: | | | | | | | | Series A Convertible Preferred Stock; par value 0.001 per share, authorized, | | | | | | | | issued and outstanding 1,436,651 shares at March 31, 2006 and December 31, | | | | | | | | 2005. Liquidation value: $3,591,628 at March 31, 2006 and December 31, 2005 | | 1,437 | | | 1,437 | | | Series B Convertible Preferred Stock; par value 0.001 per share, authorized and | | | | | | | | issued 554,859 shares at March 31, 2006 and December 31, 2005, outstanding | | | | | | | | 454,859 shares at March 31, 2006 and December 31, 2005. Liquidation value: | | | | | | | | $3,411,443 at March 31, 2006 and December 31, 2005 | | 555 | | | 555 | | | Common stock; par value 0.001 per share, authorized 25,000,000 shares at | | | | | | | | March 31, 2006 and December 31, 2005; issued 1,297,504 shares at March 31, | | | | | | | | 2006 and December 31, 2005 and outstanding 1,210,004 shares | | | | | | | | at March 31, 2006 and December 31, 2005 | | 1,299 | | | 1,299 | | | Additional paid-in capital | | 3,199,750 | | | 3,209,968 | | | Deficit accumulated during development stage | | (63,820,357 | ) | | (62,173,702 | ) | | Treasury Stock | | | | | | | | Series B Convertible Preferred Stock; at cost, 100,000 shares at | | | | | | | | March 31, 2006 and December 31, 2005 | | — | | | — | | | Common stock; at cost, 88,500 shares at March 31, 2006 and | | | | | | | | December 31, 2005 | | — | | | — | | |
| | | Total shareholders’ deficiency | | (60,617,316 | ) | | (58,960,443 | ) | |
| | | | $ | 1,071,228 | | $ | 2,338,635 | | |
| | | | | | | |
| See accompanying notes to unaudited condensed financial statements.
|
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Condensed Statements of Operations
(unaudited)
| |
| | Three months ended
March 31, | | Period from
February 4, 1998
(Inception) to
March 31,
2006 | |
|---|
| |
|---|
| 2006 | | 2005 | | |
|---|
|
| | | Consulting revenues | $ | — | | $ | — | | $ | 234,018 | | | Operating expenses: | | | | | | | | | | | Research and development | | 363,362 | | | 1,884,904 | | | 42,275,417 | | | General and administrative | | 856,803 | | | 631,106 | | | 12,111,641 | | | Business development | | 221,751 | | | 410,498 | | | 6,285,087 | | |
| | | Total expenses | | 1,441,916 | | | 2,926,508 | | | 60,672,145 | | |
| | | | | | | | | | | | | | | | | | Operating loss | | (1,441,916 | ) | | (2,926,508 | ) | | (60,438,127 | ) | | | | | | | | | | | | | | | | | Interest income | | 12,826 | | | 7,550 | | | 1,380,247 | | | Interest expense | | (217,565 | ) | | (83,746 | ) | | (860,880 | ) | |
| | | Loss before tax | | (1,646,655 | ) | | (3,002,704 | ) | | (59,918,760 | ) | | | | | | | | | | | | | | | | | Income tax benefit | | — | | | — | | | 975,926 | | |
| | | Net loss | | (1,646,655 | ) | | (3,002,704 | ) | | (58,942,834 | ) | | Preferred stock accretion | | (10,218 | ) | | (10,218 | ) | | (188,098 | ) | |
| | Net loss attributable to common
shareholders | $ | (1,656,873 | ) | $ | (3,012,922 | ) | $ | (59,130,932 | ) | | |
| | | | | |
| See accompanying notes to unaudited condensed financial statements.
|
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
Condensed Statements of Cash Flows
(unaudited)
| |
| Three months ended
March 31, | | Period from
February 4,
1998
(Inception) to
March 31,
2006 | |
|---|
| | | |
|---|
| | | |
|---|
| 2006 | | 2005 | | |
|---|
|
| | | Operating activities | | | | | | | | | | | Net loss | $ | (1,646,655 | ) | $ | (3,002,704 | ) | $ | (58,942,834 | ) | | Adjustments to reconcile net loss to net cash used in | | | | | | | | | | | operating activities: | | | | | | | | | | | Depreciation and amortization | | 17,936 | | | 25,884 | | | 345,098 | | | Loss on disposal of property and equipment | | — | | | — | | | 14,766 | | | Deferred stock compensation to consultants | | — | | | — | | | 164,736 | | | Common stock issued to consultants for services and | | | | | | | | | | | patent rights | | — | | | — | | | 85,618 | | | Preferred stock issued for interest expense | | — | | | — | | | 9,737 | | | Changes in operating assets and liabilities: | | | | | | | | | | | Restricted cash | | 345,600 | | | — | | | — | | | Prepaid expenses and other current assets | | 20,848 | | | 17,179 | | | (47,006 | ) | | Accounts payable | | 380,772 | | | (488,282 | ) | | 486,863 | | | Accrued expenses | | (219,089 | ) | | (297,317 | ) | | 288,106 | | | Accrued interest payable | | 217,565 | | | 83,746 | | | 851,145 | | |
| | | Net cash used in operating activities | | (883,023 | ) | | (3,661,494 | ) | | (56,744,771 | ) | | | | | | | | | | | | | | | | | Investing activities | | | | | | | | | | | Additions to property and equipment | | — | | | (3,592 | ) | | (484,519 | ) | | Proceeds from the sale of property and equipment | | — | | | — | | | 4,345 | | |
| | | Net cash used in investing activities | | — | | | (3,592 | ) | | (480,174 | ) | | | | | | | | | | | | | | | | | Financing activities | | | | | | | | | | | Proceeds from issuance of bridge loans | | — | | | 4,000,000 | | | 14,280,000 | | | Proceeds from issuance of common stock | | — | | | — | | | 92,251 | | | Proceeds from issuance of Series A preferred stock | | — | | | — | | | 1,122,592 | | | Proceeds from issuance of Series B preferred stock | | — | | | — | | | 1,636,205 | | | Proceeds from issuance of Series C preferred stock | | — | | | — | | | 16,216,402 | | | Proceeds from issuance of Series D preferred stock | | — | | | — | | | 24,781,407 | | |
| | | Net cash provided by financing activities | | — | | | 4,000,000 | | | 58,128,857 | | |
| | | Net (decrease) increase in cash and cash equivalents | | (883,023 | ) | | 334,914 | | | 903,912 | | | Cash and cash equivalents at beginning of period | | 1,786,935 | | | 1,861,858 | | | — | | |
| | | Cash and cash equivalents at end of period | $ | 903,912 | | $ | 2,196,772 | | $ | 903,912 | | |
| | | | | | | | | | | | | | Schedule of noncash transactions | | | | | | | | | | | Deemed dividends on Series C preferred stock | $ | — | | $ | — | | $ | 4,877,523 | | | Conversion of note payable to Series A preferred stock | | — | | | — | | | 280,000 | | | Issuance of common stock for patent rights | | — | | | — | | | 8,750 | | | Issuance of common stock for services | | — | | | — | | | 76,870 | | | Issuance of common stock warrants | | — | | | 96,095 | | | 98,595 | | | | | | | | | | | | | | | | | | Supplemental disclosure of cash flow information | | | | | | | | | | | Proceeds from sale of unused NJ State NOL tax benefit | | — | | | — | | | 975,926 | |
| | | | | | | | | | | | | | | | | | | March 31,
2006 | | December 31,
2005 | | | |
| |
| | | | (unaudited) | | | | | Assets | | | | | | | | Current assets: | | | | | | | | Cash and cash equivalents | | $ | 903,912 | | $ | 1,786,935 | | Restricted cash | | | — | | | 345,600 | | Prepaid expenses and other current assets | | | 35,009 | | | 55,857 | | | |
|
| |
|
| | Total current assets | | | 938,921 | | | 2,188,392 | | Property and equipment, net | | | 120,310 | | | 138,246 | | Other assets | | | 11,997 | | | 11,997 | | | |
|
| |
|
| | | | $ | 1,071,228 | | $ | 2,338,635 | | | |
|
| |
|
| | Liabilities, redeemable preferred stock and stockholders’ deficiency | | | | | | | | Current liabilities: | | | | | | | | Accounts payable | | $ | 486,862 | | $ | 106,091 | | Accrued expenses | | | 287,107 | | | 506,195 | | Bridge loans payable | | | 14,000,000 | | | 14,000,000 | | Accrued interest payable | | | 851,145 | | | 633,580 | | | |
|
| |
|
| | Total current liabilities | | | 15,625,114 | | | 15,245,866 | | | | | | | | | | Series C Redeemable Convertible Preferred Stock; par value $0.001 per share, authorized, issued and outstanding 2,859,650 shares at March 31, 2006 and December 31, 2005. Liquidation value: $40,750,013 at March 31, 2006 and December 31, 2005 | | | 21,149,627 | | | 21,147,128 | | Series D Redeemable Convertible Preferred Stock; par value $0.001 per share, authorized 11,959,215 shares at March 31, 2006 and December 31, 2005; issued and outstanding 7,500,075 shares at March 31, 2006 and December 31, 2005. Liquidation value: $62,500,375 at March 31, 2006 and December 31, 2005 | | | 24,913,803 | | | 24,906,084 | | | | | | | | | | Stockholders’ deficiency: | | | | | | | | Series A Convertible Preferred Stock; par value 0.001 per share, authorized, issued and outstanding 1,436,651 shares at March 31, 2006 and December 31, 2005. Liquidation value: $3,591,628 at March 31, 2006 and December 31, 2005 | | | 1,437 | | | 1,437 | | Series B Convertible Preferred Stock; par value 0.001 per share, authorized and issued 554,859 shares at March 31, 2006 and December 31, 2005, outstanding 454,859 shares at March 31, 2006 and December 31, 2005. Liquidation value: $3,411,443 at March 31, 2006 and December 31, 2005 | | | 555 | | | 555 | | Common stock; par value 0.001 per share, authorized 25,000,000 shares at March 31, 2006 and December 31, 2005; issued 1,297,504 shares at March 31, 2006 and December 31, 2005 and outstanding 1,210,004 shares at March 31, 2006 and December 31, 2005 | | | 1,299 | | | 1,299 | | Additional paid-in capital | | | 3,199,750 | | | 3,209,968 | | Deficit accumulated during development stage | | | (63,820,357 | ) | | (62,173,702 | ) | Treasury Stock | | | | | | | | Series B Convertible Preferred Stock; at cost, 100,000 shares at March 31, 2006 and December 31, 2005 | | | — | | | — | | Common stock; at cost, 88,500 shares at March 31, 2006 and December 31, 2005 | | | — | | | — | | | |
|
| |
|
| | Total stockholders’ deficiency | | | (60,617,316 | ) | | (58,960,443 | ) | | |
|
| |
|
| | | | $ | 1,071,228 | | $ | 2,338,635 | | | |
|
| |
|
| | | | | | | | | |
See accompanying notes to unaudited condensed financial statements. |
58Vela Pharmaceuticals Inc.
(A Development Stage Enterprise)
|
Condensed Statements of Operations
(unaudited) | | | | | | | | | | | | | | | | | | | | | | | | | | Period from
February 4, 1998
(Inception) to
March 31,
2006 | | | | Three months ended
March 31, | | | | | 2006 | | 2005 | | | | |
| |
| |
| | Consulting revenues | | $ | — | | $ | — | | $ | 234,018 | | Operating expenses: | | | | | | | | | | | Research and development | | | 363,362 | | | 1,884,904 | | | 42,275,417 | | General and administrative | | | 856,803 | | | 631,106 | | | 12,111,641 | | Business development | | | 221,751 | | | 410,498 | | | 6,285,087 | | | |
|
| |
|
| |
|
| | Total expenses | | | 1,441,916 | | | 2,926,508 | | | 60,672,145 | | | |
|
| |
|
| |
|
| | Operating loss | | | (1,441,916 | ) | | (2,926,508 | ) | | (60,438,127 | ) | Interest income | | | 12,826 | | | 7,550 | | | 1,380,247 | | Interest expense | | | (217,565 | ) | | (83,746 | ) | | (860,880 | ) | | |
|
| |
|
| |
|
| | Loss before tax | | | (1,646,655 | ) | | (3,002,704 | ) | | (59,918,760 | ) | Income tax benefit | | | — | | | — | | | 975,926 | | | |
|
| |
|
| |
|
| | Net loss | | | (1,646,655 | ) | | (3,002,704 | ) | | (58,942,834 | ) | Preferred stock accretion | | | (10,218 | ) | | (10,218 | ) | | (188,098 | ) | | |
|
| |
|
| |
|
| | Net loss attributable to common stockholders | | $ | (1,656,873 | ) | $ | (3,012,922 | ) | $ | (59,130,932 | ) | | |
|
| |
|
| |
|
| | | | | | | | | | | | |
See accompanying notes to unaudited condensed financial statements.
Vela Pharmaceuticals Inc.
(A Development Stage Enterprise) Condensed Statements of Cash Flows
(unaudited) | | | | | | | | | | | | | | | | | Period from
February 4,
1998
(Inception) to
March 31,
2006 | | | | | | | | | | | Three months ended
March 31, | | | | | 2006 | | 2005 | | | | |
| |
| |
| | Operating activities | | | | | | | | Net loss | | $ | (1,646,655 | ) | $ | (3,002,704 | ) | $ | (58,942,834 | ) | Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | Depreciation and amortization | | | 17,936 | | | 25,884 | | | 345,098 | | Loss on disposal of property and equipment | | | — | | | — | | | 14,766 | | Deferred stock compensation to consultants | | | — | | | — | | | 164,736 | | Common stock issued to consultants for services and patent rights | | | — | | | — | | | 85,618 | | Preferred stock issued for interest expense | | | — | | | — | | | 9,737 | | Changes in operating assets and liabilities: | | | | | | | | | | | Restricted cash | | | 345,600 | | | — | | | — | | Prepaid expenses and other current assets | | | 20,848 | | | 17,179 | | | (47,006 | ) | Accounts payable | | | 380,772 | | | (488,282 | ) | | 486,863 | | Accrued expenses | | | (219,089 | ) | | (297,317 | ) | | 288,106 | | Accrued interest payable | | | 217,565 | | | 83,746 | | | 851,145 | | | |
| |
| |
| | Net cash used in operating activities | | | (883,023 | ) | | (3,661,494 | ) | | (56,744,771 | ) | | | | | | | | | | | | Investing activities | | | | | | | | | | | Additions to property and equipment | | | — | | | (3,592 | ) | | (484,519 | ) | Proceeds from the sale of property and equipment | | | — | | | — | | | 4,345 | | | |
| |
| |
| | Net cash used in investing activities | | | — | | | (3,592 | ) | | (480,174 | ) | | | | | | | | | | | | Financing activities | | | | | | | | | | | Proceeds from issuance of bridge loans | | | — | | | 4,000,000 | | | 14,280,000 | | Proceeds from issuance of common stock | | | — | | | — | | | 92,251 | | Proceeds from issuance of Series A preferred stock | | | — | | | — | | | 1,122,592 | | Proceeds from issuance of Series B preferred stock | | | — | | | — | | | 1,636,205 | | Proceeds from issuance of Series C preferred stock | | | — | | | — | | | 16,216,402 | | Proceeds from issuance of Series D preferred stock | | | — | | | — | | | 24,781,407 | | | |
| |
| |
| | Net cash provided by financing activities | | | — | | | 4,000,000 | | | 58,128,857 | | | |
| |
| |
| | Net (decrease) increase in cash and cash equivalents | | | (883,023 | ) | | 334,914 | | | 903,912 | | Cash and cash equivalents at beginning of period | | | 1,786,935 | | | 1,861,858 | | | — | | | |
| |
| |
| | Cash and cash equivalents at end of period | | $ | 903,912 | | $ | 2,196,772 | | $ | 903,912 | | | |
| |
| |
| | | | | | | | | | | | | Schedule of noncash transactions | | | | | | | | | | | Deemed dividends on Series C preferred stock | | $ | — | | $ | — | | $ | 4,877,523 | | Conversion of note payable to Series A preferred stock | | | — | | | — | | | 280,000 | | Issuance of common stock for patent rights | | | — | | | — | | | 8,750 | | Issuance of common stock for services | | | — | | | — | | | 76,870 | | Issuance of common stock warrants | | | — | | | 96,095 | | | 98,595 | | | | | | | | | | | | | Supplemental disclosure of cash flow information | | | | | | | | | | | Proceeds from sale of unused NJ State NOL tax benefit | | | — | | | — | | | 975,926 | |
See accompanying notes to unaudited condensed financial statements.
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Unaudited Condensed Financial Statements | | 1. | 1. Organization and Description of Business
|
Vela Pharmaceuticals Inc. (the “Company”) was incorporated in Delaware on February 4, 1998. The Company is focused on the identification, development and testing of selected and important therapeutic agents for the treatment of patients with psychiatric, neurologic and other disorders. Upon completion of development, it intends to market such products. Since inception, the Company has principally been active in performing research and product development. Accordingly, the Company has been classified as a development stage enterprise. The Company’s operations constitute one business segment. Recent Developments On March 15, 2006, the Company entered into a definitive agreement with Pharmos Corporation (“Pharmos”) to sell all of the Company’s rights and assets for cash and shares of common stock. The sale transaction terms include an initial payment of $5 million in cash and the issuance of 11.5 million shares of Pharmos common stock for a combined value of approximately $29.7 million. The transaction also includes the issuance of up to 8 million additional Pharmos common stock shares contingent on achieving specific clinical milestones. No adjustments have been made to these financial statements as a result of this transaction. If the sale does not occur, the Company’s ability to continue as a going concern is dependent upon the continued sale of its securities for funds to meet its cash requirements. If the sale to Pharmos does not occur, the Company may request additional support from its current investors to continue operations until a sale or license of technology to a party different from Pharmos can be consummated; or the Company may seek to raise additional equity funding to finance the development of its assets. However, there are no assurances that these alternative plans will be achieved; as such, the Company may shutdown without a sale of its assets. At March 31, 2006, the Company has cumulative losses of approximately $63,820,000, negative working capital and negative cash flows from operations. Operating losses are expected to continue for the foreseeable future. To date the Company has funded its activities through equity investments, convertible notes and the sale of net operating losses. | | 2. | 2. Summary of Significant Accounting Policies
|
Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete annual financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three-month period ended March 31, 2006 are not necessarily indicative of the results that may be expected for the year ending December 31, 2006. For further information, refer to the financial statements and footnotes thereto for the year ended December 31, 2005 included elsewhere herein. The preparation of unaudited condensed financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. |
Vela Pharmaceuticals Inc.
(A Development State Enterprise)
Notes to Unaudited Condensed Financial Statements (continued)
Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company invests its cash in deposits with major financial institutions.
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Unaudited Condensed Financial Statements (Continued) Fair Value of Financial Instruments Certain financial instruments reflected in the condensed balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximate fair value due to their short-term nature. Restricted Cash The restricted cash as of December 31, 2005 was cash set aside and reserved for the payment of one-half of the minimum bonus payments under the Acquisition Bonus Plan (see Note 5). This amount was paid to key employees at the Company on March 1, 2006. Property and Equipment Property, equipment and leasehold improvements are stated at cost. Depreciation is provided using the straight-line method over the lesser of the estimated useful lives of the related assets, which range from three to seven years, or the term of the related lease. Liquidation Value Liquidation value of the Company’s Preferred Stock is reflected at the stated liquidation preference amounts per share, multiplied by the number of shares of Preferred Stock outstanding for each series of Preferred Stock issued. Depending on future liquidation events (including a sale of the Company), realized liquidation value may be less than or greater than these amounts, but no greater than 2.5 times the liquidation preference. Liquidation values as reflected on the condensed balance sheets at March 31, 2006 and December 31, 2005 are greater than the net assets of the Company at such dates. Research and Development All research and development costs are charged to operations as incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research for the Company. Income Taxes The Company utilizes the asset and liability method to account for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Stock-Based Compensation Prior to January 1, 2006, the Company elected to account for stock-based compensation using the intrinsic value method prescribed in Accounting Principle Board Opinion No. 25, “Accounting for Stock Issued to Employees” as permitted by Statement of Financial Accounting Standards No. 123, “Accounting for Stock Based Compensation” (Statement 123). Accordingly, prior to January 1, 2006, the Company did not recognize compensation expense for |
stock option grants made at an exercise price equal to or in excess of the fair market value of the stock at the date of grant. |
Vela Pharmaceuticals Inc.
(A Development State Enterprise)
Notes to Unaudited Condensed Financial Statements (continued)
Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS 123(R), “Share-Based Payment,” using the accelerated expense attribution method specified in FASB Interpretation No. (FIN) 28, “Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans” (FIN 28). SFAS 123(R) requires companies to recognize compensation expense in an amount equal to the fair value of all share-based payments granted to employees. The Company has elected the prospective transition method, and, therefore,
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Unaudited Condensed Financial Statements (Continued) adjustments to prior periods are not required as a result of adopting SFAS 123(R). Under this method, the provisions of SFAS 123(R) apply to all awards granted after January 1, 2006, the date of adoption. The Company estimates the value of its stock options using the calculated value on the grant date. The Company measures compensation cost of employee stock options based on the calculated value instead of fair value because it is not practical to estimate the volatility of its share price. The Company does not maintain an internal market for its shares and its shares are rarely traded privately. The Company has not been able to identify any similar public entities. The calculated value method requires that the volatility assumption used in an option-pricing model be based on the historical volatility of an appropriate industry sector index. The Company uses the Black-Scholes-Merton formula to estimate the calculated value of its share-based payments. The volatility assumption used in the Black-Scholes-Merton formula is based on the volatility of the NASDAQ Biotechnology Index. The Company calculated the historical volatility of the index using the daily closing total returns for that index for the five years immediately prior to March 31, 2006. As the Company did not grant any stock options during the three month period ended March 31, 2006, the Company recorded no stock-based compensation expense in the first quarter of 2006. The following table illustrates the pro forma effect on net loss if the Company had applied the fair value recognition provision of SFAS No. 123 to stock-based employee compensation for the three months ended March 31, 2005: | |
| | | Three months
ended
March 31, 2005 | | |
|---|
| | |
| | |
|---|
| | Net loss attributable to common
stockholders, as reported | $ | (3,002,704 | ) | | | | Add: Non-cash employee compensation
as reported | | — | | | | | Deduct: Total stock-based employee
compensation expense determined under
fair value based method for all awards | | 48,512 | | | | |
| | | | | SFAS 123 pro forma net loss | $ | (3,051,216 | ) | | | |
| | |
| | | | | | | | Three months
ended
March 31, 2005 | | | |
| | Net loss attributable to common stockholders, as reported | | $ | (3,002,704 | ) | Add: Non-cash employee compensation as reported | | | — | | Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards | | | 48,512 | | | |
|
| | SFAS 123 pro forma net loss | | $ | (3,051,216 | ) | | |
|
| |
Impairment of Long Lived Assets In accordance with SFAS No. 144, long-lived assets, such as property, plant, and equipment, software costs and purchased intangibles subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted net cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheet. |
Vela Pharmaceuticals Inc.
(A Development State Enterprise)
Notes to Unaudited Condensed Financial Statements (continued)
Preferred Stock Dividends The Company records deemed dividends when modification to its preferred stock is required in accordance with EITF 98-5 and EITF 00-27. A modification occurred in 2002 resulting in deemed dividends for the Series C of $4,877,523. | | 3. | 3. Bridge Loans Payable
|
The Company has two Bridge Loans outstanding as of March 31, 2006. Pursuant to the Note and Warrant Purchase Agreement dated as of October 6, 2004 the Company is authorized to issue up to $8,000,000 in senior convertible
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Unaudited Condensed Financial Statements (Continued) promissory notes in four equal installments of $2,000,000 to certain current investors. Interest is compounded monthly at a rate of 6% per annum. With each installment of the Bridge Loan, the Company will issue the Lenders 300,297 warrants to purchase common stock. The four installments were issued in October 2004, December 2004, January 2005 and March 2005. All installments were outstanding at March 31, 2006. In October 2005, the maturity date of the October 6, 2004 Bridge Loan was extended until June 1, 2006. Pursuant to the Note and Warrant Purchase Agreement dated as of June 1, 2005 the Company is authorized to issue up to $6,000,000 in senior convertible promissory notes in three equal installments of $2,000,000 to certain current investors. Interest is compounded monthly at a rate of 6% per annum. With each installment of the Bridge Loan, the Company will issue the Lenders 400,002 warrants to purchase common stock. The three installments were issued in June 2005, August 2005 and October 2005. All installments were outstanding as of March 31, 2006. The maturity date of the Bridge Loan dated June 1, 2005 is June 1, 2006. If the Company consummates a subsequent round of financing at an aggregate price of $30,000,000 (including outstanding bridge loan) prior to the maturity date the outstanding principal and accrued interest will automatically convert into the subsequent round securities at the same price and at the same terms per share as such capital stock or equity securities being issued. If the Company does not consummate a subsequent round of financing the outstanding principal and accrued interest of the notes are payable to the lenders on the maturity date. The maturity date is defined as the earlier of: stated maturity date of the note, the sale or transfer of a majority of the capital stock of the Company, a sale of the corporation or the acceleration of the notes in the event of a default. In the event that a qualified public offering occurs prior to a subsequent round of financing at an aggregate price of $30,000,000 (including outstanding bridge loan) or the Lenders holding at least 80% of the outstanding principal amount of the notes consent in writing, the outstanding principal and accrued interest due shall convert into shares of Series D preferred stock. The amount of shares issued will be calculated by dividing the outstanding principal and interest by the current conversion price of the Series D preferred stock. The outstanding principal and interest payable balances as of March 31, 2006 and December 31, 2005 are $14,000,000 and $851,145 and $14,000,000 and $633,580, respectively. | | 4. | 4. Redeemable Preferred Stock
|
The Company has authorized 16,810,375 and issued 12,351,235 shares of preferred stock and has also issued 250,000 warrants to purchase common stock to the holders of Series C Preferred Stock. The warrants were issued to Series C Preferred Stock holders during 2002, at $0.80 per share for five years. The Company has issued Series C and Series D Redeemable Convertible Preferred Stock and Series A and Series B Preferred Stock (collectively, the “Preferred Stock”). Such stock is subject to the following rights and privileges: |
Vela Pharmaceuticals Inc.
(A Development State Enterprise)
Notes to Unaudited Condensed Financial Statements (continued)
Voting Preferred stockholders are entitled to the number of votes equal to the number of shares of common stock into which each share of Preferred Stock is then convertible. Except for certain corporate matters described in the Company’s Amended and Restated Certificate of Incorporation or as otherwise required by law, the holders of Preferred Stock shall vote together with all other classes and series of stock of the Corporation as a class. Dividends The Company’s Preferred Stock does not bear a fixed or cumulative dividend. Preferred stockholders shall be entitled to receive dividends at the same rate as dividends are paid with respect to the common stock. Such preferred dividends will be determined by the number of shares of common stock into which each share of Preferred Stock is convertible.
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Unaudited Condensed Financial Statements (Continued) Conversion The holders of the outstanding shares of Preferred Stock shall be entitled, at any time, to cause their shares to be converted into common stock on a share-for-share basis. However, if there is a stock dividend, stock split or reverse stock split that takes place before conversion of Preferred Stock, then a new conversion factor would be calculated. This calculation is intended for the Preferred Stockholders to maintain the same equity interest upon conversion into common stock as before the common stock dividend or split. The initial conversion price for each series of Convertible Preferred Stock shall be adjusted from time to time in accordance with the agreement. In accordance with the anti-dilution feature in the Series C Preferred Stock, there was a deemed dividend in the year ended December 31, 2002 of $4,877,523. The Preferred Stock will convert automatically upon the closing of a Qualified Public Offering of the Company’s common stock in which the aggregate price paid for such shares by the public shall be at least $25,000,000 and the price per share paid by the public shall be at least $13.3332 per share. The holders of any share or shares of Preferred Stock shall have the right, at its option at any time, to convert any shares of Preferred Stock into shares of Common Stock. Mandatory Redemption Commencing on January 29, 2007 and on each of the next two anniversaries thereafter, the Company shall redeem, to the extent that it shall have funds legally available therefore, any outstanding shares of Series D Preferred Stock and Series C Preferred Stock according to the percentages listed below: | |
Date of
Redemption | | Percentages of Shares of Series C Preferred Stock
Then Outstanding to be Redeemed | |
|---|
| |
|---|
| | | | January 29, 2007 | | 33-1/3% of all the shares of Series D Preferred Stock and
Series C Preferred Stock outstanding on January 29, 2007 | | January 29, 2008 | | 50% of all the shares of Series D Preferred Stock and
Series C Preferred Stock outstanding on January 29, 2008 | | January 29, 2009 | | 100% of all the shares of Series D Preferred Stock and
Series C Preferred Stock outstanding on January 29, 2009 | |
| | | Date of Redemption | | Percentages of Shares of Series C Preferred Stock
Then Outstanding to be Redeemed |
|
|
| January 29, 2007 | | 33-1/3% of all the shares of Series D Preferred Stock and Series C Preferred Stock outstanding on January 29, 2007 | January 29, 2008 | | 50% of all the shares of Series D Preferred Stock and Series C Preferred Stock outstanding on January 29, 2008 | January 29, 2009 | | 100% of all the shares of Series D Preferred Stock and Series C Preferred Stock outstanding on January 29, 2009 |
The shares of Series D Preferred Stock and Series C Preferred Stock shall be redeemed for cash at the redemption price of $3.3333 and $5.70 per share, respectively, plus an amount equal to all dividends declared but unpaid. |
Vela Pharmaceuticals Inc.
(A Development State Enterprise)
Notes to Unaudited Condensed Financial Statements (continued)
The carrying amount of the Series C and Series D redeemable convertible preferred stock has been increased by periodic accretions so as to equal the redemption amounts at the respective dates. The future minimum accretion of the Series C and Series D redeemable convertible preferred stock based on the shares outstanding as of March 31, 2006 is as follows: | |
| | | | | | | Accretion of
Redeemable
Convertible
Preferred Stock | | | |
| | 2006 | | $ | 31,221 | | 2007 | | | 41,439 | | 2008 | | | 41,439 | | | |
|
| | Total accretion | | $ | 114,099 | | | |
|
| |
| Liquidation
Vela Pharmaceuticals Inc.
(A Development State Enterprise) Notes to Unaudited Condensed Financial Statements (Continued) In the event of any liquidation, dissolution, or winding up (either voluntary or involuntary) of the Company, (the consolidation or merger of the Company with or into another entity, or the sale, lease, abandonment, transfer or other disposition by the Company of all or substantially all of its assets, shall be deemed to be a liquidation, dissolution or winding up of the Company) the holders of the Preferred Stock are entitled to receive, prior to and in preference to the holders of common stock or any other capital stock of the Company ranking on liquidation junior to the Preferred Stock, an amount equal to $1.00, $3.00, $5.70 and $3.3333, respectively, for each outstanding share of Series A, B, C and D Preferred Stock, plus any and all accrued and unpaid dividends as of the date of liquidation (collectively, the “Series A, B, C and D Liquidation Preference”). In the event that the assets of the Company to be distributed are less than the Series A, B, C and D Liquidation Preference, then the assets of the Company shall be paid to the Series A, B, C and D preferred stockholders in the following priority: (i) to the Series D preferred stockholders; (ii) to the Series C preferred stockholders; (iii) to the Series A preferred stockholders; and (iv) to the Series B preferred stockholders. After payment in full of the Series A, B, C, and D Liquidation Preference, the remaining net assets of the Company shall be distributed ratably to the holders of common stock and holders of Preferred Stock as if the holders of Preferred Stock had converted their shares into common stock immediately prior to the liquidation; provided that the amount payable in liquidation (including the applicable Liquidation Preference) to each series of Preferred Stock shall not exceed the greater of (i) the amount each share of such series would receive if it had been converted to common stock immediately prior to the liquidation, dissolution or winding up, and (ii) $2.50 per share for the Series A, $7.50 per share for the Series B, $14.25 per share for the Series C and $8.333 per share for the Series D; and provided further that in the event the Company obtains at least $30,000,000 in an equity financing where the price per share is at least $10.00, then after the holders of Preferred Stock shall be paid in full the greater of (x) the applicable Liquidation Preference and (y) the amount each share of such Preferred Stock would receive if it had converted to common stock immediately before such liquidation, dissolution or winding up, the remaining net assets of the Company shall be distributed ratably among the holders of common stock. | | 5. | 5. Acquisition Bonus Plan
|
In August 2005, the Board approved the Acquisition Bonus Plan. The plan is designed to provide an incentive bonus to key employees and advisors upon the sale of the Company or the license of its major assets. The plan provides for a Minimum Stay Bonus to be paid to the key employees in the event the Company does not enter into a transaction for the sale or license of its assets. The Minimum Stay Bonus is to be paid on two increments within 15 days of March 1, 2006 and June 30, 2006 and provides that one half of the Minimum Stay Bonus be put into an escrow |
Vela Pharmaceuticals Inc.
(A Development State Enterprise)
Notes to Unaudited Condensed Financial Statements (continued)
account and be used for the March 1, 2006 payment. This March 2006 payment was made to key employees as scheduled. Due to the Company’s net operating losses, no provision for income taxes has been made. Furthermore, valuation allowances have been recorded to offset all deferred tax assets arising from the benefits of net operating losses. |
PHARMOS AND VELA
UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL STATEMENTS
The following unaudited pro forma condensed combined financial statements are based on the historical financial statements of Pharmos Corporation (Pharmos) and Vela Pharmaceuticals Inc. (Vela) and have been prepared to illustrate the effects of the Pharmos acquisition of Vela announced on March 15, 2006. The following data is presented as if the Merger of Pharmos and Vela was effective as of March 31, 2006 for the unaudited pro forma condensed combined balance sheet. The unaudited pro forma condensed combined statements of operations for the periods ended December 31, 2005 and March 31, 2006 are presented as if the Merger had occurred as of January 1, 2005. This unaudited condensed combined pro forma financial information reflects the purchase of Vela as an acquisition of assets and represents a current estimate of the financial information based on available information from Pharmos and Vela.
The pro forma information includes adjustments to record the assets and liabilities of Vela at their estimated fair market values and is subject to adjustment as additional information becomes available and as additional analyses are performed. To the extent there are significant changes to Vela’s business, the assumptions and estimates herein could change significantly. The pro forma financial information is presented for illustrative purposes only under one set of assumptions and does not reflect the financial results of the combined companies had consideration been given to other assumptions or to the impact of possible operating efficiencies, asset dispositions, and other factors. Further, the pro forma financial information does not necessarily reflect the historical results of the combined company that actually would have occurred had the Merger been in effect during the periods indicated or that may be obtained in the future. The unaudited pro forma condensed combined financial statements should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the historical financial statements, including the related notes, of Pharmos and Vela covering these periods included in Pharmos’ Annual Report on Form 10-K for the fiscal year ended December 31, 2005, which is included in the Annual Report to Shareholders, and in Pharmos’ Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006, each accompanying this proxy statement, as well as the historical financial statements of Vela included elsewhere in this proxy statement. The unaudited pro forma condensed combined financial information is based on agreement terms that provide for a cash payment of $5,000,000 to or on behalf of Vela at closing and the issuance at closing of 11,500,000 shares of Pharmos common stock upon the cancellation of all outstanding shares of Vela capital stock. AnThe unaudited pro forma condensed combined financial information does not give effect to the potential issuance of up to 8,000,000 additional 8,000,000 shares of Pharmos common stock that may be issued contingent upon the achievement of certain clinical milestones.
|
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
As of March 31, 2006
| |
| Pharmos | | Vela | | Pro Forma
Adjustments | | | | | Condensed
Combined
Pro Forma | |
|---|
|
| |
| |
| | | | |
| | | Assets | | | | | | | | | | | | | | | | | Current Assets | | | | | | | | | | | | | | | | | Cash and cash equivalents | $ | 5,139,887 | | $ | 903,912 | | $ | (903,912 | ) | | E | | $ | (1,168,645 | ) | | | | | | | | | | (5,000,000 | ) | | B | | | | | | | | | | | | | | (1,308,532 | ) | | C | | | | | | Short-term investments | | 36,477,828 | | | — | | | — | | | | | | 36,477,828 | | | Restricted cash | | 80,245 | | | — | | | — | | | E | | | 80,245 | | Research and development grants
receivables | | 952,953 | | | — | | | — | | | | | | 952,953 | | Prepaid expenses and other
current assets | | 1,484,046 | | | 25,958 | | | (751 | ) | | E | | | 1,509,253 | | | Debt issuance costs | | — | | | 9,051 | | | (9,051 | ) | | F | | | — | | |
| |
| |
| | | | |
| | | Total current assets | | 44,134,959 | | | 938,921 | | | (7,222,246 | ) | | | | | 37,851,634 | | | | | | | | | | | | | | | | | | | | Capitalized merger costs | | 741,468 | | | — | | | (741,468 | ) | | C | | | — | | | Fixed assets, net | | 760,472 | | | 120,310 | | | (110,310 | ) | | G | | | 770,472 | | | Restricted cash | | 63,114 | | | — | | | — | | | | | | 63,114 | | | Severance pay funded | | 803,754 | | | — | | | — | | | | | | 803,754 | | | Other assets | | 18,496 | | | 11,997 | | | — | | | | | | 30,493 | | |
| |
| |
| | | | |
| | | | | | | | | | | | | | | | | | | | Total assets | $ | 46,522,263 | | $ | 1,071,228 | | $ | (8,074,024 | ) | | | | $ | 39,519,467 | | |
| |
| |
| | | | |
| |
| | | | | | | | | | | | | | | | | | | Pharmos | | Vela | | Pro Forma
Adjustments | | | | Condensed
Combined
Pro Forma | | | |
| |
| |
| | | |
| | | | | | | | | | | | | | Assets | | | | | | | | | | | | | | | | | Current Assets | | | | | | | | | | | | | | | | | Cash and cash equivalents | | $ | 5,139,887 | | $ | 903,912 | | $ | (903,912 | ) | | E | | $ | (1,168,645 | ) | | | | | | | | | | (5,000,000 | ) | | B | | | | | | | | | | | | | | (1,308,532 | ) | | C | | | | | Short-term investments | | | 36,477,828 | | | — | | | — | | | | | | 36,477,828 | | Restricted cash | | | 80,245 | | | — | | | — | | | E | | | 80,245 | | Research and development grants receivables | | | 952,953 | | | — | | | — | | | | | | 952,953 | | Prepaid expenses and other current assets | | | 1,484,046 | | | 25,958 | | | (751 | ) | | E | | | 1,509,253 | | Debt issuance costs | | | — | | | 9,051 | | | (9,051 | ) | | F | | | — | | | |
|
| |
|
| |
|
| | | | |
|
| | Total current assets | | | 44,134,959 | | | 938,921 | | | (7,222,246 | ) | | | | | 37,851,634 | | | | | | | | | | | | | | | | | | | Capitalized merger costs | | | 741,468 | | | — | | | (741,468 | ) | | C | | | — | | Fixed assets, net | | | 760,472 | | | 120,310 | | | (110,310 | ) | | G | | | 770,472 | | Restricted cash | | | 63,114 | | | — | | | — | | | | | | 63,114 | | Severance pay funded | | | 803,754 | | | — | | | — | | | | | | 803,754 | | Other assets | | | 18,496 | | | 11,997 | | | — | | | | | | 30,493 | | | |
|
| |
|
| |
|
| | | | |
|
| | Total assets | | $ | 46,522,263 | | $ | 1,071,228 | | $ | (8,074,024 | ) | | | | $ | 39,519,467 | | | |
|
| |
|
| |
|
| | | | |
|
| |
|
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
As of March 31, 2006
| |
| | Pharmos | | Vela | | Pro Forma
Adjustments | | | Condensed
Combined
Pro Forma | |
|---|
|
| |
| |
| | | | |
| | | Liabilities and Shareholders’ Equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Accounts payable | $ | 561,280 | | $ | 486,862 | | $ | (386,862 | ) | | H | | $ | 661,280 | | | Accrued expenses | | 535,439 | | | 119,655 | | | (119,655 | ) | | H | | | 535,439 | | | Warrant liability | | 24,776 | | | — | | | — | | | | | | 24,776 | | Accrued wages and other
compensation | | 1,457,857 | | | — | | | — | | | | | | 1,457,857 | | | Accrued bonuses | | — | | | 167,452 | | | (167,452 | ) | | H | | | — | | | Bridge loan payable | | — | | | 14,000,000 | | | (14,000,000 | ) | | D | | | — | | | Accrued interest payable | | — | | | 851,145 | | | (851,145 | ) | | D | | | — | | |
| |
| |
| | | | |
| | | Total current liabilities | | 2,579,352 | | | 15,625,114 | | | (15,525,114 | ) | | | | | 2,679,352 | | | | | | | | | | | | | | | | | | | | Other liability | | 122,246 | | | — | | | — | | | | | | 122,246 | | | Severance pay | | 1,104,749 | | | — | | | — | | | | | | 1,104,749 | | |
| |
| |
| | | | |
| | | Total liabilities | | 3,806,347 | | | 15,625,114 | | | (15,525,114 | ) | | — | | | 3,906,347 | | | | | | | | | | | | | | | | | | | | Commitments and contingencies | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Redeemable Convertible
Preferred Stock | | — | | | 46,063,430 | | | (46,063,430 | ) | | D | | | — | | | | | | | | | | | | | | | | | | | | Shareholders’ Equity | | | | | | | | | | | | | | | | | Preferred stock | | — | | | 1,992 | | | (1,992 | ) | | D | | | — | | | | | | | | | | | | | | | | | | | | Common stock | | 571,973 | | | 1,299 | | | (1,299 | ) | | D | | | 916,973 | | | | | | | | | | | 345,000 | | | A | | | | | | Paid-in capital in excess of par | | 191,048,613 | | | 3,199,750 | | | (3,199,750 | ) | | D | | | 217,053,613 | | | | | | | | | | | 26,055,000 | | | A | | | | | | | | | | | | | | (50,000 | ) | | C | | | | | | Accumulated deficit | | (148,904,244 | ) | | (63,820,357 | ) | | 63,820,357 | | | D | | | (182,357,040 | ) | | | | | | | | | | (33,452,796 | ) | | I | | | | | | Treasury stock | | (426 | ) | | — | | | | | | | | | (426 | ) | |
| |
| |
| | | | |
| | | Total shareholders’ equity | | 42,715,916 | | | (60,617,316 | ) | | 53,514,520 | | | | | | 35,613,120 | | | | | | | | | | | | | | | | | | | Total liabilities and
shareholders’ equity | $ | 46,522,263 | | $ | 1,071,228 | | $ | (8,074,024 | ) | | | | $ | 39,519,467 | | |
| |
| |
| | | | |
| |
| | | | | | | | | | | | | | | | | | | Pharmos | | Vela | | Pro Forma
Adjustments | | | | Condensed
Combined
Pro Forma | | | |
| |
| |
| | | |
| | | Liabilities and Shareholders’ Equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Accounts payable | | $ | 561,280 | | $ | 486,862 | | $ | (386,862 | ) | | H | | $ | 661,280 | | Accrued expenses | | | 535,439 | | | 119,655 | | | (119,655 | ) | | H | | | 535,439 | | Warrant liability | | | 24,776 | | | — | | | — | | | | | | 24,776 | | Accrued wages and other compensation | | | 1,457,857 | | | — | | | — | | | | | | 1,457,857 | | Accrued bonuses | | | — | | | 167,452 | | | (167,452 | ) | | H | | | — | | Bridge loan payable | | | — | | | 14,000,000 | | | (14,000,000 | ) | | D | | | — | | Accrued interest payable | | | — | | | 851,145 | | | (851,145 | ) | | D | | | — | | | | |
|
| |
|
| |
|
| | | | |
|
| | Total current liabilities | | | 2,579,352 | | | 15,625,114 | | | (15,525,114 | ) | | | | | 2,679,352 | | | | | | | | | | | | | | | | | | | Other liability | | | 122,246 | | | — | | | — | | | | | | 122,246 | | Severance pay | | | 1,104,749 | | | — | | | — | | | | | | 1,104,749 | | | | |
|
| |
|
| |
|
| | | | |
|
| | Total liabilities | | | 3,806,347 | | | 15,625,114 | | | (15,525,114 | ) | | — | | | 3,906,347 | | | | | | | | | | | | | | | | | | | Commitments and contingencies | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Redeemable Convertible Preferred Stock | | | — | | | 46,063,430 | | | (46,063,430 | ) | | D | | | — | | | | | | | | | | | | | | | | | | | Shareholders’ Equity | | | | | | | | | | | | | | | | | Preferred stock | | | — | | | 1,992 | | | (1,992 | ) | | D | | | — | | | | | | | | | | | | | | | | | | | Common stock | | | 571,973 | | | 1,299 | | | (1,299 | ) | | D | | | 916,973 | | | | | | | | | | | 345,000 | | | A | | | | | Paid-in capital in excess of par | | | 191,048,613 | | | 3,199,750 | | | (3,199,750 | ) | | D | | | 217,053,613 | | | | | | | | | | | 26,055,000 | | | A | | | | | | | | | | | | | | (50,000 | ) | | C | | | | | Accumulated deficit | | | (148,904,244 | ) | | (63,820,357 | ) | | 63,820,357 | | | D | | | (182,357,040 | ) | | | | | | | | | | (33,452,796 | ) | | I | | | | | Treasury stock | | | (426 | ) | | — | | | | | | | | | (426 | ) | | | |
|
| |
|
| |
|
| | | | |
|
| | Total shareholders’ equity | | | 42,715,916 | | | (60,617,316 | ) | | 53,514,520 | | | | | | 35,613,120 | | | | | | | | | | | | | | | | | | | Total liabilities and shareholders’ equity | | $ | 46,522,263 | | $ | 1,071,228 | | $ | (8,074,024 | ) | | | | $ | 39,519,467 | | | |
|
| |
|
| |
|
| | | | |
|
| |
69
|
| | UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Year Ended December 31, 2005 | |
| Expenses | | Pharmos | | Vela | | Pro Forma
Adjustments | | | | Condensed
Combined
Pro Forma | |
|---|
| |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | | Research and development, gross | | $ | 9,568,293 | | $ | 5,115,830 | | $ | 0 | | | | $ | 14,684,123 | | | Grants | | | (1,406,508 | ) | | — | | | — | | | | | (1,406,508 | ) | Research and development, net
of grants | | | 8,161,785 | | | 5,115,830 | | | — | | | | | 13,277,615 | | Selling, general and
administrative | | | 7,165,291 | | | 2,366,087 | | | 1,134,280 | | J | | | 10,665,658 | | | Business Development | | | | | | 1,134,280 | | | (1,134,280 | ) | J | | | — | | | Depreciation and amortization | | | 381,812 | | | 266,403 | | | (175,367 | ) | K | | | 381,812 | | | | | | | | | | | | (91,036 | ) | L | | | | | | |
| |
| |
| | | |
| |
|---|
| Total operating expenses | | | 15,708,888 | | | 8,882,600 | | | (266,403 | ) | | | | 24,325,085 | | | |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | | |
| |
| |
| | | |
| |
|---|
| Loss from operations | | | (15,708,888 | ) | | (8,882,600 | ) | | 266,403 | | | | | (24,325,085 | ) | | |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | Other income (expense)
Bausch & Lomb payment, net | | | 10,725,688 | | | — | | | — | | | | | 10,725,688 | | | Interest income | | | 1,514,878 | | | 35,393 | | | (35,393 | ) | M | | | 1,305,878 | | | | | | | | | | | | (209,000 | ) | N | | | | | | Interest expense | | | (166,322 | ) | | (596,949 | ) | | 596,949 | | O | | | (166,322 | ) | | Change in value of warrants | | | 259,075 | | | — | | | — | | | | | 259,075 | | | Other income (expense) | | | (44,937 | ) | | — | | | — | | | | | (44,937 | ) | | |
| |
| |
| | | |
| |
|---|
| Other income (expense), net | | | 12,288,382 | | | (561,556 | ) | | 352,556 | | | | | 12,079,382 | | | |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | | Loss before income taxes | | | (3,420,506 | ) | | (9,444,156 | ) | | 618,959 | | | | | (12,245,703 | ) | | | | | | | | | | | | | | | | | | | Income tax benefit | | | 490,634 | | | 333,660 | | | — | | | | | 824,294 | | | |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | | Net loss | | | (2,929,872 | ) | | (9,110,496 | ) | | 618,959 | | | | | (11,421,409 | ) | | | | | | | | | | | | | | | | | | | Preferred stock accretion | | | — | | | (41,439 | ) | | 41,439 | | P | | | — | | | |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | Net loss attributable to common
shareholders | | $ | (2,929,872 | ) | $ | (9,151,935 | ) | $ | 660,398 | | | | $ | (11,421,409 | ) | | |
| |
| |
| | | |
| |
|---|
| | | | | | | | | | | | | | | | | Net loss per share attributable to
common shareholders: | | | | | | | | | | | | | | | | | Basic and diluted | | $ | (0.15 | ) | | n/a | * | | — | | | | $ | (0.37 | ) | | | | | | | | | | | | | | | | | | Weighted average shares
outstanding | | | 18,974,175 | | | n/a | * | | 11,500,000 | | Q | | | 30,474,175 | |
| | * | As a private company, Vela’s historical financial statements do not provide earnings per share calculations. |
| | | | | | | | | | | | | | | | | Expenses | | Pharmos | | Vela | | Pro Forma | | | | | Condensed
Combined
Pro Forma | |
| |
| |
| |
| | | | |
| | | | | | | | | | | | | | | | | | | Research and development, gross | | $ | 9,568,293 | | $ | 5,115,830 | | $ | 0 | | | | | $ | 14,684,123 | | Grants | | | (1,406,508 | ) | | — | | | — | | | | | | (1,406,508 | ) | Research and development, net of grants | | | 8,161,785 | | | 5,115,830 | | | — | | | | | | 13,277,615 | | Selling, general and administrative | | | 7,165,291 | | | 2,366,087 | | | 1,134,280 | | | J | | | 10,665,658 | | Business Development | | | | | | 1,134,280 | | | (1,134,280 | ) | | J | | | — | | Depreciation and amortization | | | 381,812 | | | 266,403 | | | (175,367 | ) | | K | | | 381,812 | | | | | | | | | | | (91,036 | ) | | L | | | | | | |
|
| |
|
| |
|
| | | | |
|
| | Total operating expenses | | | 15,708,888 | | | 8,882,600 | | | (266,403 | ) | | | | | 24,325,085 | | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | | |
|
| |
|
| |
|
| | | | |
|
| | Loss from operations | | | (15,708,888 | ) | | (8,882,600 | ) | | 266,403 | | | | | | (24,325,085 | ) | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Other income (expense) | | | | | | | | | | | | | | | | | Bausch & Lomb payment, net | | | 10,725,688 | | | — | | | — | | | | | | 10,725,688 | | Interest income | | | 1,514,878 | | | 35,393 | | | (35,393 | ) | | M | | | 1,305,878 | | | | | | | | | | | (209,000 | ) | | N | | | | | Interest expense | | | (166,322 | ) | | (596,949 | ) | | 596,949 | | | O | | | (166,322 | ) | Change in value of warrants | | | 259,075 | | | — | | | — | | | | | | 259,075 | | Other income (expense) | | | (44,937 | ) | | — | | | — | | | | | | (44,937 | ) | | |
|
| |
|
| |
|
| | | | |
|
| | Other income (expense), net | | | 12,288,382 | | | (561,556 | ) | | 352,556 | | | | | | 12,079,382 | | | |
|
| |
|
| |
|
| | | | |
|
| | Loss before income taxes | | | (3,420,506 | ) | | (9,444,156 | ) | | 618,959 | | | | | | (12,245,703 | ) | Income tax benefit | | | 490,634 | | | 333,660 | | | — | | | | | | 824,294 | | | |
|
| |
|
| |
|
| | | | |
|
| | Net loss | | | (2,929,872 | ) | | (9,110,496 | ) | | 618,959 | | | | | | (11,421,409 | ) | | | | | | | | | | | | | | | | | | Preferred stock accretion | | | — | | | (41,439 | ) | | 41,439 | | | P | | | — | | | |
|
| |
|
| |
|
| | | | |
|
| | Net loss attributable to common shareholders | | $ | (2,929,872 | ) | $ | (9,151,935 | ) | $ | 660,398 | | | | | $ | (11,421,409 | ) | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Net loss per share attributable to common shareholders: | | | | | | | | | | | | | | | | | Basic and diluted | | $ | (0.15 | ) | | n/a | * | | — | | | | | $ | (0.37 | ) | Weighted average shares outstanding | | | 18,974,175 | | | n/a | * | | 11,500,000 | | | Q | | | 30,474,175 | |
| | * | As a private company, Vela’s historical financial statements do not provide earnings per share calculations. |
See notes to unaudited pro forma condensed combined financial statements. |
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Quarter Ended March 31, 2006
| | | | | | | | | | | | | | | | | | Expenses | | Pharmos | | Vela | | Pro Forma
Adjustments | | | | Condensed
Combined
Pro Forma | |
| |
| |
| |
| | | |
| | Research and development, gross | | $ | 1,867,114 | | $ | 363,362 | | $ | 0 | | | | | $ | 2,230,476 | | Grants | | | (300,635 | ) | | — | | | — | | | | | | (300,635 | ) | Research and development, net of grants | | | 1,566,479 | | | 363,362 | | | — | | | | | | 1,929,841 | | Selling, general and administrative | | | 1,813,221 | | | 825,290 | | | 221,751 | | | J | | | 2,860,262 | | Business development | | | | | | 221,751 | | | (221,751 | ) | | J | | | — | | Depreciation and amortization | | | 78,484 | | | 31,513 | | | (13,577 | ) | | K | | | 78,484 | | | | | | | | | | | (17,936 | ) | | L | | | | | | |
|
| |
|
| |
|
| | | | |
|
| | Total operating expenses | | | 3,458,184 | | | 1,441,916 | | | (31,513 | ) | | | | | 4,868,587 | | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | | |
|
| |
|
| |
|
| | | | |
|
| | Loss from operations | | | (3,458,184 | ) | | (1,441,916 | ) | | 31,513 | | | | | | (4,868,587 | ) | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Other income (expense) | | | | | | | | | | | | | | | | | Bausch & Lomb payment, net | | | — | | | — | | | — | | | | | | — | | Interest income | | | 465,704 | | | 12,826 | | | (12,826 | ) | | M | | | 391,704 | | | | | | | | | | | (74,000 | ) | | N | | | | | Interest expense | | | — | | | (217,565 | ) | | 217,565 | | | O | | | — | | Change in value of warrants | | | 14,104 | | | — | | | — | | | | | | 14,104 | | Other (expense) income | | | (24,310 | ) | | — | | | — | | | | | | (24,310 | ) | | |
|
| |
|
| |
|
| | | | |
|
| | Other income (expense), net | | | 455,498 | | | (204,739 | ) | | 130,739 | | | | | | 381,498 | | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Loss before income taxes | | ($ | 3,002,686 | ) | ($ | 1,646,655 | ) | $ | 162,252 | | | | | ($ | 4,487,089 | ) | Income tax benefit | | | — | | | — | | | — | | | | | | — | | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Net loss | | | (3,002,686 | ) | | (1,646,655 | ) | | 162,252 | | | | | | (4,487,089 | ) | Preferred stock accretion | | | — | | | (10,218 | ) | | 10,218 | | | P | | | — | | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Net loss attributable to common shareholders | | $ | (3,002,686 | ) | $ | (1,656,873 | ) | $ | 172,470 | | | | | $ | (4,487,089 | ) | | |
|
| |
|
| |
|
| | | | |
|
| | | | | | | | | | | | | | | | | | | Loss attributable to common shareholders: | | | | | | | | | | | | | | | | | Basic and diluted | | $ | (0.16 | ) | | n/a | * | | | | | | | $ | (0.15 | ) | | | | | | | | | | | | | | | | | | Weighted average shares outstanding | | | 19,037,628 | | | n/a | * | | 11,500,000 | | | Q | | | 30,537,628 | |
| Expenses | | Pharmos | | Vela | | Pro Forma
Adjustments | | | | Condensed
Combined
Pro Forma | |
|---|
| |
| |
| |
| | | |
| |
|---|
| Research and development, gross | | $ | 1,867,114 | | $ | 363,362 | | $ | 0 | | | | $ | 2,230,476 | | | Grants | | | (300,635 | ) | | — | | | — | | | | | (300,635 | ) | Research and development, net
of grants | | | 1,566,479 | | | 363,362 | | | — | | | | | 1,929,841 | | | Selling, general and administrative | | | 1,813,221 | | | 825,290 | | | 221,751 | | J | | | 2,860,262 | | | Business development | | | | | | 221,751 | | | (221,751 | ) | J | | | — | | | Depreciation and amortization | | | 78,484 | | | 31,513 | | | (13,577 | ) | K | | | 78,484 | | | | | | | | | | | | (17,936 | ) | L | | | | | | | |
| |
| |
| | | |
| | | Total operating expenses | | | 3,458,184 | | | 1,441,916 | | | (31,513 | ) | | | | 4,868,587 | | | | |
| |
| |
| | | |
| | | | | | | | | | | | | | | | | |
| |
| |
| | | |
| | | Loss from operations | | | (3,458,184 | ) | | (1,441,916 | ) | | 31,513 | | | | | (4,868,587 | ) | | | |
| |
| |
| | | |
| | Other income (expense)
Bausch & Lomb payment, net | | | — | | | — | | | — | | | | | — | | | Interest income | | | 465,704 | | | 12,826 | | | (12,826 | ) | M | | | 391,704 | | | | | | | | | | | | (74,000 | ) | N | | | | | | Interest expense | | | — | | | (217,565 | ) | | 217,565 | | O | | | — | | | Change in value of warrants | | | 14,104 | | | — | | | — | | | | | 14,104 | | | Other (expense) income | | | (24,310 | ) | | — | | | — | | | | | (24,310 | ) | | |
| |
| |
| | | |
| |
|---|
| Other income (expense), net | | | 455,498 | | | (204,739 | ) | | 130,739 | | | | | 381,498 | | | | |
| |
| |
| | | |
| | | | | | | | | | | | | | | | | | | | Loss before income taxes | | | ($ 3,002,686 | ) | | ($ 1,646,655 | ) | $ | 162,252 | | | | | ($ 4,487,089 | ) | | | | | | | | | | | | | | | | | | | Income tax benefit | | | — | | | — | | | — | | | | | — | | | | |
| |
| |
| | | |
| | | | | | | | | | | | | | | | | | | | Net loss | | | (3,002,686 | ) | | (1,646,655 | ) | | 162,252 | | | | | (4,487,089 | ) | | | | | | | | | | | | | | | | | | | Preferred stock accretion | | | — | | | (10,218 | ) | | 10,218 | | P | | | — | | | | |
| |
| |
| | | |
| | Net loss attributable to common
shareholders | | $ | (3,002,686 | ) | $ | (1,656,873 | ) | $ | 172,470 | | | | $ | (4,487,089 | ) | | | |
| |
| |
| | | |
| | | | | | | | | | | | | | | | | | | Loss attributable to common
shareholders: | | | | | | | | | | | | | | | | | Basic and diluted | | $ | (0.16 | ) | | n/a | * | | | | | | $ | (0.15 | ) | | | | | | | | | | | | | | | | | | Weighted average shares
outstanding | | | 19,037,628 | | | n/a | * | | 11,500,000 | | Q | | | 30,537,628 | |
| | * | As a private company, Vela’s historical financial statements do not provide earnings per share calculations. |
NOTES TO UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL STATEMENTS 1. Description of Transaction and Basis of Presentation On March 14, 2006, Pharmos and Vela signed a Merger Agreement under which Vela will merge with and into a wholly-owned subsidiary of Pharmos in a transaction to be accounted for as an acquisition of assets by Pharmos. The assets and liabilities of Vela will be recorded as of the acquisition date at their estimated fair values. The reported consolidated financial condition and results of operations of Pharmos after completion of the merger will reflect these values, but will not be restated retroactively to reflect the historical consolidated financial position or results of operations at Vela. The transaction is expected to qualify as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code. Under the terms of the Merger Agreement, Pharmos will make a cash payment of $5,000,000 and issue 11,500,000 shares of Pharmos common stock upon the cancellation of all shares of Vela capital stock outstanding. An additional 8,000,000 shares of Pharmos common stock may be issued upon the achievement of certain milestones related to the development of dextofisopam. The merger is subject to customary closing conditions, including approval by Pharmos and Vela shareholders. 2. Purchase Price A preliminary estimate of the purchase price is as follows (table in thousands): | |
| Fair value of Pharmos shares to be issued | $ | 26,400 | | | Cash to be paid | | 5,000 | | | |
| | | | | | | 31,400 | | | Estimated transaction costs incurred by Pharmos | | 2,000 | | | |
| | | | | Estimated purchase price | $ | 33,400 | | | |
| |
|
| | | | | Fair value of Pharmos shares to be issued at closing | | $ | 26,400 | | Cash to be paid | | | 5,000 | | | |
|
| | | | | 31,400 | | Estimated transaction costs incurred by Pharmos | | | 2,000 | | | |
|
| | Estimated purchase price | | $ | 33,400 | | | |
|
| |
For pro forma purposes, the fair value of the Pharmos shares used in determining the purchase price was $2.30 per share, which is the implied price of Pharmos common stock based on the average closing price of Pharmos common stock on the two trading days immediately before, the day of, and two trading days immediately after the merger was announced on March 15, 2006. For pro forma purposes, the estimated purchase price has been allocated based on a preliminary valuation of Vela’s tangible and intangible assets and liabilities based on their estimated fair values as of December 31, 2005 (table in thousands): | |
| | | | | Total current assets | | $ | 32 | | Property and equipment and other assets | | | 22 | | In-process technology | | | 33,446 | | Total current liabilities | | | (100 | ) | | |
|
| | Total | | $ | 33,400 | | | |
|
| |
| The allocation of the purchase price is preliminary. The final determination of the purchase price allocation will be based on the fair values of assets acquired, including the fair values of in-process research and development, other identifiable intangibles and the fair values of liabilities assumed as of the date that the merger is consummated. The purchase price allocation will remain preliminary until Pharmos completes a valuation of any significant identifiable intangible assets acquired, including in-process research and development, and determines the fair values of other assets and liabilities acquired. The final determination of the purchase price allocation is expected to be completed as soon as practicable after completion of the merger. The final amounts allocated to assets and liabilities acquired could differ significantly from the amounts presented in the unaudited pro forma condensed combined financial statements. |
The estimated fair value attributed to in-process research and development represents an estimate of the fair value of purchased in-process technology for research projects that, as of the expected closing date of the merger, will not have reached technological feasibility and may not have an alternative future use. Only those research projects that had advanced to a stage of development where management believed reasonable net future cash flow forecasts could be prepared and a reasonable likelihood of technical success existed would be included in the estimated fair value. Accordingly, it is not expected that there will be any significant identifiable intangibles, other than in-process research and development. The in-process research and development primarily represents the estimated fair value of dextofisopam, Vela’s drug currently in Phase II development for the treatment of diarrhea-predominant and alternating type irritable bowel syndrome. Additionally, Vela has one other clinical drug candidate and one preclinical drug candidate in its pipeline. The estimated fair value of the in-process research and development was determined based on a discounted forecast of the estimated net future cash flows for each project, adjusted for the estimated probability of technical success and Food and Drug Administration or European Agency for the Evaluation of Medicinal Product approval for each research project. In-process research and development will be expensed immediately following completion of the merger. | | | | 3. Pro Forma Adjustments | | | | | (A) | To record the value of the 11,500,000 shares of Pharmos common stock to be issued in the merger. | | | | | (B) | To record the $5,000,000 payment to be made upon closing to or on behalf of Vela, which will be used to pay Vela’s transaction costs and other liabilities, including accrued interest and a portion of the outstanding principal on Vela’s bridge notes. | | | | | (C) | To record the estimated Pharmos transaction costs of $2,000,000 and stock issuance costs of approximately $50,000. $741,468 of acquisition costs have been incurred as of March 31, 2006 and are included in capitalized merger costs on Pharmos’ balance sheet at that date. These have been adjusted for pro forma purposes. The pro forma statements also reflect the adjustments of $1,308,532 of cash and cash equivalents, which represents the balance of the $2,000,000 of transaction costs expected to be incurred. Transaction costs incurred by Vela will be expensed as incurred; however, the payment of certain Vela transaction costs will occur at closing. The stock issuance costs of $50,000 are the costs of registering the common stock to be issued and will be charged directly to additional paid-in capital. | | | | | (D) | To eliminate Vela’s historical stockholders’ equity accounts, redeemable convertible preferred stock, bridge notes payable and accrued interest payable on bridge notes. Accrued interest and a portion of the outstanding principal on Vela’s bridge notes will be paid at closing out of the $5 million payment and the remaining principal balance will be converted to equity. | | | | | (E) | To eliminate Vela’s cash and cash equivalents, restricted cash and interest receivable. Under the terms of the agreement, all of Vela’s cash and cash equivalents, along with the $5 million payment, will be used to pay Vela’s transaction costs and other liabilities, including accrued interest and a portion of the outstanding principal on Vela’s bridge notes. | | | | | (F) | To eliminate Vela’s deferred financing costs. These costs are related to the bridge notes which will be paid off from available funds from the $5 million payment and/or converted into equity in connection with the merger. | | | | | (G) | To record the adjustment of Vela’s property and equipment to fair value. Vela’s facilities will be wound down after the merger. The property and equipment has been written down to the estimated liquidation value. | | | | | (H) | To eliminate Vela’s accounts payable, accrued bonuses and other accrued expenses in excess of $100,000. Under the terms of the merger agreement, Pharmos will assume up to $100,000 of Vela’s qualified post-closing liabilities. |
3. | Pro Forma Adjustments | | | | | | (A) | | To record the value of the 11,500,000 shares of Pharmos common stock to be issued in the merger. | | | | | | (B) | | To record the $5,000,000 payment to be made upon closing to or on behalf of Vela, which will be used to pay Vela’s transaction costs and other liabilities, including accrued interest and a portion of the outstanding principal on Vela’s bridge notes. | | | | | | (C) | | To record the estimated Pharmos transaction costs of $2,000,000 and stock issuance costs of approximately $50,000. $741,468 of acquisition costs have been incurred as of March 31, 2006 and are included in capitalized merger costs on Pharmos’ balance sheet at that date. These have been adjusted for pro forma purposes. The pro forma statements also reflect the adjustments of $1,308,532 of cash and cash equivalents, which represents the balance of the $2,000,000 of transaction costs expected to be incurred. Transaction costs incurred by Vela will be expensed as incurred; however, the payment of certain Vela transaction costs will occur at closing. The stock issuance costs of $50,000 are the costs of registering the common stock to be issued and will be charged directly to additional paid-in capital. | | | | | | (D) | | To eliminate Vela’s historical stockholders’ equity accounts, redeemable convertible preferred stock, bridge notes payable and accrued interest payable on bridge notes. Accrued interest and a portion of the outstanding principal on Vela’s bridge notes will be paid at closing out of the $5 million payment and the remaining principal balance will be converted to equity. | | | | | | (E) | | To eliminate Vela’s cash and cash equivalents, restricted cash and interest receivable. Under the terms of the agreement, all of Vela’s cash and cash equivalents, along with the $5 million payment, will be used to pay Vela’s transaction costs and other liabilities, including accrued interest and a portion of the outstanding principal on Vela’s bridge notes. | | | | | | (F) | | To eliminate Vela’s deferred financing costs. These costs are related to the bridge notes which will be paid off from available funds from the $5 million payment and/or converted into equity in connection with the merger. | | | | | | (G) | | To record the adjustment of Vela’s property and equipment to fair value. Vela’s facilities will be wound down after the merger. The property and equipment has been written down to the estimated liquidation value. | | | | | | (H) | | To eliminate Vela’s accounts payable, accrued bonuses and other accrued expenses in excess of $100,000. Under the terms of the merger agreement, Pharmos will assume up to $100,000 of Vela’s qualified post-closing liabilities. | | | | | | (I) |
| | | | (I) | To record the estimated fair value of in-process research and development acquired in the merger. Because this expense is directly attributable to the acquisition and will not have a continuing impact, it is not reflected in the pro forma condensed statements of operations. However, this item will be recorded as an expense immediately following completion of the merger. | | | | | (J) | To reclassify Vela’s Business Development expenses to Selling, General and Administrative expenses. | | | | | (K) | To eliminate Vela’s amortization of deferred financing costs associated with the bridge notes. | | | | | (L) | To eliminate depreciation expense on Vela’s property, plant and equipment, which consists primarily of furniture & fixtures, office equipment and leasehold improvements. These have been written down to their estimated liquidation value. | | | | | (M) | To eliminate Vela’s interest income. All cash & cash equivalents will be used to pay Vela’s transaction costs and accrued interest and a portion of the outstanding balance on Vela’s bridge notes upon completion of merger, therefore interest income on these has been eliminated. | | | | | (N) | To eliminate Pharmos interest income related to the $7,050,000 of cash to be paid in connection with the merger. | | | | | (O) | To eliminate Vela’s interest expense related to the bridge loan. | | | | | (P) | To eliminate Vela’s preferred stock accretion. | | | | | (Q) | To record the 11,500,000 shares of Pharmos common stock to be issued to Vela’s stockholders. | | | |
SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA The following selected unaudited pro forma condensed combined financial data are based on the historical financial statements of operations. However, this item will be recorded as an expense immediately following completionPharmos and Vela and have been prepared to illustrate the effects of the merger. |
| | | | | (J) | | To reclassify Vela’s Business Development expenses to Selling, GeneralPharmos acquisition of Vela. This selected data has been drawn from, and Administrative expenses. | | | | | | (K) | | To eliminate Vela’s amortization of deferred financing costs associatedshould be read together with, the bridge notes. | | | | | | (L) | | To eliminate depreciation expense on Vela’s property, plantPharmos and equipment,Vela unaudited pro forma condensed combined financial statements and the notes thereto which consists primarily of furniture & fixtures, office equipment and leasehold improvements. These have been written down to their estimated liquidation value. | | | | | | (M) | | To eliminate Vela’s interest income. All cash & cash equivalents willcan be used to pay Vela’s transaction costs and accrued interest and a portion of the outstanding balance on Vela’s bridge notes upon completion of merger, therefore interest income on these has been eliminated. | | | | | | (N) | | To eliminate Pharmos interest income related to the $7,050,000 of cash to be paidfound immediately preceding this information in connection with the merger. | | | | | | (O) | | To eliminate Vela’s interest expense related to the bridge loan. | | | | | | (P) | | To eliminate Vela’s preferred stock accretion. | | | | | | (Q) | | To record the 11,500,000 shares of Pharmos common stock to be issued to Vela’s stockholders. |
this proxy statement. | | | | | | | | | | Quarter Ended
March 31
2006 | | Year Ended
December 31
2005 | | | |
| |
| | Revenues | | | — | | | — | | Cost of Goods Sold (exclusive of depreciation & amortization) | | | — | | | — | | Operating expenses | | ($ | 4,868,587 | ) | ($ | 24,325,085 | ) | Other (expense), income, net | | | 381,498 | | | 12,079,382 | | Income (Loss) Before Income Taxes | | | (4,487,089 | ) | | (12,245,703 | ) | Net (Loss) Income | | | (4,487,089 | ) | | (11,421,409 | ) | Net (loss) income applicable to common shareholders | | ($ | 4,487,089 | ) | ($ | 11,421,409 | ) | | |
|
| |
|
| | | | | | | | | | Net (loss) income per share applicable to common shareholders – basic | | ($ | 0.15 | ) | ($ | 0.37 | ) | | |
|
| |
|
| | | | | | | | | | Net (loss) income per share applicable to common shareholders – diluted | | ($ | 0.15 | ) | ($ | 0.37 | ) | | |
|
| |
|
| | | | | | | | | | Total assets | | $ | 39,519,467 | | $ | 57,664,842 | | | |
|
| |
|
| | Long term obligations | | $ | 1,667,833 | | $ | 1,618,426 | | | |
|
| |
|
| | | | | | | | | | Cash dividends declared | | | — | | | — | | | | | | | | | | Average shares outstanding - basic | | | 30,537,628 | | | 30,474,175 | | | | | | | | | | Average shares outstanding – diluted | | | 30,537,628 | | | 30,474,175 | |
|
>COMPARATIVE PER SHARE DATA
The following table sets forth Pharmos'Pharmos’ selected historical share, net loss per share and book value per share information and unaudited pro forma share, net loss per share and book value per share information after giving effect to the merger between Pharmos and Vela. Under the terms of the Agreement and Plan of Merger, Pharmos will make a cash payment of $5,000,000 and exchange 11,500,000 shares of Pharmos common stock for all shares of Vela capital stock outstanding. The agreement also provides that all outstanding bridge notes at the close of the Merger will either be repaid or converted into Series D preferred stock, which will be part of the exchange for the Pharmos common stock. The pro forma equivalent information of Vela was derived using the historical share, net loss per share and book value per share information assuming that 11,500,000 shares of Pharmos common stock had been issued in exchange for all of Vela'sVela’s outstanding capital stock. You should read this information in conjunction with the historical financial information included elsewhere in this proxy statement and in Pharmos'Pharmos’ Quarterly Financial Statements on Form 10-Q for the quarter ended March 31, 2006 and Pharmos Annual Report on Form 10-K the year ended December 31, 2005. The unaudited pro forma share, net loss per share and book value per share information is derived from, and should be read in conjunction with, the Unaudited Pro Forma Condensed Combined Financial Statements and related notes included in this proxy statement. Pharmos'Pharmos’ historical share, net loss per share and book value per share information is derived from the unaudited financial statements of Pharmos as of the quarter ended March 31, 2006 and the audited financial statements as of the year ended December 31, 2006. As a private company, Vela'sVela’s historical financial statements do not provide per share information. |
| Quarter Ended
March 31, 2006 | | Year Ended
December 31, 2005 | |
|---|
|
| | | Historical | | Condensed
Combined
Pro Forma | | Historical | | Condensed
Combined
Pro Forma | |
|---|
| Net loss per share attributable to | | | | | | | | | | | | | | | | common stockholders: | | | | | | | | | | | | | | | | -basic and diluted | | | $ | (0.16 | ) | $ | (0.15 | ) | $ | (0.15 | ) | $ | (0.37 | ) | | | | | | | | | | | | | | | | | | Shares used in calculating loss per | | | | | | | | | | | | | | | | share attributable to common | | | | | | | | | | | | | | | | stockholders: | | | | | | | | | | | | | | | | -basic and diluted | | | | 19,037,628 | | | 30,537,628 | | | 18,974,175 | | | 30,474,175 | | | | | | | | | | | | | | | | | | | Book value per share | | | $ | 2.24 | | $ | 1.17 | | $ | 2.37 | | $ | 1.25 | | | | | | | | | | | | | | | | | | | Shares used in calculating book | | | | | | | | | | | | | | | | value per share | | | | 19,065,784 | | | 30,565,784 | | | 19,065,784 | | | 30,565,784 | |
| | | | | | | | | | | | | | | | Quarter Ended March 31, 2006 | | Year Ended December 31, 2005 | | | |
| |
| | | | Historical | | Condensed
Combined
Pro Forma | | Historical | | Condensed
Combined
Pro Forma | | | |
| |
| |
| |
| | | | | | | | | | | | | | | | Net loss per share attributable to common stockholders: | | | | | | | | | | | | | | -basic and diluted | | $ | (0.16 | ) | $ | (0.15 | ) | $ | (0.15 | ) | $ | (0.37 | ) | | | | | | | | | | | | | | | Shares used in calculating loss per share attributable to common stockholders: | | | | | | | | | | | | | | -basic and diluted | | | 19,037,628 | | | 30,537,628 | | | 18,974,175 | | | 30,474,175 | | | | | | | | | | | | | | | | Book value per share | | $ | 2.24 | | $ | 1.17 | | $ | 2.37 | | $ | 1.25 | | | | | | | | | | | | | | | | Shares used in calculating book value per share | | | 19,065,784 | | | 30,565,784 | | | 19,065,784 | | | 30,565,784 | |
Neither company has paid any dividends since its inception. |
PROPOSAL 2 - GRANT OF DISCRETIONARY AUTHORITY TO ADJOURN THE MEETING
TO SOLICIT ADDITIONAL PROXIES General. If, at our Meeting, the number of shares of our common stock voting in favor of the proposal to issue up to 19,500,000 shares of our common stock in connection with the Merger is insufficient to approve that proposal, our Chairman intends to move to adjourn the Meeting to solicit additional proxies in favor of that proposal. Any such adjournment may be made without notice, other than an announcement at the Meeting of the place, date and time to which the Meeting is adjourned, by approval of the holders of a majority of the shares of our common stock present in person or by proxy and entitled to vote at the Meeting. We are soliciting proxies from shareholders to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the issuance of up to 19,500,000 shares of our common stock in connection with the Merger. The individuals to whom proxies are granted will have the discretion whether or not to use the authority granted to them pursuant to this proposal to adjourn the Meeting. Vote Required. The affirmative vote of a majority of the votes cast by holders of shares of our common stock present in person or represented by proxy and entitled to vote on the matter is required for approval of this proposal, whether or not a quorum exists. Recommendation of our Board of Directors. Our Board of Directors unanimously recommends that you vote “FOR” the proposal to grant discretionary authority to the persons named as proxies to adjourn the Meeting if necessary to solicit additional proxies to approve the issuance of up to 19,500,000 shares of our common stock in connection with the Merger. STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information with respect to the beneficial ownership of the Company’s Common Stock as of June 8, 2006, except as set forth in the footnotes, by (i) each person who was known by the Company to own beneficially more than 5% of any class of the Company’s Stock, (ii) each of the Company’s Directors and executive officers, and (iii) all current Directors and executive officers of the Company as a group. Except as otherwise noted, each person listed below has sole voting and dispositive power with respect to the shares listed next to such person’s name. | |
Name and Address of
Beneficial Ownership | Amount of
Beneficial
Ownership | | Percentage of
Total (1) | |
|---|
|
| |
| | Haim Aviv, Ph.D. (2)
c/o Pharmos Ltd, Kiryat Weitzman
Rehovot 76326, Israel | | 426,049 | | | 2.3 | % | | | | | | | | | David Schlachet (3)
Syneron Medical Ltd.
Industrial Zone, Tavor Building
P.O.B. 550 Yokneam Illit,
20692 Israel | | 25,187 | | | * | | | | | | | | | | Mony Ben Dor (4)
40 Hakukia St.
Rishon Le Zion 75548, Israel | | 17,187 | | | * | | | | | | | | | | Georges Anthony Marcel M.D., Ph.D.(3)
9 ue de Magdebourg 75116 Paris, France | | 14,000 | | | * | | | | | | | | | | Elkan R. Gamzu, Ph.D. (5)
enERGetics, 199 Wells Avenue, Suite 302
Newton, MA 02459 | | 20,750 | | | * | | | | | | | | | | Lawrence F. Marshall, M.D. (3)
University of California, San Diego
Regents Court Bldg., Suite 200
4130 LaJolla Village Drive
LaJolla, CA 92037-1480 | | 12,875 | | | * | | | | | | | | | | Abraham Sartani. M.D.
c/o Recordati SpA, Via Civitali, 1
20148 Milano, Italy | | — | | | — | | | | | | | | | | Alan L. Rubino (3)
c/o Pharmos Corporation
99 Wood Avenue South, Suite 311
Iselin, NJ 08830 | | 41,000 | | | * | | | | | | | | | | James A. Meer (6)
c/o Pharmos Corporation
99 Wood Avenue South, Suite 311
Iselin, NJ 08830 | | 47,750 | | | * | | | | | | | | | | All Directors and
Executive Officers as a group
(nine persons)(8) | | 604,798 | | | 3.2 | % | | | | | | | | | Lloyd I. Miller, III (9)
4550 Gordon Drive
Naples, FL 34102 | | 1,682,912 | | | 8.8 | % |
| | | | | | | | Name and Address of Beneficial Owner | | Amount of
Beneficial
Ownership | | Percentage of
Total (1) | |
| |
| |
| | Haim Aviv, Ph.D. (2) | | | 426,049 | | | 2.3 | % | c/o Pharmos Ltd, Kiryat Weizmann | | | | | | | | Rehovot 76326, Israel | | | | | | | | | | | | | | | | David Schlachet (3) | | | 25,187 | | | * | | Syneron Medical Ltd. | | | | | | | | Industrial Zone, Tavor Building | | | | | | | | P.O.B. 550 Yokneam Illit, | | | | | | | | 20692 Israel | | | | | | | | | | | | | | | | Mony Ben Dor (4) | | | 17,187 | | | * | | 40 Hakukia St. | | | | | | | | Rishon Le Zion 75548, Israel | | | | | | | | | | | | | | | | Georges Anthony Marcel M.D., Ph.D.(3) | | | 14,000 | | | * | | 9 ue de Magdebourg 75116 Paris, France | | | | | | | |
| | | | | | | | Elkan R. Gamzu, Ph.D. (5) | | | 20,750 | | | * | | enERGetics, 199 Wells Avenue, Suite 302 | | | | | | | | Newton, MA 02459 | | | | | | | | | | | | | | | | Lawrence F. Marshall, M.D. (3) | | | 12,875 | | | * | | University of California, San Diego | | | | | | | | Regents Court Bldg., Suite 200 | | | | | | | | 4130 LaJolla Village Drive | | | | | | | | LaJolla, CA 92037-1480 | | | | | | | | | | | | | | | | Abraham Sartani. M.D. | | | — | | | — | | c/o Recordati SpA, Via Civitali, 1 | | | | | | | | 20148 Milano, Italy | | | | | | | | | | | | | | | | Alan L. Rubino (6) | | | 41,000 | | | * | | c/o Pharmos Corporation | | | | | | | | 99 Wood Avenue South, Suite 311 | | | | | | | | Iselin, NJ 08830 | | | | | | | | | | | | | | | | James A. Meer (7) | | | 47,750 | | | * | | c/o Pharmos Corporation | | | | | | | | 99 Wood Avenue South, Suite 311 | | | | | | | | Iselin, NJ 08830 | | | | | | | | | | | | | | | | All Directors and | | | 604,798 | | | 3.2 | % | Executive Officers as a group | | | | | | | | (nine persons)(8) | | | | | | | | | | | | | | | | Lloyd I. Miller, III (9) | | | 1,795,035 | | | 9.4 | % | 4550 Gordon Drive | | | | | | | | Naples, FL 34102 | | | | | | | |
* Indicates ownership of less than 1%.
76
| (1) | Based on 19,065,784 shares of common stock outstanding, plus each individual’s warrants or options which are either currently exercisable or will be exercisable within 60 days of the date set forth above. Assumes that no other individual will exercise any warrants and/or options.
|
| | | | (2) | Consists of 197,423 outstanding shares and 228,626 shares issuable upon exercise of currently exercisable warrants and/or options. | | | | | (3) | Consists entirely of shares issuable upon exercise of currently exercisable warrants and/or options. | | | (4) | Consists of 1,000 outstanding shares and 16,187 shares issuable upon exercise of currently exercisable warrants and/or options. | | | (5) | Consists of 2,000 outstanding shares and 18,750 shares issuable upon exercise of currently exercisable warrants and/or options. | | | (6) | Consists of 1,000 outstanding shares and 40,000 shares issuable upon exercise of currently exercisable options. | | | (7) | Consists of 12,000 outstanding shares and 35,750 shares issuable upon exercise of currently exercisable warrants and/or options | | | (8) | Consists of 213,423 outstanding shares and 391,375 shares issuable upon exercise of currently exercisable warrants and/or options. | | | (9) | This information is as of June 22, 2006 based on a Schedule 13D, as amended, filed by Lloyd Miller with the Securities and Exchange Commission on June 22, 2006. |
(1)
| Based on 19,065,784 shares of common stock outstanding, plus each individual’s warrants or options which are either currently exercisable or will be exercisable within 60 days of the date set forth above. Assumes that no other individual will exercise any warrants and/or options.
| | | | | (2)
| Consists of 197,423 outstanding shares and 228,626 shares issuable upon exercise of currently exercisable warrants and/or options.
| | | | | (3)
| Consists of 1,000 outstanding shares and 40,000 shares issuable upon exercise of currently exercisable warrants and/or options.
| | | | | (4)
| Consists of 1,000 outstanding shares and 17,625 shares issuable upon exercise of currently exercisable warrants and/or options.
| | | | | (5)
| Consists of 2,000 outstanding shares and 18,750 shares issuable upon exercise of currently exercisable warrants and/or options.
| | | | | (6)
| Consists of 12,000 outstanding shares and 35,750 shares issuable upon exercise of currently exercisable warrants and/or options
| | | | | (8)
| Consists of 213,423 outstanding shares and 391,375 shares issuable upon exercise of currently exercisable warrants and/or options.
| | | | | (9)
| This information is as of May 25, 2006 based on a preliminary proxy statement on Schedule 14A filed by Lloyd Miller on May 25, 2006.
|
| DESCRIPTION OF CAPITAL STOCK | | Our authorized capital stock consists of 60,000,000 shares of common stock, par value $.03 per share, and 1,250,000 shares of preferred stock, par value $.03 per share, of which 1,250,000 shares have been designated Series D Participating Preferred Stock. As of ____________ __, 2006, there were ____________ shares of common stock outstanding and no shares of preferred stock outstanding. | Common Stock Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of shareholders, and do not have cumulative voting rights. Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors out of legally available funds, and subject to any preferential dividend rights of any then outstanding preferred stock. Upon our liquidation, dissolution or winding-up, the holders of common stock are entitled to receive ratably our net assets available after the payment of all debts and other liabilities and subject to any liquidation preference of any then outstanding preferred stock. Holders of common stock have no preemptive, subscription or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. Preferred Stock Our Board of Directors has the authority, subject to certain restrictions, without further shareholder approval, to issue, at any time and from time to time, shares of preferred stock in one or more series. Each such series shall have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined by our Board of Directors, which may include, among others, dividend rights, voting rights, redemption and sinking fund provisions, liquidation preferences, conversion rights and preemptive rights, to the full extent now or hereafter permitted by the laws of the State of Nevada. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of holders of any preferred stock that may be issued in the future. Such rights may include voting and conversion rights which could adversely affect the holders of the common stock. Satisfaction of any dividend preferences of outstanding preferred stock would reduce the amount of funds available, if any, for the payment of dividends on common stock. Holders of preferred stock would typically be entitled to receive a preference payment. Shareholder Rights Plan Our Board of Directors adopted a shareholder rights plan in 2002. The shareholder rights plan was adopted to give the Board of Directors increased power to negotiate in our best interests and to discourage appropriation of control of our Company at a price that is unfair to our shareholders. The shareholder rights plan will not be applicable to the acquisition of shares of our common stock by the principal shareholders of Vela in the Merger. It is not intended to prevent fair offers for acquisition of control determined by our Board of Directors to be in our best interests and the best interests of our Company’s shareholders, nor is it intended to prevent a person or group from obtaining representation on or control of our Board of Directors through a proxy contest, or to relieve our Board of Directors of its fiduciary duty concerning any proposal for our acquisition in good faith. The shareholder rights plan involved the distribution of one “right” as a dividend on each outstanding share of our common stock to all holders of record on November 6, 2002, and an ongoing distribution of one right with respect to each share of our common stock issued subsequently, including the shares of our common stock to be issued in the Merger. Each right shall entitle the holder to purchase one one-thousandth of a share of Series D Participating Preferred Stock. The rights trade in tandem with the common stock until, and become exercisable upon, the occurrence of certain triggering events, including the acquisition of beneficial ownership of 15% or more of our common stock by anyone, and the exercise price is based on the estimated long-term value of our common stock. The exercise of these rights becomes economically attractive upon the triggering of certain “flip-in” or “flip-over” rights which work in conjunction with the shareholder rights plan’s basic provisions. The flip-in rights will permit the holders of the Series D Participating Preferred Stock to purchase shares of our common stock at a |
discounted rate, resulting in substantial dilution of an acquirer’s voting and economic interests in our Company. The flip-over element of the shareholder rights plan involves certain mergers or significant asset purchases, which trigger certain rights to purchase shares of the acquiring or surviving company at a discount. The shareholder rights plan contains a “permitted offer” exception which allows offers determined by our Board of Directors to be in our best
interests and in the best interests of our shareholders to take place free of the diluting effects of the shareholder rights plan’s mechanisms. Our Board of Directors retains the right, at all times prior to acquisition of 15% of our common stock by an acquirer, to discontinue the shareholder rights plan through the redemption of all rights, or to amend the shareholder rights plan in any respect. Our Board of Directors intends to amend our shareholder rights plan to exclude the issuance of shares of our common stock in the Merger as an event which could trigger the shareholder rights plan. CERTAIN TRANSACTIONS In June 2005, the Company’s Pharmos Ltd. subsidiary modified a License Agreement with Herbamed, Ltd., a company controlled by Dr. Haim Aviv, the Company’s Chairman and Chief Executive Officer. The License Agreement, originally entered into in May 1997, licenses to Herbamed the Company’s patent rights for the oral delivery of lipophilic substances in the limited field of nutraceuticals, which include food and dietary supplements, food additives, vitamins and herbs. Under the terms of the revised License Agreement, Herbamed will pay to Pharmos Ltd. royalties of 3% on net sales. During 2005 and 2004, the Company recognized royalties of $24,670 and $9,008, respectively. Neither the Company nor its Pharmos Ltd. subsidiary is involved in the field of nutraceuticals generally, and specifically in developing improved oral delivery of nutraceuticals. Pharmos Ltd., therefore, licensed its technology in this narrow non-pharmaceutical field of use to Herbamed as a way of seeking to benefit from a potential stream of royalty payments without having to devote any resources to the development of an application it otherwise would not have pursued. In addition, if the technology proves to be successful for the delivery of nutraceuticals, Pharmos hopes that it could be able to interest potential strategic partners in licensing the technology for pharmaceuticals applications. Dr. Aviv was not involved with either party in negotiating the terms of the License Agreement with Herbamed. Pharmos Ltd. concluded that the royalty rates and other terms of the License Agreement are commercially reasonable to it, and the License Agreement was ratified by the Board of the Company. INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PricewaterhouseCoopers, the Company’s independent registered public accounting firm, is expected to be present at the meeting and will have the opportunity to make a statement, if they desire to do so, and they are expected to be available to respond to appropriate questions. SHAREHOLDERS’ PROPOSALS FOR 2006 ANNUAL MEETING OF SHAREHOLDERS Proposals which shareholders intend to present at the 2006 annual meeting of shareholders and wish to have included in our proxy materials pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended, must be received by the Company by [______________], 2006. Proposals should be sent to: Pharmos Corporation, 99 Wood Avenue South, Suite 311, Iselin, NJ 08830, Attention: President. Shareholders who wish to make a proposal at the 2006 Annual Meeting of Shareholders, other than one that will be included in our proxy materials, should notify us no later than ____________, 2006. If a shareholder notifies us after [____________________], 2006, of an intention to present a proposal at the 2006 annual meeting of shareholders (and for any reason the proposal is voted on at the meeting), our proxy holders will have the right to exercise discretionary voting authority with respect to such proposal. |
ANNUAL REPORT ON FORM 10-K AND QUARTERLY REPORT ON FORM 10-Q A copy of the Company’s 2005 Annual Report to Shareholders, which includes the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and a copy of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006, each as filed with the Securities and Exchange Commission, is being mailed to shareholders with this proxy statement. Upon sending a written request to Pharmos Corporation, 99 Wood Avenue South, Suite 311, Iselin, NJ 08830, Attention: President, shareholders may obtain, free of charge, additional copies of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006. The consolidated financial statements of the Company, including the footnotes thereto, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, and Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure, appearing in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, are hereby incorporated into this proxy statement by reference. The consolidated financial statements of the Company, including the footnotes thereto, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations, and Item 3. Quantitative and Qualitative Disclosures About Market Risk, appearing in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006, are hereby incorporated into this proxy statement by reference. OTHER MATTERS As of the date of this Proxy Statement, the only business which management expects to be considered at the Meeting is to approve the issuance of up to 19,500,000 shares of the Company’s common stock in connection with the proposed acquisition by the Company of Vela Pharmaceuticals Inc. If any other matters come before the Meeting, the persons named in the enclosed form of proxy are expected to vote the proxy in accordance with their best judgment on such matters. | |
| BY ORDER OF THE BOARD OF DIRECTORS | | | | HAIM AVIV, PH.D. | | Chairman of the Board |
| | | BY ORDER OF THE BOARD OF DIRECTORS | | | | HAIM AVIV, PH.D. | | Chairman of the Board |
Dated: [___________], 2006 |
| APPENDIX A AGREEMENT AND PLAN OF MERGER AMONG PHARMOS CORPORATION, VELA ACQUISITION CORPORATION AND VELA PHARMACEUTICALS INC. DATED MARCH 14, 2006 |
| | | | | | | Page | | | | | 1. | The Merger | 1 | | | | 1.1 | Closing and Effective Date of Merger | 1 | | | | 1.2 | Terms and Conditions of Merger | 1 | | 2. | Antidilution; Procedures; Fractional Shares | 3 | | | | 2.1 | Antidilution | 3 | | | | 2.2 | Procedures; Fractional Shares, Etc | 3 | | 3. | Representations and Warranties of Target | 4 | | | | 3.1 | Incorporation; Authority | 4 | | | | 3.2 | Corporate Power, Binding Effect | 4 | | | | 3.3 | Subsidiaries | 5 | | | | 3.4 | Qualification | 5 | | | | 3.5 | Capitalization | 5 | | | | 3.6 | Lawful Issuance | 5 | | | | 3.7 | Financial Statements | 6 | | | | 3.8 | Absence of Certain Changes | 6 | | | | 3.9 | Title to Property, Leases, etc | 6 | | | | 3.10 | Indebtedness | 7 | | | | 3.11 | Absence of Undisclosed Liabilities | 7 | | | | 3.12 | Taxes and Tax Returns | 7 | | | | 3.13 | Litigation, etc | 8 | | | | 3.14 | Safety, Zoning and Environmental Matters | 8 | | | | 3.15 | Labor Relations | 9 | | | | 3.16 | Contracts | 9 | | | | 3.17 | Intellectual Property and Regulatory Matters | 10 | | | | 3.18 | Insurance | 11 | | | | 3.19 | Governmental Consent, Non-Contravention, etc | 11 | | | | 3.20 | Employee Benefit Plans | 11 | | | | 3.21 | Potential Conflicts of Interest | 11 | | | | 3.22 | Brokers | 12 | | | | 3.23 | Compliance with Other Instruments, Laws, etc | 12 | | | | 3.24 | Minute Books | 12 | | | | 3.25 | Absence of Registration Obligations | 12 | |
| | | | | | | | | | | | | | Page | | | | | | | |
| | | 1. | | The Merger | | 1 | | | | | | | | | | 1.1 | | Closing and Effective Date of Merger | | 1 | | | | | | | | | | | | 1.2 | | Terms and Conditions of Merger | | 1 | | | | | | | | | | 2. | | Antidilution; Procedures; Fractional Shares | | 2 | | | | | | | | | | 2.1 | | Antidilution | | 2 | | | | | | | | | | | | 2.2 | | Procedures; Fractional Shares, Etc | | 3 | | | | | | | | | | 3. | | Representations and Warranties of Target | | 4 | | | | | | | | | | 3.1 | | Incorporation; Authority | | 4 | | | | | | | | | | | | 3.2 | | Corporate Power, Binding Effect | | 4 | | | | | | | | | | | | 3.3 | | Subsidiaries | | 4 | | | | | | | | | | | | 3.4 | | Qualification | | 4 | | | | | | | | | | | | 3.5 | | Capitalization | | 5 | | | | | | | | | | | | 3.6 | | Lawful Issuance | | 5 | | | | | | | | | | | | 3.7 | | Financial Statements | | 5 | | | | | | | | | | | | 3.8 | | Absence of Certain Changes | | 5 | | | | | | | | | | | | 3.9 | | Title to Property, Leases, etc | | 6 | | | | | | | | | | | | 3.10 | | Indebtedness | | 6 | | | | | | | | | | | | 3.11 | | Absence of Undisclosed Liabilities | | 6 | | | | | | | | | | | | 3.12 | | Taxes and Tax Returns | | 6 | | | | | | | | | | | | 3.13 | | Litigation, etc | | 7 | | | | | | | | | | | | 3.14 | | Safety, Zoning and Environmental Matters | | 7 | | | | | | | | | | | | 3.15 | | Labor Relations | | 8 | | | | | | | | | | | | 3.16 | | Contracts | | 8 | | | | | | | | | | | | 3.17 | | Intellectual Property and Regulatory Matters | | 9 | | | | | | | | | | | | 3.18 | | Insurance | | 10 | | | | | | | | | | | | 3.19 | | Governmental Consent, Non-Contravention, etc | | 10 | | | | | | | | | | | | 3.20 | | Employee Benefit Plans | | 10 | | | | | | | | | | | | 3.21 | | Potential Conflicts of Interest | | 10 | | | | | | | | | | | | 3.22 | | Brokers | | 11 | | | | | | | | | | | | 3.23 | | Compliance with Other Instruments, Laws, etc | | 11 | | | | | | | | | | | | 3.24 | | Minute Books | | 11 | | | | | | | | | | | | 3.25 | | Absence of Registration Obligations | | 11 | | | | | | | | | | | | 3.26 | | Ownership of Parent Stock | | 11 | | | | | | | | | | | | 3.27 | | Agreements to Vote in Favor of the Merger | | 11 | | | | | | | | | | | | 3.28 | | Full Disclosure | | 11 | | | | | | | | | | 4. | | Representations and Warranties of Parent and Sub | | 11 | | | | | | | | | | 4.1 | | Organization and Standing; Subsidiary | | 11 | | | | | | | | | | | | 4.2 | | Corporate Power, Binding Effect | | 12 | | | | | | | | | | | | 4.3 | | Capitalization | | 12 | | | | | | | | | | | | 4.4 | | Reports and Financial Statements | | 12 | |
|
TABLE OF CONTENTS
(continued) | |
| | | | | | | | | | | | | | Page | | | | | | | |
| | | | | 4.5 | | Absence of Certain Changes | | 13 | | | | | | | | | | | | 4.6 | | Absence of Undisclosed Liabilities | | 13 | | | | | | | | | | | | 4.7 | | Lawful Issuance | | 14 | | | | | | | | | | | | 4.8 | | Taxes and Tax Returns | | 14 | | | | | | | | | | | | 4.9 | | Litigation, etc | | 14 | | | | | | | | | | | | 4.10 | | Safety, Zoning and Environmental Matters | | 15 | | | | | | | | | | | | 4.11 | | Intellectual Property | | 15 | | | | | | | | | | | | 4.12 | | Contracts | | 16 | | | | | | | | | | | | 4.13 | | Potential Conflicts of Interest | | 16 | | | | | | | | | | | | 4.14 | | Government Consents, etc | | 17 | | | | | | | | | | | | 4.15 | | Brokers | | 17 | | | | | | | | | | | | 4.16 | | Internal Controls | | 17 | | | | | | | | | | | | 4.17 | | Compliance with Other Instruments, Laws, etc | | 17 | | | | | | | | | | | | 4.18 | | Approval | | 17 | | | | | | | | | | | | 4.19 | | Absence of Registration Obligations | | 18 | | | | | | | | | | | | 4.20 | | Full Disclosure | | 18 | | | | | | | | | | 5. | | Conduct of Target Business Prior to Effective Date | | 18 | | | | | | | | | | 5.1 | | Full Access | | 18 | | | | | | | | | | | | 5.2 | | Carry on in Regular Course | | 18 | | | | | | | | | | | | 5.3 | | No Dividends, Issuances, Repurchases, etc | | 18 | | | | | | | | | | | | 5.4 | | Employment | | 18 | | | | | | | | | | | | 5.5 | | Contracts and Commitments | | 18 | | | | | | | | | | | | 5.6 | | Other Transactions | | 18 | | | | | | | | | | | | 5.7 | | Preservation of Organization | | 18 | | | | | | | | | | | | 5.8 | | No Default | | 19 | | | | | | | | | | | | 5.9 | | Compliance with Laws | | 19 | | | | | | | | | | | | 5.10 | | Advice of Change | | 19 | | | | | | | | | | | | 5.11 | | Target Stockholders Meeting | | 19 | | | | | | | | | | | | 5.12 | | Consents of Third Parties | | 19 | | | | | | | | | | | | 5.13 | | Satisfaction of Conditions Precedent | | 19 | | | | | | | | | | | | 5.14 | | Transactions with Affiliates | | 19 | | | | | | | | | | | | 5.15 | | Cooperation in the Preparation of Required Securities Laws Documents | | 19 | | | | | | | | | | 6. | | Conduct of Parent Group Business Prior to Effective Date | | 19 | | | | | | | | | | 6.1 | | Full Access | | 19 | | | | | | | | | | | | 6.2 | | Compliance with Laws | | 19 | | | | | | | | | | | | 6.3 | | Other Transactions | | 19 | | | | | | | | | | | | 6.4 | | Preservation of Organization | | 20 | |
-ii-
|
TABLE OF CONTENTS
(continued) | |
| | | | | | | | | | | | | | Page | | | | | | | |
| | | | 6.5 | | No Default | | 20 | | | | | | | | | | | | 6.6 | | Compliance with Laws | | 20 | | | | | | | | | | | | 6.7 | | Advice of Change | | 20 | | | | | | | | | | | | 6.8 | | Consents of Third Parties | | 20 | | | | | | | | | | | | 6.9 | | Satisfaction of Conditions Precedent | | 20 | | | | | | | | | | | | 6.10 | | Carry on in Regular Course | | 20 | | | | | | | | | | | | 6.11 | | Parent Stockholders Meeting | | 20 | | | | | | | | | | 7. | | Conditions Precedent to Parent’s and Sub’s Obligations | | 20 | | | | | | | | | | 7.1 | | Accuracy of Representations and Warranties by Target | | 20 | | | | | | | | | | | | 7.2 | | Compliance by Target | | 21 | | | | | | | | | | | | 7.3 | | Approval by Target Stockholders; Delivery of Certificate of Merger | | 21 | | | | | | | | | | | | 7.4 | | No Restraining Order | | 21 | | | | | | | | | | | | 7.5 | | No Material Adverse Change | | 21 | | | | | | | | | | | | 7.6 | | Officers’ Certificates | | 21 | | | | | | | | | | | | 7.7 | | Opinion of Target’s Counsel | | 21 | | | | | | | | | | | | 7.8 | | Exercise/Conversion of Stock Options, Warrants and Other Rights | | 21 | | | | | | | | | | | | 7.9 | | Liabilities of Target | | 21 | | | | | | | | | | | | 7.10 | | Consents | | 21 | | | | | | | | | | | | 7.11 | | Employment Agreements | | 21 | | | | | | | | | | | | 7.12 | | Distribution of Parent Stock | | 21 | | | | | | | | | | | | 7.13 | | Proceedings and Documents Satisfactory | | 21 | | | | | | | | | | | | 7.14 | | Private Placement | | 22 | | | | | | | | | | | | 7.15 | | Approval by Parent Stockholders | | 22 | | | | | | | | | | | | 7.16 | | Execution and Delivery of Registration Rights Agreement and the Escrow Agreement | | 22 | | | | | | | | | | | | 7.17 | | Cancelled Bridge Notes | | 22 | | | | | | | | | | | | 7.18 | | Standstill Agreement | | 22 | | | | | | | | | | | | 7.19 | | Cash Consideration | | 22 | | | | | | | | | | 8. | | Conditions Precedent to Target’s Obligations | | 22 | | | | | | | | | | 8.1 | | Accuracy of Representations and Warranties by Parent and Sub | | 22 | | | | | | | | | | | | 8.2 | | Compliance by Parent and Sub | | 22 | | | | | | | | | | | | 8.3 | | Approval by Parent Stockholders; Delivery of Certificate of Merger | | 22 | | | | | | | | | | | | 8.4 | | No Restraining Order | | 22 | | | | | | | | | | | | 8.5 | | Parent and Sub Certificates | | 22 | | | | | | | | | | | | 8.6 | | Opinions of Parent’s and Sub’s Counsel | | 22 | | | | | | | | | | | | 8.7 | | No Material Adverse Change | | 22 | | | | | | | | | | | | 8.8 | | Proceedings and Documents Satisfactory | | 23 | | | | | | | | | | | | 8.9 | | Private Placement | | 23 | | | | | | | | | | | | 8.10 | | Expansion of Parent Board of Directors | | 23 | |
-iii-
|
TABLE OF CONTENTS
(continued) | |
TABLE OF CONTENTS
(continued)
| |
| | | | | | | | | | | | | | | | Page | | | | | | | |
| | | | 8.11 | | Payment of Cash Consideration | | 23 | | | | | | | | | | | | 8.12 | | Execution and Delivery of Registration Rights Agreement and Escrow Agreement | | 23 | | | | | | | | | | 9. | | Covenants of the Parties | | 23 | | | | | | | | | | 9.1 | | No Solicitation | | 23 | | | | | | | | | | | | 9.2 | | Further Assurance | | 23 | | | | | | | | | | | | 9.3 | | Disclosure Statements | | 24 | | | | | | | | | | | | 9.4 | | Satisfaction of Conditions Precedent | | 24 | | | | | | | | | | | | 9.5 | | HSR Filing | | 24 | | | | | | | | | | | | 9.6 | | Post-Closing Covenants | | 24 | | | | | | | | | | 10. | | Confidential Information; No Publicity | | 24 | | | | | | | | 11. | | Securities Laws Matters | | 24 | | | | | | | | 12. | | No Survival of Representations | | 25 | | | | | | | | 13. | | Tax Consequences to the Parties | | 25 | | | | | | | | 14. | | Termination; Liabilities Consequent Thereon | | 25 | | | | | | | | 15. | | Indemnification | | 26 | | | | | | | | | | 15.1 | | By the Indemnifying Stockholders | | 26 | | | | | | | | | | | | 15.2 | | By Parent | | 26 | | | | | | | | | | | | 15.3 | | Of Target’s Officers and Directors | | 27 | | | | | | | | | | | | 15.4 | | Method of Asserting Claims; Payment; Offset | | 27 | | | | | | | | | | 16. | | Appointment of Representatives | | 28 | | | | | | | | 17. | | Expenses | | 29 | | | | | | | | 18. | | Certain Definitions | | 29 | | | | | | | | 19. | | Miscellaneous Provisions | | 30 | | | | | | | | | | 19.1 | | Amendments | | 30 | | | | | | | | | | | | 19.2 | | Notices and Representatives | | 30 | | | | | | | | | | | | 19.3 | | Assignment and Benefits of Agreement | | 32 | | | | | | | | | | | | 19.4 | | Governing Law | | 32 | | | | | | | | | | | | 19.5 | | Submission to Jurisdiction; Waivers | | 32 | | | | | | | | | | | | 19.6 | | Counterparts | | 33 | | | | | | | | | | | | 19.7 | | Section Headings | | 33 | | | | | | | | | | | | 19.8 | | Public Statements or Releases | | 33 | |
Exhibits Exhibit A | | Certificate of Merger | Exhibit B | | Escrow Agreement | Exhibit C | | Registration Rights Agreement | Exhibit D | | Standstill Agreement | | |
Target Disclosure Schedules | | Parent and Sub Disclosure Schedules |
AGREEMENT AND PLAN OF MERGER AGREEMENT (this “Agreement”) dated as of March 14, 2006 among Pharmos Corporation, a Nevada corporation (“Parent” or “Pharmos”), Vela Acquisition Corporation, a Delaware corporation and direct wholly-owned subsidiary of Parent (“Sub”), and Vela Pharmaceuticals Inc., a Delaware corporation (“Target” or “Vela”). WHEREAS, the Boards of Directors of each of Parent, Sub, and Target believe that the merger of Target into Sub (the “Merger”) would be advantageous and beneficial to their respective corporations and stockholders; and WHEREAS, this Agreement is intended to be and is adopted as a plan of reorganization within the meaning of §368(a) of the Internal Revenue Code of 1986, as amended (the “Code”). NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and of other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree that Target shall be merged with and into Sub upon the terms and subject to the conditions set forth in this Agreement. 1.The Merger. 1.1Closing and Effective Date of Merger.Subject to the closing conditions in Sections 7 and 8 hereof, at a closing (the “Closing”) to be held at the offices of Parent at 10:00 a.m. on the second business day immediately following the date on which the stockholders of Parent approve this Agreement or on such other date and time as may be agreed to by the parties (the “Closing Date”), Target and Sub shall cause to be definitively executed and delivered to one another the Certificate of Merger in the form attached hereto asExhibit A (the “Certificate of Merger”) and shall cause such document to be filed with the Secretary of State of the State of Delaware, in order to cause the Merger contemplated by this Agreement to become effective under the laws of the State of Delaware. The Merger shall become effective on the date and at the time of the filing of the Certificate of Merger with the Secretary of State of the State of Delaware (the “Effective Date”). References herein to the “Surviving Corporation” shall mean Sub on and after the Effective Date. 1.2Terms and Conditions of Merger.Upon the Effective Date, pursuant to the Certificate of Merger and this Agreement: (a) Target shall be merged with and into Sub and the separate existence of Target shall cease; (b) Sub shall continue as the Surviving Corporation, organized under the laws of the State of Delaware, the authorized capital stock of which shall be 1,000 shares of Common Stock, par value $0.001 per share; (c) the Certificate of Incorporation of the Surviving Corporation shall be the Certificate of Incorporation of Sub in effect on the date hereof; (d) the Surviving Corporation shall have as its By-Laws the By-Laws of Sub in effect on the date hereof; (e) Parent will pay the sum of $5,000,000 by wire transfer to or on behalf of Target at the Closing (the “Cash Consideration”), to be used, along with all of Target’s cash on hand immediately prior to the Closing, for the purpose of paying or discharging (i) all of Target’s costs and expenses incurred in connection with the consummation of the transactions contemplated hereby, (ii) Target’s obligations at Closing under its 2005 Acquisition Bonus Plan, as amended (as amended, the “ABP”), (iii) all interest accrued through the Closing Date in connection with Target’s outstanding Senior Convertible Promissory Notes set forth onSchedule 1.2(e) in the aggregate principal amount of $14,000,000 (the “Bridge Notes”), and (iv) a portion of the outstanding principal amount of the Bridge Notes; |
(f) immediately following the payment of a portion of the principal of the Bridge Notes as set forth in Section 1.2(e)(iv) above, all of the remaining outstanding principal amount of such Bridge Notes shall be converted into shares of Target’s Series D Redeemable Convertible Preferred Stock in accordance with the terms of such Bridge Notes and shall be cancelled, and certificates representing such shares of Target’s Series D Redeemable Convertible Preferred Stock shall be issued to the holders of the cancelled Bridge Notes; (g) Parent shall issue 11,500,000 shares (the “Closing Shares”) of its common stock, par value $.03 per share (“Parent Stock”), which shall be valued based on the Average Trading Price (as defined in Section 18
below) and, subject to Section 1.2(o), shall be distributed among the holders of Target Capital Stock (as defined in Section 18 below) in accordance with the written instructions of Target delivered to Parent at or prior to the Closing, which instructions shall be based solely upon the terms and conditions of Target’s Restated Certificate of Incorporation, as amended, in effect immediately prior to the Effective Date (the “Target’s Restated Certificate”); (h) within five business days following the successful completion of any Phase IIb dose-range finding trial for dextofisopam following the Closing, which trial (i) was approved by Parent’s Board of Directors, and (ii) has successfully met or exceeded p<0.05 (for at least one of the dosing arms) on the prospectively defined and FDA agreed-upon primary outcome measure (the “Phase IIb Milestone”), Parent shall issue 4,000,000 shares of Parent Stock (the “Phase IIb Milestone Shares”), which shares shall be valued based on the Average Trading Price and shall be distributed among the participants in the ABP and the holders of Target Capital Stock as of the Closing Date in accordance with the written instructions of the Representatives (as defined below) delivered to Parent on the date immediately preceding the date of issuance thereof, which instructions shall be based solely upon the terms and conditions of the ABP and Target’s Restated Certificate as determined by the Representatives; (i) within five business days following the filing of a U.S. NDA with the FDA for dextofisopam (the “NDA Milestone” and, together with the Phase IIb Milestone, the “Milestones”), Parent shall issue 4,000,000 shares of Parent Stock (the “NDA Milestone Shares” and, together with the Phase IIb Milestone Shares, the “Milestone Shares”), which shares shall be valued based on the Average Trading Price and shall be distributed among the participants in the ABP and the holders of Target Capital Stock as of the Closing Date in accordance with the written instructions of the Representatives delivered to Parent on the date immediately preceding the date of issuance thereof, which instructions shall be based solely upon the terms and conditions of the ABP and the Restated Certificate as determined by the Representatives; (j) Notwithstanding the provisions of Sections 1.2(h) and (i) hereof, if the Phase IIb Milestone has not occurred by the fourth anniversary of the Effective Date, Parent shall no longer be obligated to issue the Phase IIb Milestone Shares. Parent will only be obligated to issue the NDA Milestone Shares if the NDA Milestone occurs before the eighth anniversary of the Effective Date, regardless of whether or not the Phase IIb Milestone Shares were issued; (k) as of the Effective Date, each share of Target Capital Stock outstanding immediately prior to the Effective Date shall be cancelled and shall cease to exist and no payment or other consideration shall be made with respect thereto other than as provided for in this Agreement; (l) all outstanding options, warrants and other securities exercisable or convertible into shares of Target Capital Stock that are not otherwise exercised or converted into Target Capital Stock prior to the Effective Time shall be cancelled and terminated; (m) all of the estate, properties, rights, privileges, powers and franchises of Target and Sub and all of their property, real, personal and mixed, and all debts, liabilities and obligations of any kind of Target or Sub shall vest in the Surviving Corporation, without any further act or deed being required therefor; (n) the directors and officers of the Surviving Corporation as of the Effective Date shall be those persons identified onSchedule 1.2(n); and |
(o) notwithstanding the provisions of Section 1.2(g), 1,725,000 of the Closing Shares (the “Escrow Shares”) shall be delivered to a mutually acceptable escrow agent, as escrow agent (“Escrow Agent”) for the holders of the Target Capital Stock in accordance with the Escrow Agreement, in the form attached hereto asExhibit B, between Parent, the Representatives (as defined in Section 16 below) and the Escrow Agent (the “Escrow Agreement”), pursuant to which, among other things, the Escrow Shares shall serve as the sole source of recovery, absent fraud, with respect to Parent’s right to indemnification in accordance with the provisions of Section 15 hereof. 2.Antidilution; Procedures; Fractional Shares. 2.1Antidilution.If, subsequent to the date of this Agreement but prior to any issuance of shares of Parent Stock hereunder, the shares of Parent Stock shall be increased, decreased, or changed into or exchanged for a different number or kind of shares or securities through reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or other similar changes in Parent’s capitalization (collectively, a “Change”), then appropriate and proportionate adjustments shall be made to the number of shares of Parent Stock
issuable pursuant to this Agreement so that each holder of Target Capital Stock immediately prior to the Effective Date shall receive pursuant to Sections 1.2(g), 1.2(h) and 1.2(i) hereof that number of shares of Parent Stock, if any, that such holder would have received as a result of such Change if such Change had occurred as of the date of this Agreement (and such holders were treated for purposes of such Change as holders of Parent Stock). 2.2Procedures; Fractional Shares, Etc. (a) Certificates that represent shares of Target Capital Stock that are outstanding immediately prior to the Effective Date, including certificates representing shares of Target Capital Stock issued upon conversion of the unpaid principal and accrued interest, if any, on the Bridge Notes (each, a “Certificate”), shall, after the Effective Date, be deemed to represent the right to receive new certificates representing the shares of Parent Stock, if any, which the holders thereof are entitled to receive in accordance with the provisions of this Agreement. (b) As promptly as practicable after the Effective Date, Parent or its transfer agent for Parent Stock shall send to each holder of record of shares of Target Capital Stock (other than any such shares held directly or indirectly by Target) outstanding on the Effective Date, transmittal materials for use in exchanging the Certificates for such shares for certificates for the shares of Parent Stock, if any, which the holders thereof are entitled to receive in accordance with the provisions of this Agreement. Upon surrender of a Certificate to Parent (or the transfer agent for Parent Stock), together with a duly executed letter of transmittal and any other required documents, the holder of such Certificate shall be entitled to receive, in exchange therefor, a certificate for the number of shares of Parent Stock, if any, to which such holder is entitled in accordance with the provisions of this Agreement (and subject to the provisions of the Escrow Agreement), and such Certificate shall forthwith be canceled. (c) No dividend or other distribution payable after the Effective Date with respect to Parent Stock shall be paid to the holder of any unsurrendered Certificate until the holder thereof surrenders such Certificate, at which time such holder shall receive all dividends and distributions, without interest thereon, previously payable but withheld from such holder pursuant hereto. After the Effective Date, there shall be no transfers of shares of Target Capital Stock. If, after the Effective Date, Certificates are presented to Parent or its transfer agent for Parent Stock for transfer, they shall be canceled and exchanged for the shares of Parent Stock deliverable in respect thereof as determined in accordance with the provisions and procedures set forth in Sections 1.2(g), 1.2(h) and 1.2(i), and this Section 2.2 (or returned to the presenting Person, if the shares of Target Capital Stock formerly represented by such Certificate are held of record by a former holder of Target Capital Stock who has duly exercised the appraisal rights described in Section 2.2(d) below). (d) After the Effective Date, holders of Target Capital Stock shall cease to be, and shall have no rights as, stockholders or noteholders of Target, other than (i) the right to receive shares of Parent Stock, if any, which the holders thereof are entitled to receive in accordance with the provisions of this Agreement and (ii) any rights afforded to any such holder who has demanded appraisal rights in compliance with all provisions |
of the Delaware General Corporation law concerning the right of such holder to dissent from the Merger and demand appraisal of such shares of Target Capital Stock, provided that such rights have not been waived by such holder pursuant to that certain Amended and Restated Investor Rights Agreement dated as of January 29, 2002 by and among Target and such holders. (e) Neither Parent, Sub nor Target nor any other Person shall be liable to any former holder of shares of Target Capital Stock for any shares or any dividends or distributions with respect thereto properly delivered to a public official pursuant to applicable abandoned property, escheat or similar laws. (f) If any Bridge Note shall have been lost, stolen, or destroyed, Target will, immediately prior to the Effective Date, upon receipt (i) of appropriate evidence as to such loss, theft, or destruction and to the ownership of such Bridge Note by the person claiming such Bridge Note to be lost, stolen, or destroyed, and (ii) of appropriate and customary indemnification, issue in exchange for such lost, stolen, or destroyed Bridge Note a Certificate representing shares of Target’s Series D Redeemable Convertible Preferred Stock issuable upon the conversion of the Bridge Note pursuant to Section 1.2(f). If any Certificate shall have been lost, stolen, or destroyed, Parent or its transfer agent for Parent Stock will, upon receipt (i) of appropriate evidence as to such loss, theft, or destruction and to the ownership of such Certificate by the person claiming such Certificate to be lost, stolen, or destroyed, and (ii) of appropriate and customary indemnification, issue in exchange for such lost, stolen, or destroyed Certificate the shares of Parent Stock, if any, deliverable in respect thereof pursuant to Sections 1.2(g), 1.2(h) or 1.2(i) and this Section 2.2.
(g) If any certificate representing shares of Parent Stock is to be issued in a name other than that in which the Certificate surrendered in exchange therefor is registered, it shall be a condition to the issuance thereof that the Certificate so surrendered shall be properly endorsed (or accompanied by an appropriate instrument of transfer) and otherwise in proper form for transfer (including without limitation that the signature of the transferor shall be properly guaranteed by a commercial bank, trust company or member firm of the New York Stock Exchange), and that the Person requesting such exchange shall pay to Parent in advance any transfer or other taxes required by reason of the issuance of a certificate representing shares of Parent Stock in any name other than that of the registered holder of the Certificate surrendered, or required for any other reason, or shall establish to the satisfaction of Parent that such tax has been paid or is not payable. (h) In lieu of the issuance of fractional shares of Parent Stock pursuant to Section 1.2(g) (subject to the provisions of the Escrow Agreement), 1.2(h) or 1.2(i), cash adjustments, without interest, will be paid to the holders of Target Capital Stock in respect of any fractional share of Parent Stock that would otherwise be issuable, and the amount of such cash adjustment shall be determined by multiplying such holder’s fractional interest in a share of Parent Stock by the Average Trading Price. For purposes of determining whether, and in what amounts, a particular holder of Target Capital Stock would be entitled to receive cash adjustments under this Section 2.2(h), shares held of record by such holder and represented by two or more certificates shall be aggregated. 3.Representations and Warranties of Target.Target hereby represents and warrants to Parent and Sub as follows. For purposes of this Agreement, except as otherwise specifically set forth in herein, the term “Knowledge” in relation to Target means the actual knowledge of Target’s President/Chief Executive Officer, Chief Business Officer/Chief Financial Officer, and Senior Vice President, Research and Development after reasonable investigation consistent with the ordinary course of conduct of such officer’s duties and any member of its Board of Directors. 3.1Incorporation; Authority.Target is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own or lease and operate its properties and to carry on its business as now conducted in all material respects. Target has supplied to Parent complete and correct copies of Target’s Restated Certificate and By-Laws and all amendments thereto. 3.2Corporate Power, Binding Effect.Subject to the approval by its stockholders, Target has all requisite corporate power and authority to enter into this Agreement and the Certificate of Merger, and to perform all of its agreements and obligations under this Agreement and the Certificate of Merger in accordance with |
their respective terms. This Agreement has been duly authorized by Target’s Board of Directors, has been duly executed and delivered by Target and constitutes the legal, valid and binding obligation of Target, enforceable against Target in accordance with its terms, subject only, in respect of the consummation of the Merger, to requisite approval by the stockholders of Target, and except that (i) such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which a proceeding therefor may be brought (collectively, the “Enforcement Exceptions”). Upon execution and delivery by Target of the Certificate of Merger on the Closing Date, the Certificate of Merger will have been duly authorized, executed and delivered by, and constitute the legal, valid and binding obligation of, Target subject only to the Enforcement Exceptions. Neither the execution, delivery or performance by Target of this Agreement nor of the Certificate of Merger in accordance with their respective terms will result in any violation of or default or creation of any lien under, or the acceleration or vesting or modification of any right or obligation under, or in any conflict with, Target’s Restated Certificate or By-Laws or of any agreement, instrument, judgment, decree, order, statute, rule or regulation binding on or applicable to Target, except where any of the foregoing would not have a material adverse effect on the business, assets or financial condition of Target. 3.3Subsidiaries.Target does not have any subsidiaries and does not own or hold of record and/or beneficially any shares of any class in the capital stock of any corporation. Target does not own any legal and/or beneficial interests in any partnerships, business trusts or joint ventures or in any other unincorporated business enterprise. 3.4Qualification.Target is duly qualified and in good standing as a foreign corporation in each jurisdiction in which the character of the properties owned or leased or the nature of the activities conducted by it
makes such qualification necessary, except where the failure to be so qualified could not be reasonably expected to have a material adverse effect on the business, assets or financial condition of Target. 3.5Capitalization. (a) The authorized capital of Target consists of (i) 25,000,000 shares of common stock, $0.001 par value per share, of which 1,297,504 shares are issued and outstanding on the date hereof, (ii) 1,436,651 shares of Series A Preferred Stock, $0.001 par value per share, of which 1,436,651 shares are issued or outstanding on the date hereof, (iii) 454,859 shares of Series B Preferred Stock, $0.001 par value per share, of which 454,859 shares are issued and outstanding on the date hereof, (iv) 2,859,650 shares of Series C Preferred Stock, $0.001 par value per share, of which 2,859,650 shares are issued and outstanding on the date hereof, and (v) 11,959,215 shares of Series D Preferred Stock, $0.001 par value per share, of which 7,500,075 shares are issued and outstanding on the date hereof. As of the date hereof, all of the shares of Target Capital Stock identified in clauses (ii), (iii), (iv) and (v) of the previous sentence are convertible into the number of shares of common stock of Target set forth inSchedule 3.5(a). All outstanding shares of Target Capital Stock are owned of record by Target’s stockholders as set forth onSchedule 3.5(a) hereto and are validly issued, fully paid and non-assessable. (b) Except as set forth inSchedule 3.5(b), Target is neither a party to nor is bound by any outstanding subscriptions, options, warrants, calls, commitments or agreements of any character calling for Target to issue, deliver or sell, or cause to be issued, delivered or sold any shares of Target Capital Stock or any other equity security of Target or any securities convertible into, exchangeable for or representing the right to subscribe for, purchase or otherwise receive any shares of Target Capital Stock or any other equity security of Target or obligating Target to grant, extend or enter into any such subscriptions, options, warrants, calls, commitments or agreements. (c) Except for the obligations set forth in the Restated Certificate, as of the date hereof there are no outstanding contractual obligations of the Target to repurchase, redeem or otherwise acquire any shares of Target Capital Stock. 3.6Lawful Issuance.All of the outstanding shares of Target Capital Stock were issued pursuant to exemptions from registration under the Securities Act (as defined in Section 18) and applicable state and |
other securities laws and all rules and regulations thereunder. There exists no valid right to rescind any purchase thereof from or issuance thereof by Target. No class of securities of Target is required to be registered under any provision of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 3.7Financial Statements.Attached asSchedule 3.7 hereto are copies of (i) the audited balance sheet of Target as of December 31, 2004 and the related audited statements of operations, redeemable preferred stock and stockholders’ deficiency, and cash flows of Target for the fiscal years ended December 31, 2004 and 2003 (collectively the “Audited Financial Statements”), accompanied by a report thereon of Ernst & Young LLP and (ii) the unaudited balance sheet of Target for the fiscal year ended December 31, 2005, and related unaudited statements of operations and redeemable preferred stock and stockholders deficiency for such fiscal year (the “2005 Unaudited Financial Statements”). Target will deliver to Parent copies of (i) the audited balance sheet of Target as of December 31, 2005 and the related audited statements of operations, redeemable preferred stock and stockholders’ deficiency and cash flows of Target for the fiscal year ended December 31, 2005 (the “2005 Audited Financial Statements” and, together with the 2005 Unaudited Financial Statements, the “2005 Financial Statements”), accompanied by a report thereon of Ernst & Young LLP. Additionally, Target will deliver promptly, but no later than 45 days after the end of each financial quarter, any additional quarterly reports after December 31, 2005 up to and including the Closing Date. The balance sheet included in the Audited Financial Statements and each other such balance sheet fairly presents (and will present in the case of the balance sheet to be included in the 2005 Audited Financial Statements) the financial condition of Target in all material respects as of its date; and each of such statements of operations, redeemable preferred stock and stockholders’ deficiency, and cash flows fairly presents (and will present, in the case of the statements to be included in the 2005 Audited Financial Statements) the results of operations, redeemable preferred stock and stockholders’ deficiency, and cash flows of Target for the fiscal year covered thereby, all in conformity with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis, except as stated therein. 3.8Absence of Certain Changes.Except as set forth onSchedule 3.8, since the date of the 2005 Financial Statements, there has not been: (i) any change in the business of Target or in its relationships with suppliers, licensees, scientists, researchers, licensors or the like other than changes which were both in the ordinary course of business and have not had a material adverse effect on the business, assets or financial condition of Target;
(ii) any acquisition or disposition by Target of any material amount of assets or properties other than in the ordinary course of business; (iii) any damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting, either individually or in the aggregate, the business of Target; (iv) any declaration, setting aside or payment of any dividend or any other distributions in respect of any class of Target Capital Stock; (v) except for the deemed issuance of shares of Series D Preferred Stock upon the conversion of the Bridge Notes as set forth in Section 1.2(f), any issuance of any shares of Target Capital Stock or any direct or indirect redemption, purchase or other acquisition of any shares of any class of Target Capital Stock; (vi) except for the adoption and implementation of the ABP and payments made thereunder to date or payable at Closing, any increase in the compensation, pension or other benefits payable or to become payable by Target to any of its officers or employees, or any bonus payments or arrangements made to or with any of them; (vii) any entry by Target into any transaction other than in the ordinary course of business; (viii) any incurrence by Target of any material obligations or liabilities, whether absolute, accrued, contingent or otherwise (including, without limitation, liabilities as guarantor or otherwise with respect to obligations of others), other than obligations and liabilities incurred in the ordinary course of business; (ix) any mortgage, pledge, lien, lease, security interest or other charge or encumbrance on any of the assets, tangible or intangible, of Target, other than those arising by operation of law which do not materially impair the operation of Target’s business; (x) any change in accounting principles, practices or methods used by Target; or (xi) any discharge or satisfaction by Target of any lien or encumbrance or payment by Target of any obligation or liability (fixed or contingent) other than (A) current liabilities included in the balance sheet that is part of the 2005 Financial Statements, (B) current liabilities incurred since the date of the 2005 Financial Statements in the ordinary course of business, and (C) payments contemplated by Section 1.2(e) hereof. 3.9Title to Property, Leases, etc.Except as set forth inSchedule 3.9(a) hereto, Target has good and marketable title to all of its tangible properties and assets, including, without limitation, all those reflected in the balance sheet included in the 2005 Financial Statement (except for properties or assets sold or otherwise disposed of in the ordinary course of business since the date of the 2005 Financial Statements), all free and clear of all liens, pledges, charges, security interests, mortgages, encumbrances or title retention agreements of any kind or |
nature.Schedule 3.9(b) hereto sets forth a complete and correct list of all capital assets and real properties of Target having a book value in excess of $25,000 and also sets forth a complete and correct list of all leases of real property under which Target is lessor or lessee and all other leases having a remaining term of more than twelve (12) months or an aggregate remaining rental obligation of more than $25,000 to which Target is a party, whether as lessor or lessee. Complete and correct copies of all such leases have been delivered to Parent. Each such lease is valid and subsisting and no event or condition exists which constitutes, or after notice or lapse of time or both would constitute, a default thereunder. 3.10Indebtedness.Except for the Bridge Notes, Indebtedness (as defined in Section 18) reflected or reserved against in the balance sheet included in the 2005 Financial Statements and Indebtedness incurred in the ordinary course of business after the date of the 2005 Financial Statements, Target has no material Indebtedness outstanding at the date hereof. Target is not in default with respect to any outstanding Indebtedness or any instrument relating thereto and no such Indebtedness or any instrument or agreement relating thereto purports to limit the issuance of any securities by Target or the operation of the business of Target. Complete and correct copies of all instruments (including all amendments, supplements, waivers and consents) relating to any Indebtedness of Target have been made available to Parent. 3.11Absence of Undisclosed Liabilities.Except to the extent reflected or reserved against in the balance sheet included in the 2005 Financial Statements or incurred in the ordinary course of business after the date of the 2005 Financial Statements or described in any Schedule hereto, Target has no liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise (including, without limitation, liabilities as guarantor or otherwise with respect to obligations of others) and whether due or to become due (including, without limitation, any liabilities for taxes due or to become due) which would be required by GAAP to be reflected on a balance sheet of Target. 3.12Taxes and Tax Returns. (a) All Taxes of any nature whatsoever due and payable by Target prior to the execution hereof and all Tax Returns required to be filed prior to such date have been properly computed in all respects, duly and timely filed (taking into consideration extensions of time to file) and fully paid and discharged. There are no outstanding agreements or waivers extending the statutory period of limitations applicable to any Tax or Tax Return for any period. Target has paid all Taxes which have become due pursuant to Tax Returns and has paid all
installments of estimated Taxes due. All Taxes and other assessments and levies which it is required by law to withhold or to collect have been duly withheld and collected, and have been paid over to the proper governmental authorities to the extent due and payable. All Taxes not yet due and payable have been properly accrued on the financial statements of Target. Subsequent to the date hereof and prior to the Closing Date hereunder, all Tax Returns shall be timely and accurately filed, and any Tax payable as shown thereby shall be paid, as required by applicable law. Target has not requested nor been granted an extension of the time for filing any Tax Return to a date later than the Closing Date. There are no determined material tax deficiencies or proposed tax assessments (or to the best of its Knowledge and belief, the prospects for the same) against it. Target has not incurred any liability for penalties, assessments or interest under any federal, state, local or foreign tax laws. Target has withheld and paid all Taxes required to have been withheld and paid by it in connection with amounts paid or owing to any employee, creditor, independent contractor or other third party. (b) There are no liens for Taxes (other than current Taxes not yet due and payable) on Target’s assets. There is no audit, action, suit, or taxing authority proceeding now in progress, pending or threatened against Target or with respect to any Tax of Target, and no claim has ever been made by a taxing authority in a jurisdiction where Target does not pay Tax or file Tax Returns that Target is or may be subject to Taxes assessed by that jurisdiction. (c) Target has not been a member of any affiliated group (as defined in Section 1504 of the Code) or filed or been included in a combined, consolidated, aggregate, or unitary income Tax Return. Target has never been and is not now a party to or bound by any Tax indemnification, Tax allocation, or Tax sharing agreement or other contractual obligation pursuant to which it is or may at any time in the future be obligated to indemnify any other person or entity with respect to Taxes. |
(d) Target is not a party to any agreement, contract, arrangement, or plan that has resulted, or could result by reason of the transactions contemplated hereby, separately or in the aggregate, in the payment of any “excess parachute payments” within the meaning of Section 280G of the Code. (e) Target has provided Parent with true and complete copies of all Tax Returns filed with respect to it for taxable periods ending after 2001 and all examination reports and statements of deficiencies assessed against or agreed to be paid by it with respect to such taxable periods. 3.13Litigation, etc.No action, suit, proceeding or investigation (whether conducted by any judicial or regulatory body or other person) is pending or, to the Knowledge of Target, threatened against Target (nor, to the Knowledge of Target is there any basis therefor) which questions the validity of this Agreement or any action taken or to be taken pursuant hereto or which might reasonably be expected, either individually or in the aggregate, to adversely affect the business, assets, or financial condition of Target or impair the right or the ability of Target to carry on its business substantially as now conducted. 3.14Safety, Zoning and Environmental Matters.Neither the offices or properties in or on which Target carries on its business nor the activities carried on therein are in violation of any zoning, health or safety law or regulation, including, without limitation, the Occupational Safety and Health Act of 1970, as amended, except where a violation would not have a material adverse effect on the business, assets or financial condition of the Target. In addition: (a) Target is not in violation of any judgment, decree, order, law, license, rule or regulation purporting to regulate environmental matters, including without limitation, those arising under the Resource Conservation and Recovery Act (“RCRA”), the Comprehensive Environmental Response, Compensation and Liability Act of 1980 as amended (“CERCLA”), the Superfund Amendments and Reauthorization Act of 1986 (“SARA”), the Federal Clean Water Act, the Federal Clean Air Act, the Toxic Substances Control Act, or any state or local statute, regulation, ordinance, order or decree relating to health, safety or the environment (hereinafter “Environmental Laws”), which violation would have a material adverse effect on the business, assets, or financial condition of Target; (b) Target has not received notice from any third party including without limitation any federal, state or local governmental authority, (i) that Target or any predecessor in interest has been identified by the United States Environmental Protection Agency (“EPA”) as a potentially responsible party under CERCLA with respect to a site listed on the National Priorities List, 40 C.F.R. Part 300 Appendix B (1986); (ii) that any hazardous waste as defined by 42 U.S.C. §6903(5), any hazardous substances as defined by 42 U.S.C. §9601(14), any pollutant or
contaminant as defined by 42 U.S.C. §9601(33) and any toxic substance, oil or hazardous materials or other chemicals or substances regulated by any Environmental Laws (“Hazardous Substances”) which Target or any other person or entity has generated, transported or disposed of has been found at any site at which a federal, state or local agency or other third party has conducted or has ordered that Target conduct a remedial investigation, removal or other response action pursuant to any Environmental Law; or (iii) that Target is or shall be a named party to any claim, action, cause of action, complaint (contingent or otherwise) legal or administrative proceeding arising out of any third party’s incurrence of costs, expenses, losses or damages of any kind whatsoever in connection with the release of Hazardous Substances; (c) Except where any of the following would not have a material adverse effect on the business, assets, or financial condition of Target, (i) no portion of the property of Target has been used for the handling, manufacturing, processing, storage or disposal of Hazardous Substances except in accordance with applicable Environmental Laws; and no underground tank or other underground storage receptacle for Hazardous Substances is located on such properties; (ii) in the course of any activities conducted by Target no Hazardous Substances have been generated or are being used on such properties except in accordance with applicable Environmental Laws and for customary and routine purposes; (iii) there have been no releases (i.e. any past or present releasing, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, disposing or dumping) or threatened releases of Hazardous Substances on, upon, into or from the properties of |
Target, which releases would have a material adverse effect on the value of such properties or adjacent properties or the environment; (iv) there have been no releases on, upon, from or into any real property in the vicinity of the real properties of Target which, through soil or groundwater contamination, have come to be located on, and which would have a material adverse effect on the value of, the properties of Target; and (v) in addition, any Hazardous Substances that have been generated on the properties of Target, have been transported in accordance with applicable Environmental Laws; and (d) none of the properties of Target are currently subject to any applicable environmental cleanup responsibility law or environmental restrictive transfer law or regulation by virtue of the transactions set forth herein and contemplated hereby. 3.15Labor Relations.Target is in compliance in all material respects with all federal and state laws respecting employment and employment practices, terms and conditions of employment, wages and hours and nondiscrimination in employment, and is not engaged in any unfair labor practice. There is no charge pending or, to the Knowledge of Target, threatened against Target alleging unlawful discrimination in employment practices before any court or agency and there is no charge of or proceeding with regard to any unfair labor practice against Target pending before the National Labor Relations Board. There is no labor strike, dispute, slow-down or work stoppage actually pending or, to the Knowledge of Target, threatened against or involving Target. No grievance or arbitration proceeding arising out of or under any collective bargaining agreement is pending against Target and no claim therefor has been asserted. None of the employees of Target is covered by any collective bargaining agreement, and no collective bargaining agreement is currently being negotiated by Target. Except as described onSchedule 3.15 hereto, Target has not experienced any work stoppage or other material labor difficulty during the last five years. 3.16Contracts.Schedule 3.16 sets forth each: (a) agreement, instrument, or commitment to which Target is a party that involves the payment by or to Target of amounts in excess of $10,000 or that may materially and adversely affect its ability to consummate the transactions contemplated hereby; (b) agreement for the purchase, sale, lease, or license by or from Target of assets, products, or services; (c) agreement or other commitment pursuant to which Target has agreed to indemnify or hold harmless any other Person (including, without limitation, for any liabilities, penalties, losses, damages, or costs, or expenses related thereto) arising out of or in connection with any presence, use, generation, treatment, storage, transportation, recycling, disposal, or release of any Hazardous Substances; (d) (i) employment agreement, (ii) consulting agreement, or (iii) agreement providing for severance payments or other additional rights or benefits (whether or not optional) in the event of the sale or other change in control of Target; and
(e) agreement with any current or former affiliate, stockholder, officer or director of Target or with any Person in which, to the Knowledge of Target, any such affiliate has an interest. Target has delivered or made available to Purchaser correct and complete copies (or written summaries of the material terms of oral agreements or understandings) of each agreement, instrument, and commitment listed inSchedule 3.16 hereto, each as amended to date. Each such agreement, instrument, and commitment is a valid, binding and enforceable obligation of Target, and, to the Knowledge of Target, of the other party or parties thereto, subject as to enforcement to the Enforcement Exceptions, and is in full force and effect. Neither Target nor, to its Knowledge, any other party thereto is in breach of, default under or noncompliance with any term of any such agreement, instrument, or commitment (nor to the Knowledge of Target is there any reasonable basis for any of the foregoing). Except where identified onSchedule 3.16, no agreement, instrument, or commitment listed inSchedule 3.16 hereto includes or incorporates any provision, the effect of which could |
reasonably be expected to enlarge or accelerate any of the obligations of Target or to give additional rights to any other party thereto, or to terminate, lapse, trigger consent rights of any other person or entity in respect thereof, or in any other way be affected, by reason of the transactions contemplated by this Agreement. 3.17Intellectual Property and Regulatory Matters. (a)Schedule 3.17(a) contains an accurate and complete list of all Intellectual Property (as defined in Section 18 below) of Target (the “Target Intellectual Property”). Each patent contained in the Target Intellectual Property is valid and enforceable. Target holds a good faith belief that: (i) the requirements of 37 C.F.R. §1.56 have been complied with during the prosecution of all pending Target US patent applications; and (ii) each time that claims have been presented in all pending Target patent applications, such claims described novel, useful, non-obvious and inventive subject matter. No Target Intellectual Property which is necessary for the conduct of Target’s business as currently conducted has been or is now involved in any cancellation, dispute or litigation, and, to Target’s Knowledge, no such action is threatened. No patent of Target has been or is now involved in any interference, reissue, re-examination or opposition proceeding, and to Target’s actual Knowledge, no such interference, reissue, re-examination or opposition proceeding is threatened. (b) All of the licenses and sublicenses and consent, royalty or other agreements (including a summary of all royalties and milestones payable thereunder) concerning Target Intellectual Property which are necessary for the conduct of Target’s business as currently conducted to which Target is a party or by which any of its assets are bound (other than generally commercially available, non custom, off the shelf software application programs having a retail acquisition price of less than $10,000 per license) (collectively, “License Agreements”) are set forth onSchedule 3.17(b) and are valid and binding obligations of Target and, to Target’s Knowledge, the other parties thereto, enforceable in accordance with their terms subject to the Enforcement Exceptions, to the actual Knowledge of Target, there exists no event or condition which will result in a material violation or breach of or constitute (with or without due notice or lapse of time or both) a default by Target under any such License Agreement. (c) Target owns or has the valid right to use all of the Target Intellectual Property and all trade secrets, confidential information and know-how, including but not limited to ideas, formulae, compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications, support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related information (collectively “Confidential Information”), that is currently used by Target for the conduct of its business as currently conducted and for the ownership, maintenance and operation of its properties and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property and Confidential Information, other than licenses entered into in the ordinary course of Target’s business. Target has a valid and enforceable right (subject to the Enforcement Exceptions) to use all third party Intellectual Property and Confidential Information used or held for use in its business. (d) The conduct of Target’s business as currently conducted does not infringe or otherwise impair or conflict with (collectively, “Infringe”) any Intellectual Property rights of any third party or any confidentiality obligation owed to a third party, and, to the Knowledge of Target, the Target Intellectual Property and Confidential Information of Target which are necessary for the conduct of its business as currently conducted are not being Infringed by any third party. There is no litigation or order pending or outstanding or, to Target’s Knowledge, threatened, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any Target Intellectual Property or Confidential Information of Target and Target’s use of any
Target Intellectual Property or Confidential Information owned by a third party, and, to Target’s Knowledge, there is no valid basis for the same. (e) The consummation of the transactions contemplated in this Agreement will not result in the alteration, loss, impairment of or restriction on Target’s ownership or right to use any of the Target Intellectual Property or Confidential Information of Target which is necessary for the conduct of its business as currently conducted. |
(f) Target has taken reasonable steps to protect its rights in its Intellectual Property and Confidential Information. Each employee, consultant and contractor who has had access to Confidential Information which is necessary for the conduct of Target’s business as currently conducted or as currently proposed to be conducted has executed an agreement to maintain the confidentiality of such Confidential Information and has executed appropriate agreements that are substantially consistent with Target’s standard forms thereof. Except under confidentiality obligations, there has been no material disclosure of any of Target’s Confidential Information by Target to any third party. (g) To the Knowledge of Target, no officer or employee of Target is in violation of any term of any employment contract, patent disclosure agreement, proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant relating to the right of any such officer or employee to be employed by Target or to use the trade secrets or proprietary information of others or that could subject Parent or Sub to any liability to third parties as a result of the existence or terms of any such contracts or agreements. 3.18Insurance.Schedule 3.18 lists the policies of theft, fire, liability (including products liability), worker’s compensation, life, property and casualty, directors’ and officers’, and other insurance owned or held by Target. Such policies of insurance are maintained with financially sound and reputable insurance companies, funds, or underwriters, are of the kinds and cover such risks, and are in such amounts and with such deductibles and exclusions, as are consistent with prudent business practice. All such policies are in full force and effect, are sufficient for compliance in all material respects by it with all requirements of law and of all agreements to which Target is a party, and provide that they will remain in full force and effect through the respective dates set forth inSchedule 3.18 and will not terminate or lapse or otherwise be affected in any way by reason of the Merger or the other transactions contemplated hereby. 3.19Governmental Consent, Non-Contravention, etc.Except as described inSchedule 3.19, Target holds no licenses, permits or other authorizations issued by any governmental agency to Target related to its properties, Intellectual Property, research program or business. No consent, approval or authorization of or registration, designation, declaration or filing with any governmental authority, federal or other, on the part of Target, is required in connection with the Merger or the consummation of any other transaction contemplated hereby, except for the filing of the Certificate of Merger with the Secretary of State of the State of Delaware. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby will not violate (i) any provision of Target’s Restated Certificate or its By-Laws, or (ii) any order, judgment, injunction, award or decree of any court or state or federal governmental or regulatory body applicable to Target. 3.20Employee Benefit Plans.Target does not maintain, or have any obligation to make contributions to, any employee benefit plan (an “ERISA Plan”) within the meaning of Section 3(3) of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”), or, except as set forth onSchedule 3.20 hereto, any other retirement, profit sharing, stock option, stock bonus or employee benefit plan (a “Non-ERISA Plan”). Target has heretofore delivered to Parent true, correct and complete copies of each Non-ERISA Plan. All such Non-ERISA Plans have been maintained and operated in all material respects in accordance with all federal, state and local laws applicable to such plans, and the terms and conditions of the respective plan documents. 3.21Potential Conflicts of Interest.No officer or director of Target (i) owns, directly or indirectly, any interest in (excepting not more than 1% stock holdings for investment purposes in securities of publicly held and traded companies) or is an officer, director, employee or consultant of any Person that is a lessor, lessee, customer or supplier of Target; (ii) owns, directly or indirectly, in whole or in part, any tangible or intangible property which Target is using or the use of which is necessary for the business of Target; or (iii) has any cause of action or other claim whatsoever against, or owes any amount to, Target, except for claims in the ordinary course of business, such as for accrued vacation pay, accrued benefits under employee benefit plans and similar matters and agreements. |
3.22Brokers.Except for Cowen & Co., LLC, which is acting as Target’s financial advisor in the Merger, no finder, broker, agent or other intermediary has been retained or utilized by, or has acted for or on behalf of, Target in connection with the negotiation or consummation of the transactions contemplated hereby. 3.23Compliance with Other Instruments, Laws, etc.Target has complied in all material respects with, and is in compliance in all material respects with, (i) all laws, statutes, governmental regulations and all judicial or administrative tribunal orders, judgments, writs, injunctions, decrees or similar commands applicable to its business, (ii) all unwaived terms and provisions of all contracts, agreements and indentures to which Target is a party, or by which Target or any of its properties is subject, and (iii) the Restated Certificate and By-Laws of Target, as amended to date, except where any such failure to comply would not have a material adverse effect on the business, assets or financial condition of Target. Except as described onSchedule 3.23, Target does not have or need any licenses, permits or other authorizations from governmental authorities for the conduct of its business or in connection with the ownership or use of its properties, except where the failure to have any such license, permit or other authorization would not have a material adverse effect on the business, assets or financial condition of Target. 3.24Minute Books.The minute books of Target made available to Parent for inspection accurately record therein all actions taken by Target’s Board of Directors and stockholders. 3.25Absence of Registration Obligations.Except as set forth onSchedule 3.25 hereto, Target has no obligation, contingent or otherwise, by reason of any agreement to register any of its securities under the Securities Act. 3.26Ownership of Parent Stock.As of the date hereof, Target (i) does not beneficially own, directly or indirectly (and to its Knowledge, none of its officers, directors or Principal Stockholders (as defined in Section 18 below) owns, directly or indirectly), and (ii) is not a party to any agreement, arrangement or understanding (other than this Agreement) for the purpose of acquiring, holding, voting or disposing of (and to its Knowledge, none of its stockholders or any of their affiliates, as defined under the Securities Act, is a party to any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or disposing of), in each case, shares of capital stock of Parent, which in the aggregate represent 1% or more of the outstanding shares of capital stock of Parent entitled to vote generally in the election of directors. 3.27Agreements to Vote in Favor of the Merger.The board of directors of Target, at a meeting duly called and held, has by requisite vote under applicable law (i) determined that this Agreement and the transactions contemplated hereby, including the Merger, and the transactions contemplated thereby, taken together, are in the best interests of the stockholders of Target, and (ii) resolved to recommend that its stockholders approve this Agreement and the transactions contemplated herein, including the Merger. Target has obtained binding, written agreements to vote in favor of approving this Agreement, the Merger and the transactions contemplated hereby from the Principal Stockholders (as defined in Section 18 below). 3.28Full Disclosure.No representation or warranty by Target in this Agreement or in any Exhibit hereto or in its disclosure schedules hereto contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact required to be stated therein or necessary to make the statements contained therein not false or misleading. There is no fact relating to the business, research program or condition of Target that it has not disclosed to Parent in writing and that could reasonably be expected to result in a material adverse effect to Target. 4.Representations and Warranties of Parent and Sub.Parent and Sub each jointly and severally represents and warrants to Target as follows. For purposes of this Agreement, the term “Knowledge” in relation to Parent or Sub means the actual knowledge of Parent’s Chairman and Chief Executive Officer, President and Chief Operating Officer, Chief Financial Officer, Controller, Vice President Finance and Vice President Development after reasonable investigation consistent with the ordinary course of conduct of such officer’s duties, and any member of its Board of Directors. |
4.1Organization and Standing; Subsidiary.Parent and Sub each is a corporation duly organized, validly existing and in corporate good standing under the laws of the State of Nevada (Parent) and Delaware (Sub), and each has all requisite corporate power and authority to own or lease and operate its properties and to carry on its business as now conducted. Parent has delivered to Target complete and correct copies of its Restated Articles of Incorporation and Amended and Restated By-Laws and all amendments thereto, and of Sub’s Certificate of Incorporation and By-Laws. Parent and Sub each is duly qualified and in good standing as a foreign corporation in
each jurisdiction, if any, in which the character of the properties owned or leased or the nature of the activities conducted by it makes such qualification necessary. Parent owns all of the outstanding stock of Pharmos Ltd. (“Pharmos Ltd.”), which is a corporation duly organized, validly existing and in corporate good standing under the laws of the State of Israel. Pharmos Ltd. has all requisite corporate power and authority to own or lease and operate its properties and to carry on its business as now conducted and is duly qualified and in good standing as a foreign corporation in each jurisdiction, if any, in which the character of the properties owned or leased or the nature of the activities conducted by it makes such qualification necessary. Other than Sub and Pharmos Ltd., Parent does not have any other subsidiaries and does not own or hold of record and/or beneficially any shares of any class in the capital stock of any corporation or any legal or other beneficial interests in any partnerships, business trusts, or joint ventures, or in any other unincorporated business enterprise, other than Oculon Corporation and Xenon Vision, Inc., both of which are inactive wholly-owned Delaware subsidiaries not currently in good standing. Parent, Sub and Pharmos Ltd. are sometimes referred to in this Section 4 as the “Parent Group.” 4.2Corporate Power, Binding Effect.Subject to obtaining approval from Parent’s stockholders, each of Parent and Sub has all requisite corporate power and authority to enter into this Agreement and (in the case of Parent) the Registration Rights Agreement (as defined in Section 7.16 below) and to perform all of its agreements and obligations under this Agreement and (in the case of Parent) the Registration Rights Agreement in accordance with their respective terms. Sub has all requisite power and authority to execute and deliver the Certificate of Merger and to perform all of its obligations under the Certificate of Merger. This Agreement and (in the case of Parent) the Registration Rights Agreement have been duly authorized by each of Parent’s and Sub’s respective Boards of Directors, has been duly executed and delivered by Parent and Sub and constitutes the legal, valid and binding obligations of Parent and Sub, enforceable against Parent and Sub in accordance with their respective terms, subject only to the Enforcement Exceptions and in the case of Parent, to obtaining approval of its stockholders. Neither the execution, delivery or performance by either Parent or Sub of this Agreement or (in the case of Sub) the Certificate of Merger or (in the case of Parent) the Registration Rights Agreement, as applicable, in accordance with their respective terms will result in any violation of or default or creation of any lien under, or the acceleration or vesting or modification of any right or obligation under, or in any conflict with, either Parent’s or Sub’s Certificate of Incorporation or by-laws or of any agreement, instrument, judgment, decree, order, statute, rule or regulation binding on or applicable to Parent or Sub, except where any of the foregoing would not have a material adverse effect on the business, assets or financial condition of Parent or Sub. 4.3Capitalization. (a) The authorized capital stock of Sub consists of 1,000 shares of common stock, par value $.001 per share, all of which shares have been issued to and are owned by Parent. The authorized capital stock of Parent consists of 60,000,000 shares of Common Stock, par value $0.03 per share, of which 19,027,809 shares are issued and outstanding, and 1,250,000 shares of Preferred Stock, par value $0.03 per share, none of which shares of Preferred Stock are issued or outstanding. All of the outstanding shares of capital stock of Parent and Sub are validly issued and outstanding, fully paid and nonassessable. All shares of Parent Stock to be issued to the holders of Target Capital Stock under this Agreement will, when issued, be duly authorized, validly issued, fully paid and nonassessable and will not be subject to the pre-emptive rights of others. (b) Except as set forth in the Parent Reports (as defined below) or as otherwise issued since December 31, 2005 in accordance with the provisions of Parent’s existing stock option plan, neither Parent, Sub nor Pharmos Ltd. is a party to or is bound by any outstanding subscriptions, options, warrants, calls, commitments or agreements of any character calling for Parent, Sub or Pharmos Ltd. to issue, deliver or sell, or cause to be issued, delivered or sold any shares of any equity security of Parent, Sub or Pharmos Ltd. or any securities convertible into, exchangeable for or representing the right to subscribe for, purchase or otherwise receive |
any shares of any equity security of Parent, Sub or Pharmos Ltd. or obligating Parent, Sub or Pharmos Ltd. to grant, extend or enter into any such subscriptions, options, warrants, calls, commitments or agreements. (c) As of the date hereof, there are no outstanding contractual obligations of Parent to repurchase, redeem or otherwise acquire any shares of Parent Stock. 4.4Reports and Financial Statements.Parent has previously furnished to Target complete and accurate copies, as amended or supplemented, of its (i) Annual Reports on Form 10-K for the fiscal years ended December 31, 2003 (the “2003 10-K”) and 2004 (the “2004 10-K”), together with all exhibits thereto, as filed with the Securities and Exchange Commission (the “Commission”), (ii) the proxy statement relating to the Annual
Meeting of Stockholders held on September 20, 2005, (iii) Quarterly Reports on Form 10-Q, together with all exhibits thereto, as filed with the Commission since December 31, 2004 and (iv) other reports filed by Parent with the Commission since December 31, 2004 (such reports and other filings, together with any amendments or supplements thereto, are collectively referred to herein as the “Parent Reports”). The 2003 10-K and the 2004 10-K contain true and complete copies of Parent’s audited consolidated balance sheet as at December 31, 2003 and 2004, respectively, and audited consolidated statements of operations and cash flows for each of the years then ended (collectively, the “Parent Financial Statements”). Parent will make available to Target copies of its Form 10-K for the fiscal year ended December 31, 2005, which shall contain Parent’s audited consolidated balance sheet as at December 31, 2005 and audited consolidated statements of operations and cash flows for the period then ended (the “2005 Parent Report”). The Parent Financial Statements present (and the financial statements included in the 2005 Parent Report will present) fairly the consolidated financial position of Parent and Pharmos Ltd. as of December 31, respectively, of 2003 and 2004 (and, in the case of the financial statements included in the 2005 Parent Report, December 31, 2005) and the consolidated results of operations and cash flows for each of the respective fiscal years then ended, all in conformity with GAAP applied on a consistent basis, except as stated therein. Except as set forth onSchedule 4.4hereto and except as contemplated by this Agreement or disclosed in the 2004 10-K or the Parent Financial Statements or in subsequent Forms 10-Q filed by Parent with the Commission prior to the date hereof or in the notes thereto, since December 31, 2004, there has been no material adverse change in the business, assets, financial condition or results of operations of Parent or Pharmos Ltd., taken as a whole. Parent has timely filed with the Commission all forms, reports, schedules, statements and other documents required to be filed by it since January 1, 2003 under the Securities Act and the Exchange Act, except for any non-filings or noncompliance which are not in the aggregate material to the financial condition, results of operations or business of Parent or which will not prevent or delay in any material respect the consummation of the transactions contemplated hereby or under the Registration Rights Agreement including, but not limited to, the filing of a registration statement on Form S-3 with respect to resale of all of the shares of Parent Stock to be issued pursuant to the terms of this Agreement. No form, report, schedule, statement or other document filed by Parent with the Commission since January 1, 2003 contained any untrue statement of a material fact or omitted to state a material fact necessary, at the time such document was filed, in order to make the statements therein, in light of the circumstances under which they were made, not misleading, other than such facts as were corrected in any subsequent form, report, schedule, statement or other document filed with the Commission by Parent. 4.5Absence of Certain Changes.Since the date of the most recent Parent Report, none of any of the following events has occurred that would have required public disclosure under the Securities Act or the Exchange Act, including without limitation, on an annual report on form 10-K, a quarterly report on form 10-Q or a current report on form 8-K: (i) any change in the business of the Parent Group or in its relationships with suppliers, licensees, scientists, researchers, licensors or the like other than changes which were both in the ordinary course of business and have not had a material adverse effect on the business, assets or financial condition of the Parent Group; (ii) any acquisition or disposition by any member of the Parent Group of any material amount of assets or properties other than in the ordinary course of business; (iii) any damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting, either individually or in the aggregate, the business of the Parent Group; (iv) any declaration, setting aside or payment of any dividend or any other distributions in respect of any class of the capital stock of any member of the Parent Group; (v) any entry by any member of the Parent Group into any transaction other than in the ordinary course of business; (vi) any incurrence by any member of the Parent Group of any material obligations or liabilities, whether absolute, accrued, contingent or otherwise (including, without limitation, liabilities as guarantor or otherwise with respect to obligations of others), other than obligations and liabilities incurred in the ordinary course of business; (vii) any mortgage, pledge, lien, lease, security interest or |
other charge or encumbrance on any of the assets, tangible or intangible, of any member of the Parent Group, other than those arising by operation of law which do not materially impair the operation of any member of the Parent Group’s business; (viii) any change in accounting principles, practices or methods used by Parent; or (ix) any discharge or satisfaction by any member of the Parent Group of any lien or encumbrance or payment by any member of the Parent Group of any obligation or liability (fixed or contingent) other than (A) current liabilities included in the balance sheet that is part of the Parent Financial Statements and (B) current liabilities incurred since the date of the financial statements included in the 2005 Parent Report in the ordinary course of business. 4.6Absence of Undisclosed Liabilities.Except to the extent reflected or reserved against in the balance sheet included in Parent’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2005 or incurred in the ordinary course of business after the date of the filing of such Parent Report and except in connection with the costs associated with the transactions contemplated by this Agreement, Parent Group has no
liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise (including, without limitation, liabilities as guarantor or otherwise with respect to obligations of others) and whether due or to become due (including, without limitation, any liabilities for taxes due or to become due) which would be required by GAAP to be reflected on a consolidated balance sheet of Parent Group. 4.7Lawful Issuance.All shares of Parent Stock that have been issued since January 1, 2000, were duly registered under, or were issued pursuant to exemptions from registration under, the Securities Act and applicable state and other securities laws and all rules and regulations thereunder. To the Knowledge of Parent, there exists no valid right to rescind any purchase thereof from or issuance thereof by Parent. Except for the Parent Stock, no class of securities of Parent is required to be registered under any provision of the Exchange Act. 4.8Taxes and Tax Returns. (a) All Taxes of any nature whatsoever due and payable by Parent or Pharmos Ltd. prior to the execution hereof and all Tax Returns required to be filed prior to such date have been properly computed in all respects, duly and timely filed (taking into consideration extensions of time to file) and fully paid and discharged. There are no outstanding agreements or waivers extending the statutory period of limitations applicable to any Tax or Tax Return for any period. Each of Parent and Pharmos Ltd. has paid all Taxes which have become due pursuant to Tax Returns and has paid all installments of estimated Taxes due. All Taxes and other assessments and levies which Parent or Pharmos Ltd. is required by law to withhold or to collect have been duly withheld and collected, and have been paid over to the proper governmental authorities to the extent due and payable. All Taxes not yet due and payable have been properly accrued on the financial statements of Parent. Subsequent to the date hereof and prior to the Closing Date hereunder, all Tax Returns shall be timely and accurately filed, and any Tax payable as shown thereby shall be paid, as required by applicable law. Neither Parent nor Pharmos Ltd. has requested or been granted an extension of the time for filing any Tax Return to a date later than the Closing Date. There are no determined material tax deficiencies or proposed tax assessments (or to the Knowledge of Parent, the prospects for the same) against it. Neither Parent nor Pharmos Ltd. has incurred any liability for penalties, assessments or interest under any federal, state, local or foreign tax laws. Each of Parent and Pharmos Ltd. has withheld and paid all Taxes required to have been withheld and paid by it in connection with amounts paid or owing to any employee, creditor, independent contractor or other third party. (b) There are no liens for Taxes (other than current Taxes not yet due and payable) on Parent’s or Pharmos Ltd.’s assets. There is no audit, action, suit, or taxing authority proceeding now in progress, pending or threatened against Parent or Pharmos Ltd. or with respect to any Tax of Target, and no claim has ever been made by a taxing authority in a jurisdiction where either Parent or Pharmos Ltd. does not pay Tax or file Tax Returns that either Parent or Pharmos Ltd., as applicable, is or may be subject to Taxes assessed by that jurisdiction. (c) Except for the consolidated return of Parent and Pharmos Ltd., neither Parent nor Pharmos Ltd. has been a member of any affiliated group (as defined in Section 1504 of the Code) or filed or been included in a combined, consolidated, aggregate, or unitary income Tax Return. Each of Parent and Pharmos Ltd. has never been and is not now a party to or bound by any Tax indemnification, Tax allocation, or Tax sharing agreement or other contractual obligation pursuant to which it is or may at any time in the future be obligated to indemnify any other person or entity with respect to Taxes. |
(d) Except as disclosed in the Parent Reports, neither Parent nor Pharmos Ltd. is a party to any agreement, contract, arrangement, or plan that has resulted, or could result by reason of the transactions contemplated hereby, separately or in the aggregate, in the payment of any “excess parachute payments” within the meaning of Section 280G of the Code. (e) Parent has provided Target with true and complete copies of all Tax Returns filed with respect to it for taxable periods ending after 2001 and all examination reports and statements of deficiencies assessed against or agreed to be paid by it with respect to such taxable periods. 4.9Litigation, etc.Except as set forth in the Parent Reports, no action, suit, proceeding or investigation (whether conducted by any judicial or regulatory body or other person) is pending or, to the Knowledge of Parent, threatened against Parent or Pharmos Ltd. (nor is there any basis therefor to the Knowledge of Parent) which questions the validity of this Agreement or any action taken or to be taken pursuant hereto or which might reasonably be expected, either in any case or in the aggregate, to adversely affect the business, assets, or financial
condition of Parent or Pharmos Ltd. or impair the right or the ability of Parent or Pharmos Ltd. to carry on its business substantially as now conducted. 4.10Safety, Zoning and Environmental Matters.To the Knowledge of Parent, neither the offices or properties in or on which Parent carries on its business nor the activities carried on therein are in violation of any zoning, health or safety law or regulation, including, without limitation, the Occupational Safety and Health Act of 1970, as amended, except where a violation would not have a material adverse effect on the business, assets or financial condition of Parent. In addition: (a) Parent is not in violation of any judgment, decree, order, law, license, or Environmental Law, which violation would have a material adverse effect on the business, assets, or financial condition of Parent; (b) Parent has not received notice from any third party including without limitation any federal, state or local governmental authority, (i) that Parent or any predecessor in interest has been identified by the EPA as a potentially responsible party under CERCLA with respect to a site listed on the National Priorities List, 40 C.F.R. Part 300 Appendix B (1986); (ii) that any hazardous waste as defined by 42 U.S.C. §6903(5), any Hazardous Substances which Parent or any other person or entity has generated, transported or disposed of has been found at any site at which a federal, state or local agency or other third party has conducted or has ordered that Parent conduct a remedial investigation, removal or other response action pursuant to any Environmental Law; or (iii) that Parent is or shall be a named party to any claim, action, cause of action, complaint (contingent or otherwise) legal or administrative proceeding arising out of any third party’s incurrence of costs, expenses, losses or damages of any kind whatsoever in connection with the release of Hazardous Substances; (c) except where any of the following would not have a material adverse effect on the business, assets, or financial condition of Parent, (i) no portion of the property of Parent has been used for the handling, manufacturing, processing, storage or disposal of Hazardous Substances except in accordance with applicable Environmental Laws; and no underground tank or other underground storage receptacle for Hazardous Substances is located on such properties; (ii) in the course of any activities conducted by Parent, no Hazardous Substances have been generated or are being used on such properties except in accordance with applicable Environmental Laws and for customary and routine purposes; (iii) there have been no releases (i.e. any past or present releasing, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, disposing or dumping) or threatened releases of Hazardous Substances on, upon, into or from the properties of Parent, which releases would have a material adverse effect on the value of such properties or adjacent properties or the environment; (iv) there have been no releases on, upon, from or into any real property in the vicinity of the real properties of Parent which, through soil or groundwater contamination, have come to be located on, and which would have a material adverse effect on the value of, the properties of Parent; and (v) in addition, any Hazardous Substances that have been generated on the properties of Parent, have been transported in accordance with applicable Environmental Laws; and |
(d) none of the properties of Parent are currently subject to any applicable environmental cleanup responsibility law or environmental restrictive transfer law or regulation by virtue of the transactions set forth herein and contemplated hereby. 4.11Intellectual Property.Except as otherwise disclosed in the Parent Reports: (a) The Parent Reports accurately describe all material Parent Intellectual (as defined below) Property of Parent or Pharmos Ltd. Each patent contained in the Parent Intellectual Property is valid and enforceable. Parent holds a good faith belief that: (i) the requirements of 37 C.F.R. §1.56 have been complied with during the prosecution of all pending Parent and Pharmos Ltd. US patent applications; and (ii) each time that claims have been presented in all pending Parent and Pharmos Ltd. patent applications, such claims described novel, useful, non-obvious and inventive subject matter. No Intellectual Property of Parent or Pharmos Ltd. (the “Parent Intellectual Property”) which is necessary for the conduct of the business of Parent or Pharmos Ltd. as currently conducted has been or is now involved in any cancellation, dispute or litigation, and, to Parent’s Knowledge, no such action is threatened. No patent of Parent or Pharmos Ltd. has been or is now involved in any interference, reissue, re-examination or opposition proceeding, and, to Parent’s actual Knowledge, no such interference, reissue, re-examination or opposition proceeding is threatened. (b) All of the licenses and sublicenses and consent, royalty or other agreements concerning Parent Intellectual Property which are necessary for the conduct of Parent’s or Pharmos Ltd.’s business as currently conducted to which either is a party or by which any of their assets are bound (other than generally commercially
available, non custom, off the shelf software application programs having a retail acquisition price of less than $10,000 per license) (collectively, “Parent License Agreements”) are set forth onSchedule 4.11(b) and are valid and binding obligations of Parent and Pharmos Ltd., as applicable, and, to Parent’s Knowledge, the other parties thereto, enforceable in accordance with their terms subject to the Enforcement Exceptions, and, to the Knowledge of Parent, there exists no event or condition which will result in a material violation or breach of or constitute (with or without due notice or lapse of time or both) a default by Parent or Pharmos Ltd., as applicable, under any such Parent License Agreement. (c) Except as set forth onSchedule 4.11(c), each of Parent and Pharmos Ltd. owns or has the valid right to use all of the Parent Intellectual Property and all trade secrets, confidential information and know-how, including but not limited to ideas, formulae, compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications, support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related information (collectively “Parent Confidential Information”) that is necessary for the conduct of its business as currently conducted or as currently proposed to be conducted and for the ownership, maintenance and operation of its properties and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Parent Intellectual Property and Parent Confidential Information, other than licenses entered into in the ordinary course of their respective business. Each of Parent and Pharmos Ltd. has a valid and enforceable right (subject to the Enforcement Exceptions) to use all third party Intellectual Property and Parent Confidential Information used or held for use in its business. (d) Except as set forth onSchedule 4.11(d), the conduct of each of Parent’s and Pharmos Ltd.’s business as currently conducted does not Infringe any Intellectual Property rights of any third party or any confidentiality obligation owed to a third party, and, to the Knowledge of Parent, the Parent Intellectual Property and Parent Confidential Information which are necessary for the conduct of its and Pharmos Ltd.’s business as currently conducted are not being Infringed by any third party. There is no litigation or order pending or outstanding or, to the Knowledge of Parent, threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any Parent Intellectual Property or Parent Confidential Information and Parent’s and Pharmos Ltd’s use of any Intellectual Property or Confidential Information owned by a third party, and, to the Knowledge of Parent, there is no valid basis for the same. (e) The consummation of the transactions contemplated in this Agreement will not result in the alteration, loss, impairment of or restriction on Parent’s or Pharmos Ltd’s ownership or right to use any |
Parent Intellectual Property or Parent Confidential Information which is necessary for the conduct of its business as currently conducted. (f) Each of Parent and Pharmos Ltd. has taken reasonable steps to protect its rights in its Intellectual Property and Parent Confidential Information. Each employee, consultant and contractor who has had access to Parent Confidential Information which is necessary for the conduct of Parent’s or Pharmos Ltd.’s business as currently conducted or as currently proposed to be conducted has executed an agreement to maintain the confidentiality of such Parent Confidential Information and has executed appropriate agreements that are substantially consistent with Parent’s or Pharmos Ltd’s standard forms thereof. Except under confidentiality obligations, there has been no material disclosure of any Parent Confidential Information by any member of the Parent Group to any third party. (g) To the Knowledge of Parent, no officer or employee of Parent or Pharmos Ltd. is in violation of any term of any employment contract, patent disclosure agreement, proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant relating to the right of any such officer or employee to be employed by Parent or Pharmos Ltd. or to use the trade secrets or proprietary information of others or that could subject Parent or Pharmos Ltd. to any liability to third parties as a result of the existence or terms of any such contracts or agreements. 4.12Contracts.All agreements, contracts and obligations of Parent Group, including those involving any governmental entity, that are material to the business and operations of Parent, including without limitation grants for research or otherwise, have been filed as exhibits to, or described in, the Parent Reports. 4.13Potential Conflicts of Interest.Except as set forth in the Parent Reports, no officer or director of Parent or Pharmos Ltd. (i) owns, directly or indirectly, any interest in (excepting not more than 1% stock holdings for investment purposes in securities of publicly held and traded companies) or is an officer, director, employee or
consultant of any Person that is a lessor, lessee, customer or supplier of Parent or Pharmos Ltd.; (ii) owns, directly or indirectly, in whole or in part, any tangible or intangible property which Parent or Pharmos Ltd. is using or the use of which is necessary for the business of Parent or Pharmos Ltd.; or (iii) has any cause of action or other claim whatsoever against, or owes any amount to, Parent or Pharmos Ltd., except for claims in the ordinary course of business, such as for accrued vacation pay, accrued benefits under employee benefit plans and similar matters and agreements. 4.14Government Consents, etc.No consent, approval or authorization of or registration, designation, declaration or filing with any governmental authority, federal or other, on the part of Parent or Sub is required in connection with the Merger or the consummation of any other transaction contemplated hereby, except for (i) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, (ii) the filing of a proxy statement in connection with the stockholders’ meeting to be held for approval by Parent of this Agreement and the Merger, and the obtaining of such stockholder approval, as required by the Commission and the Nasdaq Capital Market, (iii) the filing of any Form D and related state blue sky filings required under the Securities Act and state securities laws in connection with the issuance of any shares of Parent Stock pursuant to this Agreement and (iv) the filing of any registration statements with the Commission, and any related filings with state securities regulators, required by the Registration Rights Agreement. The execution and delivery of this Agreement and the Registration Rights Agreement and the consummation of the transactions contemplated hereby and thereby will not violate (i) any provision of the Restated Articles of Incorporation and Amended and Restated By-Laws of Parent or the Certificate of Incorporation or By-Laws of Sub or Pharmos Ltd., or (ii) any order, judgment, injunction, award or decree of any court or state or federal governmental or regulatory body applicable to Parent, Sub or Pharmos Ltd. 4.15Brokers.Except for RBC Capital Markets Corporation and Tamir Fishman & Co. Ltd., which together are acting as Parent’s and Sub’s financial advisors in the Merger, neither Parent nor Sub has retained, utilized or been represented by any broker or finder in connection with the negotiation or consummation of this Agreement or the transactions contemplated hereby. 4.16Internal Controls.Except as otherwise identified in the Parent Reports and except as set forth onSchedule 4.16, Parent maintains a system of internal accounting controls sufficient to provide reasonable |
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as otherwise identified in the Parent Reports, Parent has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for Parent and designed such disclosure controls and procedures to ensure that material information relating to Parent is made known to its Chief Executive Officer or Chief Financial Officer. Parent maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP and the applicable requirements of the Exchange Act. 4.17Compliance with Other Instruments, Laws, etc.Parent, Pharmos Ltd. and Sub each has complied in all material respects with, and is in compliance in all material respects with, (i) all laws, statutes, governmental regulations and all judicial or administrative tribunal orders, judgments, writs, injunctions, decrees or similar commands applicable to its business, (ii) all unwaived terms and provisions of all contracts, agreements and indentures to which Parent, Pharmos Ltd. or Sub is a party, or by which Parent, Pharmos Ltd. or Sub or any of their respective properties is subject, and (iii) its charter and by-laws, each as amended to date, except where such failure to comply would not have a material adverse effect on the business, assets or financial condition of Parent, Pharmos Ltd. or Sub. Except as otherwise disclosed in the Parent Reports, Parent, Pharmos Ltd. and Sub do not have or need any licenses, permits or other authorizations from governmental authorities for the conduct of their respective businesses or in connection with the ownership or use of their respective properties, except where the failure to have any such license, permit or other authorization would not have a material adverse effect on the business, assets or financial condition of Parent, Pharmos Ltd. or Sub. 4.18Approval.The board of directors of Parent, at a meeting duly called and held, has by requisite vote under applicable law (i) determined that this Agreement and the Registration Rights Agreement and the transactions contemplated hereby and thereby, including the Merger, and the transactions contemplated thereby, taken together, are fair to and in the best interests of the stockholders of Parent, and (ii) resolved to recommend that its stockholders approve this Agreement and the Registration Rights Agreement and the transactions contemplated
herein and therein, including the Merger. Parent has obtained binding, written agreements to vote in favor of approving this Agreement, the Merger, the Registration Rights Agreement and the transactions contemplated hereby and thereby from the current officers and directors of Parent and from any other stockholder that is controlled by such persons. 4.19Absence of Registration Obligations.No person has or shall have any piggyback or other registration rights relating to any securities of Parent as a result of the execution and delivery by Parent of the Registration Rights Agreement at the Closing and the filing of any registration statement pursuant thereto. 4.20Full Disclosure.No representation or warranty by Parent or Sub in this Agreement or in any Exhibit hereto or in its disclosure schedules hereto contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact required to be stated therein or necessary to make the statements contained therein not false or misleading. There is no fact relating to the business, research program or condition of Parent or Pharmos Ltd., taken as a whole that it has not disclosed to Target in writing (or is otherwise included in the Parent Reports) that could reasonably be expected to result in a material adverse effect to Parent or to Pharmos Ltd., taken as a whole. 5.Conduct of Target Business Prior to Effective Date.Target covenants and agrees that, from and after the date of this Agreement and until the Effective Date, except as otherwise provided herein or specifically consented to or approved by Parent in writing: 5.1Full Access.Target shall afford to Parent and its authorized representatives full access during normal business hours and with reasonable advance notice to all properties, books, records, contracts and documents of Target and a full opportunity to make such investigations as Parent shall reasonably desire to make of Target, and Target shall furnish or cause to be furnished to Parent and its authorized representatives all such information with respect to the affairs and businesses of Target as Parent may reasonably request. |
5.2Carry on in Regular Course.Target shall use its best efforts to preserve all of its accounting and business records, corporate records, trade secrets and proprietary information and other Intellectual Property for the benefit of the Surviving Corporation. 5.3No Dividends, Issuances, Repurchases, etc.Target shall not declare or pay any dividends (whether in cash, shares of stock or otherwise) on, or make any other distribution in respect of, any shares of capital stock, or issue, purchase, redeem or acquire for value any shares of its capital stock, or issue any options, warrants or other rights to acquire shares of its capital stock or securities exchangeable for or convertible into shares of its capital stock, except for the issuance of shares of capital stock of Target upon the exercise of options or warrants outstanding on the date hereof or upon the conversion of the Bridge Notes. 5.4Employment.Except for payments and allocations under the ABP, Target shall not: increase the compensation payable to or to become payable to any director, officer or employee; grant any severance or termination pay to, or enter into any employment, consulting or severance agreement with, any director, officer or employee or their respective affiliates, other than employment or consulting agreements entered into with the consent of Parent; or establish, adopt, enter into or amend any employee benefit plan or arrangement except as may be required by applicable law. 5.5Contracts and Commitments.Target shall not enter into any contract or commitment or engage in any transaction not in the usual and ordinary course of business and consistent with its normal business practices, including without limitation, any contract or commitment relating to Target’s Intellectual Property or any contract or commitment relating to the acquisition of assets, technologies or products or the in-licensing thereof without the prior written consent of Parent, which will not be unreasonably withheld. 5.6Other Transactions.Except as disclosed onSchedule 5.6, Target shall not (i) sell, lease as lessor, license as licensor, or otherwise dispose of any capital asset with a market value in excess of $10,000, (ii) sell, lease as lessor, license as licensor, or otherwise dispose of any asset other than in the ordinary course of business; provided, that Target shall not license any of Target’s Intellectual Property, (iii) borrow money, (iv) incur or pay any material liability other than in the ordinary course of business, or (v) guarantee or otherwise incur any material liability with respect to the obligation of any other Person. 5.7Preservation of Organization.Target shall use its best efforts to preserve for Parent and Sub the present relationships with suppliers, scientists, researchers, licensors, parties to contracts and others having business
relations with Target. Target shall not amend its Restated Certificate or By-Laws. Target shall not merge or consolidate with any other corporation, or acquire any stock of, or, except in the ordinary course of business, acquire any assets or property of any other business entity whatsoever. 5.8No Default.Target shall not do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any material contract, commitment or obligation of Target. 5.9Compliance withLaws.Target shall duly comply in all material respects with all laws, regulations and orders applicable with respect to its business. 5.10Advice of Change.Target shall promptly advise Parent in writing of any development or change in circumstance (including any litigation to which it may become a party or of which it may gain Knowledge) that does or could reasonably be expected to (i) call into question the validity of this Agreement or any action taken or to be taken pursuant hereto, (ii) adversely affect the ability of the parties to consummate the transactions contemplated hereby, or (iii) have any material adverse effect on the business, financial condition, or assets of Target. 5.11Target Stockholders Meeting.Target shall either call a special meeting of its stockholders to consider and vote upon the approval of this Agreement and the Merger and the other transactions contemplated hereby or shall obtain the requisite minimum required stockholder approval by written consent in accordance with Target’s Restated Certificate and By-Laws and applicable Delaware law. The board of directors of Target shall recommend to its stockholders the approval of this Agreement and the Merger and the other transactions contemplated hereby and shall use its best efforts to solicit and obtain the requisite vote of approval. |
5.12Consents of Third Parties.Target shall secure, before the Closing Date, the consent, in form and substance satisfactory to Parent and Parent’s counsel, to the consummation of the transactions contemplated by this Agreement, by each party to any material contract, commitment or obligation of Target, in each case under which such consent is required; provided, however, that for any of the required consents identified onSchedule 5.12(a), Target shall only be required to use all commercially reasonable efforts to obtain such consents. 5.13Satisfaction of Conditions Precedent.Target shall use all commercially reasonable efforts to cause the satisfaction of the conditions precedent applicable to it contained in Section 7 hereof. 5.14Transactions with Affiliates.Target shall not enter into any transactions with any of its affiliates without the prior written consent of Parent, which consent will not be unreasonably withheld or delayed. 5.15Cooperation in the Preparation of Required Securities Laws Documents.Target will assist Parent in the preparation of those sections of the preliminary and definitive proxy statement relating to the Agreement and the Merger that concern Target and its business, as well as any other disclosure document, offering memorandum or the like required under the Securities Act to be provided to the stockholders of Target. 6.Conduct of Parent Group Business Prior to Effective Date.Each of Parent and Sub covenants and agrees that, from and after the date of this Agreement and until the Effective Date, except as otherwise provided herein or specifically consented to or approved by Target in writing: 6.1Full Access.Parent shall afford to Target and its authorized representatives full access during normal business hours and with reasonable advance notice to all properties, books, records, contracts and documents of Parent, Sub and Pharmos Ltd. and a full opportunity to make such investigations as Target shall reasonably desire to make of Parent, Sub and Pharmos Ltd., and Parent shall furnish or cause to be furnished to Target and its authorized representatives all such information with respect to the affairs and businesses of Parent, Sub and Pharmos Ltd. as Target may reasonably request. 6.2Compliance with Laws.Parent and Sub shall duly comply, and shall cause Pharmos Ltd. to comply, with all laws, regulations and orders applicable with respect to its business, except where any of the foregoing would not have a material adverse effect on the business, assets or financial condition of Parent, Pharmos Ltd. or Sub. 6.3Other Transactions.Except in the ordinary course of business and subject to the provisions of Section 9.1, neither Parent nor Pharmos Ltd. shall (i) sell, lease as lessor, license as licensor, or otherwise dispose of any capital asset with a market value in excess of $10,000, (ii) sell, lease as lessor, license as licensor, or otherwise dispose of any asset; provided that neither Parent nor Pharmos Ltd. shall license any of Parent’s Intellectual Property
except as otherwise permitted under the last sentence of Section 9.1, (iii) borrow money, (iv) incur or pay any material liability, or (v) guarantee or otherwise incur any material liability with respect to the obligation of any other Person. 6.4Preservation of Organization.Parent shall use its best efforts to preserve for Parent, Sub and Pharmos Ltd., the present relationships with suppliers, scientists, researchers, licensors, parties to contracts and others having business relations with Parent, Sub and/or Pharmos Ltd. Neither Parent nor Pharmos Ltd. shall merge or consolidate with any other corporation, or acquire any stock of, or, except in the ordinary course of business, acquire any assets or property of any other business entity whatsoever. 6.5No Default.Neither Parent nor Pharmos Ltd. shall do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any material contract, commitment or obligation of Parent or Pharmos Ltd. 6.6Compliance with Laws.Each of Parent and Pharmos Ltd. shall duly comply in all material respects with alllaws, regulations and orders applicable with respect to its business. |
6.7Advice of Change.Parent shall promptly advise Target in writing of any development or change in circumstance (including any litigation to which it may become a party or of which it may gain Knowledge) that does or could reasonably be expected to (i) call into question the validity of this Agreement or any action taken or to be taken pursuant hereto, (ii) adversely affect the ability of the parties to consummate the transactions contemplated hereby, or (iii) have any material adverse effect on the business or financial condition of Parent and/or Pharmos Ltd. 6.8Consents of Third Parties.Parent shall use all commercially reasonable efforts to secure, before the Closing Date, the consent, in form and substance satisfactory to Target and Target’s counsel, to the consummation of the transactions contemplated by this Agreement, by each party to any material contract, commitment or obligation of Parent or Pharmos Ltd., in each case under which such consent is required. 6.9Satisfaction of Conditions Precedent.Parent and Sub each shall use all commercially reasonable efforts to cause the satisfaction of the conditions precedent applicable to it contained in Section 7 hereof. 6.10Carry on in Regular Course.Parent and Sub each shall, and Parent shall cause Pharmos Ltd. to, use its best efforts to carry on its business in the usual and ordinary course and to preserve its organization and relationships and not to (i) declare or pay any dividends to its stockholders, or repurchase any shares of Parent Stock, (iii) amend its corporate charter or by-laws, (ii) pledge or agree to pledge, any shares of the capital stock of Parent or (iii) increase the size of Parent’s Board of Directors beyond nine (9) members;provided,however, that this Section 6.10 shall not operate as to prevent the entry into or consummation of any of the transactions contemplated in this Agreement or in the agreements constituting exhibits hereto. 6.11Parent Stockholders Meeting.Promptly after the date of this Agreement, Parent shall take all action as the sole stockholder of Sub to approve this Agreement, the Merger, the Registration Rights Agreement and the Escrow Agreement and the other transactions contemplated hereby and thereby. Additionally, Parent shall promptly call a special meeting of its stockholders to consider and vote upon the approval of this Agreement, the Merger, the Registration Rights Agreement and the Escrow Agreement and the other transactions contemplated hereby and thereby in accordance with Parent’s Amended and Restated Certificate of Incorporation and By-Laws and applicable Nevada law. Parent shall recommend to its stockholders the approval of this Agreement, the Merger, the Registration Rights Agreement, the Escrow Agreement and the other transactions contemplated hereby and thereby and shall use its best efforts to solicit and obtain the requisite vote of approval. In connection therewith, Parent shall promptly prepare and disseminate preliminary and definitive proxy materials in accordance with the applicable provisions of the Exchange Act and the rules and regulations promulgated thereunder. 7.Conditions Precedent to Parent’s and Sub’s Obligations.Notwithstanding the provisions of this Agreement, Parent and Sub shall be obligated to perform the acts contemplated for performance by it under this Agreement or under the agreements constituting exhibits hereto only if each of the following conditions is satisfied at or prior to the Closing Date, unless any such condition is waived by Parent and Sub: 7.1Accuracy of Representations and Warranties by Target.The representations and warranties of Target set forth in Section 3 of this Agreement (including any schedules thereto) shall be true and correct in all material respects as of the Closing Date with the same force and effect as though made again at and as of the Closing Date, except for changes permitted or required by this Agreement.
7.2Compliance by Target.Target shall have performed and complied in all material respects with all covenants and agreements contained in this Agreement required to be performed or complied with by it on or before the Closing Date. 7.3Approval by Target Stockholders; Delivery of Certificate of Merger.The stockholders of Target shall have authorized and approved this Agreement and the Merger contemplated hereby as required by applicable law and the Restated Certificate and By-laws of Target, and the holders of at least 95% of the issued and outstanding shares of Target Capital Stock (voting together as a single class on an as-converted basis) shall have voted in favor of or consented to the Merger or shall have otherwise waived or failed to perfect any appraisal rights to which they may otherwise be entitled under Section 262 of the Delaware General Corporation |
Law. Target shall have duly executed and delivered or caused to be duly executed and delivered the Certificate of Merger. 7.4No Restraining Order.No restraining order or injunction or other order issued by any court of competent jurisdiction, or other legal restraint or prohibition shall prevent the consummation of the Merger or other transactions contemplated by this Agreement, and no petition or request for any such injunction or other order shall be pending. 7.5No Material Adverse Change.There shall not have been any material adverse change in the business or assets of Target, it being agreed that a material adverse change shall not include the incurring of cash losses from operations in accordance with the conduct of Target’s business in the ordinary course. 7.6Officers’ Certificates.Target shall have executed and delivered to Sub at and as of the Closing (i) a certificate, duly executed by Target’s President or any Vice President, in form and substance satisfactory to Parent and Parent’s counsel, certifying that each of the conditions specified in this Section 7 applicable to it have been satisfied and (ii) an incumbency certificate in form and substance satisfactory to Parent and Parent’s counsel. 7.7Opinion of Target’s Counsel.Target shall have delivered to Sub an opinion of Drinker Biddle & Reath, LLP, counsel to Target, dated the Closing Date, in form and substance reasonably satisfactory to Parent and its counsel. 7.8Exercise/Conversion of Stock Options, Warrants and Other Rights.Each outstanding stock option, warrant, and other right to acquire the capital stock of Target shall have been exercised, waived, released and/or terminated, and Target’s stock option plan shall have been terminated as of the Closing Date and shall be of no further force or effect. 7.9Liabilities of Target.After payment of the Cash Consideration to or on behalf of Target and the use of the proceeds thereof as set forth in Section 1.2(d) hereof, the remaining liabilities of Target as of the Closing Date, as determined in accordance with GAAP applied on a basis consistent with the preparation of the 2005 Audited Financial Statements, shall not exceed $100,000, provided that such liabilities do not include any expenses associated with the transactions contemplated by this Agreement and that such liabilities were incurred in the ordinary course of business. Notwithstanding the foregoing, any accrued vacation pay of Target outstanding at the Closing will not be deemed to be a remaining liability of Target and instead will paid for out of the Cash Consideration or cancelled. 7.10Consents.All consents required to be secured by Target pursuant to Section 5.12 shall have been secured on or prior to the Closing Date. 7.11Employment Agreements.All of the employment and consulting agreements to which Target is a party or to or by which Target is bound shall have been terminated upon terms and conditions acceptable to Parent, and participants in the ABP will have executed and delivered a general release in form and substance reasonably acceptable to Parent. 7.12Distribution of Parent Stock.Target shall have delivered written instructions for the distribution of the Closing Shares pursuant to Section 1.2(g), other than the Escrow Shares, which will be delivered to the Escrow Agent in accordance with the provisions of the Escrow Agreement. 7.13Proceedings and Documents Satisfactory.All proceedings in connection with the Merger contemplated by this Agreement and the other transactions contemplated hereby and all certificates and documents delivered to Parent and Sub pursuant to this Section 7 or otherwise reasonably requested by Parent shall be executed and delivered by Target and shall be reasonably satisfactory to Parent and its counsel.
7.14Private Placement.The issuance of the Parent Stock to the stockholders of Target shall qualify as a private placement under Regulation D of the Securities Act and shall be exempt from registration under the Federal securities laws and all state and other securities laws. Parent and its counsel shall have been provided |
with completed investment questionnaires from the stockholders of Target and any other information necessary for Parent and counsel reasonably to have concluded that the issuance of the Parent Stock is in full compliance with applicable securities laws. 7.15Approval by Parent Stockholders.The stockholders of Parent shall have authorized and approved this Agreement, the Merger and the transactions contemplated hereby as required by applicable law and the Amended and Restated Articles of Incorporation and By-laws of Parent. 7.16Execution and Delivery of Registration Rights Agreement and the Escrow Agreement.The stockholders of Target shall have executed and delivered the Registration Rights Agreement in the form attached hereto asExhibit C (the(the “Registration Rights Agreement”), and the Representatives shall have executed and delivered the Escrow Agreement. 7.17Cancelled Bridge Notes.All of the Bridge Notes shall have been cancelled and delivered to Parent at the Closing, in accordance with the provisions of Section 1.2(f) hereof. 7.18Standstill Agreement.Each of the Principal Stockholders shall have executed and delivered a Standstill Agreement in the form attached hereto asExhibit D. 7.19Cash Consideration.Target shall have delivered a schedule to Parent detailing the disbursement of the Cash Consideration. 8. Conditions Precedent to Target’s Obligations.Notwithstanding the provisions of this Agreement, Target shall be obligated to perform the acts contemplated for performance by it under this Agreement or under the agreements constituting exhibits hereto only if each of the following conditions is satisfied at or prior to the Closing Date, unless any such condition is waived by Target: 8.1Accuracy of Representations and Warranties by Parent and Sub.The representations and warranties of Parent and Sub set forth in Section 4 of this Agreement and in any Schedules to this Agreement shall be true and correct in all material respects as of the Closing Date with the same force and effect as though made again at and as of the Closing Date, except for changes permitted or required by this Agreement. 8.2Compliance by Parent and Sub.Parent and Sub each shall have performed and complied in all material respects with all of the covenants and agreements required to be performed or complied with by it by the Closing Date. 8.3Approval by Parent Stockholders; Delivery of Certificate of Merger.The stockholders of Parent and Sub shall have authorized and approved this Agreement and the Merger contemplated hereby as required by applicable law and the Certificate of Incorporation and By-laws of Parent and Sub, as applicable, and Sub shall have duly executed and delivered or caused to be duly executed and delivered the Certificate of Merger. 8.4No Restraining Order.No restraining order or injunction or other order issued by any court of competent jurisdiction, or other legal restraint or prohibition shall prevent the Merger or other transactions contemplated by this Agreement, and no petition or request for any such injunction or other order shall be pending. 8.5Parent and Sub Certificates.Parent and Sub each shall have delivered to Target (i) a certificate of its President or one of its Vice Presidents dated the Closing Date, in form and substance satisfactory to Target and Target’s counsel, certifying that the conditions set forth in Section 8 applicable to it have been satisfied, and (ii) an incumbency certificate in form and substance satisfactory to Parent and Parent’s counsel. 8.6Opinions of Parent’s and Sub’s Counsel.Parent and Sub shall have delivered to Target opinions of Eilenberg & Krause LLP and MacDonald Carano Wilson LLP, counsel and special Nevada counsel, respectively, for Parent and Sub, dated the Closing Date, in form and substance reasonably satisfactory to Target and its counsel. |
8.7No Material Adverse Change.There shall not have been any material adverse change in the business or assets of Parent, Sub or Pharmos Ltd., taken as a whole, it being agreed that a material adverse change shall not include the incurrence of cash losses from operations in accordance with the conduct of Parent’s and Pharmos Ltd.’s business in the ordinary course and shall not be deemed to have occurred if Parent is unsuccessful in
its current motions to dismiss pending class action and derivative litigations involving Parent and currently described in the Parent Reports. 8.8Proceedings and Documents Satisfactory.All proceedings in connection with the Merger contemplated by this Agreement and the other transactions contemplated hereby and all certificates and documents delivered to Target pursuant to this Section 8 or otherwise reasonably requested by Target shall be executed and delivered by Parent and Sub and shall be reasonably satisfactory to Target and its counsel. 8.9Private Placement.The issuance of the Parent Stock to the stockholders of Target shall qualify as a private placement under Regulation D of the Securities Act and shall be exempt from registration under the Federal securities laws and all state and other securities laws. 8.10Expansion of Parent Board of Directors.Parent shall have expanded the size of its staggered Board of Directors (the “Board”) by two, for a new total of nine members, and shall have received the resignation of one existing member of the Board. The two newly-created Board positions, together with the vacated Board position, will represent the following vacancies: (i) one vacancy with a term commencing as of Closing and expiring at the Parent annual stockholders meeting in 2009, (ii) one vacancy with a term commencing as of Closing and expiring at the Parent annual stockholders meeting in 2008, and (iii) one vacancy with a term commencing as of closing and expiring at the Parent annual stockholders meeting in 2007. Such vacancies will be filled by the Board at the Closing with three designees of Target, subject to approval by Parent’s Board, with each of the affiliates of (i) J.P. Morgan Partners, (ii) Venrock Partners and (iii) New Enterprise Associates each initially appointing one such designee, in each case subject to approval of Parent’s Board (it being agreed that Srinivas Akkaraju, Anthony B. Evnin and Charles W. Newhall III are acceptable designees and have been approved by Parent’s Board). 8.11Payment of CashConsideration.Parent shall have paid the Cash Consideration to or on behalf of Target as provided in Section 1.2(e). 8.12Execution and Delivery of Registration Rights Agreement and Escrow Agreement.Parent shall have executed and delivered the Registration Rights Agreement and the Escrow Agreement. 9.Covenants of the Parties. 9.1No Solicitation.Unless and until this Agreement shall have been terminated by Parent or Target pursuant to Section 14 hereof and up to and through the Closing, neither Parent nor Target nor any of their respective officers, directors, employees, representatives, subsidiaries or agents (including without limitation their investment bankers, accountants and counsel, collectively, the “Agents”) shall directly or indirectly encourage, solicit, initiate, or participate in any discussions or negotiations with, or provide any information to, any Person (other than the other parties hereto) concerning any offer or proposal for any merger, tender offer, sale, lease as lessor, license as licensor, or other disposition of substantial assets, sale of shares of capital stock or debt securities, or similar transaction involving it (an “AcquisitionProposal”), and shall not enter into any discussion of any business transaction with a third party that would involve any receipt, transmission, or disclosure of its confidential information, except in the ordinary course of business. Each party and any of its Agents shall immediately communicate in writing to the other party the terms of any proposal, discussion, negotiation, or inquiry relating to an Acquisition Proposal (including the identity of the party making such proposal or inquiry) that it receives in respect of any such transaction (which shall mean that any such communication shall be delivered no less promptly than by telecopy within two business days of receipt of any such proposal or inquiry). Notwithstanding the foregoing, Parent and Target each acknowledges that the other party may continue to initiate and continue product in-licensing and out-licensing discussions and negotiations with third parties, but may not enter into any agreement relating to a material licensing transaction without the prior written consent of the other; provided, however, Parent may enter into a product in-licensing agreement without the prior written consent of Target, if (i) the in-licensed product is not competitive with, or will not reduce the value of, dextofisopam, and (ii) the aggregate then-irrevocable payment obligations of Parent under such in-licensing agreement do not exceed $4,000,000 (that is, excluding, without |
limitation, any potential or contingent up-front, royalty, license maintenance or milestone based payments that would not be due and payable by Parent if it elected at some future date to terminate such in-licensing agreement). 9.2Further Assurance.Subject to the terms and conditions set forth in this Agreement, each of the parties to this Agreement shall use its best efforts, as promptly as practicable, to take or cause to be taken all actions, and to do or cause to be done all other things, as are necessary, proper, or advisable under applicable laws and regulations to consummate and make effective the transactions contemplated by this Agreement.
9.3Disclosure Statements.From time to time prior to the Effective Date, and in any event immediately prior to the Effective Date, each party shall promptly supplement or amend its disclosure schedules with respect to any matter hereafter arising that, if existing, occurring, or known at the date of this Agreement, would have been required to be set forth or described in such disclosure schedules or that is necessary to correct any information in such disclosure schedules that is or has become inaccurate. If any such supplement or amendment discloses a material adverse change, the conditions to consummate the Merger set forth in Sections 7 or 8 shall be deemed not to have been satisfied. 9.4Satisfaction of Conditions Precedent.Each of the parties to this Agreement shall use its best efforts to cause the satisfaction on or before August 31, 2006 of the conditions precedent contained in Sections 7 and 8 of this Agreement that impose obligations on it or require action on its part or the part of any of its stockholders or affiliates. 9.5HSR Filing.Parent and Target shall have determined, upon advice of counsel, that no filing is required pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”). Parent and Target shall furnish to each other such necessary information and reasonable assistance as the other may reasonably require in connection with reaching such determination. 9.6Post-Closing Covenants. (a) The parties agree that following the Closing, Parent will have complete flexibility in determining the appropriate preclinical and clinical development of Target’s current compounds in development. The parties intend that Target’s operations in New Jersey will be merged into Parent’s New Jersey operations. Parent acknowledges that it is its current intention to continue Target’s existing research and development and clinical programs for a period of at least two (2) years following the Closing, subject to ongoing and periodic review by management and the Board and further subject to the budgetary restraints of Parent’s combined business operations following the Merger and the availability of outside financing. (b) Parent shall timely (i) notify the Representatives of the commencement of each Phase IIb trial conducted for dextofisopam, (ii) provide the Representatives with the results of each such Phase IIb trial, (iii) provide evidence that the NDA referenced in Section 1.2(i) above has been filed with the FDA, and (iv) provide the Representatives with all such other information (including, without limitation, protocols, clinical development plans, progress reports and chemical stability testing data) as they may reasonably request in connection with any Phase IIb trial for dextofisopam and/or leading up to and including the filing of such NDA, which information shall be subject to the confidentiality obligations set forth in Section 10 below. (c) For as long as the affiliates of each of (i) J.P. Morgan Partners, (ii) Venrock Partners and (iii) New Enterprise Associates hold at least 50% of the Closing Shares issued to them and their affiliates (including any Escrow Shares allocable to it not previously forfeited to Parent in accordance with the terms of the Escrow Agreement), then (A) its designee for Parent’s Board shall remain on the Board for the duration of his initial term, (B) each designated director shall be replaced during the initial term or any renewal term only by another individual designated by such Indemnifying Stockholder, subject to the approval of Parent’s Board, and (C) in connection with the pending expiration of the term of any such director, the Governance and Nominating Committee of Parent’s Board shall consider, in connection with the deliberations in accordance with its Charter, the re-nomination of such director to the Parent Board. 10.Confidential Information; No Publicity.Any and all non-public information disclosed by Parent to Target or by Target to Parent as a result of the negotiations leading to the execution of this Agreement, or in |
furtherance hereof, shall remain confidential and be subject to the Confidentiality Agreement dated October 28, 2005, as amended on January 27, 2006 (as amended, the “Confidentiality Agreement”) between Parent and Target. If the consummation of the transactions contemplated by this Agreement does not take place for any reason, each of Parent, Sub and Target will return promptly all materials containing non-public information relating to the other side; provided, however, that counsel for each party may retain one copy of all such materials for the sole purpose of future evaluation in connection with any dispute arising under this Agreement or the Confidentiality Agreement or otherwise between the parties. 11.Securities Laws Matters.Target agrees to cooperate with Parent in qualifying the issue of Parent Stock to the holders of Target Capital Stock under Section 4(2) and/or Regulation D under the Securities Act and in complying with all state and other securities laws in respect thereto, and in connection therewith, to assist in the
preparation of any offering materials to be delivered by Parent to the stockholders of Target. Neither Target nor any of its agents is or shall be authorized to act on Parent’s behalf with respect to any aspect of the transactions contemplated by this Agreement or make any solicitations of or representations to any of the stockholders of Target on Parent’s behalf. Neither this Agreement nor any other by Parent shall be deemed an offer with respect to Parent Stock. 12.No Survival of Representations.Each of the representations and warranties made by the parties hereto shall survive the Closing Date and the Effective Date and consummation of the transactions for a period of eighteen months from the Effective Date (the “Release Date”). 13.Tax Consequences to the Parties.Parent, Sub and Target each understand and agree that no party is making any representation or warranty to the other as to the tax consequences of this Agreement and the events and actions contemplated hereby. Nonetheless, the parties agree to report the transactions contemplated hereby on their respective federal income tax returns as a tax-free reorganization under §368(a) of the Code and to take no action inconsistent with such characterization. 14.Termination; Liabilities Consequent Thereon.This Agreement, the agreements constituting exhibits hereto and (if executed) the Certificate of Merger may be terminated and the Merger contemplated hereby abandoned at any time prior to the Effective Date (whether before or after approval of the Merger by the stockholders of Parent, Sub or Target ) only as follows: (a) by Parent or Sub, upon notice to Target (i) if Target shall be in material breach of its obligations hereunder and shall not have cured such breach within a period of ten (10) days after written notice from Parent or Sub or (ii) if the conditions set forth in Section 7 shall not have been satisfied, or waived by Sub, on or prior to August 31, 2006 or (iii) if there has been a material adverse change in the representations and warranties made by Target herein when taken as a whole or (iv) upon any material adverse change in the business or operations of Target; or (b) by Target, upon notice to Parent and Sub, (i) if Parent or Sub shall be in material breach of its obligations hereunder and shall not have cured such breach within a period of ten (10) days after receipt of written notice from Target or (ii) if the conditions set forth in Section 8 shall not have been satisfied, or waived by Target, on or prior to August 31, 2006 or (iii) if there has been a material adverse change in the representations and warranties made by Parent or Sub herein when taken as a whole or (iv) upon any material adverse change in the business or operations of Parent, Pharmos Ltd. or Sub; or (c) at any time by mutual agreement of Parent and Target. If (i) Target chooses to terminate this Agreement other than pursuant to Section 14(b) or (c), or (ii) Parent chooses to terminate this Agreement pursuant to Section 14(a)(i) in connection with a breach by Target (or its Agents) of its obligations under Section 9.1, Target shall immediately pay to Parent a breakup fee of $1,500,000 in cash, in addition to Parent’s remedies for wrongful termination. If (i) Parent chooses to terminate this Agreement other than pursuant to Section 14(a) or (c) or (ii) Target chooses to terminate this Agreement pursuant to Section 14(b)(i) in connection with a breach by Parent (or its Agents) of its obligations under Section 9.1, Parent shall immediately pay to Target a breakup fee of $1,500,000 in cash, in addition to Target’s remedies for wrongful termination. If either Parent or Target terminates this Agreement for reasons other than its unwillingness, inability, or failure to fulfill its |
obligations hereunder, it shall have the right to recover damages sustained by it as a result of any breach by the other party of any representation, warranty, covenant or agreement contained in this Agreement or fraud or willful misrepresentation; provided, however, that such terminating party is not in breach of any representation, warranty, covenant or agreement contained in this Agreement under circumstances which would have permitted the other party to terminate this Agreement under Section 14(a) or (b). The parties acknowledge and agree that if Parent stockholder approval of this Agreement and the Merger, and the transactions contemplated hereby in accordance with the provisions of Section 6.11 is not obtained, Parent shall not be obligated to pay to Target the breakup fee hereunder unless Target is otherwise entitled to such payment under the immediately preceding paragraph.
15.Indemnification. 15.1By the Indemnifying Stockholders. (a) Subject to the limitations set forth in this Section 15, from and after the Closing Date, each of the stockholders of Target receiving Closing Shares (each, an “Indemnifying Stockholder” and, collectively, the “Indemnifying Stockholders”), severally and not jointly, shall indemnify and hold Parent and the Surviving Corporation and their respective directors, officers, employees, shareholders, agents, attorneys, successors, assigns and affiliates (collectively, the “Parent Indemnified Parties”) harmless from and with respect to any and all claims, judgments, proceedings, actions, suits, investigations, liabilities, losses, reasonable costs (including the reasonable fees and disbursements of attorneys), expenses and damages, including without limitation under federal or state securities laws, but excluding any incidental, consequential or punitive damages (collectively, “Damages”), related to or arising out of (i) any material failure or breach of any representation or warranty of Target, or (ii) any material failure to perform any covenant, obligation, undertaking or agreement of Target contained in this Agreement (including any Schedules hereto) or in the agreements constituting exhibits hereto. (b) The parties hereto agree and acknowledge that the Escrow Shares shall be the sole and exclusive source of recovery by the Parent Indemnified Parties and shall limit any other remedies available to the Parent Indemnified Parties hereunder or under any applicable law for the payment of or in respect of any claims arising hereunder, except that no such limitation shall apply in the event of fraud by Target, or any Indemnifying Stockholder. For the purposes of payment in respect of any Damages incurred by the Parent Indemnified Parties pursuant to this Section 15.1, the value of each Escrow Share shall be determined based upon the average of the closing price of Parent Stock for the fifteen consecutive trading days ending one business day prior to the date of assertion of a claim for Damages. The number of Escrow Shares available to satisfy the Indemnifying Stockholders’ obligations hereunder shall be successively reduced (with such shares to be released from escrow and distributed to the Indemnifying Stockholders pursuant to the instructions set forth in the Escrow Agreement) by one-third of the original number of Escrow Shares on each of the dates that are six months and one year after the Effective Date and eliminated on the Release Date, provided that, if a claim or claims for indemnification previously have been asserted by the Parent Indemnified Parties hereunder and the amount of such claim or claims is less than the value of the Escrow Shares to be released on such date, then only such shares with a value in excess of outstanding claims shall be released on such date, all in accordance with the provisions of the Escrow Agreement and Section 15.4(b) hereof. (c) The Indemnifying Stockholders shall have no liability for indemnification hereunder unless and until the aggregate Damages of the Parent Indemnified Parties exceed Two Hundred Fifty Thousand Dollars ($250,000) (the “Threshold Amount”), in which event the Indemnifying Stockholders shall indemnify the Parent Indemnified Parties for the full amount of Damages exceeding the Threshold Amount, but not for any Damages up to the Threshold Amount. The limitations provided in the previous sentence shall not apply in case of fraud. (d) The adoption of this Agreement and the approval of the Merger by Target shall constitute approval by its stockholders of all of the arrangements relating hereto and thereto, including without limitation, (i) the appointment of the Representatives (as defined in Section 16 hereof), and (ii) the authority of the Representatives to defend and/or settle any claims for which the stockholders of Target may be required to indemnify the Parent Indemnified Parties pursuant to this Section 15. All decisions and actions by the |
Representatives shall be binding upon all stockholders of Target and no such stockholders shall have the right to object, dissent, protest or otherwise contest the same. 15.2By Parent. (a) Subject to the limitations in this Section 15, from and after the Closing Date, Parent shall indemnify and hold the stockholders of Target (collectively, the “Target Indemnified Stockholders”) harmless from and with respect to any and all Damages related to or arising out of (i) any material failure or breach of any representation or warranty of Parent or Sub, or (ii) any material failure to perform any covenant, obligation, undertaking or agreement of Parent or Sub contained in this Agreement (including any Schedules hereto) or in the agreements constituting exhibits hereto. (b) Parent shall have no liability for indemnification hereunder unless and until the aggregate Damages of the Target Indemnified Parties exceed the Threshold Amount, in which event Parent shall indemnify the Target Indemnified Stockholders for the full amount of Damages exceeding the Threshold Amount, but not for any Damages up to the Threshold Amount. The maximum amount of Damages payable by Parent to the Target
Indemnified Parties, other than in the event of fraud, shall equal the aggregate value of the Escrow Shares then held in escrow when the claim is asserted (assuming, for this purpose only, that no claim for Damages had been asserted by the Parent Indemnified Parties that would have resulted in certain of the Escrow Shares not having been released to the Indemnifying Stockholders), based upon the Average Trading Price of Parent Stock for the fifteen consecutive trading days ending one business day prior to the Effective Date. The parties hereto agree and acknowledge that the foregoing payment of Damages by Parent shall be the sole and exclusive source of recovery by the Target Indemnified Parties and shall limit any other remedies available to the Target Indemnified Parties hereunder or under any applicable law for the payment of or in respect of any claims arising hereunder, except that no such limitation with respect to any Parent shall apply in the event of fraud by Parent. 15.3Of Target’s Officers and Directors.From and after the Effective Date, the Parent and the Surviving Corporation each shall indemnify, defend and hold harmless all of the current officers and directors of Target (the “Target Indemnified Parties”, who are referred to hereinafter collectively with the Parent Indemnified Parties and the Target Indemnified Stockholders as the “Indemnified Parties”) against any Damages (including, without limitation, any Damages relating to this Agreement or the transactions contemplated hereby), but only to the extent based or arising in whole or in part on or out of the fact that such of the Target Indemnified Parties is or was an officer or director of Target, whether pertaining to any matter existing or occurring at or prior to the Effective Date, and whether asserted or claimed prior to, at, or after the Effective Date;provided,however, that notwithstanding any other provision hereof, the Target Indemnified Parties shall under no circumstances be entitled to indemnification in respect of any claims, actions or Damages relating to any matter or Damages in connection with or in respect of which the Parent Indemnified Parties are entitled to indemnification pursuant to Section 15.1 hereof. 15.4Method of Asserting Claims; Payment; Offset. (a) All claims for indemnification by any Indemnified Parties pursuant to this Section 15 shall be made in accordance with the provisions of this Agreement and the Escrow Agreement. (b) The indemnification obligations of the Indemnifying Parties (as defined below) shall survive through the Release Date except for claims based upon fraud and claims for Damages for which an Indemnified Party delivered a notice to the Indemnifying Party prior to the Release Date, which may be prosecuted until its conclusion, which may be after the Release Date. (c)Notice. An Indemnified Party shall give prompt written notification to the Representatives (on behalf of the Indemnifying Stockholders) or Parent (on its own behalf and on behalf of the Surviving Corporation), as applicable (each an “Indemnifying Party”), of the actual or threatened commencement of any action, suit or proceeding (and the facts constituting the basis therefor) or any other basis for which indemnification pursuant to this Section 15 may be sought (an “Indemnification Notice”). Such Indemnification Notice shall specify, if known, the amount or an estimate of the amount of the liability arising therefrom. No delay on the part of an Indemnified Party in giving an Indemnifying Party an Indemnification Notice will relieve the |
Indemnifying Party from any of its obligations unless and only to the extent that the Indemnifying Party is materially prejudiced by the delay, or unless the Indemnification Notice is not delivered to the Indemnifying Party on or prior to the Release Date. (d)Defense of Claims. Within thirty (30) days after delivery of an Indemnification Notice indicating any action, suit or proceeding brought by a third party against the Indemnified Party that is based upon, or includes assertions relating to, any item listed in Sections 15.1(a), 15.2(a) or 15.3 (each, a “Third Party Claim”), the Indemnifying Party may, upon written notice thereof to the applicable Indemnified Parties, assume control of the defense of such Third Party Claim with counsel reasonably satisfactory to the applicable Indemnified Parties. If the Indemnifying Party does not assume control of such defense, then the applicable Indemnified Parties shall control such defense with the costs and expenses incurred by the Indemnified Parties in connection with such defense, including reasonably attorneys’ fees, other professionals’ fees and court or arbitration costs, to be included in the Damages for which the Indemnified Parties may seek indemnification under this Section 15 whether or not such Third Party Claim is successful. The party not controlling such defense may participate therein at its own expense;provided that if the Indemnifying Party assumes control of such defense and the counsel selected by the Indemnifying Party concludes that such counsel has a conflict of interest due to the existence of conflicting or different defenses available to the Indemnifying Parties and the Indemnified Parties with respect to such Third Party Claim, then the reasonable fees and expenses of one firm of separate counsel for all of the applicable Indemnified Parties shall be paid by the Indemnifying Party. The party controlling such defense shall keep the other party
advised of the status of such action, suit or proceeding and the defense thereof (including the provision of copies of all pleadings, motions and communications) and shall consider in good faith recommendations made by the other party with respect thereto. The applicable Indemnified Parties shall not agree to any settlement of a Third Party Claim without the prior written consent of the Indemnifying Parties, which consent shall not be unreasonably withheld or delayed. The Indemnifying Parties shall not agree to any settlement of a Third Party Claim without the prior written consent of the applicable Indemnified Parties, which consent shall not be unreasonably withheld or delayed. (e)Resolution of Claims. Any Indemnification Notice received by an Indemnifying Party under this Section 15.4 will be resolved as follows: | | | | (i)Uncontested Claims. If within thirty (30) days after receipt of an Indemnification Notice by the Indemnifying Party, the Indemnifying Party has not provided the Indemnified Party with a written notice contesting all or a portion of such Indemnification Notice, the claim will be deemed an “Uncontested Claim.” The Indemnifying Party will be conclusively deemed to have consented to the recovery by the Indemnified Party of the full amount of Damages specified in the Indemnification Notice for an Uncontested Claim. In addition, the Indemnifying Party shall also be deemed to have stipulated to the entry of a final judgment for Damages against it for such amount in a federal or state court located in the County of New York, State of New York. | | | | (ii)Contested Claims. If within thirty (30) days after receipt of an Indemnification Notice by an Indemnifying Party, the Indemnifying Party gives the Indemnified Party written notice contesting all or any portion of such Indemnification, the claim will be deemed a “Contested Claim.” Contested Claims will be resolved by either (i) a written settlement agreement executed by the Indemnifying Party and the Indemnified Party or (ii) in the absence of such a written settlement agreement, by a final, non-appealable judgment by a federal or state court of competent jurisdiction located in the State of New York. | | | | (iii)Settled Claims. The terms of the written settlement agreement executed by an Indemnifying Party and an Indemnified Party will govern the resolution of any Contested Claim settled under such agreement (a “Settled Claim”). |
| (i) Uncontested Claims. If within thirty (30) days after receipt of an Indemnification Notice by the Indemnifying Party, the Indemnifying Party has not provided the Indemnified Party with a written notice contesting all or a portion of such Indemnification Notice, the claim will be deemed an “Uncontested Claim.” The Indemnifying Party will be conclusively deemed to have consented to the recovery by the Indemnified Party of the full amount of Damages specified in the Indemnification Notice for an Uncontested Claim. In addition, the Indemnifying Party shall also be deemed to have stipulated to the entry of a final judgment for Damages against it for such amount in a federal or state court located in the County of New York, State of New York.
| | | | (ii) Contested Claims. If within thirty (30) days after receipt of an Indemnification Notice by an Indemnifying Party, the Indemnifying Party gives the Indemnified Party written notice contesting all or any portion of such Indemnification, the claim will be deemed a “Contested Claim.” Contested Claims will be resolved by either (i) a written settlement agreement executed by the Indemnifying Party and the Indemnified Party or (ii) in the absence of such a written settlement agreement, by a final, non-appealable judgment by a federal or state court of competent jurisdiction located in the State of New York.
| | | | (iii) Settled Claims. The terms of the written settlement agreement executed by an Indemnifying Party and an Indemnified Party will govern the resolution of any Contested Claim settled under such agreement (a “Settled Claim”).
|
| (f)Payment. Any Damages for which the Indemnifying Stockholders shall be liable to the Parent Indemnified Parties (other than for fraud) shall be paid in Escrow Shares with such shares to be valued in accordance with the provisions of Section 15.1(b). Any Damages for which the Parent or Sub shall be liable to the Target Indemnified Stockholders shall be payable in shares of Parent |
Stock or cash, at the election of Parent in its sole discretion, with the value of each share of Parent Stock issued in connection herewith to be determined based upon the average of the closing price of Parent Stock for the fifteen consecutive trading days ending one business day prior to the Effective Date. Any Damages for which the Parent or the Surviving Corporation shall be liable to the Target Indemnified Parties shall be paid in cash by Parent. Any payment by Parent of cash or Parent Stock in satisfaction of Damages hereunder shall be made within 15 days of the date that the amount of such Damages is finally determined hereunder. (g)Insurance; Taxes. Damages in respect of which an Indemnifying Party is required to indemnify an Indemnified Party hereunder shall be reduced by an amount equal to insurance proceeds paid to or tax benefit realized by the Indemnified Party. (h)Knowledge. Notwithstanding anything herein to the contrary, no Indemnified Party shall be entitled to indemnity under this Section 15 with respect to, and no Indemnifying Party shall be liable for, any Damages sustained as a result of any matter of which the Indemnified Party had Knowledge at or prior to the Closing. (i)Survival. The provisions of this Article 15 shall survive any termination of this Agreement and shall inure to the benefit of, and be enforceable by, any heirs, successors, assigns or representatives of any of the Indemnified Parties. 16.Appointment of Representatives. (a) Target (and the stockholders of Target by approval of this Agreement and the transactions contemplated hereby) hereby appoints Srinivas Akkaraju, Anthony B. Evnin, Charles W. Newhall III, Robert F. Johnston and Jeff Calcagno (collectively, the “Representatives” and each, a “Representative”) to represent the
stockholders of Target after the Closing Date for the purposes specified in this Agreement (including acting as a purchaser representative under Regulation D of the Securities Act, if necessary) and executing on behalf of such stockholders the Escrow Agreement and the Registration Rights Agreement. (b)Additional Powers and Authority. After the Closing, in addition to the matters set forth inSection 16(a) above, the Representatives will have authority and power to act on behalf of the stockholders of Target with respect to the disposition, settlement or other handling of the Escrow Shares and any disputes, claims or other proceedings arising following the Closing and the execution and delivery of any certificates, certifications, representation letters, or other documents required to be delivered by Target or the stockholders of Target pursuant to the terms of this Agreement, including, without limitation, the Escrow Agreement and the Registration Rights Agreement. (c)Authority and Reliance by Parent. Target’s stockholders will be bound by all actions taken and documents executed by the Representatives in their capacity as such hereunder and under the Escrow Agreement, and Parent will be entitled to rely on any action or decision of the Representatives. All actions and decisions of the Representatives in their capacities as such shall require the approval of a majority of the Representatives. (d)Limitation of Liability and Indemnification. In performing the functions specified in this Agreement, the Representatives will not be liable to Target’s stockholders, Parent or Sub in the absence of willful misconduct on the part of the Representatives. Target’s stockholders will severally indemnify the Representatives and hold them harmless against any loss, claim or liability (including defense costs) incurred without willful misconduct on the part of the Representatives and arising out of or in connection with the acceptance or administration of their duties hereunder. (e)Compensation and Reimbursement. The Representatives will not be entitled to receive any compensation from Parent, Sub, Target or Target’s stockholders in connection with this Agreement. Any out-of-pocket costs and expenses reasonably incurred by the Representatives in connection with actions taken by the Representatives under the terms of this Agreement (including the hiring of legal counsel and the incurring of legal fees and costs) will be paid by the Target’s stockholders (on a pro rata basis based on the number of shares of Parent Stock received by each of them pursuant to this Agreement) to the Representatives. |
(f)Replacement. If any individual serving as a Representative dies, becomes unable to perform the responsibilities hereunder or resigns, a substitute representative will be appointed by the former stockholders of Target representing a majority of the consideration received by such stockholders pursuant to Sections 1.2(f), 1.2(g) and 1.2(h). A Representative may resign as a Representative hereunder, effective upon a new Representative being appointed in writing. The new Representative will provide notice to the Parent of the occurrence of such event. (g)Binding Nature of Election. The provisions of thisSection 16 are independent and severable, will constitute an irrevocable power of attorney, coupled with an interest and surviving death, granted by each stockholder of Target to the Representatives and will be binding upon the executors, heirs, legal representatives and successors of each stockholder of Target. 17.Expenses.All expenses incurred by Target or any stockholder of Target in connection with the preparation and execution of this Agreement and the other agreements contemplated hereby and the consummation of the transactions contemplated hereby and thereby, including any expenses of finders, brokers, attorneys or the like, shall be borne by Target or the stockholders of Target, as the case may be. All expenses incurred by Parent and Sub shall be borne by Parent. 18.Certain Definitions.As used herein the following terms not otherwise defined shall have the following respective meanings: “Average Trading Price” shall mean an amount equal to the average of the closing price of the Parent Stock as quoted on the Nasdaq Capital Market for the fifteen (15) trading days immediately preceding (i) the Effective Date in the case of the Closing Shares and (ii) the satisfaction of the applicable Milestone in the case of the Milestone Shares. “Indebtedness”: (a) All indebtedness for borrowed money or other obligations, commitments or liabilities, whether current or long-term, contingent or matured, secured or unsecured, (b) all indebtedness of the deferred purchase price of property or services represented by a note or security agreement, (c) all indebtedness created or
arising under any conditional sale or other title retention agreement (even though the rights and remedies of the seller or lender under such agreement in the event of default may be limited to repossession or sale of such property), (d) all indebtedness secured by a purchase money mortgage or other lien to secure all or part to the purchase price of property subject to such mortgage or lien, (e) all obligations under leases that have been or must be, in accordance with GAAP, recorded as capital leases in respect of which Target is liable as lessee, (f) any liability in respect of banker’s acceptances or letters of credit, and (g) all indebtedness of Target, the stockholders of Target or any other Person that is guaranteed by Target or that Target has agreed (contingently or otherwise) to purchase or otherwise acquire or in respect of which Target has otherwise assured a creditor against loss. “Intellectual Property”: all patents, patent applications, supplemental protection certificates, patent disclosures and inventions (whether or not patentable and whether or not reduced to practice), trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing, copyrights and copyrightable works, registrations, applications and renewals for any of the foregoing and proprietary computer software, including but not limited to data, data bases and documentation “Person”: any natural person, entity, or association, including without limitation any corporation, partnership, limited liability company, government (or agency or subdivision thereof), trust, joint venture, or proprietorship. “Principal Stockholders”: Affiliates of J.P. Morgan Partners, New Enterprise Associates and Venrock Associates who hold shares of Target Capital Stock as of the date hereof as reflected on Schedule 3.5(a). “Securities Act”: shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. |
“Target Capital Stock”: shall mean, collectively, shares of Target’s (i) common stock, $0.001 par value per share, (ii) Series A Convertible Preferred Stock, par value $0.001 per share, (iii) Series B Convertible Preferred Stock, par value $0.001 per share, (iii) Series C Redeemable Convertible Preferred Stock, par value $0.001 per share, and (iv) Series D Redeemable Convertible Preferred Stock, par value $0.001 per share. “Tax”: any federal, state, local, or foreign income, gross receipts, franchise, estimated, alternative minimum, add-on minimum, sales, use, transfer, registration, value added, excise, natural resources, severance, stamp, occupation, premium, windfall profit, environmental, customs, duties, real property, personal property, capital stock, intangibles, social security, unemployment, disability, payroll, license, employee, or other tax or levy, of any kind whatsoever, including any interest, penalties, or additions to tax in respect of the foregoing. “Tax Return”: any return, declaration, report, claim for refund, information return, or other document (including any related or supporting estimates, elections, schedules, statements, or information) filed or required to be filed in connection with the determination, assessment, or collection of any Tax or the administration of any laws, regulations, or administrative requirements relating to any Tax. 19.Miscellaneous Provisions. 19.1Amendments.This Agreement may be amended prior to Closing only by written instrument stating that it is an amendment of this Agreement executed by Parent, Sub and Target and approved by the Boards of Directors of Parent, Sub and Target (i) in any manner and at any time prior to the first to occur of (A) submission for approval of this Agreement to the stockholders of Target and (B) submission for approval of this Agreement to the stockholders of Parent, and (ii) after the earliest such submission for approval, to extend the Closing Date and termination date referred to in Section 14 or to make other amendments which, in the opinion of the respective counsel for Parent and Target, do not substantially alter the terms hereof. This Agreement may be amended after the Closing only by written instrument executed by Parent and the Representatives. 19.2Notices and Representatives.Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by telecopier, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one business day after delivery to such carrier. Any party and any representative designated below may, by notice to the others, change its address for receiving such
notices. Prior to the Closing Date, Target agrees to forward any notices addressed to any of the stockholders of Target to such stockholder(s) at the address of record reflected in the books and records of Target. Address for notices to Parent or Sub: | | | | | Pharmos Corporation | | 99 Wood Avenue South, Suite 311 | | Iselin, New Jersey 08830 | | Attn: Chief Executive Officer | | Fax: | (732) 452-9557 | | Phone: | (732) 452-9556 | | | | with a copy (which shall not constitute notice) to: | | | | Adam Eilenberg, Esq. | | Eilenberg & Krause LLP | | 11 East 44th Street | | New York, New York 10017 | | Fax: | (212) 986-2399 | | Phone: | (212) 986-9700 | | | | Address for notices to Target: | | | | | Vela Pharmaceuticals Inc. | | 820 Bear Tavern Road, Suite 300 | | Ewing, New Jersey 08628 | | Attention: Chief Executive Officer | | Fax: | (609) 771-8661 | | Phone: | (609) 771-8660 | | | | with a copy (which shall not constitute notice) to: | | | John E. Stoddard III | | Drinker Biddle & Reath LLP | | 105 College Road East, Suite 300 | | Princeton, New Jersey 08542 | | Fax: | (609) 799-7000 | | Phone: | (609) 716-6500 | | | | Addresses for notices to the Representatives: | | | | | Srinivas Akkaraju | | c/o J.P. Morgan Partners | | 50 California Street, 29th Floor | | San Francisco, CA 94111 | | Fax: | (415) 591-1205 | | Phone: | (415) 591-1200 |
| Pharmos Corporation | | 99 Wood Avenue South, Suite 311 | | Iselin, New Jersey 08830 | | Attn: Chief Executive Officer | | Fax: | (732) 452-9557 | | Phone: | (732) 452-9556 | | | | | with a copy (which shall not constitute notice) to: | | | | Adam Eilenberg, Esq. | | Eilenberg & Krause LLP | | 11 East 44th Street | | New York, New York 10017 | | Fax: | (212) 986-2399 | | Phone: | (212) 986-9700
| | | | Anthony B. Evnin | | c/o Venrock Associates | | 30 Rockefeller Plaza, Room 5508 | | New York, NY 10112 | | Fax: | (212) 649-5788 | | Phone: | (212) 649-5791 | | | | | Charles W. Newhall III | | c/o New Enterprise Associates | | 1119 St. Paul Street | | Baltimore, MD 21202 | | Fax: | (410) 752-7721 | | Phone: | (410) 244-0115 | | | | | Robert F. Johnston | | 181 Cherry Valley Road | | Princeton, NJ 08540 | | Fax: | (609) 924- | | Phone: | (609) 924-3131 | | | | | Jeff Calcagno | | c/o Vela Pharmaceuticals Inc. | | 820 Bear Tavern Road, Suite 300 | | Ewing, NJ 08628 | | Fax: | (609) 771-8661 | | Phone: | (609) 771-8660 | | | | | with a copy (which shall not constitute notice) to: | | | | John E. Stoddard III | | Drinker Biddle & Reath LLP | | 105 College Road East, Suite 300 | | Princeton, New Jersey 08542 | | Fax: | (609) 799-7000 | | Phone: | (609) 716-6500 |
Address for notices to Target: | | | | Vela Pharmaceuticals Inc. | | 820 Bear Tavern Road, Suite 300 | | Ewing, New Jersey 08628 | | Attention: Chief Executive Officer | | Fax: | (609) 771-8661 | | Phone: | (609) 771-8660 | | | | | with a copy (which shall not constitute notice) to: | | | | John E. Stoddard III | | Drinker Biddle & Reath LLP | | 105 College Road East, Suite 300 | | Princeton, New Jersey 08542 | | Fax: | (609) 799-7000 | | Phone: | (609) 716-6500 | | | | Addresses for notices to the Representatives: | | | | | Srinivas Akkaraju | | c/o J.P. Morgan Partners | | 50 California Street, 29th Floor | | San Francisco, CA 94111 | | Fax: | (415) 591-1205 | | Phone: | (415) 591-1200 | | | | Anthony B. Evnin | | c/o Venrock Associates | | 30 Rockefeller Plaza, Room 5508 | | New York, NY 10112 | | Fax: | (212) 649-5788 | | Phone: | (212) 649-5791 | | | | Charles W. Newhall III | | c/o New Enterprise Associates | | 1119 St. Paul Street | | Baltimore, MD 21202 | | Fax: | (410) 752-7721 | | Phone: | (410) 244-0115 | | | | Robert F. Johnston | | 181 Cherry Valley Road | | Princeton, NJ 08540 | | Fax: | (609) 924- | | Phone: | (609) 924-3131 | | | | Jeff Calcagno | | c/o Vela Pharmaceuticals Inc. | | 820 Bear Tavern Road, Suite 300 | | Ewing, NJ 08628 | | Fax: | (609) 771-8661 | | Phone: | (609) 771-8660 | | | | with a copy (which shall not constitute notice) to: |
| John E. Stoddard III | | Drinker Biddle & Reath LLP | | 105 College Road East, Suite 300 | | Princeton, New Jersey 08542 | | Fax:
| (609) 799-7000
| | Phone: | (609) 716-6500 | | | |
19.3Assignment and Benefits of Agreement.This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors, but may not be assigned without the written consent of the other parties to this Agreement. Except as aforesaid, nothing in this Agreement, express or implied, is intended to confer upon any person other than the parties hereto (and the Representatives after the Closing Date) any rights under or by reason of this Agreement. In the event that Parent shall sell substantially all of its assets or capital stock or merge, reorganize or consolidate with or into any other corporation (or engage in any other similar transaction), then appropriate provision shall be made with respect to Parent’s obligation to issue the Milestone Shares. 19.4Governing Law.This Agreement shall be construed and enforced in accordance with, and rights of the parties shall be governed by, the internal laws of the State of New York (without reference to principles of conflicts or choice of law that would cause the application of the internal laws of any other jurisdiction). 19.5Submission to Jurisdiction; Waivers.PARENT, SUB, TARGET AND THE STOCKHOLDERS OF TARGET (BY APPROVAL OF THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED
HEREBY), FOR ITSELF AND ON BEHALF OF ITS SUCCESSORS, ASSIGNS AND TRANSFEREES, HEREBY IRREVOCABLY AND UNCONDITIONALLY: (i) SUBMITS FOR ITSELF AND ITS PROPERTY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR FOR RECOGNITION AND ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, TO THE NONEXCLUSIVE GENERAL JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK, THE COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE STATE OF NEW YORK, AND APPELLATE COURTS FROM ANY THEREOF; (ii) CONSENTS THAT ANY SUCH ACTION OR PROCEEDING MAY BE BROUGHT IN SUCH COURTS, AND WAIVES ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH ACTION OR PROCEEDING IN ANY SUCH COURT OR THAT SUCH ACTION OR PROCEEDING WAS BROUGHT IN AN INCONVENIENT COURT AND AGREES NOT TO PLEAD OR CLAIM THE SAME; (iii) AGREES THAT SERVICE OF PROCESS IN ANY SUCH ACTION OR PROCEEDING MAY BE EFFECTED BY MAILING A COPY THEREOF BY REGISTERED OR CERTIFIED MAIL (OR ANY SUBSTANTIALLY SIMILAR FORM OF MAIL), POSTAGE PREPAID, AT ITS ADDRESS AS PROVIDED IN SECTION 19.2 HEREOF OR AT SUCH OTHER ADDRESS AS IT SHALL HAVE NOTIFIED EACH OF THE OTHER PARTIES HERETO IN THE MANNER PROVIDED IN SECTION 19.2 HEREOF; (iv) AGREES THAT NOTHING HEREIN SHALL AFFECT THE RIGHT TO EFFECT SERVICE OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW; AND (v) WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN. 19.6Counterparts.This Agreement may be executed by the parties in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute but one and the same instrument. 19.7Section Headings.The headings of sections or subsections are for reference only and shall not limit or control the meaning thereof. |
19.8Public Statements or Releases.The parties hereto each agree that no party to this Agreement shall make, issue or release any public announcement, statement or acknowledgment of the existence of, or reveal the status of, the transactions provided for herein, without first obtaining the consent of the other party hereto. Nothing contained in this Section 19.8 shall prevent any party from making such public announcements as such party may consider necessary in order to satisfy such party’s legal or contractual obligations. [ Remainder of Page Intentionally Left Blank ] |
| IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as an instrument under seal as of the date and year first above written. | | | | | PARENT: | | | | PHARMOS CORPORATION | | | | By:/s/ Haim Aviv | | | Name: | Haim Aviv | | | Title: | Chairman and CEO | | | | | | SUB: | | | | | | | | VELA ACQUISITION CORPORATION | | | | | | By:/s/ Haim Aviv | | | Name: | Haim Aviv | | | Title: | Chairman and CEO | | | | | | TARGET: | | | | | | VELA PHARMACEUTICALS INC. | | | | | | By:/s/ Jeff Calcagno M.D. | | | Name: | Jeff Calcagno, M.D. | | | Title: | Chief Business Officer and | | | | Chief Financial Officer | | | | | PARENT: | | | | | PHARMOS CORPORATION | | | | By: | /s/ Haim Aviv | | |
| | | Name: | Haim Aviv | | | Title: | Chairman and CEO |
| | | | | SUB: | | | | | | VELA ACQUISITION CORPORATION | | | | By: | /s/ Haim Aviv | | |
| | | Name: | Haim Aviv | | | Title: | Chairman and CEO |
| | | | | TARGET: | | | | | | VELA PHARMACEUTICALS INC. | | | | By: | /s/ Jeff Calcagno M.D. | | |
| | | Name: | Jeff Calcagno, M.D. | | | Title: | Chief Business Officer and
Chief Financial Officer |
Exhibit A to Merger Agreement CERTIFICATE OF MERGER OF VELA PHARMACEUTICALS INC.
(a Delaware corporation) INTO VELA ACQUISITION CORPORATION
(a Delaware corporation) |
| Pursuant to Section 251 of the General Corporation Law of the State of Delaware |
| | |
| | Pursuant to Section 251 of the General Corporation Law of the State of Delaware | |
| |
Vela Acquisition Corporation, a Delaware corporation (“Sub”), does hereby certify as follows: FIRST : Each of the constituent corporations, Sub and Vela Pharmaceuticals Inc., a Delaware corporation (“Target”), is a corporation duly organized and existing under the laws of the State of Delaware. SECOND : An Agreement and Plan of Merger dated March 14, 2006 (the “Merger Agreement”) among Pharmos Corporation, a Nevada corporation, Sub and Target, setting forth the terms and conditions of the merger of Target with and into Sub (the “Merger”), has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Section 251 of the General Corporation Law of the State of Delaware. THIRD : That the name of the surviving corporation of the merger is Vela Acquisition Corporation (the “Surviving Corporation”) FOURTH : That the Certificate of Incorporation of the Surviving Corporation shall be the same as the Certificate of Incorporation of Vela Acquisition Corporation as on file with the Delaware Secretary of State immediately prior to the effective time of the Merger. FIFTH: That an executed copy of the Merger Agreement is on file at the principal place of business of the Surviving Corporation at the following address: 99 Wood Avenue South, Suite 311, Iselin, New Jersey 08830. SIXTH : That a copy of the Merger Agreement will be furnished by the Surviving Corporation upon request and without cost to any stockholder of any constituent corporation. |
IN WITNESS WHEREOF, Vela Acquisition Corporation has caused this Certificate to be executed by its President and attested by its Secretary this [____] day of [______], 2006. | | | | VELA ACQUISITION CORPORATION
a Delaware corporation | | | | | By: | | | |
| | | Name: | | | Title: President
| ATTEST: | | | | | |
| | | Name: | | | Secretary | | | |
| | | VELA ACQUISITION CORPORATION | | a Delaware corporation | | | | | | | | By: | _______________________________ | | | Name: | | | Title: President | | | | ATTEST: | | | | | | | | | _______________________________ | | | Name: | | | Secretary | | |
Exhibit B to Merger Agreement ESCROW AGREEMENT This Escrow Agreement (the “Agreement”), dated as of [_______], 2006 (the “Closing Date”) by and among Pharmos Corporation, a Nevada corporation (“Parent”), Vela Acquisition Corporation, a Delaware corporation (“Sub”), Srinivas Akkaraju, Anthony B. Evnin, Charles W. Newhall III, Robert F. Johnston and Jeff Calcagno as representatives (collectively, the “Representatives”) of the former stockholders of Vela Pharmaceuticals, Inc. (the “Company”), [______], [_____] and [_____] (collectively, the “Indemnifying Stockholders”) and [___________], as escrow agent (the “Escrow Agent”). WITNESSETH: WHEREAS, Parent, Sub, and the Company are parties to that certain Agreement and Plan of Merger dated as of March 14, 2006 (the “Merger Agreement”) pursuant to which the Company’s former stockholders have received or shall receive shares of common stock, par value $0.03 per share, of Parent (“Parent Stock”); WHEREAS, in connection with the closing on the date hereof of the transactions contemplated by the Merger Agreement (the “Closing”), Parent has deposited an aggregate of 1,725,000 shares of Parent Stock (the “Escrow Shares”) into escrow with Escrow Agent, to be held by Escrow Agent pursuant to the terms and conditions set forth in this Escrow Agreement and the Merger Agreement pending the occurrence of certain events set forth herein and therein; WHEREAS, the Escrow Shares are being held to secure claims by Parent Indemnified Parties for Damages under Section 15 of the Merger Agreement; WHEREAS, the Representatives have been appointed and are authorized to act on behalf of the Company’s former stockholders pursuant to Section 16 of the Merger Agreement; and WHEREAS, Escrow Agent is willing to serve in such capacity on the terms and conditions hereinafter set forth. NOW, THEREFORE, in consideration of the aforesaid premises and the mutual covenants and conditions hereinafter set forth, the parties hereby agree as follows: 1. Definitions.. Unless otherwise defined herein, each capitalized term used in this Agreement shall have the meaning ascribed to such term in the Merger Agreement. 2. Appointment of Escrow Agent.. Each of Parent, Sub, the Indemnifying Stockholders and the Representatives hereby appoints and designates the Escrow Agent as the Escrow Agent for the purposes and upon the terms set forth herein, and the Escrow Agent hereby accepts such appointment and agrees to act as the Escrow Agent hereunder for the purposes and upon the terms set forth herein. 3. Parent to Act on behalf of Affiliates.After the Closing, each of the parties hereto agree that the Parent shall have authority to settle all claims under this Agreement or the Merger Agreement on behalf of the Sub, or any of the affiliates of Parent or Sub. Unless the context otherwise requires, any references to Parent contained herein shall be deemed to be references to Parent and Sub, and each of their affiliates. 4. Deposit of Escrowed Shares. (a)Escrow FundFund.. Parent has deposited with the Escrow Agent three stock certificates, each evidencing 575,000 shares of Parent Stock (an aggregate of 1,725,000 Escrow Shares), issued in the name of Escrow Agent or its nominee for the benefit of the Indemnifying Stockholders in accordance with their pro rata interests set forth onExhibit A. The Escrow Shares shall constitute an escrow fund (the “Escrow Fund”) with respect to claims for Damages by the Parent Indemnified Parties under the Merger Agreement. The Escrow Fund shall be held as a trust fund and shall not be subject to any lien, attachment, trustee process or any other judicial process of any |
creditor of any Indemnifying Stockholder or of any party hereto. The Escrow Agent agrees to accept delivery of the Escrow Fund and to hold the Escrow Shares in an escrow account (the “Escrow Account”), subject to the terms and conditions of this Agreement.
(b)Voting of Escrow Shares. Each Indemnifying Stockholder shall have the right, in its sole discretion, to direct the Escrow Agent in writing as to the exercise of any voting rights pertaining to the Escrow Shares, and the Escrow Agent shall comply with any such written instructions. In the absence of written instructions from an Indemnifying Stockholder, the Escrow Agent shall not vote any of the Escrow Shares held for such Indemnifying Stockholder. (c)Dividends, Etc.Parent and each of the Representatives agree among themselves, for the benefit of Parent and the Escrow Agent, that any securities or other property distributable in respect of or in exchange for any Escrow Shares as a result of a stock split or recapitalization shall not be distributed to the Indemnifying Stockholders, but rather shall be distributed to and held by the Escrow Agent in the Escrow Account. Ordinary cash dividends and dividends payable in shares of Parent Stock will be paid by Parent directly to the Indemnifying Stockholders in accordance with their pro rata interest in the Escrow Shares and not to the Escrow Agent. Unless and until the Escrow Agent shall actually receive such additional securities or other property, it may assume without inquiry that the Escrow Shares currently being held by it in the Escrow Account are all that the Escrow Agent is required to hold. At the time any Escrow Shares are required to be released from the Escrow Account to any person or entity (“Person”) pursuant to this Agreement, any securities or other property previously received by the Escrow Agent in respect of or in exchange for such Escrow Shares shall be released from the Escrow to such Person. (d)Transferability. The interest of the Indemnifying Stockholders in the Escrow Shares shall not be assignable or transferable, other than by operation of law. Notice of any such assignment or transfer by operation of law shall be given to the Escrow Agent and the Parent, and no such assignment or transfer shall be valid until such notice is given. 5. Release Dates.Subject to Section 6 of this Agreement, (i) one-third of the Escrow Shares (the “First Shares”) shall be released to the Indemnifying Stockholders on the date which is six months after the Closing Date (the “Initial Release Date”), (ii) an additional one-third of the Escrow Shares (the “Second Shares”) shall be released to the Indemnifying Stockholders on the date which is twelve months after the Closing Date (the “Second Release Date”) and (iii) the remaining one-third of the Escrow Shares (the “Final Shares”) shall be released to the Indemnifying Stockholders on the date which is eighteen months after the Closing Date (the “Final Release Date” and, collectively with the First Release Date and the Second Release Date, the “Release Dates” and each singly a “Release Date”). 6. Administration of Escrow Account.Except as otherwise provided herein, the Escrow Agent shall administer the Escrow Account as follows: (a) If, as of the Initial Release Date, the Escrow Agent has not received any Claim Notices (as hereinafter defined) pertaining to the Escrow Shares (or has received Claim Notices in aggregate amount less than the value of the First Shares as of the Initial Release Date), then the First Shares (or such portion thereof representing the excess of the value of the First Shares as of the Initial Release Date, over the aggregate amount of such Claim Notices) shall promptly (and in any event no later than 10 business days thereafter) be released and delivered to the Indemnifying Stockholders, in accordance with each Indemnifying Stockholder’s pro rata interest as set forth onExhibit A. (b) If, as of the Second Release Date, the Escrow Agent has not received any Claim Notices pertaining to the Escrow Shares then held in escrow (or has received Claim Notices in aggregate amount less than the value of the Second Shares as of the Second Release Date), then the Second Shares (or such portion thereof representing the excess of the value of the Second Shares as of the Second Release Date, over the amount of such Claim Notices) shall promptly (and in any event no later than 10 business days thereafter) be released and delivered to the Indemnifying Stockholders, in accordance with each Indemnifying Stockholder’s pro rata interest as set forth onExhibitA. |
(c) If, as of the Final Release Date, the Escrow Agent has not received any Claim Notices pertaining to the Escrow Shares then held in escrow (or has received Claim Notices in aggregate amount less than the value of the Final Shares as of the Final Release Date), then the Final Shares (or such portion thereof representing the excess of the value of the Final Shares as of the Final Release Date, over the amount of such Claim Notices) shall promptly (and in any event no later than 10 business days thereafter) be released and delivered to the
Indemnifying Stockholders, in accordance with each Indemnifying Stockholder’s pro rata interest as set forth onExhibitA. (d) If, at any time prior to any of the respective Release Dates, Parent on its own behalf or on behalf of the Parent Indemnified Parties desires to make a claim for Damages against the Escrow Shares, then Parent shall, on or prior to a Release Date, deliver a written claim notice (a “Claim Notice”) to the Representatives and to the Escrow Agent. Such Claim Notice shall (i) state that Parent believes that it is entitled to all or any portion of the Escrow Shares; (ii) contain a brief description of the circumstances supporting such belief; and (iii) indicating the claimed amount of Damages and the number of Escrow Shares (valued as provided in Section 15.1(b) of the Merger Agreement) necessary to satisfy such indemnification claim (such shares, the “Damage Shares”). If the Representatives do not contest any portion of the claim described in a Claim Notice and all of such claim becomes an Uncontested Claim under Section 15.4(e) (i) of the Merger Agreement, Escrow Agent shall release the Damage Shares to Parent in satisfaction of such Uncontested Claim. If the Representatives contest all or any portion of a claim described in a Claim Notice and all or a portion of such claim becomes a Contested Claim under Section 15.4(e) (ii) of the Merger Agreement, Escrow Agent shall release Damage Shares that are the subject of a Claim Notice only after such Contested Claim has been resolved in accordance with Section 15.4(e) (ii) of the Merger Agreement. (e) Anything to the contrary set forth herein notwithstanding, the Escrow Agent shall also release all or a portion of the Escrow Shares if the Escrow Agent receives joint written instructions executed by the Representatives, on the one hand, and Parent, on the other hand, authorizing such release. (f) Whenever the Escrow Agent shall release Escrow Shares from the Escrow Account for the account of the Indemnifying Stockholders, Escrow Agent shall instruct the transfer agent for Parent’s Common Stock to cancel such certificate and to divide the shares evidenced thereby in accordance with pro rata interests of the Indemnifying Stockholders as set forth onExhibit A hereto. Parent will take also such further actions that may be reasonably necessary to authorize the transfer agent to effectuate any such distribution of shares released from the Escrow Account to the Indemnifying Stockholders. 7. Escrow Agent Compensation.Except as hereinafter provided, the Escrow Agent shall be reimbursed for all actual out-of-pocket expenses incurred in performing the services required hereunder by Parent. The fees of the Escrow Agent and any replacement Escrow Agent shall be paid by Parent. 8. Limitation ofEscrow Agent’s Liability. (a) Except for Escrow Agent’s gross negligence or willful misconduct, Escrow Agent shall not be responsible or liable in any manner whatsoever for the sufficiency, correctness, genuineness or validity of any instrument deposited with it, or any notice or demand given to it or for the form of execution of any such instrument, notice or demand or for the identification, authority or rights of any person executing, depositing or giving the same or for the terms and conditions of any instrument, pursuant to which the parties may act. (b) Escrow Agent shall not have any duties or responsibilities except those expressly set forth in this Agreement and shall not incur any liability: (i) in acting upon any signature, notice, demand, request, waiver, consent, receipt or other paper or document reasonably believed by Escrow Agent to be genuine and Escrow Agent may assume that any person purporting to give it any notice on behalf of any party in accordance with the provisions hereof has been duly authorized to do so; or (ii) in otherwise acting or failing to act under this Agreement, except in the case of Escrow Agent’s gross negligence or willful misconduct. (c)Escrow Agent shall not be bound by any modification, cancellation or rescission of this Agreement unless the same is in writing and signed by each of the other parties hereto and a copy thereof has been received by Escrow Agent. |
(d) Escrow Agent has executed this Agreement for the sole purpose of agreeing to act as such in accordance with the terms of this Agreement. (e) Subject to Section 7 hereof, Parent, on the one hand, and the Representatives, on the other hand, the parties hereto further agree to equally indemnify Escrow Agent from and against any and all losses, claims, damages or liabilities and expenses, including reasonable attorneys fees which may be asserted against it or to which it may be exposed or may incur by reason of its performance hereunder, except when such performance was grossly or willfully negligent.
9. Successor Escrow Agent.In the event the Escrow Agent becomes unavailable or unwilling to continue as escrow agent under this Agreement, the Escrow Agent may resign and be discharged from its duties and obligations hereunder by giving its written resignation to the parties to this Agreement. Such resignation shall take effect not less than 30 days after it is given to all parties hereto. Parent may appoint a successor Escrow Agent only with the consent of the Representatives (which consent shall not be unreasonably withheld or delayed). The Escrow Agent shall act in accordance with written instructions from Parent and the Representatives as to the transfer of the Escrow Fund to a successor escrow agent. 10. Miscellaneous.Miscellaneous. (a)Notice.All notices hereunder shall be given in accordance with the notice provisions of the Merger Agreement. In addition, notices to Escrow Agent shall be addressed to it at: | |
| _______________ | | _______________ | | _______________ | | Attention: ____________ | | |
In addition, notices to the Representatives shall be addressed to: | | | | Srinivas Akkaraju | | c/o J.P. Morgan Partners | | 50 California Street, 29th Floor | | San Francisco, CA 94111 | | Fax: | (415) 591-1205 | | Phone: | (415) 591-1200 | | | | Anthony B. Evnin | | c/o Venrock Associates | | 30 Rockefeller Plaza, Room 5508 | | New York, NY 10112 | | Fax: | (212) 649-5788 | | Phone: | (212) 649-5791 | | | | Charles W. Newhall III | | c/o New Enterprise Associates | | 1119 St. Paul Street | | Baltimore, MD 21202 | | Fax: | (410) 752-7721 | | Phone: | (410) 244-0115 | | | | Robert F. Johnston | | 181 Cherry Valley Road | | Princeton, NJ 08540 | | Fax: | (609) 924- | | Phone: | (609) 924-3131 | |
| Srinivas Akkaraju | | c/o J.P. Morgan Partners | | 50 California Street, 29th Floor | | San Francisco, CA 94111 | | Fax: | (415) 591-1205 | | Phone: | (415) 591-1200 | | | | Anthony B. Evnin | | c/o Venrock Associates | | 30 Rockefeller Plaza, Room 5508 | | New York, NY 10112 | | Fax: | (212) 649-5788 | | Phone: | (212) 649-5791 | | | | Charles W. Newhall III | | c/o New Enterprise Associates | | 1119 St. Paul Street | | Baltimore, MD 21202 | | Fax: | (410) 752-7721 | | Phone: | (410) 244-0115 | | | | Robert F. Johnston | | 181 Cherry Valley Road | | Princeton, NJ 08540 | | Fax: | (609) 924- | | Phone: | (609) 924-3131 | | Jeff Calcagno |
4
| | c/o Vela Pharmaceuticals Inc. | | 820 Bear Tavern Road, Suite 300 | | Ewing, NJ 08628 | | Fax: | (609) 771-8661 | | Phone: | (609) 771-8660
|
| Jeff Calcagno | | c/o Vela Pharmaceuticals Inc. | | 820 Bear Tavern Road, Suite 300 | | Ewing, NJ 08628 | | Fax: | (609) 771-8661 | | Phone: | (609) 771-8660 |
| | with a copy (which shall not constitute notice) to: | | | | | John E. Stoddard III | | Drinker Biddle & Reath LLP | | 105 College Road East, Suite 300 | | Princeton, New Jersey 08542 | | Fax: | (609) 799-7000 | | Phone: | (609) 716-6504 |
| John E. Stoddard III | | Drinker Biddle & Reath LLP | | 105 College Road East, Suite 300 | | Princeton, New Jersey 08542 | | Fax: | (609) 799-7000 | | Phone: | (609) 716-6504 |
| Notices to the Parent shall be addressed to: | | | | | Pharmos Corporation | | 99 Wood Avenue South, Suite 311 | | Iselin, New Jersey 08830 | | Attn: Chief Executive Officer | | Fax: | (732) 452-9557 | | Phone: | (732) 452-9556 |
| Pharmos Corporation | | 99 Wood Avenue South, Suite 311 | | Iselin, New Jersey 08830 | | Attn: Chief Executive Officer | | Fax: | (732) 452-9557 | | Phone: | (732) 452-9556 |
| with a copy (which shall not constitute notice) to: | | | | | Adam Eilenberg, Esq. | | Eilenberg & Krause LLP | | 11 East 44th Street | | New York, New York 10017 | | Fax: | (212) 986-2399 | | Phone: | (212) 986-9700 |
| Adam Eilenberg, Esq. | | Eilenberg & Krause LLP | | 11 East 44th Street | | New York, New York 10017 | | Fax: | (212) 986-2399 | | Phone: | (212) 986-9700 |
| (b)Successors and Assigns.This Agreement shall be binding upon each of the parties hereto and each of their respective successors and assigns, if any. Except as provided in the next sentence, nothing in this Agreement is intended to confer, or shall be deemed to confer, any rights or remedies upon any person or entity other than the parties hereto and their successors and assigns. This Agreement shall inure to the benefit of: the Representatives, the Indemnifying Stockholders, Parent, Escrow Agent and their respective successors and assigns, if any, of the foregoing. (c)Amendments.This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf Parent, Sub, Escrow Agent, the Representatives and the Indemnifying Stockholders. (d)Entire Agreement.This Agreement and the other agreements referred to herein set forth the entire understanding of the parties hereto relating to the subject matter hereof and thereof and supersede all prior agreements and understandings among or between any of the parties relating to the subject matter hereof and thereof. (e)Tax Reporting Information and Certification of Tax Identification Numbers. (i) The parties hereto agree that, for tax reporting purposes, all dividends on or other income, if any, attributable to the Escrow Shares or any other amount held in escrow by the Escrow Agent pursuant
to this Agreement shall be allocable to the Indemnifying Stockholders in accordance with their respective pro rata interest set forth inExhibit A. |
(ii) Parent agrees to, and the Representative agrees to cause each Indemnifying Stockholder to, provide the Escrow Agent with certified tax identification numbers for each of them by furnishing appropriate forms W-9 (or Forms W-8, in the case of non-U.S. persons) and other forms and documents that the Escrow Agent may reasonably request (collectively, “Tax Reporting Documentation”) to the Escrow Agent within 30 days after the date hereof. The parties hereto understand that, if such Tax Reporting Documentation is not so certified to the Escrow Agent, the Escrow Agent may be required by the Internal Revenue Code, as it may be amended from time to time, to withhold a portion of any interest or other income earned on the investment of monies or other property held by the Escrow Agent pursuant to this Agreement. (f)Construction. (i) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. (ii) The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. (iii) As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” (iv) This Agreement shall be construed pursuant to the laws of the State of New York in effect at the time of such construction without giving effect to conflicts of laws principles. (v) Nothing in this Agreement shall be construed to limit or abridge the rights and obligations of Parent, Sub, the Company, the Representatives or the Indemnifying Stockholders under the Merger Agreement. (g)Termination.This Agreement shall terminate upon the earliest occurrence of any of the following events: (i) the written agreement of all parties hereto; or (ii) upon the delivery by Escrow Agent of all of the Escrow Shares in accordance with the terms of this Agreement. (h)Incorporation.The preamble to this Agreement and all annexes, schedules and exhibits annexed hereto are incorporated herein by this reference as if set forth herein in their entirety. (i)Severability.In the event any provision of this Agreement shall be held invalid or unenforceable by any court of competent jurisdiction, such holding shall not invalidate or render unenforceable any other provision of this Agreement and each and every other provision of this Agreement shall continue in full force and effect. (j)Waiver of Breach.The waiver by any party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any other or subsequent breach by any party. (k)Section Headings. Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. (l)Counterparts.This Agreement may be executed in one or more counterparts in which event all of said counterparts shall be deemed to constitute one original of this Agreement. |
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above-written. | | | | | | | | | PARENT | | REPRESENTATIVES | | | | | | Pharmos Corporation | | | | By: | | | | | |
| |
| | Printed Name: | | Srinivas Akkaraju | | Title: | | | | | |
| | | | Anthony B. Evnin | | | | | | | |
| | | | Charles W. Newhall III | | | | | | | |
| | | | Robert F. Johnston | | | | | | | |
| | | | Jeff Calcagno | | | | | | SUB | | | | | | ESCROW AGENT | | Vela Acquisition Corp. | | [__________] | | | | | | By: | | | By: | | | |
| | |
| | Printed Name: | | Printed Name: | | | | | |
| | Title: | | Title: | | | | | |
| | | | | | | | | | INDEMNIFYING STOCKHOLDERS | | | | | | | | [__________] | | | |
PARENT | REPRESENTATIVES | | | | Pharmos Corporation | | By:_________________________ | ____________________________________ | Printed Name: | Srinivas Akkaraju | Title: | | | | ____________________________________ | | | Anthony B. Evnin | | | | | | ____________________________________ | | | Charles W. Newhall III | | | | | | ____________________________________ | | | Robert F. Johnston | | | | | | ____________________________________ | | | Jeff Calcagno | | | | SUB | | | | ESCROW AGENT | Vela Acquisition Corp. | [__________] | | | | By:_________________________ | By:__________________________________ | Printed Name: | Printed Name:_________________________ | Title: | Title:________________________________ | | | | INDEMNIFYING STOCKHOLDERS | | | | [__________] | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
| |
|
|
|
|
|